22137 sets of interacting proteins for metabolites from the curated HMDB Metabolites of Enzymes dataset.
| Gene Set |
Description |
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(24:0/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/22:1(13Z))
|
|
|
TG(22:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Methylergonovine
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
PE(22:1(13Z)/P-18:0)
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
Enoximone
|
|
|
TG(20:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
5-Hydroxyindoleacetaldehyde
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/24:1(15Z))
|
|
|
DG(18:1n9/0:0/18:1n9)
|
|
|
Pristanoyl-CoA
|
A multi-methyl-branched fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of pristanic acid.
|
|
TG(16:1(9Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
AICAR
|
|
|
Vitamin K1 2,3-epoxide
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/0:0)
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
SM(d18:0/22:1(13Z)(OH))
|
|
|
Encainide
|
|
|
TG(24:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
5-Aminoimidazole-4-carboxamide
|
An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.
|
|
DG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/0:0)
|
|
|
PC(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Trifluoroacetic acid
|
A monocarboxylic acid that is the trifluoro derivative of acetic acid.
|
|
TG(16:0/22:0/22:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(16:1(9Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(P-18:1(11Z)/20:0)
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
PI(18:2(9Z,12Z)/20:1(11Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3n6/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/14:1(9Z)/22:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:2(13Z,16Z)/P-18:1(9Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
CE(18:1(9Z))
|
|
|
Nitrazepam
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Cefepime
|
A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
PIP(20:3(8Z,11Z,14Z)/16:0)
|
|
|
TG(20:3n6/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
1-Nitro-7-hydroxy-8-glutathionyl-7,8-dihydronaphthalene
|
A peptide that has formula C20H24N4O9S.
|
|
Lactosylceramide (d18:1/26:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/15:0)
|
|
|
Oxyphencyclimine
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/o-18:0)
|
|
|
TG(22:1(13Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/o-18:0)
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
5-Methylcytosine
|
|
|
TG(24:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PE(15:0/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/22:0/22:1(13Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
PC(22:0/18:2(9Z,12Z))
|
|
|
TG(20:2n6/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
Glucosamine-1P
|
|
|
8,9-Epoxyeicosatrienoic acid
|
|
|
TG(16:0/22:0/24:0)
|
|
|
PE(24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(15:0/24:0/20:0)
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/14:0)
|
|
|
Cholesterol sulfate
|
A steroid sulfate that has formula C27H46O4S.
|
|
DG(16:0/18:1(11Z)/0:0)
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/o-18:0/22:1(13Z))
|
|
|
Eplerenone
|
A steroid acid ester that has formula C24H30O6.
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/20:3n6)
|
|
|
S-(2-Chloroacetyl)glutathione
|
A peptide that has formula C12H18ClN3O7S.
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/o-18:0/20:2n6)
|
|
|
TG(20:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Palonosetron
|
|
|
PC(16:1(9Z)/22:1(13Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
trans-3,4-Dihydro-3,4-dihydroxy-7,12-dimethylbenz[a]anthracene
|
A phenanthrol that has formula C20H18O2.
|
|
TG(22:2(13Z,16Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
Dephospho-CoA
|
|
|
PC(20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:1(11Z))
|
|
|
TG(15:0/15:0/15:0)
|
|
|
Chlorphenesin
|
|
|
Ganglioside GT1b (d18:1/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:1(9Z)/20:1(11Z))
|
|
|
TG(20:2n6/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(9Z)/22:1(13Z))
|
|
|
TG(15:0/22:1(13Z)/16:0)
|
|
|
Flucytosine
|
An organofluorine compound that has formula C4H4FN3O.
|
|
TG(20:0/18:2(9Z,12Z)/20:1(11Z))
|
|
|
TG(16:1(9Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/20:3n6)
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
Isoallolithocholic acid
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:2n6)
|
|
|
TG(20:2n6/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Auranofin
|
|
|
PC(P-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
N-Acetylmannosamine
|
Any mannosamine carrying an N-acetyl substituent
|
|
DG(22:4(7Z,10Z,13Z,16Z)/14:0/0:0)
|
|
|
TG(15:0/20:1(11Z)/20:3n6)
|
|
|
TG(18:0/22:0/18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
PE(P-16:0/20:3(8Z,11Z,14Z))
|
|
|
TG(20:2n6/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
3-alpha,20-alpha-Dihydroxy-5-beta-pregnane 3-glucuronide
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
DG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GM2 (d18:1/24:1(15Z))
|
|
|
TG(14:1(9Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
Vigabatrin
|
|
|
TG(16:1(9Z)/22:1(13Z)/18:1(11Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/24:1(15Z))
|
|
|
Chlorthalidone
|
An isoindole that has formula C14H11ClN2O4S.
|
|
Isocarboxazid
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
PE(P-16:0e/16:0)
|
|
|
CE(22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(P-18:1(11Z)/18:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
7-Hydroxymethyl-12-methylbenz[a]anthracene sulfate
|
A phenanthrene that has formula C20H16O4S.
|
|
TG(20:0/22:2(13Z,16Z)/24:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
5,7,24(28)-Ergostatrienol
|
An ergostanoid that has formula C28H44O.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
3-O-beta-D-Galactopyranosyl-L-arabinose
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:1(11Z)/24:0)
|
|
|
TG(16:0/16:1(9Z)/20:2n6)
|
|
|
Oxyphenonium
|
|
|
TG(18:0/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/22:2(13Z,16Z))
|
|
|
LysoPE(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
4-Hydroxypropofol
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/o-18:0)
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z))
|
|
|
TG(24:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:5n6/0:0/22:5n6)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/24:1(15Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:0/20:1(11Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
PE(20:1(11Z)/22:0)
|
|
|
TG(14:0/24:1(15Z)/20:2n6)
|
|
|
(R)-mevalonate
|
A mevalonate that has formula C6H11O4.
|
|
TG(22:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:0/22:1(13Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
D-Urobilinogen
|
A biladiene that has formula C33H42N4O6.
|
|
PC(o-16:1(9Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:5n3/0:0/22:6n3)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Tetracycline
|
A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.
|
|
PC(16:1(9Z)/15:0)
|
|
|
Ganglioside GT2 (d18:0/12:0)
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/18:1(9Z))
|
|
|
PE(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(0:0/20:0/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/18:1(9Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Phenformin
|
|
|
TG(22:1(13Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
trans-3-Chloro-2-propene-1-ol
|
|
|
PE(P-18:0/14:1(9Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
Domperidone
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/16:1(9Z)/20:2n6)
|
|
|
TG(18:1(11Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
Homocitric acid
|
A tricarboxylic acid that has formula C7H10O7.
|
|
TG(18:1(11Z)/20:2n6/18:2(9Z,12Z))
|
|
|
Inositol 1,4,5-trisphosphate
|
|
|
TG(20:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/24:0/22:2(13Z,16Z))
|
|
|
PC(20:1(11Z)/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(18:2n6/0:0/18:4n3)
|
|
|
PC(16:0/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso3]
|
|
|
PC(14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
Ganglioside GM1 (18:1/9Z-18:1)
|
|
|
Ganglioside GM1 (d18:1/24:0)
|
|
|
DG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(22:0/20:0/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Argininosuccinic acid
|
|
|
TG(18:1(11Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
LysoPE(0:0/18:1(11Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
1-(beta-D-Ribofuranosyl)-1,4-dihydronicotinamide
|
A pyridine nucleoside consisting of 1,4-dihydronicotinamide with a beta-D-ribofuranosyl moiety at the 1-position.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Thromboxane
|
A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.
|
|
PC(o-24:0/18:3(9Z,12Z,15Z))
|
|
|
DG(22:0/0:0/22:5n6)
|
|
|
TG(24:1(15Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(22:0/16:1(9Z)/18:1(9Z))
|
|
|
Lauroyl-CoA
|
A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of lauric (dodecanoic) acid.
|
|
Aceprometazine
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
CDP-DG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:0/0:0/16:1n7)
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/0:0)
|
|
|
TG(15:0/14:1(9Z)/18:1(11Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(15:0/22:0/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
D-Glucuronic acid 1-phosphate
|
A uronic acid phosphate consisting of D-glucuronic acid having a phosphate group attached at the 1-position.
|
|
TG(24:0/24:1(15Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/16:0)
|
|
|
TG(14:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GD2 (d18:1/14:0)
|
|
|
Beta-D-Glucopyranuronic acid
|
A D-glucopyranuronic acid in which the anomeric centre has beta-configuration.
|
|
Hydrogen selenide
|
A selenium hydride that has formula H2Se.
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:1(11Z)/20:0)
|
|
|
PIP(18:3(6Z,9Z,12Z)/18:0)
|
|
|
DG(18:1n7/0:0/22:5n6)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/15:0/22:2(13Z,16Z))
|
|
|
3a,7a,12a-Trihydroxy-5b-24-oxocholestanoyl-CoA
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
7-Methylguanosine 5'-diphosphate
|
A guanosine 5'-phosphate that consists of guanosine 5'-diphosphate bearing a 7-methyl substituent and having a negatively charged diphosphate group.
|
|
TG(20:1(11Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:2n6)
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
OPC4-CoA
|
An organic molecule that has formula C35H56N7O18P3S.
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Emedastine
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/15:0)
|
|
|
PC(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD2 (d18:1/16:0)
|
|
|
Praziquantel
|
A pyrazinoisoquinoline that has formula C19H24N2O2.
|
|
TG(16:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
Clotrimazole
|
A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to a nitrogen is replaced by a monochlorotrityl group.
|
|
TG(14:0/24:0/20:2n6)
|
|
|
TG(14:1(9Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/14:0/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
DG(20:0/0:0/18:4n3)
|
|
|
PC(18:3(6Z,9Z,12Z)/P-18:0)
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
DG(16:0/20:1(11Z)/0:0)
|
|
|
TG(18:1(11Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(14:0/22:0/20:0)
|
|
|
TG(14:0/22:2(13Z,16Z)/22:0)
|
|
|
PIP2(20:2(11Z,14Z)/18:0)
|
|
|
TG(20:1(11Z)/20:2n6/20:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/20:2n6/24:0)
|
|
|
TG(14:0/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
Tyramine
|
|
|
TG(22:0/18:0/20:2n6)
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
DG(22:0/18:1(11Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:0/o-18:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z)/16:0)
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(P-16:0/20:2(11Z,14Z))
|
|
|
TG(14:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Biotinyl-5'-AMP
|
A biotin that has formula C20H28N7O9PS.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(22:2(13Z,16Z)/18:0)
|
|
|
DG(18:0/0:0/18:4n3)
|
|
|
P1,P4-Bis(5'-xanthosyl) tetraphosphate
|
A purine ribonucleoside 5'-tetraphosphate compound having 5'-xanthosyl residues at the P(1)- and P(4)-positions.
|
|
DG(14:1(9Z)/16:1(9Z)/0:0)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:0/15:0)
|
|
|
TG(24:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(16:0/14:1(9Z)/20:2n6)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GM1 (d18:0/25:0)
|
|
|
PC(o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
PC(P-18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/14:0/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
DG(20:1(11Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GM1 (d18:0/23:0)
|
|
|
PC(o-18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/o-18:0)
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/20:2n6/22:2(13Z,16Z))
|
|
|
PE(24:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Metyrapone
|
|
|
TG(18:1(9Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Trichloroethanol glucuronide
|
A glucosiduronic acid that has formula C8H11Cl3O7.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT1c (d18:0/26:1(17Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:1(11Z))[iso6]
|
|
|
PC(24:1(15Z)/18:0)
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/22:1(13Z))
|
|
|
Dolichol-20
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/0:0)
|
|
|
TG(14:0/16:0/14:0)
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
Terfenadine
|
|
|
DG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
Ofloxacin
|
An oxazinoquinolone carrying carboxy, fluoro, methyl and 4-methylpiperazino substituents. A synthetic fluoroquinolone antibacterial agent, it inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
|
|
PIP2(18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
PE(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
3-alpha-Androstanediol glucuronide
|
|
|
TG(24:1(15Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:2n6/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
Mannosyl-diinositol-phosphorylceramide
|
|
|
TG(24:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/20:3n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:0/o-18:0)
|
|
|
TG(16:0/18:0/22:1(13Z))
|
|
|
3a-Hydroxy-5b-pregnane-20-one
|
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:1n9/0:0/22:6n3)
|
|
|
TG(20:1(11Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/20:1(11Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GM1 (18:1/22:0)
|
|
|
TG(24:1(15Z)/14:0/24:1(15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
CL(20:1(11Z)/18:2(9Z,12Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(14:0/24:1(15Z)/14:1(9Z))
|
|
|
PC(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/16:0/14:1(9Z))
|
|
|
(S)-Hydroxydecanoyl-CoA
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
PIP2(16:0/22:3(10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
Diethylphosphate
|
|
|
TG(18:1(11Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z)/18:1(9Z))
|
|
|
PI(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
PE(18:2(9Z,12Z)/14:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(16:1(9Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
Pyridoxine 5'-phosphate
|
A vitamin B6 phosphate that has formula C8H12NO6P.
|
|
DG(24:1(15Z)/14:1(9Z)/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/o-18:0)
|
|
|
Topiramate
|
A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.
|
|
Ganglioside GT2 (d18:0/25:0)
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(15:0/18:1(11Z)/16:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:2n6/18:0)
|
|
|
Acitretin
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(20:2n6/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
4-Hydroxyphenylacetaldehyde
|
A phenylacetaldehyde that has formula C8H8O2.
|
|
TG(15:0/o-18:0/20:3n6)
|
|
|
PE(14:0/18:0)
|
|
|
B-Carotene
|
|
|
PE(18:2(9Z,12Z)/16:0)
|
|
|
TG(20:3n6/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Betahistine
|
|
|
TG(22:1(13Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Propionylcarnitine
|
|
|
TG(20:3n6/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PG(16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/16:0/18:0)
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
PC(22:2(13Z,16Z)/P-18:1(11Z))
|
|
|
Palmityl-CoA
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Nicotinic acid mononucleotide
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/14:0)
|
|
|
TG(16:0/24:1(15Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(18:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(P-18:1(9Z)/18:1(9Z))
|
|
|
DG(18:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(24:1(15Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:1(13Z)/22:0/22:2(13Z,16Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:1(11Z))
|
|
|
TG(18:1(11Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/16:0/o-18:0)
|
|
|
TG(20:2n6/22:0/20:3n6)
|
|
|
TG(18:0/22:0/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(20:2n6/14:0/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/o-18:0/18:2(9Z,12Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
PE(14:1(9Z)/22:2(13Z,16Z))
|
|
|
LysoPC(P-18:0)
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(20:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
Cholecalciferol
|
|
|
TG(15:0/14:0/20:2n6)
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/16:0/0:0)
|
|
|
DG(20:1n9/0:0/18:4n3)
|
|
|
Enalapril
|
A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:0/18:1(11Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:3n6/18:2(9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:4n6/0:0/22:4n6)
|
|
|
TG(20:0/22:1(13Z)/20:0)
|
|
|
DG(18:1(11Z)/18:0/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
DG(14:0/16:1(9Z)/0:0)
|
|
|
PE(20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
Chlorpromazine
|
A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(16:1(9Z)/22:0/20:1(11Z))
|
|
|
N-Acetylgalactosamine 4-sulphate
|
|
|
TG(18:1(11Z)/14:1(9Z)/20:2n6)
|
|
|
PE(20:3(5Z,8Z,11Z)/24:0)
|
|
|
Oxygen
|
A chalcogen that has formula O.
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(9Z)/22:0)
|
|
|
Ganglioside GT1c (d18:1/18:1(11Z))
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(22:1(13Z)/18:0/20:2n6)
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:1n9/0:0/20:5n3)
|
|
|
NAD
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Nonoxynol-9
|
|
|
TG(20:0/22:1(13Z)/22:0)
|
|
|
TG(22:0/20:2n6/16:1(9Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
Calcitriol
|
A hydroxycalciol that is calcidiol in which the pro-S hydrogen of calcidiol is replaced by a hydroxy group. It is the active form of vitamin D3, produced fom calciol via hydoxylation in the liver to form calcidiol, which is subsequently oxidised in the kidney to give calcitriol.
|
|
TG(20:3(5Z,8Z,11Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:1(9Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(15:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/0:0)
|
|
|
DG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(18:0/24:0)
|
|
|
TG(22:1(13Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:0/24:1(15Z))
|
|
|
Tetrahydroaldosterone-3-glucuronide
|
|
|
TG(20:3n6/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP2(16:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
LysoPE(0:0/14:0)
|
|
|
PIP2(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
N-[(3a,5b,7a,12a)-3,7-dihydroxy-24-oxo-12-(sulfooxy)cholan-24-yl]-Glycine
|
|
|
TG(16:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(18:1(9Z)/20:1(11Z))
|
|
|
Ganglioside GQ1c (d18:1/16:0)
|
|
|
LPA(18:2(9Z,12Z)/0:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Megestrol
|
A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a hydroxy group at position 17.
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))[iso6]
|
|
|
Perphenazine
|
A member of the class of phenothiazines that is phenothiazine having a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position.
|
|
Ganglioside GQ1c (d18:1/18:0)
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/24:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:1(13Z)/20:2(11Z,14Z)/0:0)
|
|
|
cis-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA
|
An organic molecule that has formula C31H50N7O17P3S.
|
|
TG(22:0/18:1(9Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/24:0/18:1(9Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:1(11Z))
|
|
|
CDP-DG(18:1(9Z)/18:1(11Z))
|
|
|
TG(20:2n6/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
PIP2(18:0/18:1(9Z))
|
|
|
Reboxetine
|
|
|
TG(24:0/14:0/o-18:0)
|
|
|
PE(14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
1,2-Dihydronaphthalene-1,2-diol
|
A member of the class of naphthalenediols that is 1,2-dihydronaphthalene substituted by hydroxy groups at positions 1 and 2 respectively.
|
|
TG(15:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:0/16:0)
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(14:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Aspartame
|
|
|
TG(22:2(13Z,16Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
Formaldehyde
|
The simplest aldehyde.
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Aripiprazole
|
A quinolone that has formula C23H27Cl2N3O2.
|
|
PC(20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/16:0)
|
|
|
TG(20:2n6/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
N-Acetylserotonin
|
A member of the class of hydroxyindoles that is the N-acetyl derivative of serotonin.
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Cefadroxil
|
A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.
|
|
TG(14:1(9Z)/15:0/14:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Doxylamine
|
A tertiary amine that has formula C17H22N2O.
|
|
TG(18:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/15:0/o-18:0)
|
|
|
DG(18:3(9Z,12Z,15Z)/22:1(13Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Terlipressin
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/22:1(13Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
DG(20:3n6/0:0/22:6n3)
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(18:0/P-18:1(11Z))
|
|
|
PE(16:1(9Z)/P-18:1(11Z))
|
|
|
TG(20:1(11Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(P-18:1(9Z)/18:0)
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
LysoPE(24:0/0:0)
|
|
|
DG(24:1n9/0:0/22:5n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Methylphenidate
|
A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
|
|
DG(18:0/22:0/0:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(18:1(11Z)/o-18:0/22:1(13Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Misoprostol
|
A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.
|
|
Tiludronate
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
1-Methylhistamine
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/16:1(9Z)/18:1(9Z))[iso6]
|
|
|
2-Methoxyestradiol
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
Methoxsalen
|
|
|
TG(14:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/14:0)
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
3,4-Dihydroxybenzeneacetic acid
|
|
|
Ganglioside GT3 (d18:0/22:1(13Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Grepafloxacin
|
|
|
TG(16:0/o-18:0/22:0)
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Cefacetrile
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
DG(20:2(11Z,14Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
DG(14:0/0:0/20:3n9)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/24:0/o-18:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Thioproperazine
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/15:0)
|
|
|
PIP(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Meclofenamic acid
|
An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.
|
|
PG(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Coenzyme Q10
|
A ubiquinone having a side chain of 10 isoprenoid units. In the naturally-occurring isomer, all isoprenyl double bonds are in the E- configuration.
|
|
Pentazocine
|
A benzazocine that has formula C19H27NO.
|
|
TG(20:0/22:1(13Z)/16:1(9Z))
|
|
|
TG(16:1(9Z)/18:0/20:1(11Z))[iso6]
|
|
|
TG(14:0/24:1(15Z)/22:1(13Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
2-(3-carboxy-3-(trimethylammonio)propyl)-L-histidine
|
|
|
PE(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(24:1(15Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(24:0/20:1(11Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(14:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:0/20:1(11Z))
|
|
|
Carboxyphosphamide
|
A nitrogen mustard that has formula C7H15Cl2N2O4P.
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:0/o-18:0)
|
|
|
Gamma-linolenoyl-CoA
|
An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of gamma-linolenic acid.
|
|
TG(16:1(9Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
Ganglioside GT1b (d18:0/16:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/P-18:0)
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:0/20:3n6)
|
|
|
TG(14:1(9Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Gentisate aldehyde
|
|
|
TG(15:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(24:0/0:0/22:2n6)
|
|
|
Fluspirilene
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Androsterone sulfate
|
A steroid sulfate that is the 3-sulfate of androsterone.
|
|
TG(22:2(13Z,16Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/14:0/20:3n6)
|
|
|
Amprenavir
|
|
|
TG(18:1(11Z)/14:1(9Z)/20:1(11Z))
|
|
|
Ganglioside GT1b (d18:0/14:0)
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:0/18:1(9Z))[iso6]
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(14:0/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(16:0/20:3(8Z,11Z,14Z))
|
|
|
Sucralfate
|
|
|
TG(20:3n6/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(15:0/18:2(9Z,12Z)/18:0)
|
|
|
DG(22:1(13Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(24:0/20:3n6/o-18:0)
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/15:0)
|
|
|
PC(22:0/22:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/20:3n6)
|
|
|
TG(20:0/22:0/24:1(15Z))
|
|
|
Ganglioside GD3 (d18:1/26:0)
|
|
|
TG(15:0/22:0/16:0)
|
|
|
TG(18:1(11Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
DG(14:0/0:0/18:3n6)
|
|
|
TG(22:2(13Z,16Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:0/22:1(13Z))
|
|
|
PG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PI(18:0/18:0)
|
|
|
TG(24:0/14:0/18:2(9Z,12Z))
|
|
|
PC(18:0/14:0)
|
|
|
Valeric acid
|
A straight-chain saturated fatty acid containing five carbon atoms.
|
|
TG(20:2n6/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Selenomethionine
|
|
|
TG(24:1(15Z)/16:0/22:2(13Z,16Z))
|
|
|
PC(16:1(9Z)/20:1(11Z))
|
|
|
Niflumic Acid
|
|
|
Cyanocobalamin
|
|
|
TG(18:2(9Z,12Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
Chenodeoxycholoyl-CoA
|
A choloyl-CoA formed by thioester linkage between chenodeoxycholic acid and coenzyme A.
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
3-O-Sulfogalactosylceramide (d18:1/26:1(17Z))
|
|
|
TG(22:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Hydroxypropionyl-CoA
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
(24R)-Cholest-5-ene-3-beta,7-alpha,24-triol
|
A 7alpha,24-dihydroxycholesterol that has formula C27H46O3.
|
|
TG(24:1(15Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
dTDP
|
A thymidine phosphate having a diphosphate group at the 5'-position.
|
|
TG(14:1(9Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/16:0/20:1(11Z))
|
|
|
TG(20:3n6/22:0/o-18:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
Ganglioside GD3 (d18:0/25:0)
|
|
|
TG(14:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/22:2(13Z,16Z))
|
|
|
DG(22:6n3/0:0/22:6n3)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
PS(18:2(9Z,12Z)/16:1(9Z))
|
|
|
DG(16:1(9Z)/18:1(11Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/24:1(15Z)/20:0)
|
|
|
PE(20:3(8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
DG(15:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(24:1(15Z)/18:0/24:1(15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:0/18:1(11Z))[iso3]
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PIP(18:2(9Z,12Z)/18:1(11Z))
|
|
|
Dihydrolipoamide
|
A dithiol that has formula C8H17NOS2.
|
|
TG(18:0/20:1(11Z)/22:1(13Z))
|
|
|
TG(14:0/20:2n6/22:0)
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
DG(18:1n7/0:0/18:2n6)
|
|
|
TG(15:0/20:3n6/24:1(15Z))
|
|
|
TG(22:0/20:0/16:1(9Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/22:1(13Z)/0:0)
|
|
|
TG(14:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/14:1(9Z))
|
|
|
DG(14:1(9Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
PE(P-18:1(11Z)/18:1(9Z))
|
|
|
TG(24:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Bupivacaine
|
A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(14:1n5/0:0/18:3n3)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:2n6/24:0)
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
PE(14:0/18:2(9Z,12Z))
|
|
|
TG(24:0/15:0/18:2(9Z,12Z))
|
|
|
R-Methylmalonyl-CoA
|
The (R)-enantiomer of methylmalonyl-CoA.
|
|
Oxidized glutathione
|
|
|
TG(24:0/24:0/14:1(9Z))
|
|
|
CE(20:1(11Z))
|
|
|
TG(22:0/24:0/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
14,15-Epoxy-5,8,11-eicosatrienoic acid
|
|
|
Xanthan
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(16:1(9Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(14:1n5/0:0/18:1n7)
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Amcinonide
|
A corticosteroid that has formula C28H35FO7.
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/22:2(13Z,16Z))
|
|
|
TG(16:0/16:0/24:1(15Z))
|
|
|
Oxoadipic acid
|
|
|
PG(18:0/18:1(11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:1(11Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Methylphenobarbital
|
|
|
3-Methylhistidine
|
A histidine derivative in which the methyl group is located at N-3.
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/20:3n6)
|
|
|
PC(14:1(9Z)/24:1(15Z))
|
|
|
5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate
|
Conjugate base of 5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylic acid.
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(16:0/0:0/24:0)
|
|
|
TG(16:0/24:1(15Z)/20:1(11Z))
|
|
|
TG(24:0/22:1(13Z)/16:1(9Z))
|
|
|
Indacaterol
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
Stavudine
|
A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase
|
|
TG(20:1(11Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/o-18:0)
|
|
|
DG(22:0/0:0/20:2n6)
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:2n6/24:1(15Z))
|
|
|
Bupropion
|
A propanone that is propan-1-one substituted by a tert-butylamino group at position 2 and a 3-chlorophenyl group at position 1.
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Murocholic acid
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
Gestodene
|
|
|
TG(14:0/16:0/22:2(13Z,16Z))
|
|
|
12-Ketodeoxycholic acid
|
|
|
PC(20:2(11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
Methylimidazole acetaldehyde
|
|
|
PI(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(14:0/16:0/20:3n6)
|
|
|
TG(14:1(9Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:1(11Z)/18:1(11Z))
|
|
|
Lisuride
|
|
|
DG(18:2n6/0:0/20:5n3)
|
|
|
TG(16:0/16:1(9Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(24:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(15:0/16:1(9Z)/20:3n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP2(18:1(11Z)/16:1(9Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/0:0)
|
|
|
TG(14:1(9Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
PE(20:0/20:3(8Z,11Z,14Z))
|
|
|
PE(P-18:1(9Z)/14:1(9Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/20:1(11Z)/24:0)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
Sodium
|
|
|
Lewis X trisaccharide
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Pyrophosphate
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
Corticosterone
|
A 21-hydroxy steroid that is consists of pregn-4-ene substituted by hydroxy groups at positions 11 and 21 and oxo groups at positions 3 and 20. Corticosterone is a 21-carbon steroid hormone of the corticosteroid type produced in the cortex of the adrenal glands.
|
|
PG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/20:1(11Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/15:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Hexacosanoyl-CoA
|
A very long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of hexacosanoic (cerotic) acid..
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
MG(20:5(5Z,8Z,11Z,14Z,17Z)/0:0/0:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:0/0:0)
|
|
|
11beta,17beta-Dihydroxy-4-androsten-3-one
|
A 3-hydroxy steroid that has formula C19H28O3.
|
|
TG(18:1(9Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/16:1(9Z)/20:1(11Z))
|
|
|
(2E)-Tetradecenoyl-CoA
|
An acyl-CoA oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of trans-tetradec-2-enoyl-CoA; major species at pH 7.3.
|
|
DG(22:1(13Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/o-18:0)
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(16:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
N-Acetyl-L-phenylalanine
|
The N-acetyl derivative of L-phenylalanine.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Pentoxifylline
|
|
|
PIP(16:0/20:1(11Z))
|
|
|
TG(18:0/24:0/20:2n6)
|
|
|
LysoPE(20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Fosphenytoin
|
|
|
TG(22:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:1(9Z)/16:1(9Z))[iso6]
|
|
|
PE(18:3(6Z,9Z,12Z)/P-18:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:0/20:0)
|
|
|
TG(15:0/22:0/o-18:0)
|
|
|
TG(15:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/24:0/18:0)
|
|
|
Oxalacetic acid
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:3n6/15:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Hyperforin
|
A sesquarterpenoid that has formula C35H52O4.
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/24:1(15Z)/22:0)
|
|
|
TG(20:0/15:0/20:2n6)
|
|
|
TG(14:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Sulfaphenazole
|
A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.
|
|
Ganglioside GT3 (d18:1/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
1-Hexadecanol
|
|
|
TG(18:0/14:1(9Z)/22:1(13Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/0:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(14:0/20:0)
|
|
|
TG(16:0/20:3n6/16:0)
|
|
|
DG(16:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
16-alpha,17-beta-estriol 17-beta-D-glucuronide
|
A steroid saponin that has formula C24H31O9.
|
|
DG(24:1(15Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Porfimer
|
|
|
TG(15:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:3n6/18:0)
|
|
|
Mefenamic acid
|
An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.
|
|
TG(20:0/o-18:0/24:0)
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(24:0/22:0/24:1(15Z))
|
|
|
TG(24:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/16:1(9Z)/20:2n6)
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(22:2(13Z,16Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/15:0/22:1(13Z))
|
|
|
Sorafenib
|
|
|
TG(16:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
PC(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
PE(14:0/22:0)
|
|
|
TG(15:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Indoleacetic acid
|
|
|
TG(18:2(9Z,12Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(16:2(9Z,12Z)/18:0)
|
|
|
TG(22:1(13Z)/22:0/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
Calcium
|
|
|
PC(22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT3 (d18:0/12:0)
|
|
|
TG(24:1(15Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Zoledronate
|
|
|
TG(24:1(15Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Vorinostat
|
|
|
TG(18:1(9Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
3-Methylguanine
|
A methylguanine carrying the methyl substituent at position 3.
|
|
DG(18:1(9Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:3n6)
|
|
|
TG(20:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GQ1c (d18:1/20:0)
|
|
|
PC(18:1(11Z)/18:1(9Z))
|
|
|
PC(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
5,6-Dihydrouridine
|
The uridine derivative obtained by formal hydrogenation of the endocyclic double bond in the uracil ring.
|
|
TG(15:0/22:1(13Z)/14:1(9Z))
|
|
|
TG(22:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:0/o-18:0)
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
DG(18:3n6/0:0/22:6n3)
|
|
|
TG(16:0/22:0/18:2(9Z,12Z))
|
|
|
3a,6b,7b,12b-Tetrahydroxy-5b-cholanoic acid
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(16:0/P-18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
(25S)-3alpha,7alpha-Dihydroxy-5beta-cholestanoyl-CoA
|
An organic molecule that has formula C48H80N7O19P3S.
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/o-18:0)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Decyl alcohol
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(22:0/16:1(9Z)/22:1(13Z))
|
|
|
TG(22:1(13Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Hexacarboxylporphyrin III
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
3-Hydroxy-5-methylhex-4-enoyl-CoA
|
A polyol that has formula C28H46N7O18P3S.
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Ganglioside GM3 (d18:1/24:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Chenodeoxycholic acid
|
A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GM3 (d18:1/22:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Superoxide
|
An oxygen radical that has formula O2.
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/24:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Levorphanol
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:0/0:0/20:4n3)
|
|
|
TG(18:1(9Z)/24:1(15Z)/18:1(9Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
PC(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/24:0/16:1(9Z))
|
|
|
Cellobiose
|
A glycosylglucose that is disaccharide containing two glucose units linked via a beta(1->4) bond.
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
12a-Hydroxy-3-oxocholadienic acid
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CDP-DG(18:0/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Benzo[a]pyrene-4,5-oxide
|
A carbopolycyclic compound that has formula C20H12O.
|
|
TG(24:0/15:0/20:2n6)
|
|
|
2-Oxosuccinamate
|
The conjugate base of 2-oxosuccinamic acid; major species at pH 7.3.
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
PIP(18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(14:1n5/0:0/18:2n6)
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(18:1(9Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
Hypoxanthine
|
A purine nucleobase that consists of purine bearing an oxo substituent at position 6.
|
|
TG(20:3n6/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(16:1(9Z)/P-18:0)
|
|
|
PE(20:1(11Z)/15:0)
|
|
|
PE(P-18:1(9Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Cefalotin
|
A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
sn-glycero-3-Phosphoethanolamine
|
A glycerophosphatidylethanolamine that has formula C5H14NO6P.
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ranitidine
|
A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/24:1(15Z)/16:1(9Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sulpiride
|
|
|
DG(20:3n9/0:0/20:5n3)
|
|
|
Ganglioside GD1b (d18:1/20:0)
|
|
|
TG(16:1(9Z)/18:0/22:1(13Z))
|
|
|
PE(20:1(11Z)/P-18:1(11Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:3(8Z,11Z,14Z))[iso3]
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
PC(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/18:1(9Z)/18:0)
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Riboflavin
|
D-Ribitol in which the hydroxy group at position 5 is substituted by a 7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl moiety. It is a nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables, but the richest natural source is yeast. The free form occurs only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide.
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate
|
|
|
TG(20:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6/o-18:0)
|
|
|
TG(20:0/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
dGTP
|
A purine 2'-deoxyribonucleoside 5'-triphosphate having guanine as the nucleobase.
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:1(9Z)/16:1(9Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:1(11Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
PE(14:1(9Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
PG(16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Tetrahydrofolyl-[Glu](2)
|
|
|
25-Hydroxycholesterol
|
A 25-hydroxy steroid that has formula C27H46O2.
|
|
TG(18:1(9Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:0/18:1(11Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
2-Polyprenyl-3-methyl-6-methoxy-1,4-benzoquinone
|
|
|
TG(20:0/22:1(13Z)/20:3n6)
|
|
|
1-Naphthaldehyde
|
A naphthaldehyde with a formyl group at position 1.
|
|
Ardeparin
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/0:0)
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Caproic acid
|
A C6, straight-chain saturated fatty acid.
|
|
Methotrexate
|
A pteridine that has formula C20H22N8O5.
|
|
Chondroitin 6'-sulfate
|
A chondroitin sulfate in which the site of sulfation is carbon 6 of the N-acetylgalactosamine (GalNAc) sugar.
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
CDP-DG(16:0/18:1(9Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(14:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
DG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/16:0/24:0)
|
|
|
TG(18:1(9Z)/20:2n6/20:3n6)
|
|
|
TG(14:0/15:0/o-18:0)
|
|
|
PIP(22:2(13Z,16Z)/16:0)
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/18:2(9Z,12Z))[iso3]
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
2-Phospho-D-glyceric acid
|
A 2-Phosphoglyceric acid in which the glyceric acid moiety has D (R) configuration.
|
|
3-Methoxy-4-hydroxyphenylglycol glucuronide
|
|
|
TG(15:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:1(11Z)/o-18:0)
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
2-Oxo-4-methylthiobutanoic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/P-16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
PC(P-18:1(9Z)/22:0)
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
LysoPE(18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:1(11Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/15:0)
|
|
|
TG(14:1(9Z)/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
Cyanide
|
A pseudohalide anion that is the conjugate base of hydrogen cyanide.
|
|
S-Adenosylhomocysteine
|
|
|
DG(20:5n3/0:0/22:5n3)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Indecainide
|
|
|
Dopamine 3-O-sulfate
|
An aryl sulfate that has formula C8H11NO5S.
|
|
TG(18:1(9Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
Beta-Aminopropionitrile
|
An aminopropionitrile carrying an amino group at the beta-position.
|
|
Conivaptan
|
|
|
TG(16:0/22:0/20:1(11Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/o-18:0)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z)/o-18:0)
|
|
|
6-Dehydrotestosterone glucuronide
|
|
|
PC(P-18:1(11Z)/18:2(9Z,12Z))
|
|
|
Sitagliptin
|
A triazolopyrazine that exhibits hypoglycemic activity.
|
|
PE(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:1(11Z)/24:0)
|
|
|
TG(20:3n6/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
S-Acetyldihydrolipoamide-E
|
|
|
TG(16:0/24:0/14:1(9Z))
|
|
|
PI(20:2(11Z,14Z)/16:0)
|
|
|
PE(18:0/15:0)
|
|
|
PC(24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ajmaline
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
PE(14:0/16:0)
|
|
|
PI(20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
7-Hydroxymethyl-12-methylbenz[a]anthracene
|
A phenanthrene that has formula C20H16O.
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/18:3(9Z,12Z,15Z))[iso3]
|
|
|
Stearoyl-CoA
|
A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of stearic acid.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(24:1(15Z)/20:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ursocholic acid
|
A bile acid that has formula C24H40O5.
|
|
TG(16:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(22:1(13Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/24:1(15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Fluorine
|
A monoatomic fluorine that has formula F.
|
|
5-Amino-6-ribitylamino uracil
|
|
|
TG(20:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GQ1c (d18:0/12:0)
|
|
|
TG(14:1(9Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
PE(22:0/P-18:1(9Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:0)
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(11Z)/14:1(9Z))
|
|
|
PIP2(16:2(9Z,12Z)/16:0)
|
|
|
TG(14:1(9Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Tiagabine
|
|
|
DG(20:1n9/0:0/18:2n6)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1n7/0:0/20:1n9)
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
L-Malic acid
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
DG(22:2n6/0:0/22:4n6)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:0)
|
|
|
3-Dehydroxycarnitine
|
|
|
7alpha,25-Dihydroxy-4-cholesten-3-one
|
A cholestanoid that has formula C27H44O3.
|
|
TG(22:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/16:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(20:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
PC(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
DG(18:1n9/0:0/20:4n6)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GQ1c (d18:1/18:1(9Z))
|
|
|
TG(14:1(9Z)/14:0/18:2(9Z,12Z))
|
|
|
LysoPC(P-16:0)
|
A 1-O-(alk-1-enyl)-sn-glycero-3-phosphocholine in which the alk-1-enyl group contains 16 carbons and no additional double bonds.
|
|
TG(20:0/22:0/18:1(9Z))
|
|
|
TG(18:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
DG(20:2(11Z,14Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(14:1(9Z)/22:0/24:1(15Z))
|
|
|
TG(20:3n6/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
CE(20:2(6Z,9Z))
|
|
|
TG(20:2n6/20:3n6/20:2n6)
|
|
|
2-Phenyl-1,3-propanediol monocarbamate
|
A benzene that has formula C10H13NO3.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(15:0/14:0/22:0)
|
|
|
Ganglioside GD1b (d18:1/18:1(11Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/18:0)
|
|
|
TG(15:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Melilotussaponin O1
|
|
|
PE(18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(18:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
Halazepam
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
S-(Hydroxymethyl)glutathione
|
Conjugate base of S-(hydroxymethyl)glutathione.
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/22:1(13Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/16:0/0:0)
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
DG(14:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PIP3(18:2(9Z,12Z)/20:1(11Z))
|
|
|
Trichlormethiazide
|
|
|
DG(20:2(11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Thiosulfate
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/16:1(9Z))
|
|
|
Penbutolol
|
|
|
Valproic acid glucuronide
|
|
|
PG(16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:0/14:1(9Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/20:2(11Z,14Z))
|
|
|
PC(16:0/18:3(9Z,12Z,15Z))
|
|
|
3,4-Dihydroxy-trans-cinnamate
|
|
|
TG(18:1(11Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(14:0/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(14:0/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Propericiazine
|
|
|
Nafarelin
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/15:0/18:1(9Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(15:0/20:2n6/20:1(11Z))
|
|
|
TG(22:1(13Z)/14:0/20:2n6)
|
|
|
TG(14:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Carbachol
|
An ammonium salt that has formula C6H15N2O2.Cl.
|
|
TG(14:1(9Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/16:0/22:1(13Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))
|
|
|
Urocanic acid
|
An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.
|
|
TG(20:3n6/16:0/o-18:0)
|
|
|
4-ene-Valproic acid
|
|
|
TG(24:1(15Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(16:0/0:0/16:0)
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:3n6/18:1(11Z))
|
|
|
TG(24:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:0/18:1(9Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/18:0/18:1(9Z))[iso6]
|
|
|
TG(16:1(9Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/0:0)
|
|
|
PC(22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
Isomaltose
|
A glycosylglucose consisting of two D-glucopyranose units connected by an alpha-(1->6)-linkage.
|
|
TG(16:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
3beta-Hydroxypregn-5-en-20-one sulfate
|
|
|
PC(P-18:1(11Z)/14:0)
|
|
|
TG(18:1(9Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
DG(18:3n6/0:0/20:4n6)
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
PC(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
3-Demethylubiquinone-9
|
An ubiquinone that has formula C53H80O4.
|
|
PC(P-18:1(11Z)/16:0)
|
|
|
TG(18:0/16:1(9Z)/22:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:1(11Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:3n6)
|
|
|
PI(18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)/0:0)
|
|
|
TG(20:0/20:0/20:1(11Z))[iso3]
|
|
|
NADPH
|
|
|
Cetrorelix
|
|
|
TG(20:3n6/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(P-18:0/22:0)
|
|
|
3-Hydroxyanthranilic acid
|
An aminobenzoic acid that is benzoic acid substituted at C-2 by an amine group and at C-3 by a hydroxy group. It is an intermediate in the metabolism of the amino acid tryptophan.
|
|
N,N-Dimethylformamide
|
A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.
|
|
TG(15:0/o-18:0/18:0)
|
|
|
TG(24:0/o-18:0/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Leukotriene B4
|
A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents.
|
|
TG(18:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Lactosylceramide (d18:1/26:1(17Z))
|
|
|
TG(24:0/24:0/24:0)
|
|
|
PE(18:1(9Z)/22:2(13Z,16Z))
|
|
|
PC(dm18:1(11Z)/dm18:1(11Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/o-18:0/22:2(13Z,16Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
DG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/14:0/0:0)
|
|
|
TG(14:0/16:0/20:0)
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cholest-5-ene
|
A cholestanoid that has formula C27H46.
|
|
PE(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:1(9Z)/16:0)
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(15:0/24:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/15:0/24:0)
|
|
|
Tolazamide
|
|
|
PC(14:1(9Z)/20:1(11Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/15:0)
|
|
|
Glucosylceramide (d18:1/12:0)
|
|
|
LysoPC(O-18:0)
|
|
|
TG(24:1(15Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:0/24:0/0:0)
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
Suramin
|
|
|
Theobromine
|
|
|
TG(18:1(11Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1b (d18:0/25:0)
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
PC(24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Epirubicin
|
|
|
Capric acid
|
|
|
TG(16:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:0/0:0)
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/20:2n6/20:0)
|
|
|
Tirofiban
|
|
|
TG(20:3n6/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(20:4(5Z,8Z,11Z,14Z)/0:0/0:0)
|
|
|
TG(24:1(15Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/24:1(15Z)/20:0)
|
|
|
Ganglioside GQ1c (d18:0/26:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:1(9Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/18:1(9Z)/o-18:0)
|
|
|
TG(16:1(9Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Cotinine
|
An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
DG(20:1n9/0:0/20:4n6)
|
|
|
TG(20:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:1(11Z)/14:0)[iso6]
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
Hexafluronium
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(16:0/20:3n6/20:0)
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:1(11Z)/24:0)
|
|
|
TG(18:0/16:1(9Z)/18:1(11Z))
|
|
|
TG(20:3n6/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(15:0/0:0/18:1n7)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:1(11Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
Cytidine monophosphate N-acetylneuraminic acid
|
|
|
PIP2(18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(20:2n6/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Valrubicin
|
|
|
PC(o-18:2(9Z,12Z)/22:0)
|
|
|
TG(18:1(9Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
CL(20:1(11Z)/18:2(9Z,12Z)/18:1(11Z)/18:1(9Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/P-18:1(11Z))
|
|
|
TG(20:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cortolone-3-glucuronide
|
|
|
Ganglioside GD1a (d18:1/23:0)
|
|
|
DG(15:0/24:1(15Z)/0:0)
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Alpha-ketoisovaleric acid
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GQ1c (d18:0/20:0)
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/20:3n6)
|
|
|
Hydroxylansoprazole
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(18:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3n6/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/20:1(11Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/14:1(9Z)/16:1(9Z))
|
|
|
Benzaldehyde
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
PE(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:0/16:1(9Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(15:0/16:0/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/24:1(15Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM1 (18:1/18:0)
|
|
|
Carglumic acid
|
|
|
Solifenacin
|
|
|
TG(16:1(9Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:1n7/0:0/18:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/o-18:0)
|
|
|
Terbinafine
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
5'-Hydroxypiroxicam
|
|
|
TG(18:2(9Z,12Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GD1b (d18:1/23:0)
|
|
|
Irinotecan
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
MG(18:0e/0:0/0:0)
|
|
|
TG(16:1(9Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
N-acetyl-alpha-D-galactosamine 1-phosphate
|
The alpha-anomer of N-acetyl-D-galactosamine 1-phosphate.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
2,5-Dioxopentanoate
|
The conjugate base of 2,5-dioxopentanoic acid; major species at pH 7.3.
|
|
DG(18:1n9/0:0/18:4n3)
|
|
|
DG(18:3n3/0:0/22:6n3)
|
|
|
PC(18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/o-18:0/18:2(9Z,12Z))
|
|
|
TG(20:2n6/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Etoposide
|
A furonaphthodioxole that has formula C29H32O13.
|
|
Adenosine triphosphate
|
|
|
TG(18:0/18:1(9Z)/20:3n6)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(16:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/24:0/20:1(11Z))
|
|
|
Propinol adenylate
|
|
|
TG(16:0/20:0/24:1(15Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(24:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
Ceramide (d18:1/16:0)
|
|
|
TG(24:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Indolepyruvate
|
|
|
LysoPC(14:0)
|
A lysophosphatidylcholine in which the remaining acyl group is specified as tetradecanoyl (myristoyl). If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
|
|
TG(20:0/o-18:0/22:2(13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:0/o-18:0)
|
|
|
Clenbuterol
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:0/0:0)
|
|
|
TG(22:1(13Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
DG(20:1(11Z)/18:1(11Z)/0:0)
|
|
|
LysoPE(24:1(15Z)/0:0)
|
|
|
TG(15:0/22:0/18:0)
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Cer(d18:0/26:0)
|
|
|
TG(14:1(9Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(18:1(9Z)/20:0/18:1(9Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
albendazole S-oxide
|
A sulfoxide that has formula C12H15N3O3S.
|
|
TG(20:1(11Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(24:0/18:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sulfasalazine
|
An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
|
|
LysoPE(0:0/22:0)
|
|
|
TG(20:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Ceramide (d18:1/25:0)
|
|
|
Gliquidone
|
|
|
DG(18:0e/2:0/0:0)
|
|
|
Homovanillin
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:2n6/18:2(9Z,12Z))
|
|
|
DG(18:0/20:1(11Z)/0:0)
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
PG(18:0/16:1(9Z))
|
|
|
SM(d18:0/24:1(15Z))
|
|
|
DG(18:1n7/0:0/18:1n9)
|
|
|
TG(20:2n6/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/20:2n6)
|
|
|
TG(15:0/16:0/24:1(15Z))
|
|
|
DG(22:1n9/0:0/20:5n3)
|
|
|
TG(15:0/14:0/22:1(13Z))
|
|
|
PC(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(22:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/18:2(9Z,12Z))
|
|
|
Methyl beta-D-glucopyranoside
|
A beta-D-glucopyranoside having a methyl substituent at the anomeric position.
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:2n6/20:1(11Z)/o-18:0)
|
|
|
PE(P-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
12b-Hydroxy-5b-cholanoic acid
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/18:1(9Z))[iso]
|
|
|
Felodipine
|
The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
|
|
TG(14:1(9Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(16:1(9Z)/16:1(9Z))
|
|
|
PIP2(22:3(10Z,13Z,16Z)/16:0)
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(18:0/16:1(9Z)/20:1(11Z))
|
|
|
TG(14:1(9Z)/20:0/20:2n6)
|
|
|
Erythromycin
|
Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:1(11Z)/o-18:0/22:1(13Z))
|
|
|
TG(15:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
p-Octopamine
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
N-Acetyl-L-methionine
|
A L-methionine derivative that is the N-acetyl derivative of L-methionine.
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(20:2n6/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(15:0/0:0/20:3n6)
|
|
|
TG(18:1(9Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Apelin-13
|
|
|
PE(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/14:0/24:0)
|
|
|
PC(20:2(11Z,14Z)/18:1(11Z))
|
|
|
Pectin
|
Any mixture of complex, colloidal, macromolecular plant galacturonans containing a large proportion of D-galactopyranosyluronic acid residues in alpha-(1->4) linkage, the carboxy groups of which may be esterified to varying degrees by methyl groups or be partially or completely converted into salts. The structure shown is that of the parent polygalacturonan.
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Glucosylceramide (d18:1/25:0)
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
Nitric oxide
|
A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom.
|
|
1,3,12-Trihydroxycholan-24-oic acid
|
|
|
24-Hydroxycholesterol
|
A 24-hydroxy steroid that has formula C27H46O2.
|
|
Acetylglycine
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
Alfentanil
|
A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.
|
|
Dopamine
|
Catechol in which the hydrogen at position 4 is substituted by a 2-aminoethyl group.
|
|
PC(24:0/20:1(11Z))
|
|
|
TG(14:0/18:0/22:1(13Z))
|
|
|
3a,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid
|
|
|
Dihydrobiopterin
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
N5-Formyl-THF
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(24:0/22:0/20:1(11Z))
|
|
|
Cotinine glucuronide
|
|
|
Pyrazinamide
|
|
|
TG(22:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/20:1(11Z))
|
|
|
PE(P-18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:0/20:3(8Z,11Z,14Z))
|
|
|
PE(24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/15:0/14:1(9Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/24:1(15Z))
|
|
|
TG(20:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
Octadecanol
|
|
|
TG(22:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Benzoyl glucuronide (Benzoic acid)
|
|
|
TG(20:1(11Z)/22:1(13Z)/20:3n6)
|
|
|
TG(14:1(9Z)/14:1(9Z)/16:1(9Z))
|
|
|
TG(24:0/22:0/18:2(9Z,12Z))
|
|
|
TG(20:0/16:0/16:1(9Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
PI(16:1(9Z)/18:1(11Z))
|
|
|
DG(15:0/0:0/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/22:1(13Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(24:0/16:0/20:3n6)
|
|
|
Amoxapine
|
A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.
|
|
PE(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/16:0/0:0)
|
|
|
DG(15:0/0:0/22:0)
|
|
|
Vapreotide
|
|
|
PE(18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Eprosartan
|
|
|
TG(20:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Practolol
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/16:1(9Z)/20:3n6)
|
|
|
DG(14:1(9Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/20:2n6/22:2(13Z,16Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(18:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
1-Pyrroline-4-hydroxy-2-carboxylate
|
|
|
PE(20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Dyphylline
|
An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.
|
|
TG(16:0/24:1(15Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/18:1(9Z))
|
|
|
Rabeprazole
|
A sulfoxide that has formula C18H21N3O3S.
|
|
TG(14:0/16:1(9Z)/18:1(11Z))
|
|
|
Ethosuximide
|
A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Alosetron
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/24:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
MG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0/0:0)
|
|
|
TG(16:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/15:0/o-18:0)
|
|
|
TG(16:0/20:2n6/14:1(9Z))
|
|
|
Androstenedione
|
|
|
Valproic acid
|
A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:2n6/20:1(11Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
PE(20:2(11Z,14Z)/P-18:1(9Z))
|
|
|
TG(20:1(11Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP(18:2(9Z,12Z)/18:0)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Captopril
|
A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.
|
|
TG(20:2n6/24:1(15Z)/20:2n6)
|
|
|
TG(20:0/22:0/14:1(9Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
Hydroxyzine
|
A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.
|
|
TG(22:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:3n6/18:2(9Z,12Z))
|
|
|
Ganglioside GT1c (d18:1/18:1(9Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Mycophenolic acid O-acyl-glucuronide
|
A carboxylic ester resulting from the formal condensation of the carboxylic acid group of mycophenolic acid with the anomeric hydroxy group of beta-D-glucuronic acid.
|
|
TG(14:1(9Z)/14:1(9Z)/18:1(11Z))
|
|
|
DG(20:0/0:0/22:4n6)
|
|
|
DG(16:1(9Z)/24:1(15Z)/0:0)
|
|
|
TG(24:0/16:1(9Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(16:0/0:0/20:2n6)
|
|
|
TG(18:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(14:0/18:3(6Z,9Z,12Z))
|
|
|
DG(24:0/24:0/0:0)
|
|
|
TG(14:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(14:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:1(9Z)/14:1(9Z))
|
|
|
Bepotastine
|
|
|
L-2-Hydroxyglutaric acid
|
|
|
PE(16:0/20:2(11Z,14Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/24:0/0:0)
|
|
|
TG(24:1(15Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Biperiden
|
|
|
TG(15:0/18:1(9Z)/14:1(9Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z))
|
|
|
Ganglioside GD1a (d18:0/18:0)
|
|
|
TG(15:0/22:1(13Z)/20:2n6)
|
|
|
TG(22:0/20:1(11Z)/16:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Hydroxycelecoxib
|
|
|
PE(16:0/P-16:0)
|
|
|
Ganglioside GT3 (d18:0/20:0)
|
|
|
Cyclizine
|
|
|
TG(15:0/16:0/16:1(9Z))
|
|
|
PG(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(20:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
Difucosyllactohexaose
|
|
|
TG(20:0/20:0/18:1(9Z))
|
|
|
D-Mannose 1-phosphate
|
A mannose phosphate that is D-mannose carrying a phosphate group at position 1.
|
|
TG(24:1(15Z)/16:0/24:1(15Z))
|
|
|
TG(18:0/16:1(9Z)/18:1(9Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/15:0)
|
|
|
(Z)-But-1-ene-1,2,4-tricarboxylate
|
|
|
DG(18:1n7/0:0/24:1n9)
|
|
|
TG(14:1(9Z)/24:1(15Z)/16:1(9Z))
|
|
|
Pralidoxime
|
A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2.
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/o-18:0)
|
|
|
Temazepam
|
|
|
TG(22:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
D-2-Hydroxyglutaric acid
|
|
|
TG(18:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:2(11Z,14Z)/18:2(9Z,12Z))
|
|
|
LPA(18:0/0:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:0/P-18:1(11Z))
|
|
|
TG(24:0/15:0/20:3n6)
|
|
|
TG(20:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
Cob(II)alamin
|
A cobalamin in which the central cobalt atom has an oxidation state of +2.
|
|
TG(18:0/20:0/16:1(9Z))
|
|
|
TG(16:1(9Z)/14:0/22:2(13Z,16Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Trihexosylceramide (d18:1/24:1(15Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(20:0/18:0/24:0)
|
|
|
TG(16:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(14:0/15:0/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(24:0/15:0/24:0)
|
|
|
TG(15:0/20:0/24:1(15Z))
|
|
|
Ganglioside GD3 (d18:0/26:0)
|
|
|
PC(P-16:0/22:1(13Z))
|
|
|
TG(20:0/22:1(13Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
PG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
5-Fluorouridine
|
An organofluorine compound that is uridine bearing a fluoro substituent at position 5 on the uracil ring.
|
|
TG(16:1(9Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:2n6/0:0/20:4n3)
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Avenasterol
|
|
|
Ercalcitriol
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
Quinone
|
Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).
|
|
TG(15:0/14:0/16:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
5-Methyltetrahydrofolic acid
|
A tetrahydrofolic acid that has formula C20H25N7O6.
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(15:0/0:0/18:3n6)
|
|
|
Stearidonic acid
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/16:0)
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(18:1(9Z)/20:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
PE(22:0/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(15:0/20:0/20:1(11Z))
|
|
|
Ganglioside GD2 (d18:1/23:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:1(11Z)/o-18:0)
|
|
|
Ganglioside GD1b (d18:0/26:1(17Z))
|
|
|
TG(20:3n6/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
Ganglioside GT1b (d18:1/26:1(17Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(16:0/20:2n6/22:2(13Z,16Z))
|
|
|
4-Nitrophenyl phosphate
|
An aryl phosphate resulting from the mono-esterification of phosphoric acid with 4-nitrophenol.
|
|
TG(22:2(13Z,16Z)/16:0/22:2(13Z,16Z))
|
|
|
PE(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
cis-4-Carboxymethylenebut-2-en-4-olide
|
A 4-carboxymethylenebut-2-en-4-olide that has formula C6H4O4.
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Elatoside I
|
|
|
D-Ribose 5-phosphate
|
A ribose monophosphate that is D-ribose substituted at position 5 by a phosphate group. It is an intermediate in the pentose phosphate pathway.
|
|
TG(20:0/18:1(11Z)/24:1(15Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
PC(20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(24:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
Dronabinol
|
|
|
Quetiapine
|
A dibenzothiazepine that has formula C21H25N3O2S.
|
|
TG(14:1(9Z)/o-18:0/22:1(13Z))
|
|
|
Formamidopyrimidine nucleoside triphosphate
|
A pyrimidine ribonucleoside 5'-triphosphate that has formula C10H18N5O15P3.
|
|
TG(20:0/18:0/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(o-16:1(9Z)/14:1(9Z))
|
|
|
MG(0:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/24:1(15Z))
|
|
|
TG(14:0/20:2n6/24:1(15Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
(S)-3-Hydroxybutyric acid
|
The S-enantiomer of 3-hydroxybutyric acid; a normal human metabolite, that has been found elevated in geriatric patients remitting from depression.
|
|
PIP(20:2(11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/14:0/20:3n6)
|
|
|
N-Acetylgalactosamine
|
|
|
Argatroban
|
An alpha-N-substituted L-arginine that has formula C23H36N6O5S.
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
DG(24:0/18:0/0:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/o-18:0)
|
|
|
Crotonoyl-CoA
|
The (E)-isomer of but-2-enoyl-CoA.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:0/22:1(13Z)/16:0)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/14:0/0:0)
|
|
|
TG(20:1(11Z)/18:0/22:2(13Z,16Z))
|
|
|
PIP2(16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/14:0/14:1(9Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/0:0)
|
|
|
Mianserin
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
DG(18:4n3/0:0/18:4n3)
|
|
|
TG(14:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Edrophonium
|
|
|
PE(20:2(11Z,14Z)/14:1(9Z))
|
|
|
TG(22:0/16:1(9Z)/16:1(9Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(22:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(14:0/22:1(13Z)/14:0)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/24:0)
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/24:0/0:0)
|
|
|
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1b (d18:1/18:0)
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
7,8-Dihydropteroic acid
|
A pteroic acid derivative arising from formal hydrogenation of the 7,8-double bond of pteroic acid.
|
|
Dopamine glucuronide
|
|
|
Diethylpropion
|
An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.
|
|
PC(P-18:1(11Z)/16:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/15:0/o-18:0)
|
|
|
Vidarabine
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
Ethanolamine
|
|
|
TG(18:0/16:1(9Z)/o-18:0)
|
|
|
TG(20:1(11Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
(S)-4-Hydroxymandelonitrile
|
A 4-hydroxymandelonitrile that has (S)-configuration.
|
|
Poly-N-acetyllactosamine
|
An aminoglycan composed of a backbone of N-acetyllactosamine repeating units that are joined to each other via beta-(1->3)-linkages.
|
|
3-Methoxytyramine
|
A methoxybenzene that has formula C9H13NO2.
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
Pravastatin
|
A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Prednisone
|
A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
|
|
PIP(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Buspirone
|
An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the nitrogen atom.
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(9Z)/22:1(13Z))
|
|
|
TG(20:2n6/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(20:0/18:0/24:1(15Z))
|
|
|
(S)-3-Hydroxytetradecanoyl-CoA
|
A (S)-3-hydroxyacyl-CoA that has formula C35H62N7O18P3S.
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
DG(18:2(9Z,12Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(18:0/20:3n6/o-18:0)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Angiotensin III
|
|
|
TG(22:1(13Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:2(9Z,12Z)/P-18:0)
|
|
|
TG(24:1(15Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:2n6/0:0/22:5n6)
|
|
|
TG(20:0/24:0/24:0)
|
|
|
TG(24:0/24:0/18:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(14:1(9Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
DG(14:1(9Z)/24:1(15Z)/0:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/16:1(9Z)/20:0)
|
|
|
TG(14:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
3-O-Sulfogalactosylceramide (d18:1/18:1(9Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:1(9Z))
|
|
|
DG(14:0/0:0/24:1n9)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:1(9Z)/14:1(9Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/o-18:0)
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(18:1(9Z)/0:0/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/15:0/o-18:0)
|
|
|
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol
|
A pyridine that has formula C10H15N3O2.
|
|
15(S)-HETE
|
An optically active form of 15-HETE having 15(S)-configuration..
|
|
TG(14:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(24:0/0:0/22:5n3)
|
|
|
DG(18:0/16:0/0:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/14:0)
|
|
|
PE(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(14:0/o-18:0/18:1(9Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
LysoPC(20:3(8Z,11Z,14Z))
|
|
|
PE(18:0/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
B-Sulfinyl pyruvate
|
|
|
TG(14:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
TG(22:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
5'-Deoxy-5-fluorocytidine
|
A N-glycosyl compound that has formula C9H12FN3O4.
|
|
TG(16:0/18:0/16:1(9Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(14:0/20:2n6/22:1(13Z))
|
|
|
DG(24:1(15Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:0/0:0/22:0)
|
|
|
PIP(18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/14:0)
|
|
|
TG(20:1(11Z)/20:2n6/20:2n6)
|
|
|
Ganglioside GM1 (d18:0/24:1(15Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1b (d18:1/18:1(11Z))
|
|
|
Ganglioside GT3 (d18:0/18:1(9Z))
|
|
|
L-Arabinose
|
The L-enantiomer of arabinose.
|
|
Venlafaxine
|
A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.
|
|
TG(24:0/18:1(9Z)/24:0)
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
Palmitoyl glucuronide
|
|
|
TG(16:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:0)
|
|
|
TG(16:1(9Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/P-18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Lipoyl-GMP
|
|
|
TG(16:0/15:0/18:1(9Z))
|
|
|
LysoPE(0:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Amantadine
|
A member of the class of adamantanes that is used as an antiviral and antiparkinson drug.
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
PIP(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/16:1(9Z)/16:1(9Z))
|
|
|
TG(16:1(9Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
4,5-Dihydroorotic acid
|
|
|
Fentanyl
|
The carboxamide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(16:1n7/0:0/18:3n6)
|
|
|
LysoPE(0:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
PI(22:3(10Z,13Z,16Z)/16:0)
|
|
|
PC(18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/20:3n6)
|
|
|
TG(15:0/16:1(9Z)/18:2(9Z,12Z))
|
|
|
PC(14:1(9Z)/P-18:1(11Z))
|
|
|
Dicloxacillin
|
A penicillin that has formula C19H17Cl2N3O5S.
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(16:1(9Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
PE(22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:0/18:1(9Z))
|
|
|
PE(24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/16:0/22:1(13Z))
|
|
|
DG(18:1(9Z)/20:0/0:0)
|
|
|
Sunitinib
|
A pyrrole that has formula C22H27FN4O2.
|
|
TG(14:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
Galantamine
|
|
|
TG(20:1(11Z)/20:3n6/20:3n6)
|
|
|
TG(16:0/15:0/22:1(13Z))
|
|
|
TG(24:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:1(13Z)/24:1(15Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(15:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Canavaninosuccinate
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
N-Acetylarylamine
|
An acetamide where at at least one of the amide hydrogens is substituted by an aryl group.
|
|
Salicylic acid
|
A monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves.
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Saprisartan
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/20:0/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:0/20:1(11Z))
|
|
|
TG(15:0/22:0/24:0)
|
|
|
Cefradine
|
|
|
PS(18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/24:1(15Z))
|
|
|
DG(18:4n3/0:0/22:6n3)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Prednisolone
|
A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPC(20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:3n6/22:1(13Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:0/0:0/22:1n9)
|
|
|
TG(14:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/22:1(13Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/14:0)
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/15:0/18:1(9Z))
|
|
|
Tazarotene
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(18:0/20:0/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:0/14:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/20:2n6/20:0)
|
|
|
LysoPE(0:0/20:2(11Z,14Z))
|
|
|
Aminoacetone
|
A propanone consisting of acetone having an amino group at the 1-position.
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
DG(24:0/15:0/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:2n6/22:0)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
DG(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(o-18:1(9Z)/20:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
DG(14:0/22:2(13Z,16Z)/0:0)
|
|
|
TG(16:1(9Z)/20:0/16:1(9Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
1,2,3-Propanetricarboxylic acid
|
|
|
DG(18:1n9/0:0/18:3n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:1(11Z)/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3a,6a,7b-Trihydroxy-5b-cholanoic acid
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Pterin
|
|
|
TG(18:2(9Z,12Z)/24:0/o-18:0)
|
|
|
PE(22:1(13Z)/15:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/24:0/22:2(13Z,16Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:0/18:1(9Z))
|
|
|
PE(16:0/14:0)
|
|
|
DG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/22:0/o-18:0)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
SM(d18:1/12:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
DG(14:0/22:1(13Z)/0:0)
|
|
|
TG(24:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Aniline
|
A primary arylamine in which an amino functional group is substituted for one of the benzene hydrogens.
|
|
TG(20:3n6/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
2,3-Diphosphoglyceric acid
|
|
|
Thiamine
|
|
|
Ganglioside GT3 (d18:1/23:0)
|
|
|
PG(16:1(9Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/15:0/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:0/P-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
PC(o-16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(22:1(13Z)/24:0/20:3n6)
|
|
|
PC(18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
MG(14:1(9Z)/0:0/0:0)
|
|
|
DG(22:1n9/0:0/24:1n9)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/P-16:0)
|
|
|
PC(dm18:1(9Z)/dm18:1(9Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Octane
|
A straight chain alkane composed of 8 carbon atoms.
|
|
TG(16:1(9Z)/18:0/20:0)[iso6]
|
|
|
TG(18:1(11Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
20-Hydroxyeicosatetraenoic acid
|
|
|
DG(18:1n9/0:0/20:5n3)
|
|
|
PE(16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/o-18:0/14:1(9Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
SM(d18:1/14:0)
|
|
|
L-Cysteine
|
An optically active form of cysteine having L-configuration.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/o-18:0)
|
|
|
PE(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Molybdate
|
A divalent inorganic anion obtained by removal of both protons from molybdic acid
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:0/24:1(15Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/22:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
Trihexosylceramide (d18:1/22:0)
|
|
|
DG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
Hydroxykynurenine
|
|
|
Ganglioside GT1c (d18:0/26:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
Chenodeoxycholic acid glycine conjugate
|
|
|
PC(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
Galabiosylceramide (d18:1/16:0)
|
|
|
TG(22:0/22:0/22:2(13Z,16Z))
|
|
|
DG(14:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
DG(20:0/18:1(9Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Phytosphingosine
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(22:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
Doxorubicin
|
An anthracycline antibiotic that has formula C27H29NO11.
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/24:0/24:0)
|
|
|
PC(20:3(8Z,11Z,14Z)/P-16:0)
|
|
|
DG(16:1(9Z)/22:0/0:0)
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:0/16:0/18:3(9Z,12Z,15Z))
|
|
|
Uridine
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
Penicillamine
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(16:1(9Z)/16:0/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
PE(20:1(11Z)/16:1(9Z))
|
|
|
PIP2(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PI(20:0/18:2(9Z,12Z))
|
|
|
2-Hexaprenyl-6-methoxy-1,4-benzoquinone
|
A polyprenylbenzoquinone that has formula C37H54O3.
|
|
Methylcobalamin
|
A cobalamin that has formula C63H91CoN13O14P.
|
|
TG(20:3(5Z,8Z,11Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Tartronate semialdehyde
|
|
|
Clomifene
|
|
|
CDP-DG(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/18:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(22:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
L-Carnitine
|
|
|
PI(20:2(11Z,14Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GD3 (d18:1/9Z-18:1)
|
|
|
Ganglioside GD1a (d18:0/18:1(9Z))
|
|
|
MG(0:0/18:0/0:0)
|
|
|
TG(14:1(9Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
Cer(d18:1/23:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Orotic acid
|
|
|
Deoxyuridine
|
|
|
TG(14:1(9Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))
|
|
|
Ganglioside GD1a (d18:0/24:0)
|
|
|
PE(16:0/18:1(9Z))
|
|
|
TG(20:1(11Z)/22:0/20:1(11Z))
|
|
|
TG(24:1(15Z)/22:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
Ribavirin
|
A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. An inhibitor of HCV polymerase.
|
|
TG(20:2n6/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:2(9Z,12Z)/18:1(9Z)/0:0)
|
|
|
3-O-Sulfogalactosylceramide (d18:1/24:0)
|
|
|
TG(15:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(16:0/20:3(8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
DL-Glutamate
|
|
|
PE(22:2(13Z,16Z)/22:0)
|
|
|
Mexiletine
|
An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
|
|
TG(24:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
Aluminum
|
|
|
PC(16:1(9Z)/18:0)
|
|
|
Quercetin 3-O-glucuronide
|
|
|
PE(22:2(13Z,16Z)/24:0)
|
|
|
Ganglioside GD1a (d18:0/26:0)
|
|
|
PC(16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(14:1(9Z)/20:2(11Z,14Z))
|
|
|
PC(20:2(11Z,14Z)/18:0)
|
|
|
DG(14:0/22:0/0:0)
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(14:0/24:1(15Z)/16:0)
|
|
|
TG(22:2(13Z,16Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/24:1(15Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Methoxyflurane
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:3n6)
|
|
|
TG(18:0/14:1(9Z)/o-18:0)
|
|
|
TG(16:0/18:1(11Z)/16:0)
|
|
|
Bromide
|
A monoatomic bromine that has formula Br.
|
|
TG(20:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Procaterol
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/22:1(13Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(14:1(9Z)/20:0/20:3n6)
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:0/20:3n6)
|
|
|
Ropivacaine
|
The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.
|
|
TG(15:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/24:1(15Z)/14:0)
|
|
|
DG(18:1(9Z)/24:1(15Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:3n6)
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Cyclandelate
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/18:1(9Z)/o-18:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/16:0/16:1(9Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(22:0/20:3n6/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/14:0/24:0)
|
|
|
PE(22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Lathosterol
|
|
|
TG(18:2(9Z,12Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:1(11Z))
|
|
|
TG(24:0/18:1(9Z)/20:1(11Z))
|
|
|
Trehalose
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
2-Phenylacetamide
|
A monocarboxylic acid amide that is acetamide substituted by a phenyl group at position 2.
|
|
PE(18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
CDP-DG(18:1(11Z)/18:0)
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
2-Hydroxyphytanoyl-CoA
|
A multi-methyl-branched fatty acyl-CoA having 2-hydroxyphytanoyl as the S-acyl group.
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/14:0/24:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:2(9Z,12Z)/20:1(11Z)/0:0)
|
|
|
TG(14:0/18:1(9Z)/18:1(9Z))
|
|
|
DG(18:0/15:0/0:0)
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
S-Methylmalonyl-CoA
|
The (S)-enantiomer of methylmalonyl-CoA.
|
|
TG(16:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:0/o-18:0)
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Acetylcholine
|
|
|
TG(20:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PIP2(20:2(11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(24:0/18:3(9Z,12Z,15Z))
|
|
|
Sparfloxacin
|
|
|
TG(22:0/18:0/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:2(11Z,14Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
PI(20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(20:2n6/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/o-18:0)
|
|
|
Lipoamide
|
A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of lipoic acid with ammonia.
|
|
TG(14:1(9Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(15:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/24:1(15Z))
|
|
|
PIP2(16:0/22:4(10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:1(11Z)/22:1(13Z))
|
|
|
3a,4b,7a-Trihydroxy-5b-cholanoic acid
|
|
|
1b-Hydroxycholic acid
|
|
|
Lisinopril
|
A dipeptide that has formula C21H31N3O5.
|
|
TG(14:0/18:1(9Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(16:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
DG(22:1(13Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(24:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/20:3n6/16:1(9Z))
|
|
|
PC(P-16:0/18:1(11Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/22:2(13Z,16Z))
|
|
|
Methylmalonyl-CoA
|
A member of the class of malonyl-CoAs that is malonyl-CoA carrying a methyl group on the malony side chain.
|
|
TG(24:1(15Z)/22:0/20:2n6)
|
|
|
PIP(16:2(9Z,12Z)/16:0)
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Lactosylceramide (d18:1/18:0)
|
|
|
TG(16:0/18:2(9Z,12Z)/20:1(11Z))[iso6]
|
|
|
Acetyldigitoxin
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:2n6/14:1(9Z))
|
|
|
PC(15:0/24:1(15Z))
|
|
|
TG(14:0/15:0/18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Cyclothiazide
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Potassium
|
An alkali metal atom that has formula K.
|
|
TG(18:1(11Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
CL(20:2(11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Phenelzine
|
|
|
Betavulgaroside I
|
|
|
TG(16:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
4-Hydroxyproline
|
A hydroxyproline where the hydroxy group is located at the 4-position. It is found in fibrillar collagen.
|
|
TG(24:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
7-a,27-Dihydroxycholesterol
|
|
|
Pyrroline hydroxycarboxylic acid
|
|
|
TG(24:1(15Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Acetyl-N-formyl-5-methoxykynurenamine
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:2n6/22:0)
|
|
|
TG(20:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:1(11Z)/20:0)
|
|
|
DG(20:0/0:0/22:5n6)
|
|
|
PS(18:1(9Z)/14:1(9Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/15:0)
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(20:2(11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(16:1(9Z)/16:0/24:1(15Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:1(9Z)/22:1(13Z)/0:0)
|
|
|
TG(18:1(11Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
12(S)-HPETE
|
The (S)-enantiomer of 12-HPETE.
|
|
TG(14:1(9Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/20:2n6/20:3n6)
|
|
|
N1-Methyl-4-pyridone-3-carboxamide
|
|
|
Zolmitriptan
|
|
|
TG(20:2n6/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(15:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/15:0/22:0)
|
|
|
DG(15:0/0:0/22:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:0/24:1(15Z))
|
|
|
TG(15:0/15:0/20:0)
|
|
|
(2E,6Z,9Z,12Z,15Z,18Z)-Tetracosahexa-2,6,9,12,15,18-enoyl-CoA
|
An organic molecule that has formula C45H70N7O17P3S.
|
|
TG(20:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:0/0:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(P-18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
5-Amino-2-oxopentanoic acid
|
The 2-oxo-5-amino derivative of valeric acid.
|
|
TG(15:0/o-18:0/20:2n6)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(24:1(15Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(18:1(9Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3n9/0:0/18:3n3)
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
Tetrahexosylceramide (d18:1/26:1(17Z))
|
|
|
Decamethonium
|
A quaternary ammonium ion that is a depolarising muscle relaxant whose structure comprises a decane-1,10-diamine core in which each amino group carries three methyl substituents.
|
|
3a,12b-Dihydroxy-5b-cholanoic acid
|
|
|
TG(14:0/20:2n6/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/0:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/24:1(15Z)/18:1(11Z))
|
|
|
TG(15:0/18:1(9Z)/20:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/o-18:0)
|
|
|
TG(16:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:1(9Z)/22:0)
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(24:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GD1a (d18:1/16:0)
|
|
|
PC(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/20:2n6)
|
|
|
DG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
Oxoglutaric acid
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:1n9/0:0/20:4n6)
|
|
|
TG(22:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
4-OH-Retinal
|
|
|
2-Ketobutyric acid
|
|
|
TG(18:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PI(20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(20:0/20:2n6/20:2n6)
|
|
|
DG(16:0/18:0/0:0)
|
|
|
TG(18:1(9Z)/20:3n6/18:1(9Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
N-Arachidonoyl glycine
|
Biologically active derivative of anandamide
|
|
TG(16:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1a (d18:1/14:0)
|
|
|
TG(15:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
Rizatriptan
|
A tryptamine that has formula C15H19N5.
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/20:2n6/o-18:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/0:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(24:0/20:2n6/24:1(15Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:1(13Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Thyroxine glucuronide
|
|
|
Ganglioside GM3 (d18:0/25:0)
|
|
|
TG(22:0/14:1(9Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
LPA(P-16:0e/0:0)
|
|
|
TG(14:1(9Z)/18:1(11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/14:0/20:1(11Z))
|
|
|
Ganglioside GT2 (d18:1/23:0)
|
|
|
TG(20:0/16:0/20:1(11Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
4,8-Dimethylnonanoyl-CoA
|
A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 4,8-dimethylnonanoic acid.
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/16:0/20:1(11Z))
|
|
|
Benzo[a]pyrene-7,8-diol
|
A pyrene that has formula C20H14O2.
|
|
PC(15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Galabiosylceramide (d18:1/25:0)
|
|
|
Ganglioside GD1a (d18:1/24:1(15Z))
|
|
|
Salicyluric acid
|
An N-acylglycine in which the acyl group is specified as 2-hydroxybenzoyl.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:1(9Z)/18:1(11Z))
|
|
|
TG(18:0/22:0/16:1(9Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
Heptabarbital
|
A barbiturate that has formula C13H18N2O3.
|
|
PE(P-18:1(11Z)/22:1(13Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(24:0/22:1(13Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/14:0/20:3n6)
|
|
|
TG(16:0/24:0/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3n6/18:1(9Z))
|
|
|
PC(24:1(15Z)/16:0)
|
|
|
PE(18:1(11Z)/24:0)
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
dCMP
|
A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having cytosine as the nucleobase.
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/20:2n6)
|
|
|
5,10-Methylene-THF
|
|
|
TG(14:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
SM(d19:1/24:1(15Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
7a,12b-dihydroxy-5b-Cholan-24-oic acid
|
|
|
TG(24:0/16:0/14:1(9Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(18:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/14:0/22:0)
|
|
|
DG(24:0/0:0/18:1n7)
|
|
|
TG(24:0/18:0/20:3n6)
|
|
|
TG(24:0/18:0/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:1(9Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:1(11Z)/22:1(13Z))
|
|
|
TG(14:0/14:1(9Z)/20:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
Prostaglandin G2
|
A prostaglandins G that has formula C20H32O6.
|
|
1D-Myo-inositol 3,4-bisphosphate
|
A myo-inositol bisphosphate that has formula C6H14O12P2.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
2-Hydroxyestradiol-3-methyl ether
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(22:3(10Z,13Z,16Z)/16:2(9Z,12Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cholic acid glucuronide
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
3a,7a,12a-Trihydroxy-5b-cholestan-26-al
|
|
|
TG(20:2n6/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:1(11Z)/15:0/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
DG(18:2n6/0:0/22:2n6)
|
|
|
TG(20:3n6/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z)/o-18:0)
|
|
|
TG(18:0/18:1(9Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GM1 (d18:0/24:0)
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
Glycoursodeoxycholic acid
|
|
|
PIP(20:3(8Z,11Z,14Z)/18:0)
|
|
|
PIP2(16:0/20:3(8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/24:0/16:1(9Z))
|
|
|
3-Mercaptopyruvic acid
|
A 2-oxo monocarboxylic acid that is pyruvic acid substituted by a sulfanyl group at position 3.
|
|
DG(18:2n6/0:0/22:5n3)
|
|
|
TG(16:0/18:1(11Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Fumaric acid
|
A butenedioic acid in which the C=C double bond has E geometry. It is an intermediate metabolite in the citric acid cycle.
|
|
2-Arachidonylglycerol
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(18:0/22:1(13Z)/20:1(11Z))
|
|
|
Zuclopenthixol
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
DG(20:2n6/0:0/18:3n3)
|
|
|
TG(16:0/20:2n6/18:1(9Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/20:2(11Z,14Z)/0:0)
|
|
|
Palmitaldehyde
|
|
|
TG(18:1(9Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/o-18:0)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
DG(14:0/0:0/22:5n3)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-16:0/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:3n6/18:1(9Z))
|
|
|
PC(15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/14:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/18:1(9Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2(9Z,12Z)/18:1(11Z)/0:0)
|
|
|
Cer(d18:1/18:1(11Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/20:2n6)
|
|
|
TG(14:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:1n9/0:0/22:5n3)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
PG(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/15:0/22:1(13Z))
|
|
|
TG(18:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
3-Oxotetradecanoic acid
|
A C14, long-chain fatty acid carrying an oxo- group at position 3.
|
|
5'-Hydroxylornoxicam
|
|
|
Losartan N2-glucuronide
|
|
|
MG(0:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/20:2n6)
|
|
|
TG(22:1(13Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(22:4n6/0:0/22:6n3)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/16:0/18:2(9Z,12Z))[iso3]
|
|
|
DG(24:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(14:0/24:0/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(20:3n6/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(15:0/14:0)
|
|
|
PS(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/24:0/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
Cloxacillin
|
A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.
|
|
TG(24:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:0/18:1(11Z))
|
|
|
DG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(18:1(11Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:1(13Z)/16:0/0:0)
|
|
|
Metixene
|
A thioxanthene that has formula C20H23NS.
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(16:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/15:0)
|
|
|
DG(14:1(9Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(14:0/18:0/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
DG(18:1(9Z)/22:0/0:0)
|
|
|
TG(18:0/18:0/22:0)
|
|
|
TG(20:0/16:1(9Z)/18:1(9Z))
|
|
|
PG(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Cyclic pyranopterin monophosphate
|
|
|
PC(15:0/16:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/15:0/22:2(13Z,16Z))
|
|
|
5-Fluorodeoxyuridine monophosphate
|
A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate that has formula C9H12FN2O8P.
|
|
TG(18:1(11Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Norspermidine
|
|
|
PI(20:1(11Z)/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:2n6)
|
|
|
TG(18:0/20:0/20:3n6)
|
|
|
PE(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
3Z-dodecenoyl-CoA
|
|
|
3 alpha,7 alpha,24-Trihydroxy-5beta-cholestanoyl-CoA
|
|
|
Ganglioside GM2 (d18:0/16:0)
|
|
|
TG(20:1(11Z)/14:0/22:1(13Z))
|
|
|
PIP2(18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GM2 (d18:1/26:1(17Z))
|
|
|
PC(o-22:3(10Z,13Z,16Z)/22:3(10Z,13Z,16Z))
|
|
|
Verapamil
|
A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
Tungsten
|
A chromium group element atom that has formula W.
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/22:2(13Z,16Z))
|
|
|
CE(24:0)
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:3(5Z,8Z,11Z))[iso3]
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Cer(d18:1/14:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/P-18:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Nilutamide
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/16:0/o-18:0)
|
|
|
(S)-Hydroxyoctanoyl-CoA
|
|
|
TG(22:1(13Z)/20:2n6/20:3n6)
|
|
|
TG(20:0/20:1(11Z)/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3n6/0:0/18:3n3)
|
|
|
Chloroacetic acid
|
A chlorocarboxylic acid that is acetic acid carrying a 2-chloro substituent.
|
|
TG(15:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
FADH
|
A flavin adenine dinucleotide that has formula C27H34N9O15P2.
|
|
TG(18:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
PS(18:1(9Z)/18:0)
|
|
|
DG(18:1(9Z)/18:2(9Z,12Z)/0:0)
|
|
|
DG(18:2n6/0:0/20:4n3)
|
|
|
Trihexosylceramide (d18:1/12:0)
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
PE(18:1(9Z)/P-18:1(11Z))
|
|
|
PC(20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
(25R)-3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-26-oyl-CoA
|
A 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-CoA in which the carbon at position 25 of the steroidal side chain has R configuration.
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/15:0)
|
|
|
TG(18:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:1(11Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PE(16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/20:2n6)
|
|
|
DG(20:1n9/0:0/22:1n9)
|
|
|
TG(16:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(P-18:1(9Z)/18:0)
|
|
|
TG(20:1(11Z)/20:3n6/20:2n6)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
Cortisone
|
A C21-steroid that is pregn-4-ene substituted by hydroxy groups at positions 17 and 21 and oxo group at positions 3, 11 and 20.
|
|
CE(22:0)
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Palmitic acid
|
A straight-chain, sixteen-carbon, saturated long-chain fatty acid.
|
|
TG(20:3n6/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(16:0/0:0/20:1n9)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:0/20:3n6/20:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:2n6)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(9Z)/20:3n6)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:0/0:0)
|
|
|
TG(16:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
PE(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
PC(16:1(9Z)/14:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:1(11Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/22:2(13Z,16Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(16:1(9Z)/24:0)
|
|
|
L-Threonine
|
An optically active form of threonine having L-configuration.
|
|
Oseltamivir
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1b (d18:0/18:1(11Z))
|
|
|
5,10-Methylenetetrahydromethanopterin
|
A tetrahydromethanopterin that has formula C31H45N6O16P.
|
|
TG(20:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
UDP-L-rhamnose
|
A UDP-rhamnose in which the rhamnose component has L-configuration.
|
|
TG(15:0/18:1(9Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GD2 (d18:1/9Z-18:1)
|
|
|
TG(18:0/22:1(13Z)/18:0)
|
|
|
Farnesyl pyrophosphate
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:1(13Z)/20:1(11Z))
|
|
|
Aprindine
|
|
|
TG(18:1(11Z)/24:1(15Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(16:1(9Z)/22:0)
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/14:0/22:1(13Z))
|
|
|
TG(16:0/14:0/18:0)[iso6]
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:2(9Z,12Z)/18:0)
|
|
|
7-Methylguanine
|
A methylguanine that is guanine substituted by a methyl group at position 7. It is a metabolite obtained during the methylation of DNA.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/o-18:0)
|
|
|
Selegiline
|
|
|
TG(20:0/20:3n6/24:1(15Z))
|
|
|
TG(20:2n6/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/15:0)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(22:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/18:1(9Z))[iso3]
|
|
|
Fenofibrate
|
A chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring.
|
|
Ganglioside GT1b (d18:0/18:0)
|
|
|
TG(14:1(9Z)/16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
cis,cis-3,6-Dodecadienoyl-CoA
|
|
|
TG(22:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/P-16:0)
|
|
|
PS(14:1(9Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/16:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Dimethyl sulfoxide
|
A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.
|
|
DG(14:0/0:0/18:3n3)
|
|
|
TG(24:1(15Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
CDP-DG(16:0/22:3(10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(14:1(9Z)/14:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:1(11Z)/16:1(9Z)/0:0)
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:0)
|
|
|
DG(24:1(15Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
DG(14:1(9Z)/24:0/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PC(20:2(11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/16:1(9Z)/24:0)
|
|
|
Ganglioside GM3 (d18:1/24:1(15Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(14:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(22:0/16:0/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/14:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(16:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(22:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Tamoxifen N-oxide
|
An N-oxide derived from tamoxifen.
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
PE(18:0/P-18:1(9Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(14:0/14:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
5-Hydroxy-N-formylkynurenine
|
An alpha-amino acid that is 5-hydroxykynurenine bearing an N-formyl substituent.
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(20:1(11Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(18:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
DG(24:0/24:1(15Z)/0:0)
|
|
|
PS(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(P-18:0/24:1(15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GT3 (d18:1/22:1(13Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/18:0)
|
|
|
DG(18:2(9Z,12Z)/15:0/0:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Bendroflumethiazide
|
A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.
|
|
PS(14:0/18:1(9Z))
|
|
|
TG(24:0/18:1(11Z)/20:2n6)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
Quinacrine
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
Ammonia
|
|
|
Bevantolol
|
A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(18:0/18:1(9Z)/24:1(15Z))
|
|
|
PE(20:1(11Z)/20:2(11Z,14Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(18:1(9Z)/22:2(13Z,16Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/24:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:0)
|
|
|
Estriol
|
|
|
Pancuronium
|
A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.
|
|
TG(18:1(11Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:2(9Z,12Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/16:0)
|
|
|
DG(22:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
DG(18:2n6/0:0/18:3n3)
|
|
|
(1R)-Glutathionyl-(2R)-hydroxy-1,2-dihydronaphthalene
|
A peptide that has formula C20H25N3O7S.
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(14:0/0:0/15:0)
|
|
|
Fexofenadine
|
A piperidine-based anti-histamine compound.
|
|
TG(24:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/o-18:0/22:1(13Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:0/0:0/24:1n9)
|
|
|
trans-3-Chloroacrylic acid
|
|
|
PI(16:0/22:4(10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/16:1(9Z)/14:1(9Z))
|
|
|
Galabiosylceramide (d18:1/26:0)
|
|
|
Menaquinol
|
Any polyprenylhydroquinone having a polyprenyl moiety at position 2 and a methyl group at position 3..
|
|
TG(15:0/16:1(9Z)/16:0)
|
|
|
Oxandrolone
|
An oxa-steroid that has formula C19H30O3.
|
|
TG(14:1(9Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
Topaquinone
|
An alpha-amino acid that is alanine substituted at position 3 by a 4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl group.
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/20:3n6/o-18:0)
|
|
|
DG(18:1(9Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
DG(14:1n5/0:0/20:3n6)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(16:1n7/0:0/20:4n6)
|
|
|
TG(14:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Dyspropterin
|
A tetrahydropterin that is 2-amino-5,6,7,8-tetrahydropteridin-4(3H)-one substituted by a 2-oxopropanoyl group at position 6.
|
|
TG(18:1(9Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
beta-Alanyl-L-lysine
|
A dipeptide consisting of beta-alanine and L-lysine units joined by a peptide linkage.
|
|
TG(18:0/18:2(9Z,12Z)/22:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GD2 (d18:0/14:0)
|
|
|
PIP(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/18:0)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Acetazolamide
|
A thiadiazole that has formula C4H6N4O3S2.
|
|
DG(18:0/18:1(9Z)/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(P-18:1(11Z)/20:2(11Z,14Z))
|
|
|
PE(20:0/P-18:1(9Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
PE(18:1(11Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
(24R)-24,25-Dihydroxycalciol
|
A seco-cholestane that has formula C27H44O3.
|
|
N-Acetylvaline
|
|
|
Chondroitin sulfate
|
Any of a class of 10--60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ethanolamine Oleate
|
|
|
11-Hydroxyprogesterone 11-glucuronide
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
Deoxycholic acid disulfate
|
|
|
TG(18:1(9Z)/22:1(13Z)/o-18:0)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
SM(d18:0/22:2(13Z,16Z)(OH))
|
|
|
TG(18:1(9Z)/18:1(9Z)/22:1(13Z))[iso3]
|
|
|
DG(22:0/24:0/0:0)
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
PC(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/16:0/20:3(8Z,11Z,14Z))[iso6]
|
|
|
TG(20:1(11Z)/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Quinine
|
A cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy.
|
|
DG(20:4(5Z,8Z,11Z,14Z)/15:0/0:0)
|
|
|
dTDP-D-glucose
|
A dTDP-alpha-D-glucose that has formula C16H26N2O16P2.
|
|
PI(16:0/18:1(9Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
Levofloxacin
|
An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase
|
|
dIDP
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(9Z))
|
|
|
5a-Pregnane-3,20-dione
|
|
|
L-Isoleucine
|
The L-enantiomer of isoleucine.
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/0:0/16:1n7)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Methylarsonate
|
An organoarsonic acid anion that has formula CH3AsO3.
|
|
TG(18:1(11Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP2(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
10-Formyltetrahydrofolate
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:1(11Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
DG(22:0/0:0/22:5n3)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
Acetic acid
|
A simple monocarboxylic acid containing two carbons.
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid
|
A dioxo monocarboxylic acid that has formula C10H9NO5.
|
|
TG(22:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(20:0/24:1(15Z))
|
|
|
TG(14:1(9Z)/o-18:0/20:3n6)
|
|
|
TG(18:1(9Z)/18:0/20:1(11Z))
|
|
|
PC(20:0/22:0)
|
|
|
Nalidixic Acid
|
A monocarboxylic acid comprising 1,8-naphthyridin-4-one substituted by carboxylic acid, ethyl and methyl groups at positions 3, 1, and 7, respectively.
|
|
Cocaine
|
A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.
|
|
PE(P-16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(18:0/20:0/22:1(13Z))
|
|
|
TG(20:2n6/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Phosphorylcholine
|
|
|
TG(20:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
Zaleplon
|
A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.
|
|
DG(14:1n5/0:0/16:1n7)
|
|
|
PC(24:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(P-16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/14:0/14:1(9Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/24:1(15Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
CL(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
Formic acid
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
D-Xylono-1,5-lactone
|
A xylonolactone that has formula C5H8O5.
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(18:1(11Z)/16:0/22:1(13Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
TG(15:0/20:1(11Z)/o-18:0)
|
|
|
TG(20:3n6/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/14:0)
|
|
|
Fructose 1-phosphate
|
A ketohexose monophosphate consisting of fructose having a phosphate group located at the 1-position
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Dextrin
|
|
|
TG(14:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM2 (d18:0/25:0)
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/16:1(9Z)/o-18:0)
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:1(11Z)/20:3n6)
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP2(18:1(11Z)/18:1(9Z))
|
|
|
Flurazepam
|
|
|
11-cis-Retinaldehyde
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/22:1(13Z))
|
|
|
TG(20:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(22:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
PE(18:0/16:1(9Z))
|
|
|
PE(22:2(13Z,16Z)/14:1(9Z))
|
|
|
PE(20:0/18:1(9Z))
|
|
|
5'-Phosphoribosyl-N-formylglycinamide
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP2(22:2(13Z,16Z)/16:0)
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Isoursodeoxycholic acid
|
A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by beta-hydroxy groups at positions 3 and 7.
|
|
PG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Estriol-3-glucuronide
|
|
|
TG(20:2n6/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
DG(18:0/18:0/0:0)
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
Dextrothyroxine
|
|
|
TG(14:1(9Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/o-18:0)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Dihydroergotamine
|
Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:0/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:0/18:1(9Z))
|
|
|
TG(15:0/20:3n6/20:3n6)
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(15:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Glycogen
|
A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/22:1(13Z)/18:1(11Z))
|
|
|
PC(16:1(9Z)/20:0)
|
|
|
Glyciram
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(16:0/20:3n6/20:2n6)
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/0:0)
|
|
|
TG(14:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:0/22:0)
|
|
|
PC(P-18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
PIP2(20:1(11Z)/18:1(9Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:1(11Z)/20:2n6/20:2n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
Rolitetracycline
|
A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.
|
|
PE(20:2(11Z,14Z)/18:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:2(13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(18:1(9Z)/16:0/18:1(9Z))
|
|
|
Histamine Phosphate
|
A phosphate salt that is the diphosphate salt of histamine.
|
|
TG(18:1(9Z)/20:3n6/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
Ganglioside GQ1c (d18:1/12:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GQ1c (d18:1/26:1(17Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
5-(methylthio)-2,3-Dioxopentyl phosphate
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:0)
|
|
|
1-Methoxypyrene
|
A pyrene that has formula C17H12O.
|
|
TG(18:0/o-18:0/18:2(9Z,12Z))
|
|
|
DG(20:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
Phenprocoumon
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:1(11Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
Thiethylperazine
|
|
|
TG(22:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GT1c (d18:0/14:0)
|
|
|
PE(22:2(13Z,16Z)/22:1(13Z))
|
|
|
LysoPC(22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Galactosylsphingosine
|
|
|
TG(16:0/18:0/24:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/o-18:0)
|
|
|
Efavirenz
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Pyrrolidonecarboxylic acid
|
|
|
TG(15:0/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(14:1(9Z)/22:1(13Z)/18:1(9Z))
|
|
|
LysoPE(0:0/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/15:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:0/o-18:0)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(16:0/0:0/22:4n6)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:0/15:0/0:0)
|
|
|
TG(14:0/20:0/18:1(11Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Digoxin
|
Digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.
|
|
DG(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
CE(14:1(9Z))
|
|
|
SM(d18:1/22:0)
|
|
|
DG(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
SM(d18:0/18:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:0/o-18:0)
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
PI(20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(15:0/20:3n6/18:1(9Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
SM(d18:1/20:0)
|
|
|
TG(18:1(11Z)/20:0/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/o-18:0)
|
|
|
TG(20:3n6/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Cer(d18:0/24:1(15Z))
|
|
|
DG(22:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:3n6/20:2n6)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/20:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/o-18:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/o-18:0)
|
|
|
DG(14:1n5/0:0/22:2n6)
|
|
|
TG(18:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/24:1(15Z))
|
|
|
TG(20:0/18:1(9Z)/22:0)
|
|
|
TG(14:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
3-Oxohexadecanoyl-CoA
|
|
|
3-O-Sulfogalactosylceramide (d18:1/14:0)
|
|
|
TG(24:0/18:0/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:1(11Z)/20:0)
|
|
|
Hydrogen cyanide
|
A hydracid that has formula CHN.
|
|
TG(20:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:0/14:0/0:0)
|
|
|
PG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:3n6)
|
|
|
3-O-Sulfogalactosylceramide (d18:1/12:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6/o-18:0)
|
|
|
TG(24:0/14:0/14:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:0/20:2n6)
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
DG(18:1n7/0:0/20:5n3)
|
|
|
TG(18:1(11Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:1(11Z)/22:0)
|
|
|
PC(dm18:1(11Z)/dm18:1(9Z))
|
|
|
TG(16:1(9Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(14:0/20:3(8Z,11Z,14Z))
|
|
|
Beta-1,4-D-Mannosylchitobiosyldiphosphodolichol
|
Conjugate base of beta-D-mannosyldiacetylchitobiosyldiphosphodolichol.
|
|
Thymine
|
A pyrimidine nucleobase that is uracil in which the hydrogen at position 5 is replaced by a methyl group.
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Procainamide
|
4-Aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.
|
|
TG(14:1(9Z)/20:3n6/20:1(11Z))
|
|
|
5a-Cholesta-8,24-dien-3-one
|
|
|
PC(20:2(11Z,14Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/16:0/24:1(15Z))
|
|
|
TG(16:1(9Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(24:0/P-18:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
Ganglioside GD1b (d18:0/25:0)
|
|
|
Guanosine
|
A purine nucleoside in which guanine is attached to ribofuranose via a beta-N(9)-glycosidic bond.
|
|
PIP(18:0/20:3(8Z,11Z,14Z))
|
|
|
TG(20:0/20:0/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:1(13Z)/20:0)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
Galabiosylceramide (d18:1/24:1(15Z))
|
|
|
2,5-Dichloro-carboxymethylenebut-2-en-4-olide
|
A butenolide that has formula C6H2Cl2O4.
|
|
TG(18:0/22:0/18:1(11Z))
|
|
|
TG(24:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
Ganglioside GA1 (d18:1/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(14:0/20:2(11Z,14Z))
|
|
|
PC(14:1(9Z)/18:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/P-18:1(9Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/18:1(11Z)/o-18:0)
|
|
|
TG(20:1(11Z)/18:1(9Z)/22:1(13Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/15:0)
|
|
|
TG(18:2(9Z,12Z)/14:0/18:2(9Z,12Z))[iso3]
|
|
|
TG(16:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3n6/20:1(11Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
PC(20:3(5Z,8Z,11Z)/P-18:1(11Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/16:0/22:1(13Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/14:1(9Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(14:0/20:2n6/18:1(9Z))
|
|
|
Cadmium
|
A zinc group element atom that has formula Cd.
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ethyl p-anisate
|
|
|
Famotidine
|
A guanidine that has formula C8H15N7O2S3.
|
|
Ganglioside GD3 (d18:1/23:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(20:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/14:1(9Z)/20:2n6)
|
|
|
TG(18:0/18:0/18:1(9Z))[iso3]
|
|
|
TG(22:1(13Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
3,7-Dihydroxy-12-oxocholanoic acid
|
|
|
TG(20:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Fe2+
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/16:1(9Z)/20:3n6)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:1(13Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
MG(0:0/16:0/0:0)
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
MG(0:0/16:1(9Z)/0:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(9Z)/20:1(11Z))[iso6]
|
|
|
Keratan
|
|
|
PE(18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(20:0/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(18:1(11Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
Sodium Tetradecyl Sulfate
|
|
|
TG(20:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
6-(alpha-D-Glucosaminyl)-1D-myo-inositol
|
A D-glucosaminide consisting of 2-aminoglucosamine attached to 1D-myo-inositol at the 6-position via an alpha-linkage.
|
|
Ganglioside GT1c (d18:1/14:0)
|
|
|
TG(24:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/16:0/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GT1c (d18:1/16:0)
|
|
|
TG(15:0/22:0/14:1(9Z))
|
|
|
Episterol
|
A 9xi-episterol that has formula C28H46O.
|
|
LysoPE(16:0/0:0)
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:1(11Z)/20:1(11Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
Xanthosine 5-triphosphate
|
|
|
7a-Hydroxy-cholestene-3-one
|
|
|
TG(16:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/16:0/14:1(9Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(o-18:1(9Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))[iso3]
|
|
|
TG(20:0/16:1(9Z)/24:1(15Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(16:0/20:0/16:1(9Z))
|
|
|
TG(20:2n6/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
6-Mercaptopurine ribonucleoside triphosphate
|
An organic molecule that has formula C10H15N4O13P3S.
|
|
6-Thioxanthine 5'-monophosphate
|
An organic molecule that has formula C10H13N4O8PS.
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:2(11Z,14Z))[iso3]
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Agomelatine
|
|
|
Glutarylglycine
|
|
|
TG(20:0/20:3n6/18:1(9Z))
|
|
|
Ganglioside GM3 (d18:0/26:0)
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Glyburide
|
An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/15:0/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
5-Carboxy-2-pentenoyl-CoA
|
A polyol that has formula C27H42N7O19P3S.
|
|
TG(20:0/20:1(11Z)/14:1(9Z))
|
|
|
TG(24:0/20:0/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/22:1(13Z)/22:0)
|
|
|
PC(24:0/P-16:0)
|
|
|
Stachyose
|
A tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1->6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
|
|
trans-Dodec-2-enoic acid
|
|
|
Dobutamine
|
A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
Pyridoxal 5'-phosphate
|
The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Cysteamine
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
Vindesine
|
|
|
TG(20:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(24:1(15Z)/24:0/0:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(14:0/18:1(9Z)/o-18:0)
|
|
|
Nicotinamide ribotide
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/24:1(15Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:3n6/20:2n6)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
PS(18:3(9Z,12Z,15Z)/18:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
L-Kynurenine
|
A kynurenine that has L configuration.
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/18:1(11Z))
|
|
|
TG(15:0/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Uroporphyrinogen I
|
An uroporphyrinogen that has formula C40H44N4O16.
|
|
TG(18:0/15:0/18:0)
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(18:1(11Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PI(20:1(11Z)/18:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(16:0/22:0/20:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
Diazoxide
|
A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(18:0/16:0/18:1(11Z))[iso6]
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
Lithocholic acid
|
A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.
|
|
TG(24:1(15Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:0/20:2n6)
|
|
|
PIP(20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
CL(18:2(9Z,12Z)/18:1(11Z)/18:1(9Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
PC(P-18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(22:2(13Z,16Z)/20:0/0:0)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(20:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/o-18:0/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GT1c (d18:0/22:1(13Z))
|
|
|
PIP(18:1(11Z)/18:1(11Z))
|
|
|
TG(15:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:1(13Z)/o-18:0)
|
|
|
TG(22:0/18:1(9Z)/24:0)
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
DG(18:3(6Z,9Z,12Z)/18:0/0:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
Tolmetin
|
|
|
TG(18:1(9Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/P-16:0)
|
|
|
TG(24:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
2-Chloromaleylacetate
|
An organochlorine compound that has formula C6H5ClO5.
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
5-Amino-6-(5'-phosphoribitylamino)uracil
|
|
|
Ganglioside GT3 (d18:1/18:1(9Z))
|
|
|
Pelargonic acid
|
|
|
PC(o-18:0/18:2(9Z,12Z))
|
|
|
1,5-Anhydrosorbitol
|
|
|
PE(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(22:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Leukotriene E4
|
A leukotriene that has formula C23H37NO5S.
|
|
DG(14:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:0/0:0/20:1n9)
|
|
|
TG(20:2n6/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/14:0/o-18:0)
|
|
|
TG(16:0/24:0/20:1(11Z))
|
|
|
TG(20:3n6/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(18:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/16:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(16:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(14:0/0:0/18:1n7)
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
Antazoline
|
|
|
TG(16:0/18:1(11Z)/24:1(15Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/15:0/20:2n6)
|
|
|
TG(24:1(15Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Piperacillin
|
A penicillin that has formula C23H27N5O7S.
|
|
TG(20:2n6/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:2n6/24:1(15Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:1(11Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
(S)-2,3-Epoxysqualene
|
A squalene triterpenoid formed by epoxidation across the 2,3 C=C bond
|
|
dADP
|
A purine 2'-deoxyribonucleoside 5'-diphosphate having adenine as the nucleobase.
|
|
PE(14:1(9Z)/24:0)
|
|
|
DG(22:0/0:0/20:3n9)
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/14:0/24:1(15Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/20:2n6/20:2n6)
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Ganglioside GM2 (d18:1/23:0)
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
Xylometazoline
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(16:1(9Z)/P-18:0)
|
|
|
TG(24:1(15Z)/20:0/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(14:1n5/0:0/20:1n9)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/24:0/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:0/18:0)
|
|
|
TG(22:1(13Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(14:0/20:2(11Z,14Z))
|
|
|
TG(20:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/24:1(15Z)/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Tacrine
|
|
|
TG(16:0/16:0/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/14:0/20:0)
|
|
|
L-Arginine
|
An L-alpha-amino acid that is the L-isomer of arginine.
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
PC(16:0/14:1(9Z))
|
|
|
PE(14:1(9Z)/22:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
DG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(22:1(13Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/22:0/20:3n6)
|
|
|
Estrone-2,3-quinone
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(15:0/16:1(9Z))
|
|
|
TG(16:0/20:1(11Z)/16:1(9Z))
|
|
|
TG(15:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/24:0/0:0)
|
|
|
DG(22:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(18:1(11Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:2(11Z,14Z)/20:0)
|
|
|
Nilvadipine
|
|
|
TG(20:0/18:0/16:1(9Z))
|
|
|
Galactosylceramide (d18:1/20:0)
|
|
|
TG(18:0/18:0/20:2n6)
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:2(13Z,16Z)/18:1(9Z))
|
|
|
PE(24:1(15Z)/16:0)
|
|
|
Tacrolimus
|
|
|
TG(14:1(9Z)/16:1(9Z)/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Tolcapone
|
|
|
4-Acetamidobutanoic acid
|
An N-acylamino acid resulting from the monoacetylation of the nitrogen of GABA.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/o-18:0)
|
|
|
TG(16:0/14:0/24:1(15Z))
|
|
|
PC(24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(o-22:2(13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/24:0/0:0)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/18:1(11Z)/14:1(9Z))
|
|
|
DG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/20:2n6)
|
|
|
TG(14:1(9Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/24:1(15Z)/24:0)
|
|
|
Myoinositol
|
An inositol having myo- configuration.
|
|
Ergotamine
|
A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.
|
|
PE(24:1(15Z)/14:0)
|
|
|
TG(18:0/24:0/18:1(11Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
D-1,5-Anhydrofructose
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z))
|
|
|
TG(22:0/24:0/16:1(9Z))
|
|
|
PE(P-18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/15:0/22:2(13Z,16Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/20:2n6/18:1(11Z))
|
|
|
Ortho-Hydroxyphenylacetic acid
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(20:0/15:0/24:0)
|
|
|
TG(20:3n6/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
PI(18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/o-18:0)
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(18:1(11Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/20:2(11Z,14Z)/0:0)
|
|
|
Tyramine glucuronide
|
|
|
TG(20:2n6/20:3n6/20:3n6)
|
|
|
LysoPE(18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Selenophosphate
|
A trivalent inorganic anion obtained by removal of all three protons from selenophosphoric acid.
|
|
Etonogestrel
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
PEP-16:0/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(16:0/14:0/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
CE(20:4(5Z,8Z,11Z,14Z)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/o-18:0/20:1(11Z))
|
|
|
Benzoyl-CoA
|
An aroyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of benzoic acid.
|
|
Cidofovir
|
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/o-18:0)
|
|
|
TG(16:1(9Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
DG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:1(11Z)/14:0/20:2n6)
|
|
|
TG(22:1(13Z)/20:3n6/20:3n6)
|
|
|
PC(15:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
PE(14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PG(18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(22:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:3n6/20:2n6)
|
|
|
PE(18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
Alpha-Lactose
|
The alpha-anomer of lactose.
|
|
DG(18:1(11Z)/14:0/0:0)
|
|
|
PE(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Maprotiline
|
|
|
PG(16:0/18:3(9Z,12Z,15Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/0:0)
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
3-Oxodecanoyl-CoA
|
An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of 3-oxodecanoic acid.
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0/0:0)
|
|
|
PIP2(18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GT1b (d18:1/24:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/16:1(9Z)/20:0)
|
|
|
TG(20:3n6/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
CoA-[4'-phosphopantetheine]
|
|
|
Allochenodeoxycholic acid
|
A cholanoid that has formula C24H40O4.
|
|
DG(20:4n6/0:0/22:5n6)
|
|
|
Ganglioside GT1b (d18:1/26:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
PIP2(16:0/16:1(9Z))
|
|
|
TG(22:0/14:1(9Z)/24:1(15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GM2 (d18:1/22:1(13Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
16a-Hydroxyestrone
|
|
|
TG(24:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PIP(16:0/18:2(9Z,12Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Dantron
|
|
|
TG(24:0/20:0/24:1(15Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:2n6)
|
|
|
PE(16:1(9Z)/15:0)
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Thiamine pyrophosphate
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
N-Acetyl-b-glucosaminylamine
|
|
|
TG(16:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(20:1(11Z)/14:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
16a-Hydroxydehydroisoandrosterone
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPC(20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(16:0/o-18:0/14:1(9Z))
|
|
|
TG(15:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
DG(22:2n6/0:0/22:6n3)
|
|
|
TG(22:0/14:1(9Z)/20:1(11Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
S-aminomethyldihydrolipoamide
|
|
|
TG(20:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/16:0/18:2(9Z,12Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Carbetocin
|
Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus.
|
|
TG(15:0/14:1(9Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(P-18:1(9Z)/24:1(15Z))
|
|
|
TG(15:0/15:0/o-18:0)
|
|
|
PC(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/16:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
PC(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(16:0/16:0/o-18:0)
|
|
|
PA(16:0/16:0)
|
|
|
TG(18:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(11Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
Tetrahydropteroyltri-L-glutamate
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
11b,21-Dihydroxy-5b-pregnane-3,20-dione
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
Dabigatran etexilate
|
|
|
TG(18:1(11Z)/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/18:1(9Z))
|
|
|
PIP2(18:1(9Z)/16:0)
|
|
|
TG(20:3n6/o-18:0/20:3n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
Nisoldipine
|
|
|
PC(18:1(11Z)/P-18:1(9Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3 beta-Hydroxy-5-cholestenoate
|
|
|
Isobutanol
|
An alkyl alcohol that is propan-1-ol substituted by a methyl group at position 2.
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/20:2n6)
|
|
|
PIP(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
2-trans,6-trans-Farnesal
|
A farnesal that has formula C15H24O.
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/22:1(13Z))
|
|
|
4'-Hydroxydiclofenac
|
An monocarboxylic acid that is the 4'-hydroxylated metabolite of diclofenac.
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Aspirin
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PIP2(18:1(9Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:2n6/20:2n6)
|
|
|
PG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(o-16:0/18:0)
|
|
|
TG(22:0/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:0/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/18:1(11Z)/14:1(9Z))
|
|
|
TG(20:2n6/18:0/22:2(13Z,16Z))
|
|
|
Thiopental
|
A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
5-Hydroxyconiferyl alcohol
|
A methoxybenzene that has formula C10H12O4.
|
|
TG(20:2n6/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Glucosylceramide (d18:1/9Z-18:1)
|
|
|
PE(16:1(9Z)/P-18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(15:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z)/0:0)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Octanal
|
A fatty aldehyde formally arising from reduction of the carboxy group of caprylic acid (octanoic acid).
|
|
19-Hydroxyandrost-4-ene-3,17-dione
|
A 19-hydroxy steroid that has formula C19H26O3.
|
|
Leflunomide
|
A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Glucose 1-phosphate
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:2(9Z,12Z)/22:1(13Z))
|
|
|
PIP(18:2(9Z,12Z)/16:0)
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/16:0)
|
|
|
TG(14:0/24:1(15Z)/22:0)
|
|
|
TG(14:0/22:0/18:1(11Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:0/18:1(9Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/16:0)
|
|
|
TG(18:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Oxaprozin
|
|
|
TG(18:1(11Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
PS(18:0/14:1(9Z))
|
|
|
TG(18:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(11Z)/20:3n6)
|
|
|
PC(24:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:1(11Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PE(P-16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:1(11Z)/18:1(11Z))
|
|
|
TG(15:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/22:2(13Z,16Z))
|
|
|
Indole-5,6-quinone
|
An indoledione that has formula C8H5NO2.
|
|
2,5-Diaminopyrimidine nucleoside triphosphate
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:0/20:3n6)
|
|
|
TG(24:1(15Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:0/16:1(9Z))
|
|
|
Levallorphan
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
O-acetyl-ADP-ribose
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Hexacarboxylporphyrin I
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:1(11Z)/18:1(9Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(24:0/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(16:1n7/0:0/20:5n3)
|
|
|
TG(20:2n6/14:0/20:2n6)
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/18:0/20:2n6)
|
|
|
DG(14:0/0:0/16:1n7)
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(18:0/15:0/16:1(9Z))
|
|
|
PC(o-14:0/16:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:1(9Z)/18:1(9Z))[iso3]
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Fosamprenavir
|
|
|
DG(18:1n9/0:0/22:2n6)
|
|
|
TG(16:1(9Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Pentanoyl-CoA
|
A short-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of pentanoic acid.
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
PIP(20:1(11Z)/18:1(9Z))
|
|
|
TG(14:0/18:1(9Z)/22:0)
|
|
|
N-Methylputrescine
|
An N-monosubstituted putrescine where the N-substituent is methyl.
|
|
DG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(14:1(9Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/14:1(9Z)/18:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/14:1(9Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(15:0/P-18:1(11Z))
|
|
|
TG(16:1(9Z)/22:0/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
DG(18:1n9/0:0/22:5n3)
|
|
|
Memantine
|
|
|
TG(14:1(9Z)/14:0/18:1(9Z))
|
|
|
TG(14:1(9Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
TG(15:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:0/o-18:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(14:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/18:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
PE(20:0/22:1(13Z))
|
|
|
5-Dehydroavenasterol
|
A steroid that has formula C29H46O.
|
|
DG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
DG(22:2(13Z,16Z)/20:1(11Z)/0:0)
|
|
|
TG(20:2n6/o-18:0/22:2(13Z,16Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/15:0)
|
|
|
TG(16:0/20:2n6/18:0)
|
|
|
TG(16:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
PC(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/o-18:0)
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
(9S,10S)-9,10-dihydroxyoctadecanoate
|
Conjugate base of (9S,10S)-9,10-dihydroxyoctadecanoic acid.
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Fomepizole
|
A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.
|
|
L-Sorbose
|
The L enantiomer of sorbose, a ketone-containing hexose (a six-carbon monosaccharide).
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(24:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(15:0/o-18:0/16:0)
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/18:1(9Z))
|
|
|
PC(P-16:0/16:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Riboflavin reduced
|
|
|
PC(o-18:1(11Z)/16:0)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
3a,7a,12a-Trihydroxy-5b-cholestanoic acid
|
|
|
TG(14:0/24:1(15Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Tetracosatetraenoyl CoA
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(14:0/24:0/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:0/o-18:0)
|
|
|
Ceramide (d18:1/22:0)
|
|
|
TG(24:0/22:0/20:3n6)
|
|
|
TG(16:1(9Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPC(22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/14:1(9Z)/20:2n6)
|
|
|
Ceramide (d18:1/20:0)
|
|
|
Cinoxacin
|
|
|
(S)-Succinyldihydrolipoamide
|
|
|
PE(24:1(15Z)/P-18:0)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/o-18:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/o-18:0/20:3n6)
|
|
|
cis-Acetylacrylate
|
|
|
PS(14:0/18:0)
|
|
|
TG(24:1(15Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
PE(20:0/14:0)
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Kaempferol 3-glucuronide
|
|
|
DG(24:1(15Z)/18:1(9Z)/0:0)
|
|
|
TG(20:2n6/18:0/o-18:0)
|
|
|
Vardenafil
|
The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.
|
|
Protoanemonin
|
A butenolide that has formula C5H4O2.
|
|
PE(18:2(9Z,12Z)/P-18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/16:0/22:0)
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/24:1(15Z)/22:0)
|
|
|
Ketorolac
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:1(11Z)/P-16:0)
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:0/18:3(6Z,9Z,12Z))
|
|
|
Angiotensin II
|
|
|
TG(22:0/15:0/20:3n6)
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:0)
|
|
|
PE(24:1(15Z)/P-16:0)
|
|
|
TG(16:0/14:0/16:0)[iso3]
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Oxtriphylline
|
|
|
PC(16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
Ceftibuten
|
|
|
PC(18:2(9Z,12Z)/14:0)
|
|
|
Farnesol
|
|
|
TG(15:0/14:1(9Z)/20:1(11Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/o-18:0)
|
|
|
TG(14:0/14:1(9Z)/14:1(9Z))
|
|
|
1-Hydroxyphenanthrene
|
|
|
TG(14:1(9Z)/24:0/o-18:0)
|
|
|
TG(24:0/14:1(9Z)/20:3n6)
|
|
|
TG(20:1(11Z)/24:0/22:1(13Z))
|
|
|
TG(22:0/18:0/20:3n6)
|
|
|
TG(20:3n6/20:3n6/20:3n6)
|
|
|
Ixabepilone
|
|
|
DG(18:3(6Z,9Z,12Z)/14:1(9Z)/0:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:0)
|
|
|
DG(18:0/22:2(13Z,16Z)/0:0)
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(9Z)/16:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(20:3n6/20:3n6/22:2(13Z,16Z))
|
|
|
Tamoxifen
|
A stilbenoid that has formula C26H29NO.
|
|
TG(18:1(11Z)/20:1(11Z)/o-18:0)
|
|
|
TG(15:0/22:1(13Z)/22:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/16:0/20:2n6)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
PE(18:1(9Z)/18:1(9Z))
|
|
|
DG(22:0/20:2(11Z,14Z)/0:0)
|
|
|
TG(20:2n6/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:1(9Z)/22:1(13Z))
|
|
|
Glycerol
|
A triol with a structure of propane substituted at positions 1, 2 and 3 by hydroxy groups.
|
|
4-Coumaryl alcohol
|
|
|
Naltrexone
|
An organic heteropentacyclic compound that is 4,5-epoxymorphinan-6-one substituted by a cyclopropylmethyl group at position 17 and hydroxy groups at positions 3 and 14. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
Ganglioside GD1a (d18:1/22:0)
|
|
|
TG(22:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Mesoridazine
|
|
|
TG(20:3n6/15:0/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PIP(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
PE(18:1(11Z)/P-18:1(11Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Treprostinil
|
|
|
Troleandomycin
|
|
|
TG(18:0/20:1(11Z)/18:1(9Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
PIP(18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/o-18:0)
|
|
|
TG(20:0/20:1(11Z)/18:1(9Z))
|
|
|
Selenium
|
A chalcogen that has formula Se.
|
|
TG(20:2n6/20:2n6/20:2n6)
|
|
|
Uridine 5'-monophosphate
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/24:1(15Z)/22:1(13Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
1,6-Dimethoxypyrene
|
A pyrene that has formula C18H14O2.
|
|
TG(24:1(15Z)/18:1(11Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/20:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Cefotaxime
|
A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.
|
|
TG(20:3n6/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
Brinzolamide
|
|
|
TG(18:1(9Z)/22:0/20:1(11Z))
|
|
|
TG(14:0/16:0/24:1(15Z))
|
|
|
DG(24:0/20:2(11Z,14Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(20:1(11Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1c (d18:1/24:1(15Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:0/14:1(9Z))
|
|
|
Galabiosylceramide (d18:1/26:1(17Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/14:1(9Z)/20:3n6)
|
|
|
TG(18:1(9Z)/20:1(11Z)/20:3n6)
|
|
|
1-Butanol
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(16:0/0:0/20:3n6)
|
|
|
DG(14:0/0:0/22:4n6)
|
|
|
Arachidic acid
|
A C20 striaght-chain saturated fatty acid which forms a minor constituent of peanut (L. arachis) and corn oils. Used as an organic thin film in the production of liquid crystals for a wide variety of technical applications.
|
|
TG(14:1(9Z)/20:1(11Z)/20:3n6)
|
|
|
PC(18:1(11Z)/16:1(9Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
Chondroitin D-glucuronate
|
A mucopolysaccharide composed of repeating beta-D-glucopyranuronosyl-(1->3)-beta-D-N-acetylgalactosaminyl units.
|
|
Vanylglycol
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
PC(P-16:0/16:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sulfamethizole
|
|
|
LysoPC(15:0)
|
An acyl-sn-glycero-3-phosphocholine in which the acyl group contains fifteen carbons with no double bonds and is attached to the glycero moiety at either position 1 or 2.
|
|
PE(22:0/22:2(13Z,16Z))
|
|
|
PI(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/24:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Inositol 1,3,4-trisphosphate
|
|
|
PC(P-16:0/14:0)
|
|
|
TG(14:0/20:0/18:0)
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GA2 (d18:1/12:0)
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
PC(16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
1-Hexanol
|
|
|
TG(22:1(13Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ethacrynic acid
|
|
|
trans-4-Carboxymethylenebut-2-en-4-olide
|
A 4-carboxymethylenebut-2-en-4-olide that has formula C6H4O4.
|
|
TG(20:3(5Z,8Z,11Z)/16:0/22:2(13Z,16Z))
|
|
|
Cephalosporin C
|
A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.
|
|
Aminophylline
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:0)
|
|
|
PC(22:2(13Z,16Z)/15:0)
|
|
|
Heptanoic acid
|
|
|
Nicardipine
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(9Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Thiamine monophosphate
|
|
|
PIP2(22:3(10Z,13Z,16Z)/16:2(9Z,12Z))
|
|
|
TG(15:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
PC(20:2(11Z,14Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:2n6/14:1(9Z))
|
|
|
PE(18:1(11Z)/14:0)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
DG(16:0/0:0/14:1n5)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(15:0/20:0/16:0)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/24:1(15Z)/24:0)
|
|
|
TG(24:0/16:0/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(dm16:0/dm16:0)
|
|
|
TG(18:0/16:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/24:1(15Z))
|
|
|
S-(1,2-Dichlorovinyl)glutathione
|
A peptide that has formula C12H17Cl2N3O6S.
|
|
PG(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(16:1n7/0:0/18:3n3)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/o-18:0)
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Bimatoprost
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(16:0/22:1(13Z)/18:1(11Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/16:0/0:0)
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/18:0/20:3n6)
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z)/16:1(9Z))
|
|
|
TG(18:0/o-18:0/20:0)
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
7 alpha,24-Dihydroxy-4-cholesten-3-one
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Baclofen
|
A monocarboxylic acid that is butanoic acid substituted by an amino group at position 4 and a 4-chlorophenyl group at position 3. It acts as a central nervous system depressant, GABA agonist and muscle relaxant.
|
|
Ganglioside GM1 (d18:1/26:1(17Z)))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
Epiandrosterone
|
A 3beta-hydroxy steroid that is (5alpha)-androstane substituted by a beta-hydroxy group at position 3 and an oxo group at position 17.
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:3n6/20:0)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/24:1(15Z))
|
|
|
TG(20:2n6/15:0/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
Arecoline
|
A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.
|
|
PC(24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/o-18:0)
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/15:0/o-18:0)
|
|
|
TG(18:0/18:0/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(18:0/o-18:0/22:0)
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Malic acid
|
A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.
|
|
TG(22:1(13Z)/15:0/20:3n6)
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Raloxifene
|
A benzothiophene that has formula C28H27NO4S.
|
|
TG(18:1(11Z)/14:1(9Z)/20:3n6)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/14:0/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(24:1(15Z)/15:0/o-18:0)
|
|
|
8,11,14-Eicosatrienoic acid
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
CE(20:5(5Z,8Z,11Z,14Z,17Z)
|
A cholesterol ester obtained by the formal condensation of cholesterol with all-cis-5,8,11,14,17-icosapentaenoic acid.
|
|
TG(22:1(13Z)/22:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:0/20:3n6)
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/24:0/22:2(13Z,16Z))
|
|
|
DG(20:0/0:0/24:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
DG(20:0/0:0/22:6n3)
|
|
|
DG(18:1n9/0:0/18:3n3)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/14:0/22:2(13Z,16Z))
|
|
|
TG(15:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
Pyruvic acid
|
A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
|
|
TG(24:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT2 (d18:0/24:1(15Z))
|
|
|
2,3-Butanediol
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
DG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(18:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:0/18:2(9Z,12Z))
|
|
|
Indoleacetaldehyde
|
An aldehyde that is acetaldehyde substituted by an indolyl group.
|
|
Ethotoin
|
|
|
TG(22:2(13Z,16Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Tetrahydrocortisol
|
A glucocorticoid that has formula C21H34O5.
|
|
TG(24:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
Niclosamide
|
|
|
3b,7b,12a-Trihydroxy-5a-Cholanoic acid
|
|
|
TG(15:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Beta-D-Glucose
|
D-Glucopyranose with beta configuration at the anomeric centre.
|
|
TG(16:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:1(11Z)/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
Streptomycin
|
A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class
|
|
Ganglioside GT3 (d18:0/23:0)
|
|
|
TG(14:0/22:2(13Z,16Z)/14:0)
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(20:0/18:1(9Z)/14:1(9Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Mometasone
|
A chlorinated steroid that has formula C22H28Cl2O4.
|
|
TG(15:0/20:2n6/14:1(9Z))
|
|
|
TG(14:1(9Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
7a-Hydroxy-3-oxo-5b-cholanoic acid
|
|
|
Cholesteryl acetate
|
A cholesterol ester obtained by formal acylation of the hydroxy group of cholesterol by acetic acid.
|
|
TG(16:1(9Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
TG(18:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:1(13Z)/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:2(11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
PC(20:2(11Z,14Z)/20:1(11Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
PIP2(18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
PE(14:1(9Z)/16:1(9Z))
|
|
|
TG(18:0/18:1(11Z)/22:1(13Z))
|
|
|
DG(15:0/20:2(11Z,14Z)/0:0)
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(18:1(11Z)/16:1(9Z)/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/20:0/o-18:0)
|
|
|
(S)-b-aminoisobutyric acid
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/16:0/14:1(9Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(18:0/24:0/18:2(9Z,12Z))
|
|
|
TG(24:0/22:0/18:1(11Z))
|
|
|
DG(16:0/15:0/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/o-18:0)
|
|
|
PE(18:1(9Z)/P-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/20:3n6)
|
|
|
17-beta-estradiol 3-sulfate-17-(beta-D-glucuronide)
|
A steroid glucosiduronic acid that has formula C24H31O11S.
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/14:0/20:3n6)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/o-18:0)
|
|
|
PC(P-18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(14:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:1(13Z)/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/22:1(13Z))
|
|
|
TG(20:2n6/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:0/20:1(11Z)/0:0)
|
|
|
TG(18:1(11Z)/15:0/24:1(15Z))
|
|
|
DG(22:1(13Z)/18:1(9Z)/0:0)
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(18:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(20:1(11Z)/24:1(15Z)/0:0)
|
|
|
DG(18:3(9Z,12Z,15Z)/24:0/0:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
Arsenic trioxide
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
CE(22:4(7Z,10Z,13Z,16Z)
|
|
|
PE(18:0/P-16:0)
|
|
|
TG(20:1(11Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
DG(20:0/20:1(11Z)/0:0)
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/14:1(9Z)/14:0)
|
|
|
Ganglioside GD1b (d18:1/24:1(15Z))
|
|
|
TG(14:1(9Z)/24:0/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/o-18:0)
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(24:0/20:1(11Z)/20:1(11Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/18:1(9Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GA2 (d18:1/25:0)
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:0/20:0)
|
|
|
DG(22:2(13Z,16Z)/14:1(9Z)/0:0)
|
|
|
TG(14:0/14:1(9Z)/16:0)
|
|
|
dTDP-D-galactose
|
The D-enantiomer of dTDP-galactose.
|
|
TG(15:0/16:0/15:0)
|
|
|
PE(18:0/20:2(11Z,14Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(24:0/15:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/20:3n6/22:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:0/0:0)
|
|
|
Allolithocholic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
DG(20:3(5Z,8Z,11Z)/16:1(9Z)/0:0)
|
|
|
Ciprofloxacin
|
A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
SM(d18:0/12:0)
|
|
|
TG(20:2n6/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:0/18:1(9Z))
|
|
|
PC(o-16:0/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/22:1(13Z))
|
|
|
Pentolinium
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/20:3n6)
|
|
|
TG(14:0/18:1(9Z)/15:0)
|
|
|
PC(20:3(8Z,11Z,14Z)/P-18:0)
|
|
|
L-Gulonolactone
|
|
|
TG(20:1(11Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
TG(18:0/20:2n6/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
3a,7a-Dihydroxy-5b-cholestan-26-al
|
|
|
N-Acetylmuramoyl-Ala
|
|
|
S-Acetyldihydrolipoamide
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)/0:0)
|
|
|
TG(16:1(9Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:1(9Z)/16:0)[iso6]
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(16:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(14:0/18:1(11Z)/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
MG(22:4(7Z,10Z,13Z,16Z)/0:0/0:0)
|
|
|
Isovalerylglycine
|
|
|
PC(14:0/P-18:1(11Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:1(9Z)/14:0)
|
|
|
TG(18:1(11Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:2(11Z,14Z))[iso3]
|
|
|
TG(16:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
SN-38
|
A pyranoindolizinoquinoline that has formula C22H20N2O5.
|
|
1-Nitro-5,6-dihydroxy-dihydronaphthalene
|
A nitronaphthalene that has formula C10H9NO4.
|
|
TG(16:1(9Z)/20:1(11Z)/22:1(13Z))
|
|
|
PE(18:1(9Z)/16:0)
|
|
|
DG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:0/22:1(13Z))
|
|
|
Glisoxepide
|
|
|
Nafcillin
|
A penicillin that has formula C21H22N2O5S.
|
|
N-Acetyl-L-aspartic acid
|
An N-acyl-L-aspartic acid in which the acyl group is specified as acetyl.
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(14:0/22:1(13Z)/18:0)
|
|
|
TG(18:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/16:0/20:1(11Z))[iso3]
|
|
|
Dapiprazole
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(22:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(16:1(9Z)/16:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
1-Deoxynojirimycin
|
|
|
TG(22:0/24:1(15Z)/20:3n6)
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Quinoline-4,8-diol
|
A dihydroxyquinoline that has formula C9H7NO2.
|
|
TG(24:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/18:1(11Z)/20:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0)
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(20:2n6/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
Rimonabant
|
|
|
TG(14:1(9Z)/24:1(15Z)/18:1(9Z))
|
|
|
Cer(d18:1/22:1(13Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(24:1(15Z)/P-18:1(11Z))
|
|
|
TG(22:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PIP2(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:3n6/22:0)
|
|
|
Trans-Hexa-dec-2-enoic acid
|
|
|
TG(20:1(11Z)/15:0/20:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
PIP2(20:1(11Z)/18:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:2n6/o-18:0)
|
|
|
TG(16:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:1(9Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:1(11Z)/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
Ganglioside GM1 (d18:1/18:1(11Z))
|
|
|
Ganglioside GQ1c (d18:1/22:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cefdinir
|
A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.
|
|
PIP2(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
PS(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PC(16:0/20:3(8Z,11Z,14Z))
|
|
|
Tryptamine
|
An aminoalkylindole consisting of indole having a 2-aminoethyl group at the 3-position.
|
|
PC(20:4(8Z,11Z,14Z,17Z)/14:0)
|
|
|
TG(22:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
N-desmethylimatinib
|
|
|
TG(22:1(13Z)/16:0/o-18:0)
|
|
|
TG(22:1(13Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
N-Methyl-D-aspartic acid
|
An aspartic acid derivative having an N-methyl substituent and D-configuration.
|
|
PE(18:3(6Z,9Z,12Z)/20:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:0)[iso3]
|
|
|
PE(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPE(18:0/0:0)
|
|
|
Flavoxate
|
A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.
|
|
Oxprenolol
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Nandrolone
|
A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.
|
|
TG(16:0/22:0/14:1(9Z))
|
|
|
5-O-Desmethyldonepezil
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/16:0/22:1(13Z))
|
|
|
PC(18:2(9Z,12Z)/20:2(11Z,14Z))
|
|
|
PC(22:2(13Z,16Z)/14:1(9Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/24:1(15Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/22:0)
|
|
|
PE(22:0/22:0)
|
|
|
TG(16:1(9Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
Dihydroxyacetone Phosphate Acyl Ester
|
A glycerone 3-phosphate having an unspecified O-acyl substituent at the 1-position.
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
Ganglioside GT3 (d18:0/18:0)
|
|
|
Ganglioside GM1 (d18:1/22:1(13Z))
|
|
|
Loratadine
|
|
|
PC(o-22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/24:0/22:0)
|
|
|
TG(18:1(11Z)/14:1(9Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
17-Hydroxyprogesterone
|
|
|
TG(24:0/20:2n6/20:1(11Z))
|
|
|
TG(16:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(22:1(13Z)/24:0/20:2n6)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:0/20:1(11Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
PE(24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
Isoflurane
|
An organofluorine compound that has formula C3H2ClF5O.
|
|
CE(20:3(8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/o-18:0)
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
DG(24:0/0:0/20:5n3)
|
|
|
1,1-Dichloroethylene epoxide
|
An epoxide that has formula C2H2Cl2O.
|
|
TG(16:1(9Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
5-Methoxytryptamine
|
|
|
TG(15:0/18:0/22:2(13Z,16Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:2n6/20:3n6)
|
|
|
Citalopram aldehyde
|
A benzene that has formula C18H14FNO2.
|
|
PE(18:2(9Z,12Z)/16:1(9Z))
|
|
|
Presqualene diphosphate
|
A triterpenyl phosphate that has formula C30H52O7P2.
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Coproporphyrinogen I
|
A coproporphyrinogen that has formula C36H44N4O8.
|
|
TG(15:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:1(11Z)/16:0/0:0)
|
|
|
TG(18:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
4,4-Dimethyl-5-alpha-cholest-7-en-3-beta-ol
|
A cholestanoid that is 5alpha-cholest-7-ene substituted by a beta-hydroxy group at position 3 and two methyl groups at position 4.
|
|
TG(18:1(11Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
LysoPE(18:1(11Z)/0:0)
|
|
|
TG(18:1(11Z)/15:0/18:1(11Z))
|
|
|
PC(o-24:0/18:3(6Z,9Z,12Z))
|
|
|
LysoPE(22:1(13Z)/0:0)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Oxycodone
|
An organic heteropentacyclic compound that has formula C18H21NO4.
|
|
TG(14:1(9Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:0/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PIP2(16:1(9Z)/18:0)
|
|
|
TG(14:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
DG(20:3n9/0:0/18:3n6)
|
|
|
TG(16:0/20:1(11Z)/24:1(15Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(20:2n6/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/16:0/20:3n6)
|
|
|
TG(14:0/16:0/20:2n6)
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Cilazapril
|
|
|
PE(24:1(15Z)/24:0)
|
|
|
TG(24:1(15Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
CDP-DG(18:1(9Z)/16:0)
|
|
|
2-Phenylethanol glucuronide
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
LysoPC(20:1(11Z))
|
|
|
O-Deethylated candesartan
|
|
|
TG(15:0/18:1(9Z)/24:1(15Z))
|
|
|
PE(24:1(15Z)/22:0)
|
|
|
Zymosterol intermediate 2
|
A 3-oxo steroid that has formula C27H42O.
|
|
PE(16:0/24:0)
|
|
|
TG(18:1(9Z)/20:2n6/22:1(13Z))
|
|
|
4-Hydroxyandrostenedione glucuronide
|
|
|
Nandrolone decanoate
|
A steroid ester that has formula C28H44O3.
|
|
PC(18:0/P-18:1(9Z))
|
|
|
TG(14:0/18:1(11Z)/14:0)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/0:0)
|
|
|
TG(15:0/18:0/24:1(15Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
Mitoxantrone
|
A hydroxyanthraquinone that has formula C22H28N4O6.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:0/o-18:0)
|
|
|
PC(18:0/22:2(13Z,16Z))
|
|
|
TG(24:0/24:1(15Z)/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(18:1(11Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Tetrahexosylceramide (d18:1/16:0)
|
|
|
TG(18:1(11Z)/20:2n6/20:1(11Z))
|
|
|
TG(14:0/22:0/14:1(9Z))
|
|
|
TG(18:1(9Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/24:0/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(16:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
DG(24:0/0:0/16:1n7)
|
|
|
TG(22:0/20:2n6/24:1(15Z))
|
|
|
Tetrahexosylceramide (d18:1/18:0)
|
|
|
PG(18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Milrinone
|
A member of the class of bipyridines that is 2-pyridone which is substituted at positions 3, 5, and 6 by cyano, pyrid-4-yl, and methyl groups, respectively. It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure.
|
|
TG(18:0/16:1(9Z)/14:1(9Z))
|
|
|
2-hydroxy-dAMP
|
A purine 2'-deoxyribonucleoside 5'-monophosphate in which the purine moiety is 2-hydroxyadenine.
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(15:0/14:0/20:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(22:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Lornoxicam
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/o-18:0/20:2n6)
|
|
|
TG(20:2n6/16:0/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
ADP-Ribosyl-L-arginine
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(15:0/18:1(11Z)/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/20:1(11Z)/22:0)
|
|
|
TG(18:1(11Z)/16:0/18:2(9Z,12Z))[iso3]
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
2b,3a,7a-Trihydroxy-5b-cholanoic acid
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
PC(20:2(11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
SM(d18:0/23:0)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(18:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
DG(16:1(9Z)/16:1(9Z)/0:0)
|
|
|
TG(24:0/20:3n6/20:3n6)
|
|
|
TG(15:0/22:0/16:1(9Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/18:1(11Z))[iso3]
|
|
|
TG(15:0/18:1(11Z)/22:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(24:1(15Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sildenafil
|
|
|
PC(P-18:0/18:2(9Z,12Z))
|
|
|
TG(15:0/22:0/20:0)
|
|
|
MG(0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
5-Hydroxyindoleacetic acid
|
|
|
DG(18:3n6/0:0/22:4n6)
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(18:2(9Z,12Z)/22:0)
|
|
|
TG(16:1(9Z)/20:3n6/22:1(13Z))
|
|
|
TG(14:0/14:0/16:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:0/22:2(13Z,16Z))
|
|
|
Aflatoxin B1 dialcohol
|
|
|
TG(15:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/15:0/24:1(15Z))
|
|
|
Propyl alcohol
|
|
|
TG(24:1(15Z)/24:0/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Inosine triphosphate
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
DG(18:3(9Z,12Z,15Z)/14:1(9Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/15:0/20:2n6)
|
|
|
TG(14:1(9Z)/20:2n6/20:3n6)
|
|
|
TG(22:1(13Z)/20:2n6/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:1(11Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
CDP-DG(18:1(11Z)/22:3(10Z,13Z,16Z))
|
|
|
Inodxyl glucuronide
|
|
|
Pyruvaldehyde
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/20:2(11Z,14Z))
|
|
|
TG(18:0/20:1(11Z)/o-18:0)
|
|
|
PIP(18:1(15Z)/20:1(11Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Bromazepam
|
|
|
TG(18:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:2n6)
|
|
|
TG(22:0/18:0/20:1(11Z))
|
|
|
DG(22:2n6/0:0/22:5n3)
|
|
|
TG(14:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Alfacalcidol
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/24:1(15Z)/22:1(13Z))
|
|
|
Alpha-Linolenoyl-CoA
|
An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of alpha-linolenic acid.
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GQ1c (d18:0/26:1(17Z))
|
|
|
TG(14:0/24:1(15Z)/o-18:0)
|
|
|
PE(16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(24:1n9/0:0/20:3n6)
|
|
|
TG(20:2n6/14:1(9Z)/20:2n6)
|
|
|
TG(22:0/18:1(9Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
D-Xylulose
|
The D-enantiomer of xylulose.
|
|
Diphemanil Methylsulfate
|
The alkene resulting from the formal Wittig olefination of benzophenone and 1,1-dimethyl-4-bromopiperidinium methylsulfate. A quaternary ammonium anticholinergic, it binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids, saliva and sweat, It is used topically in the treatment of hyperhidorsis (excessive sweating).
|
|
PC(P-16:0/20:1(11Z))
|
|
|
Glutathione
|
|
|
TG(16:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:0/0:0/22:5n6)
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:3n6/14:0/20:3n6)
|
|
|
TG(20:2n6/20:2n6/20:3n6)
|
|
|
3-Methyl-1-hydroxybutyl-ThPP
|
A thiamine phosphate that has formula C17H29N4O8P2S.
|
|
PIP2(20:0/18:2(9Z,12Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
(25R)-3alpha,7alpha-Dihydroxy-5beta-cholestanoyl-CoA
|
An organic molecule that has formula C48H80N7O19P3S.
|
|
TG(24:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
PC(P-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
11,12-Epoxyeicosatrienoic acid
|
|
|
DG(20:3(8Z,11Z,14Z)/24:1(15Z)/0:0)
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
PC(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3,4-Dihydroxymandelic acid
|
A catechol that is the 3,4-dihydroxy derivative of mandelic acid; a metabolite of L-dopa.
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
CDP-DG(16:0/18:0)
|
|
|
5-b-Cholestane-3a ,7a ,12a-triol
|
|
|
DHAP(18:0)
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Nalbuphine
|
An organic heteropentacyclic compound that has formula C21H27NO4.
|
|
TG(20:0/14:0/o-18:0)
|
|
|
CL(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PIP(18:1(9Z)/16:0)
|
|
|
Xanthosine
|
A purine nucleoside in which xanthine is attached to ribofuranose via a beta-N(9)-glycosidic bond.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/o-18:0)
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
20alpha-Hydroxycholesterol
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
Glucose 6-phosphate
|
|
|
TG(18:2(9Z,12Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
PE(20:0/16:0)
|
|
|
Testosterone
|
An androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5..
|
|
PE(18:3(9Z,12Z,15Z)/P-18:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(24:0/22:0/14:1(9Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/o-18:0)
|
|
|
TG(14:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/24:1(15Z))
|
|
|
2-Methylbutyryl-CoA
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
3-Methylcrotonylglycine
|
An N-acylglycine in which the acyl group is specified as 3-methylbut-2-enoyl.
|
|
PG(18:0/18:2(9Z,12Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:2(13Z,16Z)/16:1(9Z))
|
|
|
2-Aminomuconic acid
|
The 2-amino derivative of muconic acid.
|
|
7-Hydroxyticlopidine
|
|
|
TG(18:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Isothipendyl
|
|
|
CL(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:1(13Z)/18:1(11Z))
|
|
|
TG(14:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(20:2(11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z))
|
|
|
TG(22:0/24:0/o-18:0)
|
|
|
D-Ribose
|
A ribose in which the chiral carbon atom furthest away from the aldehyde group (C4') has the same configuration as in D-glyceraldehyde.
|
|
TG(18:1(9Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:3n6/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Propylhexedrine
|
|
|
TG(24:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:0/16:1(9Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
3a,7a-Dihydroxycholanoic acid
|
|
|
TG(18:1(9Z)/24:0/22:1(13Z))
|
|
|
DG(14:0/16:0/0:0)
|
|
|
TG(16:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/20:2n6)
|
|
|
TG(16:0/22:2(13Z,16Z)/24:0)
|
|
|
(6Z,9Z,12Z,15Z,18Z)-3-Oxotetracosapenta-6,9,12,15,18-enoyl-CoA
|
An organic molecule that has formula C45H70N7O18P3S.
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(16:0/22:2(13Z,16Z))
|
|
|
PC(24:1(15Z)/P-16:0)
|
|
|
5-Fluoromuconolactone
|
A butenolide that has formula C6H5FO4.
|
|
TG(16:0/14:1(9Z)/22:1(13Z))
|
|
|
4,4-Dimethylcholesta-8,14,24-trienol
|
|
|
TG(15:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
Mycophenolate mofetil
|
|
|
TG(24:0/22:1(13Z)/20:3n6)
|
|
|
Menthol
|
|
|
Clorazepate
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:1(13Z)/20:0)
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:0/22:1(13Z))
|
|
|
Oxalic acid
|
An alpha,omega-dicarboxylic acid that is ethane substituted by carboxyl groups at positions 1 and 2.
|
|
DG(18:3n6/0:0/20:5n3)
|
|
|
Uric acid
|
An oxopurine that is the final oxidation product of purine metabolism.
|
|
TG(18:1(11Z)/20:3n6/24:1(15Z))
|
|
|
TG(18:1(9Z)/o-18:0/18:1(9Z))
|
|
|
Ganglioside GQ1c (d18:0/24:0)
|
|
|
Cytidine triphosphate
|
|
|
TG(24:0/22:2(13Z,16Z)/24:0)
|
|
|
TG(20:0/24:1(15Z)/18:1(11Z))
|
|
|
PE(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PC(15:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/16:0/o-18:0)
|
|
|
TG(15:0/20:3n6/16:1(9Z))
|
|
|
TG(18:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GQ1c (d18:0/18:1(11Z))
|
|
|
PC(P-18:1(11Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/24:1(15Z)/18:0)
|
|
|
TG(22:1(13Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/o-18:0)
|
|
|
Cycrimine
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(16:0/o-18:0/18:1(9Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
D-Mannose
|
A mannose with D-configuration.
|
|
PIP2(18:2(9Z,12Z)/16:0)
|
|
|
TG(14:0/15:0/24:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(24:0/18:1(9Z))
|
|
|
DG(20:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(16:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/22:0/0:0)
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(22:1(13Z)/14:1(9Z)/22:1(13Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/24:1(15Z))
|
|
|
TG(18:0/18:1(11Z)/18:1(9Z))
|
|
|
TG(20:0/20:0/24:0)
|
|
|
TG(24:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:1(13Z)/14:1(9Z))
|
|
|
2'-Deoxyinosine triphosphate
|
|
|
Ganglioside GD3 (d18:0/24:1(15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(P-18:1(11Z)/22:0)
|
|
|
Carnosine
|
|
|
TG(16:0/20:3n6/22:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/20:3n6/18:1(9Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Gonadorelin
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
Glyceraldehyde
|
An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.
|
|
6-Phosphonoglucono-D-lactone
|
|
|
TG(22:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Mesalazine
|
|
|
TG(20:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
MG(0:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
MG(0:0/14:0/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:0/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/o-18:0)
|
|
|
TG(18:1(11Z)/18:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/24:0/20:2n6)
|
|
|
12-Keto-tetrahydro-leukotriene B4
|
|
|
DG(14:0/0:0/20:5n3)
|
|
|
Ganglioside GD1b (d18:0/12:0)
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
Cysteinylglycine
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(15:0/20:3n6/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:1(13Z)/22:1(13Z))
|
|
|
PE(P-18:1(9Z)/15:0)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(24:0/24:0/18:1(11Z))
|
|
|
TG(20:0/24:1(15Z)/20:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/o-18:0)
|
|
|
TG(22:0/14:1(9Z)/16:1(9Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/16:1(9Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1c (d18:1/26:1(17Z))
|
|
|
TG(18:1(11Z)/24:0/18:2(9Z,12Z))
|
|
|
DG(14:0/18:1(9Z)/0:0)
|
|
|
TG(18:1(9Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))[iso3]
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/20:0/24:1(15Z))
|
|
|
PC(24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/14:0/16:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PE(18:1(9Z)/14:1(9Z))
|
|
|
PG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(15:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:3n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Meprobamate
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
DG(20:1n9/0:0/18:3n6)
|
|
|
TG(20:1(11Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
PG(18:1(11Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GQ1c (d18:0/24:1(15Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/18:1(9Z))
|
|
|
TG(16:0/20:2n6/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Dermatan
|
A mucopolysaccharide consisting of repeating beta-(1->4)-linked L-iduronyl-(beta1->3)-N-acetyl-D-galactosamine units.
|
|
PE(20:3(8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:2n6/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:0/16:1(9Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z))
|
|
|
(25S)-3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-26-oyl-CoA
|
A polyol that has formula C48H80N7O20P3S.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
(6Z,9Z,12Z,15Z,18Z,21Z)-3-Oxotetracosahexa-6,9,12,15,18,21-enoyl-CoA
|
|
|
PI(16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
PE(18:0/18:3(9Z,12Z,15Z))
|
|
|
Angiotensin IV
|
|
|
Ganglioside GD1b (d18:1/24:0)
|
|
|
LysoPC(16:0)
|
A lysophosphatidylcholine in which the acyl group has a fully saturated C16 chain and is attached to the glycero moiety at either position 1 or 2.
|
|
TG(16:1(9Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/o-18:0)
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/16:0)
|
|
|
TG(20:1(11Z)/22:1(13Z)/22:1(13Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:0/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/20:2n6)
|
|
|
3,5-Diiodo-L-tyrosine
|
A diiodotyrosine that is L-tyrosine carrying iodo-substituents at positions C-3 and C-5 of the benzyl group. It is an intermediate in the thyroid hormone synthesis.
|
|
O-Phosphoethanolamine
|
The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.
|
|
TG(14:1(9Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/15:0/o-18:0)
|
|
|
TG(20:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
MG(20:4(8Z,11Z,14Z,17Z)/0:0/0:0)
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/o-18:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(24:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
(23S)-23,25-dihdroxy-24-oxovitamine D3 23-(beta-glucuronide)
|
|
|
PE(24:1(15Z)/20:1(11Z))
|
|
|
TG(18:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Foscarnet
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
MG(22:1(13Z)/0:0/0:0)
|
|
|
TG(16:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(20:1(11Z)/20:0/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GT1c (d18:1/25:0)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(15:0/18:3(6Z,9Z,12Z))
|
|
|
5-Hydroxykynurenine
|
A modified amino acid that is kynurenine bearing a hydroxy group at the position para to the anilino group.
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
Butanal
|
A member of the class of butanals that consists of propane bearing a formyl substituent at the 1-position. The parent of the class of butanals.
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:2(13Z,16Z)/18:0/0:0)
|
|
|
TG(18:1(9Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Ganglioside GT1b (d18:1/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
L-Tryptophan
|
The L-enantiomer of tryptophan.
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
CDP-DG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:1(13Z)/14:0)
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
5-Aminoimidazole ribonucleotide
|
|
|
beta-D-Fructose 1,6-bisphosphate
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(15:0/20:2(11Z,14Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
Indapamide
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(22:1(13Z)/18:1(11Z)/20:3n6)
|
|
|
DG(18:2n6/0:0/18:3n6)
|
|
|
TG(22:1(13Z)/15:0/22:2(13Z,16Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/16:1(9Z)/0:0)
|
|
|
Amylose
|
A glucan composed of unbranched chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage.
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3n6/22:2(13Z,16Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(16:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Betamethasone
|
A glucocorticoid that has formula C22H29FO5.
|
|
PC(22:1(13Z)/16:0)
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1a (d18:1/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
DG(20:0/0:0/20:4n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Formyl-5-hydroxykynurenamine
|
A hydroxykynurenamine that is 5-hydroxykynurenamine with the hydrogen on the aryl amine replaced by a formyl group.
|
|
PC(18:1(11Z)/24:0)
|
|
|
TG(14:1(9Z)/20:0/22:1(13Z))
|
|
|
2-Chloro-5-methylmaleylacetate
|
An oxo carboxylic acid that has formula C7H7ClO5.
|
|
PC(P-16:0/24:0)
|
|
|
TG(24:0/20:2n6/18:1(11Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(P-18:0/22:1(13Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
Methimazole
|
A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.
|
|
Desvenlafaxine
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/15:0/18:2(9Z,12Z))
|
|
|
PC(24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/16:1(9Z)/18:1(11Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/16:1(9Z)/0:0)
|
|
|
PE(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:0/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:1(13Z)/20:0)
|
|
|
PE(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
DG(18:0/0:0/20:3n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
Ganglioside GD2 (d18:1/24:1(15Z))
|
|
|
DL-O-Phosphoserine
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:1(11Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1a (d18:1/12:0)
|
|
|
PC(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:0/16:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Choloyl-CoA
|
A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of cholic acid.
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(18:1(11Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
DG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(15:0/24:0/16:0)
|
|
|
Guanosine 3'-diphosphate 5'-triphosphate
|
A guanosine bisphosphate having a diphosphate at the 3'-position and a triphosphate at the 5'-position.
|
|
TG(22:2(13Z,16Z)/16:0/o-18:0)
|
|
|
PE(14:0/20:1(11Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(24:0/0:0/20:4n3)
|
|
|
PIP(18:0/16:0)
|
|
|
TG(24:0/18:0/22:2(13Z,16Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT2 (d18:1/25:0)
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/14:0/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/18:2(9Z,12Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z))
|
|
|
TG(16:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/16:1(9Z)/20:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Thioguanine
|
|
|
TG(22:0/16:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
L-Octanoylcarnitine
|
|
|
4-Hydroxy-2-oxoglutaric acid
|
An oxo dicarboxylic acid comprising glutaric acid having oxo- and hydroxy substituents at the 2- and 4-positions respectively.
|
|
Esmolol
|
A carboxylic ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenoic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery.
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z))
|
|
|
Gamma Hydroxybutyric Acid
|
|
|
3a,7a,12a-Trihydroxy-5b-cholest-24-enoyl-CoA
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/20:2n6)
|
|
|
TG(14:0/20:3n6/o-18:0)
|
|
|
Phenacemide
|
|
|
Xanthylic acid
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z))
|
|
|
TG(24:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:3n6/20:2n6)
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
Itraconazole
|
A dioxolane that has formula C35H38Cl2N8O4.
|
|
TG(24:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
Abacavir
|
|
|
TG(24:0/o-18:0/22:2(13Z,16Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Liotrix
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(16:0/18:0/20:0)[iso6]
|
|
|
TG(15:0/20:0/16:1(9Z))
|
|
|
TG(18:1(11Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Erythrityl Tetranitrate
|
|
|
PIP(20:1(11Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(11Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/0:0)
|
|
|
TG(20:3n6/14:1(9Z)/o-18:0)
|
|
|
TG(18:0/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/20:0)
|
|
|
TG(24:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/16:1(9Z)/20:3n6)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(O-16:1(1Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
SM(d18:0/18:0)
|
|
|
Tocainide
|
|
|
PE(20:3(5Z,8Z,11Z)/22:0)
|
|
|
Bezafibrate
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
PI(16:0/16:0)
|
A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is also hexadecanoyl.
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(20:1(11Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Genistein
|
7-Hydroxyisoflavone with additional hydroxy groups at positions 5 and 4'. It is a phytoestrogenic isoflavone with antioxidant properties.
|
|
PC(18:3(9Z,12Z,15Z)/14:0)
|
|
|
TG(18:1(9Z)/20:2n6/18:1(9Z))
|
|
|
TG(20:2n6/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:0/20:1(11Z))
|
|
|
2-Polyprenyl-6-methoxy-1,4-benzoquinone
|
|
|
TG(20:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:2(11Z,14Z)/18:1(11Z)/0:0)
|
|
|
Triphosphate
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/20:1(11Z)/16:0)
|
|
|
TG(22:0/22:0/16:1(9Z))
|
|
|
Moxifloxacin
|
A quinolone that consits of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.
|
|
Fluorouracil
|
|
|
TG(14:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/16:0/18:1(9Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
PC(16:1(9Z)/18:1(11Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/0:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/o-18:0)
|
|
|
DG(20:0/0:0/22:5n3)
|
|
|
TG(16:1(9Z)/20:0/18:1(9Z))
|
|
|
DG(16:0/24:0/0:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
Hemin
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/24:0/o-18:0)
|
|
|
TG(22:0/14:0/22:2(13Z,16Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
Isocitric acid
|
A tricarboxylic acid that is propan-1-ol with a hydrogen at each of the 3 carbon positions substituted with a carboxy group.
|
|
2,8-Dihydroxyquinoline-beta-D-glucuronide
|
|
|
PC(20:2(11Z,14Z)/22:0)
|
|
|
LPA(16:0/0:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(18:1(11Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/16:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:2(11Z,14Z)/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Zonisamide
|
A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
|
|
PC(18:2(9Z,12Z)/24:1(15Z))
|
|
|
Diphthine
|
A quaternary ammonium ion consisting of L-histidine with a 3-(trimethylammonio)-3-carboxypropyl group at the 2-position of the the imidazole ring.
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(24:1(15Z)/20:0/0:0)
|
|
|
Molybdenum
|
A chromium group element atom that has formula Mo.
|
|
PS(16:0/16:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD1a (d18:0/26:1(17Z))
|
|
|
DG(22:1(13Z)/24:1(15Z)/0:0)
|
|
|
TG(14:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
TG(15:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Nitroglycerin
|
A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
|
|
TG(20:2n6/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Diflunisal
|
An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.
|
|
TG(18:0/18:0/20:0)[iso3]
|
|
|
L-Aspartic acid
|
The L-enantiomer of aspartic acid.
|
|
TG(14:1(9Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:3n6/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:3n6/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Pheniramine
|
|
|
TG(18:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(22:1(13Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:3n6/20:1(11Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/14:0/0:0)
|
|
|
TG(16:0/20:0/18:1(11Z))
|
|
|
PC(22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/20:0/22:2(13Z,16Z))
|
|
|
Trypanothione disulfide
|
Trypanothione disulfide is the oxidized form of N(1),N(8)-bis(glutathionyl)-spermidine from the insect-parasitic trypanosomatid Crithidia fasciculata.
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(20:0/20:2n6/16:1(9Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
Melibiose
|
A glycosylglucose formed by an alpha-(1->6)-linkage between D-galactose and D-glucose.
|
|
TG(14:1(9Z)/20:3n6/22:2(13Z,16Z))
|
|
|
Tridecanoyl-CoA
|
A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of tridecanoic acid.
|
|
TG(18:0/18:0/24:0)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/P-16:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
CE(10:0)
|
|
|
TG(20:1(11Z)/14:0/o-18:0)
|
|
|
CE(12:0)
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(14:0/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM3 (d18:1/23:0)
|
|
|
Cinnavalininate
|
A phenoxazine that has formula C14H8N2O6.
|
|
TG(20:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/24:0/18:2(9Z,12Z))
|
|
|
CE(18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:3(8Z,11Z,14Z))[iso3]
|
|
|
TG(20:2n6/22:1(13Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:1(13Z)/24:1(15Z))
|
|
|
TG(14:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/14:0/22:1(13Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:1(13Z)/0:0)
|
|
|
TG(20:1(11Z)/22:0/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
3-Aminosalicylic acid
|
|
|
TG(14:0/14:0/18:1(9Z))
|
|
|
Delta7-Avenasterol
|
A steroid that has formula C29H48O.
|
|
DG(16:1(9Z)/15:0/0:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(9Z)/24:1(15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
PI(16:0/18:0)
|
|
|
TG(22:0/18:1(9Z)/18:1(11Z))
|
|
|
DG(18:1n9/0:0/20:4n3)
|
|
|
TG(22:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(24:1(15Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/24:1(15Z)/18:0)
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
L-Palmitoylcarnitine
|
|
|
TG(22:1(13Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/P-18:1(11Z))
|
|
|
PG(16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD2 (d18:0/22:0)
|
|
|
DG(20:0/20:2(11Z,14Z)/0:0)
|
|
|
TG(22:0/22:1(13Z)/22:0)
|
|
|
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PC(22:0/P-18:0)
|
|
|
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Olanzapine
|
A benzodiazepine that has formula C17H20N4S.
|
|
Levosimendan
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PE(P-18:0/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Bismuth Subsalicylate
|
A bismuth salt of salicylic acid.
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
L-Iditol
|
The L-enantiomer of iditol.
|
|
DG(20:3n9/0:0/20:3n9)
|
|
|
TG(14:1(9Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PI(18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Glyceric acid 1,3-biphosphate
|
|
|
TG(20:2n6/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:0/18:2(9Z,12Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/0:0)
|
|
|
Allodeoxycholic acid
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP(18:1(11Z)/16:1(9Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Prostaglandin H2
|
A prostaglandins H that has formula C20H32O5.
|
|
DG(18:3(9Z,12Z,15Z)/20:1(11Z)/0:0)
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
(S)-3-Hydroxy-N-methylcoclaurine
|
An isoquinoline alkaloid having a tetrahydroisoquinoline core with 3,4-dihydroxybenzyl, methoxy and hydroxy groups at the 1-, 6- and 7-positions respectively; major species at pH 7.3.
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
PE(24:0/15:0)
|
|
|
TG(20:0/22:0/20:2n6)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
PIP2(16:1(9Z)/18:1(9Z))
|
|
|
TG(18:0/15:0/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3n6/20:2n6)
|
|
|
Oxybutynin
|
An acetylenic compound that has formula C22H31NO3.
|
|
TG(16:0/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(14:0/20:1(11Z)/22:0)
|
|
|
TG(15:0/18:1(9Z)/15:0)
|
|
|
Diethylcarbamazine
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Rescinnamine
|
|
|
DG(22:1n9/0:0/22:1n9)
|
|
|
PC(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:2(13Z,16Z)/20:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/0:0)
|
|
|
Riluzole
|
|
|
DG(18:3n6/0:0/22:5n6)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3-O-Sulfogalactosylceramide (d18:1/16:0)
|
|
|
TG(16:0/20:0/20:1(11Z))[iso6]
|
|
|
PC(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
Pentostatin
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Carbon dioxide
|
A one-carbon compound with formula CO2 in which the carbon is attached to each oxygen atom by a double bond. A colourless, odourless gas under normal conditions, it is produced during respiration by all animals, fungi and microorganisms that depend directly or indirectly on living or decaying plants for food.
|
|
TG(20:1(11Z)/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/20:2n6)
|
|
|
TG(22:1(13Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
6-Methylthiopurine 5'-monophosphate ribonucleotide
|
An organic molecule that has formula C11H15N4O7PS.
|
|
TG(20:1(11Z)/20:1(11Z)/20:1(11Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/20:0/0:0)
|
|
|
Calcidiol
|
A hydroxycalciol that is calciol in which the hydrogen at position 25 has been replaced by a hydroxy group. A prehormone resulting from the oxidation of calciol in the liver, it is further hydroxylated in the kidney to give calcitriol, the active form of vitamin D3.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:1(11Z)/P-18:1(11Z))
|
|
|
PE(24:1(15Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
19-Hydroxytestosterone
|
A 3-oxo Delta(4)-steroid that is testosterone which is substituted by a hydroxy group at positions 19.
|
|
TG(20:3n6/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
Deoxyhypusine
|
An L-lysine derivative in which the N(6) of the lysine is substituted with a 4-aminobutyl group.
|
|
DG(18:2n6/0:0/22:5n6)
|
|
|
TG(18:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Acamprosate
|
|
|
TG(16:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP3(18:0/18:1(11Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
PC(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))
|
|
|
N-Desmethylaminopyrine
|
|
|
Betaine aldehyde
|
A quaternary ammonium ion that is nitrogen substituted by three methyl groups and a 2-oxoethyl group. It is an intermediate in the metabolism of amino acids like glycine, serine and threonine.
|
|
TG(22:1(13Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
TG(20:1(11Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(14:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
Methylcysteine
|
|
|
TG(20:1(11Z)/20:0/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Tiglyl-CoA
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
Prunasin
|
A cyanogenic glycoside that has formula C14H17NO6.
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(16:0/22:1(13Z)/16:1(9Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
PC(24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/16:1(9Z)/22:0)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
4-Hydroxyphenylpyruvic acid
|
An oxo carboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.
|
|
DG(20:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
PIP(16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/16:0/22:0)
|
|
|
TG(24:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
Quercetin
|
A pentahydroxyflavone having the five hydroxy groups placed at the 3-, 3'-, 4'-, 5- and 7-positions.
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
Daidzin
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/P-18:0)
|
|
|
TG(20:2n6/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Thiothixene
|
|
|
TG(18:1(9Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/15:0)
|
|
|
3-Hexaprenyl-4-hydroxy-5-methoxybenzoic acid
|
A methoxybenzoic acid that has formula C38H56O4.
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:2n6/20:1(11Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
1b,3a,12a-Trihydroxy-5b-cholanoic acid
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:4n6/0:0/18:4n3)
|
|
|
TG(20:0/22:1(13Z)/18:1(9Z))
|
|
|
LysoPC(22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:0/20:2n6)
|
|
|
TG(18:1(11Z)/20:0/18:2(9Z,12Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Allantoic acid
|
A member of the class of ureas that consists of acetic acid in which the two methyl hydrogens are replaced by carbamoylamino groups respectively.
|
|
PC(18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
D-Arginine
|
A D-alpha-amino acid that is the D-isomer of arginine.
|
|
TG(24:1(15Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:0/o-18:0)
|
|
|
DG(18:1(11Z)/20:0/0:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/o-18:0)
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/16:1(9Z)/18:1(11Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/24:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
3-Sulfopyruvic acid
|
A carboxyalkanesulfonic acid comprising pyruvic acid with a sulfo group attached at the C-3 position.
|
|
Oxamniquine
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(24:0/14:1(9Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
DG(16:1(9Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
D-Tagatose 1,6-bisphosphate
|
A ketohexose bisphosphate that is D-tagatose carrying phosphate groups at positions 1 and 6.
|
|
Sibutramine
|
|
|
PIP(20:3(8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
DG(16:1(9Z)/14:1(9Z)/0:0)
|
|
|
DG(20:2(11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:1(11Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Hydrogen Ion
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:0/20:2n6)
|
|
|
TG(24:1(15Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/24:1(15Z)/14:1(9Z))
|
|
|
DG(18:3n6/0:0/18:3n6)
|
|
|
TG(18:1(11Z)/20:3n6/18:2(9Z,12Z))
|
|
|
DG(22:0/0:0/14:1n5)
|
|
|
TG(18:0/16:1(9Z)/16:1(9Z))
|
|
|
PC(24:0/14:1(9Z))
|
|
|
TG(15:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
5-Methylthioribulose 1-phosphate
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
7-Ketocholesterol
|
A cholestanoid that consists of cholesterol bearing an oxo substituent at position 7.
|
|
TG(14:1(9Z)/20:1(11Z)/o-18:0)
|
|
|
Nicotinuric acid
|
An N-acylglycine having nicotinoyl as the acyl substituent.
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0/o-18:0)
|
|
|
TG(20:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(24:0/24:1(15Z)/24:1(15Z))
|
|
|
Cyclobenzaprine
|
5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.
|
|
TG(22:0/15:0/20:1(11Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(14:0/22:0/18:1(9Z))
|
|
|
TG(14:0/o-18:0/18:2(9Z,12Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Nebularine
|
A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.
|
|
TG(22:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/22:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(14:1(9Z)/16:1(9Z))
|
|
|
Cytidine
|
A pyrimidine nucleoside in which cytosine is attached to ribofuranose via a beta-N(1)-glycosidic bond.
|
|
TG(15:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Anandamide
|
A fatty amide obtained by the formal condensation of arachidonic acid with ethanolamine.
|
|
Sphingosine 1-phosphate
|
A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1
|
|
Dimethyl selenide
|
An organoselenium compound of two methyl groups covalently bound to a selenium.
|
|
DG(22:5n6/0:0/18:3n3)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(18:0/20:1(11Z)/20:0)
|
|
|
PC(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/o-18:0)
|
|
|
TG(22:0/o-18:0/20:3n6)
|
|
|
(S)-N-Methylcoclaurine
|
The (S)-enantiomer of N-methylcoclaurine.
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:0/22:1(13Z))
|
|
|
TG(14:0/20:1(11Z)/15:0)
|
|
|
TG(24:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/24:0/20:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/14:0/20:1(11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:0/o-18:0)
|
|
|
TG(16:1(9Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
beta-Alanyl-L-arginine
|
A dipeptide that has formula C9H19N5O3.
|
|
Vinblastine
|
|
|
PE(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/15:0/14:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/14:0/20:3n6)
|
|
|
PE(18:1(11Z)/20:1(11Z))
|
|
|
PI(22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3n6/0:0/22:2n6)
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(22:1(13Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/16:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(20:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/18:0/20:3n6)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Butenafine
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
Propranolol
|
A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
|
|
PE(20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(15:0/20:2n6/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/22:2(13Z,16Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/24:1(15Z)/20:3n6)
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(16:0/o-18:0/16:0)
|
|
|
Succinyl-CoA
|
An omega-carboxyacyl-CoA having succinoyl as the S-acyl component.
|
|
TG(24:1(15Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:2n6)
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:0/o-18:0)
|
|
|
DG(20:2(11Z,14Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
DG(16:1(9Z)/16:0/0:0)
|
|
|
Didemethylcitalopram
|
An organic amino compound that has formula C18H17FN2O.
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Mannose 6-phosphate
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GD1a (d18:1/26:0)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
CMP-2-aminoethylphosphonate
|
A nucleotide 2-aminoethylphosphonate that has formula C11H20N4O10P2.
|
|
Nicotinic acid
|
A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/16:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(14:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:1(13Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/15:0/24:1(15Z))
|
|
|
MG(24:1(15Z)/0:0/0:0)
|
|
|
Allopurinol
|
A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
L-3-Hydroxykynurenine
|
Tha amino acid zwitterion formed from 5-hydroxy-L-kynurenine by transfer of a proton from the carboxy to the amino group; principal microspecies at pH 7.3.
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
Hydroxyzileuton
|
|
|
PE(15:0/18:1(11Z))
|
|
|
TG(22:0/o-18:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(24:0/14:1(9Z)/24:1(15Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:0/15:0/0:0)
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
LysoPC(18:1(11Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
Ketoleucine
|
|
|
TG(22:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
3-Oxo-OPC4-CoA
|
An organic molecule that has formula C35H54N7O19P3S.
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
Ganglioside GD3 (d18:0/18:0)
|
|
|
TG(20:2n6/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/24:1(15Z))
|
|
|
DG(18:1(9Z)/18:1(9Z)/0:0)
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Tropicamide
|
|
|
PE(15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
Meperidine
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
PG(18:0/20:3(8Z,11Z,14Z))
|
|
|
TG(20:2n6/22:0/22:2(13Z,16Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
5-Fluorouridine monophosphate
|
|
|
TG(22:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:0/dm18:0)
|
|
|
TG(20:2n6/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Pimecrolimus
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
TG(16:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cholesterol
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1b (d18:0/24:0)
|
|
|
TG(14:0/14:0/14:0)
|
|
|
Dihydroneopterin triphosphate
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(22:1(13Z)/15:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/18:1(9Z))
|
|
|
TG(24:0/20:0/24:0)
|
|
|
TG(22:0/24:0/24:0)
|
|
|
Phenol sulphate
|
|
|
3-Mercaptolactic acid
|
A (2R)-2-hydroxy monocarboxylic acid consisting of lactic acid having a sulfanyl group at the 3-position.
|
|
Diadenosine hexaphosphate
|
|
|
PE(16:1(9Z)/14:0)
|
|
|
TG(18:0/18:1(9Z)/18:1(9Z))[iso3]
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
Benzocaine
|
A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
DG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
DG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/o-18:0)
|
|
|
Ganglioside GT1b (d18:0/22:0)
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
Dalfopristin
|
|
|
Hydroxymethylbilane
|
|
|
(S)-2-amino-6-oxohexanoate
|
|
|
TG(24:1(15Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)
|
|
|
DG(16:1n7/0:0/20:4n3)
|
|
|
Carmustine
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PIP(18:1(9Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/18:1(11Z))
|
|
|
PC(18:1(11Z)/P-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/22:1(13Z))
|
|
|
PC(20:2(11Z,14Z)/P-18:1(9Z))
|
|
|
TG(20:0/16:0/20:2n6)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(o-22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Ceramide (d18:1/9Z-18:1)
|
|
|
LysoSM(d18:1)
|
|
|
TG(22:1(13Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/16:1(9Z)/18:0)
|
|
|
SM(d18:1/23:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/20:2n6)
|
|
|
Phendimetrazine
|
|
|
TG(20:0/24:0/24:1(15Z))
|
|
|
PC(20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
Hydroxyacetone
|
A propanone that is acetone in which one of the methyl hydrogens is replaced by a hydroxy group.
|
|
TG(14:1(9Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
Glycochenodeoxycholic acid 3-glucuronide
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(24:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
D-Tryptophan
|
The D-enantiomer of tryptophan.
|
|
TG(18:1(9Z)/16:0/22:2(13Z,16Z))
|
|
|
PA(18:1(11Z)/18:1(11Z))
|
|
|
TG(20:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:2n6/16:0/22:2(13Z,16Z))
|
|
|
TG(20:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:1(11Z)/P-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(20:3n6/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
Olomoucine
|
|
|
TG(24:1(15Z)/18:0/18:2(9Z,12Z))
|
|
|
DG(14:1(9Z)/16:0/0:0)
|
|
|
3a,7a-Dihydroxy-5b-24-oxocholestanoyl-CoA
|
|
|
25-Hydroxyvitamin D2-25-glucuronide
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:2(13Z,16Z)/P-16:0)
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GM1 (d18:0/20:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/0:0)
|
|
|
Ganglioside GM2 (d18:1/26:0)
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Dopaquinone
|
|
|
TG(14:1(9Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GM2 (d18:1/24:0)
|
|
|
TG(22:0/24:0/18:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/0:0)
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
PE(24:1(15Z)/P-18:1(9Z))
|
|
|
TG(20:3n6/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(11Z)/24:0)
|
|
|
TG(18:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
Methylimidazoleacetic acid
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
PC(o-18:1(9Z)/16:0)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:1(11Z)/16:0)
|
|
|
TG(22:0/16:0/16:1(9Z))
|
|
|
Podofilox
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
Phenmetrazine
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:3n6/20:2n6)
|
|
|
PS(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Cer(d18:0/25:0)
|
|
|
PE(15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:1(13Z)/18:1(11Z))
|
|
|
TG(20:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:4n6/0:0/22:5n3)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
Prochlorperazine
|
A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.
|
|
PC(14:1(9Z)/14:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:0)
|
|
|
PC(P-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:1(11Z)/18:0)
|
|
|
PC(24:1(15Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Decanoyl-CoA (n-C10:0CoA)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/o-18:0)
|
|
|
TG(20:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(16:0/0:0/22:1n9)
|
|
|
2-Hydroxyestrone-4-S-glutathione
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(18:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3,4-Dihydroxyphenylacetaldehyde
|
A phenylacetaldehyde in which the 3 and 4 positions of the phenyl group are substituted by hydroxy groups.
|
|
Hesperidin
|
A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.
|
|
TG(14:0/18:3(9Z,12Z,15Z)/16:0)
|
|
|
Phosphoribosyl-ATP
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
N-Acetylneuraminic acid
|
An N-acylneuraminic acid where the N-acyl group is specified as acetyl.
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/24:1(15Z)/18:1(11Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
Procaine
|
A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.
|
|
Dactinomycin
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
DG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PIP(18:0/18:1(11Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
Undecanoic acid
|
A straight-chain, eleven-carbon saturated medium-chain fatty acid found in body fluids; the most fungitoxic of the C7:0 - C18:0 fatty acid series.
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/20:2n6)
|
|
|
TG(18:1(11Z)/24:0/20:3(5Z,8Z,11Z))
|
|
|
PE(22:0/18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:2n6/24:0)
|
|
|
TG(16:1(9Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Fusidic Acid
|
A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(18:1(9Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Benzylamine
|
A primary amine compound having benzyl as the N-substituent. It has been isolated from Moringa oleifera (horseradish tree).
|
|
TG(14:0/20:3n6/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/14:1(9Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Nelarabine
|
|
|
TG(22:2(13Z,16Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:1(9Z)/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1b (d18:0/20:0)
|
|
|
TG(20:1(11Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP2(20:3(8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Talbutal
|
|
|
TG(22:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:1(13Z)/14:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
1-Methylpyrrolinium
|
An organic cation that is 1-pyrroline bearing an N-methyl substituent.
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3a,11b,21-Trihydroxy-20-oxo-5b-pregnan-18-al
|
|
|
Ethyl pyruvate
|
|
|
Mevalonic acid-5P
|
|
|
TG(22:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/20:0/20:2n6)
|
|
|
TG(16:1(9Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
PG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
(3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-3-yl-b-D-Glucopyranosiduronic acid
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
3b,12b-Dihydroxy-5b-cholanoic acid
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CDP-DG(18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Porphobilinogen
|
A dicarboxylic acid that is pyrole bearing aminomethyl, carboxymethyl and 2-carboxyethyl substituents at positions 2, 3 and 4 respectively.
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
3b,7b,12a-Trihydroxy-5b-cholanoic acid
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PA(18:1(11Z)/18:1(9Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:0)
|
|
|
TG(22:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/18:1(11Z)/24:1(15Z))
|
|
|
1D-Myo-inositol 1,3-bisphosphate
|
|
|
N-Desmethylcitalopram
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Adenosyl cobyrinic acid a,c diamide
|
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:1(11Z)/16:0)
|
|
|
TG(22:1(13Z)/22:0/24:1(15Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:0)
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
PE(P-18:1(9Z)/22:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Masoprocol
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(15:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:0)
|
|
|
PE(P-18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:1(13Z)/18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:0/o-18:0)
|
|
|
N-Methylserotonin
|
A member of the class of tryptamines that is serotonin in which one of the hydrogens attached to the primary amino group is replaced by a methyl group.
|
|
PE(P-18:1(11Z)/14:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/o-18:0/24:1(15Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
PE(P-18:1(9Z)/20:0)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
PC(14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/20:3n6)
|
|
|
TG(20:1(11Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Carbenicillin
|
|
|
2-Chloro-5-methyl-cis-dienelactone
|
A butenolide that has formula C7H5ClO4.
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/15:0/o-18:0)
|
|
|
DG(18:0/0:0/20:1n9)
|
|
|
DG(24:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:1(11Z)/20:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3n6/18:1(9Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/24:0/20:1(11Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/20:3n6)
|
|
|
PE(22:1(13Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/20:0/22:1(13Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
5-Thymidylic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:0/18:1(9Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/o-18:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/20:2n6/18:2(9Z,12Z))
|
|
|
TG(16:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Paliperidone
|
|
|
TG(20:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Pregnanediol-3-glucuronide
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
Arachidonyl-CoA
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Propylthiouracil
|
|
|
PS(18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(14:0/16:0/16:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3n6/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Phenylpropanolamine
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:2n6)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
PC(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
Ganglioside GM3 (d18:0/23:0)
|
|
|
TG(18:2(9Z,12Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
DG(15:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(18:1(9Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
20a-Dihydroprogesterone
|
|
|
TG(15:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
SM(d18:1/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/24:0/22:1(13Z))
|
|
|
D-erythro-Eritadenine
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/14:0/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
Metronidazole
|
A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:2n6)
|
|
|
TG(15:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
Ethopropazine
|
|
|
Purine
|
A heterobicyclic aromatic organic compound comprising a pyrimidine ring fused to an imidazole ring; the parent compound of the purines.
|
|
TG(18:1(9Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/18:1(9Z)/22:0)
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Nimodipine
|
A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
|
|
PC(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/o-18:0/24:1(15Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:4n6/0:0/20:4n3)
|
|
|
PC(20:0/18:1(11Z))
|
|
|
TG(18:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:1(11Z)/20:1(11Z)/0:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(20:1(11Z)/14:0/20:3n6)
|
|
|
Imiquimod
|
An imidazoquinoline that has formula C14H16N4.
|
|
PC(22:0/20:2(11Z,14Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:0/20:3n6)
|
|
|
TG(20:0/22:0/20:1(11Z))
|
|
|
PS(16:0/18:0)
|
|
|
9(S)-HPODE
|
An HPODE (hydroperoxy-octadecadienoic acid) in which the double bonds are at positions 10 and 12 (E and Z geometry, respectively) and the hydroperoxy group is at position 9 (S configuration). It is an intermediate in the metabolic pathway for linoleic acid.
|
|
PC(18:2(9Z,12Z)/20:1(11Z))
|
|
|
PG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:1(11Z)/22:1(13Z))
|
|
|
DG(22:2(13Z,16Z)/22:0/0:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
Neuraminic acid
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Edetic Acid
|
|
|
TG(14:0/20:3n6/20:2n6)
|
|
|
PE(18:1(11Z)/16:1(9Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(16:0/20:0/20:3n6)
|
|
|
TG(24:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
Phenethylamine glucuronide
|
|
|
TG(20:0/18:0/14:1(9Z))
|
|
|
TG(20:1(11Z)/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/22:2(13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(24:0/15:0)
|
|
|
DG(20:2(11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(20:2n6/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/24:1(15Z))
|
|
|
DG(18:2n6/0:0/22:4n6)
|
|
|
Ranolazine
|
|
|
3-Hydroxy-N6,N6,N6-trimethyl-L-lysine
|
The 3-hydroxy derivative of N(6),N(6),N(6)-trimethyl-L-lysine
|
|
TG(15:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
DG(22:0/0:0/20:4n3)
|
|
|
PIP2(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:0/20:1(11Z))
|
|
|
PE(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:1(11Z)/18:1(11Z))
|
|
|
Perillyl alcohol
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
Ecabet
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Acetohexamide
|
An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.
|
|
Celecoxib
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/o-18:0)
|
|
|
5-HETE
|
A HETE having a 5-hydroxy group and (6E)-, (8Z)-, (11Z)- and (14Z)-double bonds.
|
|
TG(18:0/16:0/22:2(13Z,16Z))
|
|
|
PC(P-18:1(11Z)/24:1(15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/24:0/22:1(13Z))
|
|
|
3a,4b,12a-Trihydroxy-5b-cholanoic acid
|
|
|
TG(16:1(9Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
CDP-glycerol
|
A nucleotide-alditol having cytidine-5'-diphosphate and glycerol as the nucleotide and alditol components respectively.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/20:0/22:1(13Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(16:1(9Z)/18:0/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:1(13Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
PE(18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(9Z)/16:0)
|
|
|
DG(16:1n7/0:0/22:6n3)
|
|
|
TG(20:2n6/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Galactosylglycerol
|
|
|
TG(18:1(11Z)/o-18:0/18:1(11Z))
|
|
|
TG(14:1(9Z)/20:2n6/o-18:0)
|
|
|
TG(14:1(9Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
PI(16:0/18:2(9Z,12Z))
|
|
|
Dodecanoic acid
|
A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.
|
|
TG(16:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(18:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
Bethanechol
|
The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.
|
|
PE(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(24:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/14:0)
|
|
|
TG(15:0/18:0/14:1(9Z))
|
|
|
Phenylethylamine
|
|
|
11,12-EpETrE
|
|
|
DG(14:1n5/0:0/20:2n6)
|
|
|
TG(16:1(9Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
Mannosyl-inositol-phosphorylceramide
|
A class of complex phosphoglycosphingolipids with a mannose-inositol-P head group. As with other ceramide derivatives, substituents R(1) and R(2) vary with different sphingoid bases and fatty acyl moieties.
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
5,6-Epoxy-8,11,14-eicosatrienoic acid
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:0)
|
|
|
PC(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:1(9Z)/18:0)
|
|
|
PE(22:2(13Z,16Z)/14:0)
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/18:1(9Z))
|
|
|
5-Aminopentanal
|
An aldehyde that has formula C5H11NO.
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
Griseofulvin
|
Antibiotic produced by Penicillium griseofulvum.
|
|
DG(22:2(13Z,16Z)/16:0/0:0)
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
Toremifene
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:1(11Z)/18:0/0:0)
|
|
|
Hexylcaine
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(o-18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:2(9Z,12Z)/14:0/0:0)
|
|
|
TG(24:1(15Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/24:0/o-18:0)
|
|
|
Pantoprazole
|
A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:2(11Z,14Z)/15:0/0:0)
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
PE(16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:2(13Z,16Z)/16:0)
|
|
|
TG(22:2(13Z,16Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Isohyodeoxycholic acid
|
|
|
Ganglioside GT2 (d18:0/18:0)
|
|
|
TG(16:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/18:1(11Z))
|
|
|
TG(20:0/24:1(15Z)/20:0)
|
|
|
TG(20:1(11Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:1(11Z)/18:2(9Z,12Z)/0:0)
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(16:1(9Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
CDP-DG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD1a (d18:1/18:1(9Z))
|
|
|
TG(18:1(9Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Estriol-17-glucuronide
|
|
|
TG(15:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Phenoxybenzamine
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:1(9Z))[iso3]
|
|
|
TG(20:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PG(18:0/18:3(6Z,9Z,12Z))
|
|
|
PC(14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/16:0/0:0)
|
|
|
Olsalazine
|
|
|
Ganglioside GM1 (18:1/12:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/20:3n6)
|
|
|
TG(24:0/16:0/18:3(9Z,12Z,15Z))
|
|
|
Tetrahydrofolyl-[Glu](n)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/22:2(13Z,16Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Brompheniramine
|
Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.
|
|
Ganglioside GM1 (d18:0/18:1(11Z))
|
|
|
TG(16:0/20:2n6/22:0)
|
|
|
TG(20:2n6/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
L-Asparagine
|
An optically active form of asparagine having L-configuration.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Acetohydroxamic Acid
|
|
|
DG(22:4n6/0:0/22:5n3)
|
|
|
TG(15:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
PC(16:0/20:0)
|
|
|
Cerulenin
|
An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.
|
|
TG(20:3n6/20:1(11Z)/20:3n6)
|
|
|
TG(20:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(16:0/22:0)
|
|
|
PE(20:0/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GT1b (d18:1/25:0)
|
|
|
TG(24:0/20:0/14:1(9Z))
|
|
|
PC(22:0/15:0)
|
|
|
PC(P-16:0/18:0)
|
|
|
TG(22:0/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
D-Galactose
|
|
|
DG(16:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(16:0/24:0/22:2(13Z,16Z))
|
|
|
TG(18:0/14:0/20:2n6)
|
|
|
Mepyramine
|
An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.
|
|
TG(24:1(15Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/16:1(9Z))
|
|
|
DG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
PE(20:2(11Z,14Z)/P-18:0)
|
|
|
DG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
Heparin
|
A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1->4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/22:0/22:2(13Z,16Z))
|
|
|
Pyrimethamine
|
|
|
Tiaprofenic acid
|
An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group.
|
|
TG(18:2(9Z,12Z)/14:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
PE(20:2(11Z,14Z)/P-16:0)
|
|
|
PIP2(20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(15:0/14:0/20:1(11Z))
|
|
|
DG(22:1n9/0:0/22:5n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:2(11Z,14Z)/14:0/0:0)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(16:1(9Z)/o-18:0/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/14:1(9Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(15:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(20:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GD3 (d18:0/26:1(17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:0/18:1(9Z))
|
|
|
Ganglioside GT3 (d18:0/24:1(15Z))
|
|
|
Ganglioside GT1b (d18:1/23:0)
|
|
|
TG(15:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/20:2n6/20:2n6)
|
|
|
TG(18:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Retinyl ester
|
A carboxylic ester obtained by formal condensation of the hydroxy group of retinol with the carboxy group of any carboxylic acid.
|
|
PC(P-18:1(9Z)/14:1(9Z))
|
|
|
TG(18:0/22:1(13Z)/o-18:0)
|
|
|
PE(P-18:0/16:0)
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:0)
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/14:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/15:0/22:1(13Z))
|
|
|
TG(14:1(9Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:0)
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
Lofexidine
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
PE(P-18:0/14:0)
|
|
|
Galabiosylceramide (d18:1/22:0)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0/0:0)
|
|
|
DG(20:3n6/0:0/20:3n6)
|
|
|
Ganglioside GD2 (d18:1/12:0)
|
|
|
TG(18:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:0/20:2n6)
|
|
|
Ganglioside GD2 (d18:0/16:0)
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
4-Methylpentanal
|
An alpha-CH2-containing aldehyde that has formula C6H12O.
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Galabiosylceramide (d18:1/24:0)
|
|
|
TG(22:1(13Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/15:0/o-18:0)
|
|
|
TG(20:2n6/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(24:0/o-18:0/18:1(9Z))
|
|
|
PC(20:1(11Z)/22:0)
|
|
|
TG(16:0/20:1(11Z)/20:2n6)
|
|
|
TG(22:0/20:2n6/22:0)
|
|
|
PE(22:0/18:1(11Z))
|
|
|
TG(22:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/20:3n6/18:1(9Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(18:1(11Z)/22:0/22:2(13Z,16Z))
|
|
|
Ceramide (d18:1/12:0)
|
|
|
DG(16:0/0:0/18:1n9)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PIP2(18:1(9Z)/18:0)
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
2-Bromoacetaldehyde
|
An organobromine compound that has formula C2H3BrO.
|
|
TG(18:0/22:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/20:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)/o-18:0)
|
|
|
Propoxyphene
|
A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.
|
|
TG(20:0/20:0/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
8-oxo-dGDP
|
A purine 2'-deoxyribonucleoside 5'-diphosphate having 8-oxoguanine as the nucleobase.
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/20:2n6)
|
|
|
Testosterone Propionate
|
A steroid ester that has formula C22H32O3.
|
|
PE(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:0/22:1(13Z))
|
|
|
Metoclopramide
|
A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
|
|
TG(18:3(6Z,9Z,12Z)/15:0/20:3n6)
|
|
|
TG(18:0/15:0/18:1(11Z))
|
|
|
Galactosylceramide (d18:1/18:0)
|
|
|
PG(18:2(9Z,12Z)/18:1(11Z))
|
|
|
Codeine-6-glucuronide
|
A morphinane alkaloid that has formula C24H29NO9.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3n9/0:0/18:2n6)
|
|
|
Betazole
|
Pyrazole in which a hydrogen adjacent to one of the nitrogen atoms is substituted by a 2-aminoethyl group. It is a histamine H2-receptor agonist used clinically to test gastric secretory function.
|
|
Terbutaline
|
A member of the class of phenylethanolamines that is catechol substuted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.
|
|
5a-Cholest-8-en-3b-ol
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
S-(Formylmethyl)glutathione
|
A peptide that has formula C12H19N3O7S.
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Metocurine Iodide
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Biotin
|
An organic heterobicyclic compound that consists of 2-oxohexahydro-1H-thieno[3,4-d]imidazole having a valeric acid substituent attached to the tetrahydrothiophene ring. The parent of the class of biotins.
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
Allocholic acid
|
A bile acid that has formula C24H40O5.
|
|
PE(P-16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/16:0/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/20:2n6)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0/0:0)
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/18:0/18:1(9Z))
|
|
|
Mevalonic acid
|
A dihydroxy monocarboxylic acid comprising valeric acid having two hydroxy groups at the 3- and 5-positions together with a methyl group at the 3-position.
|
|
(S)-3-Hydroxyisobutyric acid
|
A 3-hydroxyisobutyric acid that has formula C4H8O3.
|
|
TG(24:0/18:0/14:1(9Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:0)
|
|
|
Phosphocreatine
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/18:2(9Z,12Z))[iso3]
|
|
|
Galactosylceramide (d18:1/26:1(17Z))
|
|
|
TG(22:0/16:1(9Z)/24:1(15Z))
|
|
|
PIP(18:2(9Z,12Z)/20:1(11Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/22:1(13Z)/0:0)
|
|
|
DG(14:0/0:0/18:0)
|
|
|
Dezocine
|
|
|
PC(P-16:0/24:1(15Z))
|
|
|
PC(22:2(13Z,16Z)/16:0)
|
|
|
Trihexyphenidyl
|
|
|
N-Acetylglutamic acid
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Nelfinavir
|
|
|
TG(18:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
MG(0:0/20:1(11Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/24:1(15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/24:0/22:2(13Z,16Z))
|
|
|
PC(22:2(13Z,16Z)/14:0)
|
|
|
Biocytin
|
A monocarboxylic acid amide that results from the formal condensation of the carboxylic acid group of biotin with the N(6)-amino group of L-lysine.
|
|
Perhexiline
|
|
|
TG(20:2n6/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/16:0/16:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Orotidylic acid
|
|
|
Adenosylcobalamin
|
|
|
PI(20:3(8Z,11Z,14Z)/16:0)
|
|
|
Trospium
|
|
|
TG(14:1(9Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
CL(20:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
Pectic acid
|
An polyanionic polymer obtained by global deprotonation of the carboxy groups of pectin.
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
(S)-p-Mentha-1,8-dien-7-ol
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
PG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
D-1-Piperideine-2-carboxylic acid
|
|
|
PI(22:4(10Z,13Z,16Z,19Z)/16:0)
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/o-18:0/24:0)
|
|
|
PG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(18:2(9Z,12Z)/16:1(9Z)/0:0)
|
|
|
TG(22:1(13Z)/20:2n6/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Tetrahexosylceramide (d18:1/25:0)
|
|
|
Coniferyl alcohol
|
|
|
PIP2(18:1(9Z)/16:1(9Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Heparan sulfate
|
A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.
|
|
TG(18:0/20:2n6/18:1(9Z))
|
|
|
Trandolapril
|
|
|
TG(24:1(15Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(16:1(9Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/0:0)
|
|
|
DG(20:0/18:0/0:0)
|
|
|
Sotalol
|
A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is sustituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
|
|
TG(14:0/16:1(9Z)/20:2n6)
|
|
|
PG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
Diethylthiophosphate
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(16:1(9Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(14:0/14:1(9Z)/18:0)
|
|
|
PS(16:0/16:1(9Z))
|
|
|
Clobazam
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(P-16:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/P-16:0)
|
|
|
PE(P-18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/15:0/18:1(11Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(14:0/20:1(11Z)/18:0)
|
|
|
TG(22:0/18:1(9Z)/20:2n6)
|
|
|
PE(16:0/P-18:1(11Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
PC(P-18:1(9Z)/18:1(11Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/24:0/18:2(9Z,12Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
LysoPE(0:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/o-18:0/15:0)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:0/14:1(9Z)/0:0)
|
|
|
TG(24:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
Ganglioside GD1b (d18:0/18:1(9Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:1(11Z)/16:1(9Z))
|
|
|
Lactosamine
|
A disaccharide that consists of D-glucosamine having a beta-D-galactosyl residue attached at position 4.
|
|
CL(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:2(11Z,14Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/14:0/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(16:0/18:0/20:3n6)
|
|
|
PS(18:2(9Z,12Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/14:0/24:1(15Z))
|
|
|
PS(14:0/14:0)
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
PE(20:2(11Z,14Z)/P-18:1(11Z))
|
|
|
DG(20:2(11Z,14Z)/20:1(11Z)/0:0)
|
|
|
PC(18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(16:0/15:0/22:0)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Minoxidil
|
A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
|
|
R-95913
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
Nicotine glucuronide
|
|
|
TG(22:1(13Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/14:0/24:1(15Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/15:0/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
DG(22:0/0:0/22:6n3)
|
|
|
TG(20:0/22:1(13Z)/24:0)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Amaranthin
|
A disaccharide derivative that is betanidin in which a beta-D-glucuronosyl-(1->2)-beta-D-glucosyl moiety is attached at position 5.
|
|
Ganglioside GD3 (d18:1/26:1(17Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
PE(P-18:0/24:0)
|
|
|
TG(24:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
PC(18:0/22:0)
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Creatine
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD1a (d18:0/12:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Cholestenone
|
|
|
TG(22:2(13Z,16Z)/20:2n6/o-18:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(22:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/15:0/22:2(13Z,16Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/14:0/22:1(13Z))
|
|
|
TG(14:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
5-Hydroxy-6-methoxyindole glucuronide
|
|
|
PE(18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:0/o-18:0)
|
|
|
TG(22:0/22:2(13Z,16Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:0/20:0)
|
|
|
TG(20:2n6/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:0/20:1(11Z))[iso6]
|
|
|
TG(22:2(13Z,16Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(18:1(9Z)/16:0/22:1(13Z))
|
|
|
Dimethylsulfide
|
A methyl sulfide in which the sulfur atom is substituted by two methyl groups. It is produced naturally by some marine algae.
|
|
TG(16:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:2(11Z,14Z)/24:1(15Z))
|
|
|
27-Hydroxycholesterol
|
|
|
TG(18:1(11Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Fondaparinux sodium
|
An organic sodium salt, being the decasodium salt of fondaparinux.
|
|
PE(15:0/20:0)
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GQ1c (d18:1/14:0)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PS(14:0/18:3(9Z,12Z,15Z))
|
|
|
Primaquine
|
A N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
|
|
PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/o-18:0/24:1(15Z))
|
|
|
PE(20:0/20:2(11Z,14Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3n6/o-18:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
LysoPE(0:0/16:0)
|
|
|
DG(20:4n3/0:0/22:6n3)
|
|
|
Fospropofol
|
|
|
PC(P-18:1(11Z)/18:1(9Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
Phenylbutazone
|
A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.
|
|
TG(22:0/16:0/18:1(11Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/14:0)
|
|
|
5(S)-Hydroperoxyeicosatetraenoic acid
|
|
|
Probenecid
|
|
|
PE(24:0/20:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/18:1(9Z)/18:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/16:0)
|
|
|
TG(24:1(15Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(18:4(6Z,9Z,12Z,15Z)/0:0/0:0)
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:0/22:1(13Z))
|
|
|
PE(P-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/14:0)
|
|
|
PE(24:1(15Z)/20:2(11Z,14Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/16:0/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:1(13Z)/22:1(13Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PE(22:1(13Z)/20:0)
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PI(20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Chloroprocaine
|
Procaine in which one of the hydrogens ortho- to the carboxylic acid group is substituted by chlorine. It is used as its monohydrochloride salt as a local anaesthetic, particularly for oral surgery. It has the advantage over lidocaine of constricting blood vessels, so reducing bleeding.
|
|
TG(22:1(13Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
Cytarabine
|
A pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond.
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
S-(2,2-Dichloro-1-hydroxy)ethyl glutathione
|
A peptide that has formula C12H19Cl2N3O7S.
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(16:0/0:0/18:2n6)
|
|
|
TG(22:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Malonic acid
|
An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group.
|
|
7 alpha,26-Dihydroxy-4-cholesten-3-one
|
|
|
DG(20:0/18:1(11Z)/0:0)
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/15:0)
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
3b-Hydroxy-5-cholenoic acid
|
|
|
D-Maltose
|
|
|
DG(24:1n9/0:0/20:4n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Hexanoylglycine
|
|
|
TG(16:0/o-18:0/24:0)
|
|
|
PC(22:0/20:0)
|
|
|
TG(14:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PG(18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/14:0/18:2(9Z,12Z))[iso6]
|
|
|
PC(20:1(11Z)/P-18:1(11Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
Phenindamine
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
PC(18:2(9Z,12Z)/14:1(9Z))
|
|
|
PG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/20:0/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(16:1(9Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:2n6/20:2n6)
|
|
|
TG(15:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
Glucaric acid
|
A hexaric acid derived by oxidation of sugar such as glucose with nitric acid.
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(18:0/22:2(13Z,16Z))
|
|
|
Canavanine
|
|
|
DG(16:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(14:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:2n6/16:1(9Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/22:1(13Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(18:1n9/0:0/22:5n6)
|
|
|
PC(20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
PC(P-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GA2 (d18:1/18:0)
|
|
|
TG(15:0/14:1(9Z)/16:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(24:1(15Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
2-Methylhippuric acid
|
|
|
PE(18:0/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/o-18:0)
|
|
|
TG(14:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/15:0/22:2(13Z,16Z))
|
|
|
TG(24:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:2(11Z,14Z))
|
|
|
all-trans-Decaprenyl diphosphate
|
A decaprenyl diphosphate having (E)-stereochemistry exclusively in the double bonds.
|
|
TG(20:3n6/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:1n7/0:0/20:4n6)
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:3n6)
|
|
|
TG(18:1(11Z)/20:1(11Z)/20:1(11Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/15:0/16:1(9Z))
|
|
|
TG(24:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/22:5n6)
|
|
|
TG(20:3n6/24:1(15Z)/o-18:0)
|
|
|
TG(15:0/15:0/20:3n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/o-18:0)
|
|
|
PG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM2 (d18:1/14:0)
|
|
|
Dexbrompheniramine
|
The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.
|
|
TG(18:1(11Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/15:0/22:1(13Z))
|
|
|
TG(14:0/20:0/24:1(15Z))
|
|
|
TG(22:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/P-18:0)
|
|
|
N-Acetylglutamine
|
|
|
TG(22:0/20:1(11Z)/24:1(15Z))
|
|
|
TG(15:0/16:1(9Z)/24:1(15Z))
|
|
|
TG(24:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:3n9/0:0/20:2n6)
|
|
|
TG(16:1(9Z)/14:0/18:1(11Z))[iso6]
|
|
|
TG(20:0/20:1(11Z)/20:2n6)
|
|
|
Ganglioside GM2 (d18:1/12:0)
|
|
|
Phosphite
|
|
|
TG(20:2n6/22:2(13Z,16Z)/20:2n6)
|
|
|
PI(18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(14:0/20:1(11Z)/o-18:0)
|
|
|
TG(18:0/18:0/16:1(9Z))
|
|
|
DG(20:0/0:0/18:1n9)
|
|
|
DG(18:1n7/0:0/18:3n3)
|
|
|
PI(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
UDP-D-galacturonate
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/20:2n6)
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/0:0)
|
|
|
Ganglioside GM1 (d18:1/14:0)
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/18:2(9Z,12Z))[iso3]
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:2(9Z,12Z)/20:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/14:1(9Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:1(9Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(20:2n6/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(14:0/20:0/14:1(9Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/14:0/20:3(5Z,8Z,11Z))
|
|
|
PC(P-18:1(9Z)/20:1(11Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
DG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
PIP(22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(22:2(13Z,16Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:2n6/16:1(9Z))
|
|
|
2-Hydroxyphenethylamine
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:3n6/18:2(9Z,12Z))
|
|
|
PE(P-18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
Trimeprazine
|
|
|
PC(P-18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
Perillic acid
|
A cyclohexenecarboxylic acid that has formula C10H14O2.
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:1(13Z)/20:3n6)
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/22:0/20:2n6)
|
|
|
TG(16:0/16:0/18:1(9Z))[iso3]
|
|
|
N-Desmethyltamoxifen
|
A stilbenoid that has formula C25H27NO.
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
CDP-DG(18:0/18:1(11Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/P-18:1(11Z))
|
|
|
Propafenone
|
An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
|
|
TG(16:0/20:0/22:0)
|
|
|
PI(18:1(11Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(24:1(15Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
Estrone glucuronide
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/16:1(9Z)/18:2(9Z,12Z))[iso6]
|
|
|
TG(18:1(11Z)/20:3n6/20:1(11Z))
|
|
|
TG(22:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/16:0)
|
|
|
TG(22:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
2-Methylpropan-2-ol
|
A tertiary alcohol alcohol that is isobutane substituted by a hydroxy group at position 2.
|
|
TG(15:0/18:1(9Z)/20:1(11Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:1(9Z)/20:1(11Z))[iso6]
|
|
|
Cyclic AMP
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))
|
|
|
Salmeterol
|
|
|
PE(18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP2(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/20:0/24:0)
|
|
|
TG(18:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
N-Dealkylated tolterodine
|
|
|
PE(P-18:0/18:2(9Z,12Z))
|
|
|
PA(16:0/18:2(9Z,12Z))
|
|
|
N-Acetylmuramate
|
|
|
TG(16:1(9Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP(18:2(9Z,12Z)/20:2(11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:1(11Z)/o-18:0)
|
|
|
TG(20:0/20:2n6/24:1(15Z))
|
|
|
TG(22:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:0/22:1(13Z)/0:0)
|
|
|
PC(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(P-18:1(9Z)/20:0)
|
|
|
CDP-DG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Indinavir
|
|
|
TG(15:0/24:0/18:2(9Z,12Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/15:0/24:1(15Z))
|
|
|
TG(14:0/22:1(13Z)/24:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
N-Methylphenylethanolamine
|
An alkaloid that is ethanolamine having the phenyl group at the 1-position and a methyl group attached to the nitrogen. It has been isolated from Halostachys caspica.
|
|
TG(18:3(6Z,9Z,12Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/14:1(9Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
Deoxyribose
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(15:0/15:0/22:2(13Z,16Z))
|
|
|
Rosuvastatin
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Glycylproline
|
|
|
TG(20:1(11Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3n6/24:0)
|
|
|
TG(20:3n6/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/20:1(11Z)/22:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Trimethyl sulfonium
|
A sulfonium compound in which the substituents on sulfur are three methyl groups. It is found in the midgut gland of the sea hare, Aplysia brasiliana, and exhibits probable ability to inhibit cholinergic responses.
|
|
TG(22:1(13Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:1(9Z)/22:0/0:0)
|
|
|
PE(P-18:1(11Z)/24:1(15Z))
|
|
|
PE(22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Estradiol-17alpha 3-D-glucuronoside
|
|
|
Citalopram propionic acid
|
A benzene that has formula C18H14FNO3.
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/16:0)
|
|
|
TG(14:1(9Z)/16:1(9Z)/18:1(11Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(18:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
PE(P-18:1(11Z)/24:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Chlormezanone
|
|
|
TG(14:1(9Z)/14:1(9Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:4n3/0:0/20:4n3)
|
|
|
PE(P-18:1(11Z)/22:0)
|
|
|
TG(18:0/20:1(11Z)/14:1(9Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)/o-18:0)
|
|
|
TG(15:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(18:1(9Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/14:0/16:1(9Z))[iso6]
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/o-18:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
Aflatoxin B1exo-8,9-epoxide-GSH
|
|
|
Vildagliptin
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/o-18:0/24:1(15Z))
|
|
|
TG(20:3n6/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(15:0/22:0)
|
|
|
Oxiconazole
|
|
|
TG(14:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:2(11Z,14Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
DG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
11-Oxo-androsterone glucuronide
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(16:0/18:0)
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
PE(18:1(9Z)/15:0)
|
|
|
DG(16:0/0:0/22:2n6)
|
|
|
TG(14:0/20:2n6/20:1(11Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
2-Oxoclopidogrel
|
|
|
TG(22:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/15:0/20:1(11Z))
|
|
|
TG(20:2n6/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:1(11Z)/22:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
L-Alanine
|
The L-enantiomer of alanine.
|
|
TG(18:0/15:0/22:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
PE(20:3(8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM1 (d18:0/26:1(17Z))
|
|
|
PC(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Risperidone
|
A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
cyclic GMP-AMP
|
An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of c-GMP-AMP; major species at pH 7.3.
|
|
TG(20:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Lycopene
|
An acyclic carotene commonly obtained from tomatoes and other red fruits.
|
|
DG(20:1(11Z)/24:0/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CL(20:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(24:1(15Z)/20:2n6/20:3n6)
|
|
|
Lenalidomide
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(24:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(14:0/18:1(11Z)/20:0)
|
|
|
TG(18:1(11Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(18:0/16:1(9Z))
|
|
|
TG(20:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/20:2(11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(o-22:0/20:1(11Z))
|
|
|
TG(20:0/20:0/18:1(11Z))
|
|
|
TG(16:0/20:1(11Z)/22:1(13Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/15:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/24:1(15Z))
|
|
|
TG(18:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/22:0/20:3(5Z,8Z,11Z))
|
|
|
Aflatoxin B1 diol
|
A coumarin that has formula C17H14O8.
|
|
TG(16:1(9Z)/20:2n6/20:3n6)
|
|
|
TG(18:1(9Z)/o-18:0/18:2(9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(16:1(9Z)/24:1(15Z))
|
|
|
TG(20:2n6/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Remoxipride
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/15:0/24:1(15Z))
|
|
|
Acetoacetic acid
|
A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:0/0:0/22:4n6)
|
|
|
DG(24:0/16:0/0:0)
|
|
|
TG(18:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:2n6)
|
|
|
PIP(16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
PIP2(16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Phenazopyridine
|
|
|
11b-PGF2a
|
|
|
PC(P-18:1(11Z)/15:0)
|
|
|
TG(20:0/20:3n6/o-18:0)
|
|
|
Phenindione
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/22:2(13Z,16Z))
|
|
|
Methionine sulfoxide
|
|
|
PS(18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GQ1c (d18:1/24:0)
|
|
|
PS(16:0/18:1(9Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
CDP-DG(18:1(11Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/20:3n6)
|
|
|
Ganglioside GT3 (d18:0/14:0)
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
DG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
Pipecolic acid
|
A piperidinemonocarboxylic acid in which the carboxy group is located at position C-2.
|
|
PI(18:2(9Z,12Z)/20:0)
|
|
|
CDP-DG(18:0/22:3(10Z,13Z,16Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:2n6/18:2(9Z,12Z))
|
|
|
DG(14:0/0:0/18:1n9)
|
|
|
TG(15:0/16:1(9Z)/14:1(9Z))
|
|
|
Ganglioside GQ1c (d18:1/26:0)
|
|
|
TG(16:0/22:0/16:1(9Z))
|
|
|
TG(14:1(9Z)/18:0/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/15:0/22:2(13Z,16Z))
|
|
|
DG(16:0/14:1(9Z)/0:0)
|
|
|
(R)-3-Hydroxydodecanoic acid
|
|
|
PC(16:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
(2R)-2-Hydroxy-2-methylbutanenitrile
|
The (2R)-enantiomer of 2-hydroxy-2-methylbutanenitrile.
|
|
TG(16:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:0/20:0)[iso3]
|
|
|
PIP(16:0/20:2(11Z,14Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Fluticasone Propionate
|
A trifluorinated corticosteroid that consits of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.
|
|
TG(20:2n6/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
(R)-3-Hydroxyoctanoic acid
|
The (R)-enantiomer of 3-hydroxyoctanoic acid; an important building block in the biomedical and pharmaceutical fields.
|
|
Aminosalicylic Acid
|
|
|
TG(14:0/20:3n6/15:0)
|
|
|
TG(18:0/o-18:0/18:1(9Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/20:3n6)
|
|
|
TG(20:3n6/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/18:0/18:1(11Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(20:3n6/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Phosphatidylserine
|
|
|
TG(18:1(11Z)/16:1(9Z)/18:1(9Z))[iso6]
|
|
|
Pipotiazine
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
Alclometasone
|
A prednisolone compound having an alpha-chloro substituent at the 7-position and an alpha-methyl substituent at the 16-position.
|
|
TG(20:3n6/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
Methazolamide
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
7-Hydroxygliclazide
|
|
|
Oxacillin
|
A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6.
|
|
TG(20:0/24:1(15Z)/o-18:0)
|
|
|
Testosterone glucuronide
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
DG(20:1n9/0:0/24:1n9)
|
|
|
TG(18:1(9Z)/18:0/18:2(9Z,12Z))
|
|
|
PC(o-18:0/18:0)
|
|
|
TG(15:0/22:2(13Z,16Z)/22:0)
|
|
|
TG(14:1(9Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/18:1(11Z)/20:3n6)
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
Fenoprofen
|
Propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.
|
|
TG(15:0/22:2(13Z,16Z)/20:0)
|
|
|
PS(16:0/18:2(9Z,12Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Guanosine 3',5'-bis(diphosphate)
|
A guanosine bisphosphate having diphosphate groups at both the 3' and 5'-positions.
|
|
TG(16:0/14:1(9Z)/16:0)
|
|
|
DG(14:1(9Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GM1 (d18:1/25:0)
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
Methanol
|
|
|
PG(16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
MG(0:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(24:0/20:1(11Z)/18:1(11Z))
|
|
|
PA(P-16:0e/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:3n6/20:3n6)
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
Lactosylceramide (d18:1/12:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:1(11Z)/20:1(11Z))[iso3]
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
Ganglioside GD1b (d18:1/26:0)
|
|
|
PE(22:1(13Z)/P-18:1(9Z))
|
|
|
PI(18:3(6Z,9Z,12Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/0:0/18:1n9)
|
|
|
Tubocurarine
|
|
|
TG(18:2(9Z,12Z)/22:0/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(14:1(9Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Caprylic acid
|
|
|
TG(22:0/18:1(11Z)/18:1(9Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/14:1(9Z)/18:1(9Z))
|
|
|
TG(18:0/18:1(9Z)/14:1(9Z))
|
|
|
PC(24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
D-Xylulose 1-phosphate
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:1(11Z))
|
|
|
TG(18:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
PC(22:1(13Z)/18:0)
|
|
|
Dihydropteridine
|
|
|
TG(20:2n6/24:0/20:2n6)
|
|
|
PC(18:2(9Z,12Z)/20:0)
|
|
|
DG(22:1(13Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(24:1(15Z)/24:0/24:1(15Z))
|
|
|
TG(14:1(9Z)/18:0/24:1(15Z))
|
|
|
Almotriptan
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/24:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Trimetrexate
|
|
|
TG(14:1(9Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
LysoPC(22:2(13Z,16Z))
|
|
|
TG(24:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/o-18:0)
|
|
|
PI(16:0/20:3(8Z,11Z,14Z))
|
|
|
TG(16:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z))
|
|
|
Norelgestromin
|
|
|
Amrinone
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(24:0/0:0/20:4n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/0:0)
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/14:1(9Z)/o-18:0)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Tofisopam
|
|
|
Ganglioside GM1 (18:1/20:0)
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/20:3n6/24:1(15Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/22:1(13Z))
|
|
|
DG(18:0/22:1(13Z)/0:0)
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
Cephaloglycin
|
|
|
Amifostine
|
An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
|
|
TG(14:1(9Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(20:3(8Z,11Z,14Z)/18:0)
|
|
|
TG(24:0/16:1(9Z)/22:1(13Z))
|
|
|
Sandosaponin B
|
|
|
Sandosaponin A
|
|
|
TG(15:0/24:1(15Z)/24:0)
|
|
|
DG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
DG(18:0/0:0/14:1n5)
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Citrulline
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/0:0)
|
|
|
TG(16:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Deoxyuridine triphosphate
|
|
|
TG(20:3n6/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(24:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Hesperetin
|
A trihydroxyflavanone having the three hydroxy gropus located at the 3'-, 5- and 7-positions and an additional methoxy substituent at the 4'-position.
|
|
Dolichyl beta-D-mannosyl phosphate
|
|
|
PC(P-18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/P-18:1(9Z))
|
|
|
TG(15:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP2(18:0/18:2(9Z,12Z))
|
|
|
DG(15:0/0:0/18:4n3)
|
|
|
TG(24:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Dolichol phosphate
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(P-18:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
DG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:1(9Z)/20:3n6/22:2(13Z,16Z))
|
|
|
Imidazole
|
|
|
PE(20:3(8Z,11Z,14Z)/20:2(11Z,14Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Amoxicillin
|
A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.
|
|
TG(20:3(5Z,8Z,11Z)/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/22:1(13Z)/22:1(13Z))
|
|
|
Ganglioside GQ1c (d18:0/16:0)
|
|
|
trans-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA
|
An organic molecule that has formula C31H50N7O17P3S.
|
|
TG(16:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
5b-Dihydrotestosterone
|
|
|
TG(20:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(20:2n6/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/P-16:0)
|
|
|
PC(20:1(11Z)/P-18:1(9Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
11b,17a,21-Trihydroxypreg-nenolone
|
|
|
TG(15:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:0/o-18:0)
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(18:1(9Z)/16:1(9Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1(9Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GQ1c (d18:0/14:0)
|
|
|
TG(18:2(9Z,12Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
N-Acetyllactosamine
|
A beta-D-galactopyranosyl-(1->4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre.
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:1(13Z)/20:3n6)
|
|
|
TG(18:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:0/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CL(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
MG(18:3(6Z,9Z,12Z)/0:0/0:0)
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
Porphinehexacarboxylic acid
|
|
|
Cholestane-3,7,12,25-tetrol-3-glucuronide
|
|
|
TG(14:0/24:1(15Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
LysoPC(20:2(11Z,14Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/14:0)
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/14:1(9Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
D-Tartaric acid
|
The D-enantiomer of tartaric acid.
|
|
DG(20:3(5Z,8Z,11Z)/18:0/0:0)
|
|
|
DG(15:0/0:0/16:1n7)
|
|
|
Selenocystathionine
|
A member of the class of cystathionines derived from homoselenocysteine and serine residues joined by a selenide bond.
|
|
TG(24:1(15Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:2n6)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:1n9/0:0/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Adenosine
|
A ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond.
|
|
TG(14:1(9Z)/24:0/22:1(13Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
DG(16:1(9Z)/18:1(9Z)/0:0)
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
2-Hydroxychlorpropamide
|
|
|
TG(18:1(11Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/20:3n6)
|
|
|
Deoxycholic acid 3-glucuronide
|
|
|
TG(16:0/20:1(11Z)/18:1(9Z))
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/16:0)
|
|
|
TG(18:1(11Z)/15:0/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:0/20:0/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
1D-Myo-inositol 1,4-bisphosphate
|
A myo-inositol bisphosphate that has formula C6H14O12P2.
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/20:3n6/22:2(13Z,16Z))
|
|
|
Trichloroethylene
|
|
|
DG(22:1n9/0:0/18:3n3)
|
|
|
DG(22:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(20:1(11Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:0/18:1(11Z))
|
|
|
TG(15:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/14:0/14:1(9Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z))
|
|
|
TG(14:1(9Z)/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:3n6)
|
|
|
PE(20:3(8Z,11Z,14Z)/20:0)
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/22:2(13Z,16Z))
|
|
|
Risedronate
|
|
|
DG(18:3(9Z,12Z,15Z)/15:0/0:0)
|
|
|
TG(16:1(9Z)/24:0/24:1(15Z))
|
|
|
DG(14:1(9Z)/20:2(11Z,14Z)/0:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/14:0/0:0)
|
|
|
Glutaric acid
|
An alpha,omega-dicarboxylic acid that is a linear five-carbon dicarboxylic acid.
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP(18:0/18:1(9Z))
|
|
|
Trihydroxycoprostanoic acid
|
|
|
Methylhippuric acid
|
An N-acylamino acid that is the N-benzoyl derivative of alanine.
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
PC(14:0/P-16:0)
|
|
|
PIP(18:1(9Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/20:3n6/18:1(11Z))
|
|
|
TG(20:3n6/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:1(9Z)/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/18:2(9Z,12Z))
|
|
|
DG(18:1n9/0:0/22:4n6)
|
|
|
N-Acetyl-D-Glucosamine 6-Phosphate
|
An N-acyl-D-glucosamine 6-phosphate that is the N-acetyl derivative of D-glucosamine 6-phosphate. It is a component of the aminosugar metabolism.
|
|
Amiloride
|
A monocarboxylic acid amide that is N-carbamimidoylpyrazine-2-carboxamide substituted by amino groups at positions 3 and 5 and a chloro group at position 6.
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Sedoheptulose 1-phosphate
|
A ketoheptose phosphate that has formula C7H15O10P.
|
|
TG(18:2(9Z,12Z)/18:0/o-18:0)
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
3-Methyladenine
|
A methyladenine that is adenine substituted with a methyl group at position N-3.
|
|
TG(16:0/16:1(9Z)/20:0)[iso6]
|
|
|
TG(22:0/20:2n6/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(16:1(9Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PS(16:0/14:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/22:1(13Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
LysoPE(0:0/18:0)
|
|
|
TG(22:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/18:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
trans-3-Chloroallyl aldehyde
|
|
|
16b-Hydroxyestrone
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(24:1(15Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
LysoPE(14:0/0:0)
|
|
|
TG(18:0/24:0/22:1(13Z))
|
|
|
TG(16:0/16:0/20:3n6)
|
|
|
TG(22:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
PIP(18:2(9Z,12Z)/20:0)
|
|
|
Glucosylceramide (d18:1/18:0)
|
|
|
PA(16:0/18:1(11Z))
|
|
|
PIP2(18:2(9Z,12Z)/18:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:0/0:0/18:1n7)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Luteolin 7-O-[beta-D-glucuronosyl-(1->2)-beta-D-glucuronide]-4'-O-beta-D-glucuronide
|
|
|
Isodeoxycholic acid
|
A cholanoid that has formula C24H40O4.
|
|
PE(18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
DG(18:4n3/0:0/22:5n3)
|
|
|
TG(20:0/20:2n6/18:1(9Z))
|
|
|
TG(15:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
heparan sulfate alpha-D-glucosaminide
|
A heparan sulfate having an alpha-D-glucosaminyl residue at the non-reducing end. The heparan sulfate part consists of a variably sulfated repeating disaccharide unit.
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:0/18:2(9Z,12Z))[iso3]
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
CL(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
Granisetron
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
MG(0:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
2-Methoxyestrone 3-glucuronide
|
|
|
Didanosine
|
A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen.
|
|
TG(24:0/18:1(11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(9Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
PS(18:1(9Z)/16:0)
|
|
|
Ceftriaxone
|
A cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:0/18:0/0:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
DG(20:0/14:0/0:0)
|
|
|
TG(22:2(13Z,16Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/16:0/18:1(9Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Alcaftadine
|
|
|
4a-Methylzymosterol-4-carboxylic acid
|
|
|
Deoxyribose 1-phosphate
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/15:0/20:0)
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
TG(20:0/o-18:0/20:2n6)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:3n6/24:0)
|
|
|
LysoPE(18:2(9Z,12Z)/0:0)
|
|
|
PC(18:1(9Z)/22:1(13Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(P-18:1(9Z)/16:0)
|
|
|
TG(24:1(15Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
Disopyramide
|
A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
|
|
PS(18:1(9Z)/14:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(24:0/18:1(11Z))
|
|
|
Prostaglandin E1
|
A prostaglandins E that has formula C20H34O5.
|
|
Prostaglandin E2
|
Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.
|
|
Atomoxetine
|
A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.
|
|
Retinoyl b-glucuronide
|
|
|
TG(16:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(15:0/P-18:0)
|
|
|
TG(18:0/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(22:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
DG(18:1(11Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(22:0/14:0/22:0)
|
|
|
TG(20:1(11Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
Minocycline
|
A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.
|
|
TG(20:3n6/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(14:1(9Z)/18:1(9Z)/0:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/22:0/20:3n6)
|
|
|
CE(20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PC(o-22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
PE(15:0/P-16:0)
|
|
|
TG(14:0/14:0/18:1(11Z))
|
|
|
DG(15:0/15:0/0:0)
|
|
|
TG(18:1(11Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:1(11Z)/16:0)
|
|
|
Quinethazone
|
|
|
PC(20:3(8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(24:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/24:0/16:1(9Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(24:0/22:1(13Z)/24:1(15Z))
|
|
|
DG(20:1n9/0:0/22:2n6)
|
|
|
TG(15:0/16:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
PE(P-16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP2(20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GD1a (d18:1/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(20:0/14:1(9Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(24:1(15Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:2n6/22:1(13Z))
|
|
|
TG(15:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/o-18:0)
|
|
|
TG(22:0/14:0/24:0)
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/18:0)
|
|
|
Linezolid
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/18:0/22:2(13Z,16Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/20:1(11Z))
|
|
|
PE(P-18:1(9Z)/18:1(11Z))
|
|
|
PE(16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
PC(P-18:1(11Z)/20:2(11Z,14Z))
|
|
|
Diphenylpyraline
|
|
|
4-Hydroxyphenyl acetate
|
|
|
DG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/20:1(11Z)/0:0)
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
2-Aminobenzoic acid
|
An aminobenzoic acid that is benzoic acid having a single amino substituent located at position 2. It is a metabolite produced in L-tryptophan-kynurenine pathway in the central nervous system.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/24:1(15Z))
|
|
|
TG(20:0/22:0/o-18:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/o-18:0)
|
|
|
PC(18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/14:0/24:1(15Z))
|
|
|
Glycerophosphocholine
|
The glycerol phosphate ester of a phosphocholine. A nutrient with many different roles in human health.
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
SM(d18:0/20:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(20:1(11Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Sorbitol
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Probucol
|
|
|
TG(24:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:0)
|
|
|
PC(P-18:1(11Z)/22:1(13Z))
|
|
|
TG(18:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:0/22:1(13Z))
|
|
|
Salicylate-sodium
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ribose 1-phosphate
|
|
|
PC(18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(22:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
cis-3-Chloro-2-propene-1-ol
|
|
|
Ganglioside GT1c (d18:1/24:0)
|
|
|
TG(16:1(9Z)/24:1(15Z)/20:1(11Z))
|
|
|
TG(24:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:0/20:2(11Z,14Z))
|
|
|
TG(16:1(9Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/o-18:0/18:1(11Z))
|
|
|
TG(14:1(9Z)/15:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
4-Hydroxycyclophosphamide
|
A phosphorodiamide that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide having two 2-chloroethyl groups attached to the exocyclic nitrogen.
|
|
TG(18:1(11Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
1D-Myo-inositol 1,4,5,6-tetrakisphosphate
|
A myo-inositol tetrakisphosphate having the four phosphate groups at the 1-, 4-, 5- and 6-positions.
|
|
DG(18:1(11Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PS(18:0/14:0)
|
|
|
Farnesylcysteine
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Guanadrel Sulfate
|
A sulfate salt resulting from the reaction of 2 eq. guanadrel with 1 eq. sulfuric acid. A postganglionic adrenergic blocking agent formerly used for the management of hypertension, it has been largely superseded by other drugs less likely to cause orthostatic hypotension (dizzy spells on standing up or stretching).
|
|
Sulfurous acid
|
A sulfur oxoacid that has formula H2O3S.
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Clidinium
|
The ester resulting from formal condensation of benzilic acid and 3-hydroxy-1-methyl-1-azoniabicyclo[2.2.2]octane. It is used, generally as the bromide, for the symptomatic treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/o-18:0)
|
|
|
TG(15:0/14:1(9Z)/24:1(15Z))
|
|
|
Ganglioside GM2 (d18:0/24:1(15Z))
|
|
|
TG(18:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1c (d18:1/22:0)
|
|
|
Adenosine 3',5'-diphosphate
|
|
|
1-hydroxy-2-Oxopropyl tetrahydropterin
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/24:1(15Z)/20:3n6)
|
|
|
Ganglioside GM1 (d18:0/12:0)
|
|
|
TG(18:0/24:0/24:1(15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
Neolactotetraose
|
|
|
TG(15:0/20:0/18:2(9Z,12Z))
|
|
|
TG(14:0/16:0/18:1(9Z))
|
|
|
TG(24:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(24:0/16:0)
|
|
|
TG(15:0/18:0/20:2n6)
|
|
|
TG(20:0/20:1(11Z)/18:1(11Z))
|
|
|
(R)-3-Hydroxy-tetradecanoic acid
|
A C14, long-chain hydroxy fatty acid which plays an intermediate role in fatty acid biosynthesis.
|
|
PE(24:0/14:0)
|
|
|
DG(20:2(11Z,14Z)/16:0/0:0)
|
|
|
TG(16:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/16:0/24:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(P-16:0/18:3(9Z,12Z,15Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
Hydrocortisone
|
|
|
TG(24:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Chloropyramine
|
|
|
TG(22:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Nitrofurazone
|
|
|
TG(14:0/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
6-Hydroxyfluvastatin
|
|
|
TG(16:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:2n6/o-18:0)
|
|
|
TG(20:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:1(9Z)/14:0)
|
|
|
TG(18:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/o-18:0/18:2(9Z,12Z))
|
|
|
TG(16:0/14:0/22:0)
|
|
|
Candoxatril
|
The 2,3-dihydro-1H-inden-5-yl ester of the active enantiomer of candoxatrilat. Candoxatril is an orally active prodrug of candoxatrilat, a potent neutral endopeptidase (NEP, neprilysin) inhibitor used in the treatment of chronic heart failure.
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/20:2n6)
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/14:0/20:0)
|
|
|
3-Hydroxybutyryl-CoA
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(14:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
PG(18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/20:3n6)
|
|
|
LysoPE(22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Testolactone
|
|
|
TG(22:1(13Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/22:0)
|
|
|
TG(14:0/24:0/16:1(9Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/16:1(9Z))
|
|
|
3 beta,7 alpha-Dihydroxy-5-cholestenoate
|
A cholanoid that has formula C27H44O4.
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
Promethazine
|
A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT2 (d18:1/24:0)
|
|
|
Pentanal
|
A fatty aldehyde composed from five carbons in a straight chain
|
|
TG(14:1(9Z)/15:0/16:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Anagrelide
|
A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.
|
|
TG(22:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:3n6/o-18:0)
|
|
|
TG(24:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:0/18:1(9Z))
|
|
|
Norepinephrine
|
|
|
TG(18:2(9Z,12Z)/18:0/18:2(9Z,12Z))
|
|
|
PE(22:1(13Z)/18:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/16:0)
|
|
|
DG(18:3(6Z,9Z,12Z)/24:0/0:0)
|
|
|
TG(18:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/20:2n6/22:1(13Z))
|
|
|
Pyrimidine
|
The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.
|
|
7,12-Dimethylbenz[a]anthracene 5,6-oxide
|
A dibenzooxazepine that has formula C20H16O.
|
|
TG(18:1(9Z)/20:1(11Z)/o-18:0)
|
|
|
Fluocinolone Acetonide
|
A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.
|
|
Ergothioneine
|
A L-histidine derivative that is N(alpha),N(alpha),N(alpha)-trimethyl-L-histidine in which the hydrogen at position 2 on the imdazole ring is replaced by a mercapto group. A naturally occurring metabolite of histidine with antioxidant properties; abundant in most plants and animals, obtained in animals through the diet.
|
|
3-Phosphoadenylylselenate
|
An organoselenium compound that is adenylyl selenate with the hydroxy at position 3' replaced by a phosphate group.
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
PE(14:0/15:0)
|
|
|
PS(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(14:0/P-18:1(9Z))
|
|
|
DG(15:0/0:0/24:0)
|
|
|
Digoxin n
|
|
|
TG(22:2(13Z,16Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(11Z)/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(16:0/20:1(11Z))
|
|
|
DG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(22:0/14:0/o-18:0)
|
|
|
TG(18:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Apraclonidine
|
An imidazoline compound having a 4-amino-2,6-dichloroanilino group at the 2-position.
|
|
PC(22:0/14:0)
|
|
|
PE(16:0/18:1(11Z))
|
|
|
(1S)-Hydroxy-(2S)-glutathionyl-1,2-dihydronaphthalene
|
A peptide that has formula C20H25N3O7S.
|
|
TG(22:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:1(13Z)/24:1(15Z))
|
|
|
Isopentanol
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
8-Oxo-dGTP
|
A purine 2'-deoxyribonucleoside 5'-triphosphate having 8-oxo-7,8-dihydroguanine as the nucleobase.
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(22:1(13Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:3n6/24:0)
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/18:0/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
L-Tyrosine
|
An optically active form of tyrosine having L-configuration.
|
|
TG(14:0/20:0/15:0)
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
Suberylglycine
|
|
|
TG(20:1(11Z)/22:1(13Z)/20:1(11Z))
|
|
|
PIP3(16:0/16:1(9Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/o-18:0)
|
|
|
TG(18:1(11Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:0/18:0)[iso3]
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:3n6/o-18:0)
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Bopindolol
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/16:0)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(16:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/24:0/o-18:0)
|
|
|
Arachidonic acid
|
A long-chain fatty acid that is a C20, polyunsaturated fatty acid having four (Z)-double bonds at positions 5, 8, 11 and 14.
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:1n9/0:0/20:3n9)
|
|
|
PC(16:1(9Z)/P-18:1(11Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/18:0/20:1(11Z))[iso6]
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:1n9/0:0/20:1n9)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3-Keto-b-D-galactose
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
Hypusine
|
An L-lysine derivative that is L-lysine bearing A (2R)-4-amino-2-hydroxybutyl substituent at position N6.
|
|
TG(22:1(13Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/22:0/22:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
4-Hydroxynonenal
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(14:0/22:0/20:2n6)
|
|
|
PI(18:1(9Z)/16:1(9Z))
|
|
|
PG(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
PIP2(18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Prostaglandin F2a
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/20:1(11Z)/16:1(9Z))
|
|
|
TG(14:0/o-18:0/16:0)
|
|
|
Olopatadine
|
|
|
TG(14:1(9Z)/20:1(11Z)/20:2n6)
|
|
|
PIP2(16:0/22:2(13Z,16Z))
|
|
|
PI(22:3(10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
2'-Deoxyguanosine 5'-monophosphate
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/o-18:0/18:0)
|
|
|
TG(14:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
D-Xylitol
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
L-Proline
|
Pyrrolidine in which the pro-S hydrogen at position 2 is substituted by a carboxylic acid group. L-Proline is the only one of the twenty DNA-encoded amino acids which has a secondary amino group alpha to the carboxyl group. It is an essential component of collagen and is important for proper functioning of joints and tendons. It also helps maintain and strengthen heart muscles.
|
|
TG(20:3n6/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:2n6/18:2(9Z,12Z))
|
|
|
PIP(18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
4-Glutathionyl cyclophosphamide
|
A peptide that has formula C17H30Cl2N5O8PS.
|
|
PC(16:0/18:2(9Z,12Z))
|
|
|
TG(20:2n6/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(16:0/20:0/20:0)[iso3]
|
|
|
Inositol-P-ceramide
|
|
|
TG(16:0/22:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/16:1(9Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
Lindane
|
|
|
DG(18:1n7/0:0/18:4n3)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/20:2n6)
|
|
|
D-Fructose
|
Fructose is a levorotatory monosaccharide and an isomer of glucose. Although fructose is a hexose (6 carbon sugar), it generally exists as a 5-member hemiketal ring (a furanose).
|
|
TG(20:3n6/15:0/20:3n6)
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/0:0)
|
|
|
N-Desmethyleletriptan
|
|
|
Ganglioside GT1b (d18:1/14:0)
|
|
|
3b,7a,12a-Trihydroxy-5b-cholanoic acid
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cimetidine
|
A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
|
|
TG(18:0/24:1(15Z)/18:1(11Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(P-18:0/18:3(6Z,9Z,12Z))
|
|
|
PE(20:1(11Z)/P-16:0)
|
|
|
4-Guanidinobutanoic acid
|
The 4-guanidino derivative of butanoic acid.
|
|
DG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/0:0)
|
|
|
PC(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
(+)-Limonene
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(P-18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
PS(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Gallamine Triethiodide
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(16:1n7/0:0/16:1n7)
|
|
|
Ganglioside GM2 (d18:0/22:1(13Z))
|
|
|
1-Phosphatidyl-1D-myo-inositol 3-phosphate
|
A phosphatidylinositol 3-phosphate in which the inositol moiety is the D-myo-isomer.
|
|
DG(22:1(13Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(18:1(11Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1b (d18:0/26:0)
|
|
|
DG(14:0/24:1(15Z)/0:0)
|
|
|
Vitamin K1
|
|
|
Vitamin K2
|
|
|
TG(24:1(15Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
Pemirolast
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/14:1(9Z)/18:1(11Z))
|
|
|
PS(16:0/18:3(9Z,12Z,15Z))
|
|
|
Flavin Mononucleotide
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Topotecan
|
A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GQ1c (d18:0/22:1(13Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
7-Methylguanosine 5'-phosphate
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:2n6)
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
PE(16:0/14:1(9Z))
|
|
|
TG(16:0/15:0/18:0)
|
|
|
SM(d18:1/24:0)
|
|
|
TG(15:0/14:0/18:0)
|
|
|
Dihydroceramide
|
A ceramide consisting of sphinganine in which one of the amino hydrogens is substituted by a fatty acyl group.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(22:1(13Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(14:0/18:1(9Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
PI(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD2 (d18:0/23:0)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(14:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
Ganglioside GM1 (d18:0/14:0)
|
|
|
PE(20:0/22:2(13Z,16Z))
|
|
|
Methyprylon
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
Ibuprofen
|
A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
CE(19:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/0:0)
|
|
|
Alpha-Linolenic acid
|
A linolenic acid with cis-double bonds at positions 9, 12 and 15. Shown to have an antithrombotic effect.
|
|
TG(22:1(13Z)/22:1(13Z)/20:3n6)
|
|
|
Ganglioside GD1b (d18:1/16:0)
|
|
|
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
|
|
|
LysoPE(20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:1(9Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Lanosterin
|
|
|
TG(20:2n6/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(11Z)/P-16:0)
|
|
|
TG(24:1(15Z)/18:1(9Z)/24:1(15Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:4n6/0:0/20:5n3)
|
|
|
TG(16:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
Tetrahexosylceramide (d18:1/24:1(15Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/o-18:0)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/P-18:1(11Z))
|
|
|
TG(18:1(11Z)/16:0/18:1(11Z))[iso3]
|
|
|
Fluorometholone
|
A member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
|
|
3-Acetamidobutanal
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:3n6/20:3n6)
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
TG(22:1(13Z)/o-18:0/24:1(15Z))
|
|
|
Trimethadione
|
|
|
DG(22:0/0:0/18:4n3)
|
|
|
TG(18:0/24:1(15Z)/24:1(15Z))
|
|
|
PC(16:1(9Z)/24:0)
|
|
|
TG(16:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
D-Myo-inositol 3,4,5,6-tetrakisphosphate
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/15:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1c (d18:1/22:1(13Z))
|
|
|
TG(18:1(11Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(24:0/16:1(9Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/14:1(9Z)/24:0)
|
|
|
TG(15:0/18:2(9Z,12Z)/20:0)
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
PC(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
Paricalcitol
|
|
|
PC(P-18:0/20:3(8Z,11Z,14Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/22:0)
|
|
|
1,2-Dihydroxy-3-keto-5-methylthiopentene
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:0/20:2n6)
|
|
|
TG(18:1(11Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(16:1(9Z)/20:3n6/o-18:0)
|
|
|
TG(22:0/18:1(11Z)/22:1(13Z))
|
|
|
DG(22:0/0:0/20:5n3)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
DG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
PE(22:0/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Reserpine
|
An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
|
|
TG(20:2n6/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:0/0:0/22:5n3)
|
|
|
3-O-Sulfogalactosylceramide (d18:1/18:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1a (d18:0/24:1(15Z))
|
|
|
DG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PC(16:1(9Z)/22:0)
|
|
|
MG(20:1(11Z)/0:0/0:0)
|
|
|
PC(P-18:0/14:0)
|
|
|
TG(14:1(9Z)/20:3n6/16:1(9Z))
|
|
|
7a,12a-Dihydroxy-5b-cholestan-3-one
|
|
|
TG(20:0/24:0/20:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(20:2n6/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
5-Hydroxylysine
|
The lysine derivative that is 2,6-diamino-5-hydroxyhexanoic acid, a chiral alpha-amino acid.
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/0:0)
|
|
|
Secalciferol
|
|
|
PIP2(18:1(9Z)/18:1(9Z))
|
|
|
PE(14:1(9Z)/P-18:1(9Z))
|
|
|
TG(18:0/20:2n6/16:1(9Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:0/16:0)
|
|
|
4-Hydroxy-L-glutamic acid
|
An amino dicarboxylic acid that is L-glutamic acid substituted by a hydroxy group at position 4.
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Donepezil
|
Donepezil is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
|
|
TG(15:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
PG(18:1(9Z)/18:0)
|
|
|
TG(15:0/20:2n6/20:2n6)
|
|
|
TG(24:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
PE(18:1(11Z)/P-18:1(9Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM3 (d18:1/9Z-18:1)
|
|
|
TG(14:0/18:1(11Z)/16:1(9Z))
|
|
|
Montelukast
|
An aliphatic sulfide that has formula C35H36ClNO3S.
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
17a-Ethynylestradiol
|
|
|
TG(14:0/18:1(11Z)/16:0)
|
|
|
Uridine diphosphategalactose
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Methoxyanthranilate
|
An aminobenzoate that results from the removal of a proton from the carboxylic acid group of 3-methoxyanthranilic acid.
|
|
TG(22:1(13Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Docetaxel
|
|
|
PE(14:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/16:1(9Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(18:0/22:1(13Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/22:1(13Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:1(11Z)/20:2n6)
|
|
|
TG(14:0/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
3-Carbamoyl-2-phenylpropionaldehyde
|
A phenylacetaldehyde that has formula C10H11NO3.
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
PC(o-20:0/22:0)
|
|
|
PG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:2n6/0:0/22:5n6)
|
|
|
Phosphoroselenoic acid
|
A phosphoric acid derivative in which one of the OH groups of phosphoric acid is replaced by SeH.
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3b,12a-Dihydroxy-5a-cholanoic acid
|
|
|
PC(20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/o-18:0/18:2(9Z,12Z))
|
|
|
N(6)-(Octanoyl)lysine
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(15:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
MG(0:0/14:1(9Z)/0:0)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/14:0)
|
|
|
TG(20:2n6/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:2n6/0:0/20:3n6)
|
|
|
TG(22:1(13Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-16:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/22:0/18:2(9Z,12Z))
|
|
|
S-Adenosylmethionine
|
|
|
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
DG(20:0/0:0/14:1n5)
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PI(20:3(8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/16:0/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
Disulfiram
|
An organic disulfide that is 1,1'-[disulfanediylbis(carbonothioylimino)]diethane substituted by ethyl groups at the N atom. An EC 1.2.1.3 [aldehyde dehydrogenase (NAD+)] inhibitor, it is used as an alcohol deterrent.
|
|
TG(16:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:2n6/0:0/20:4n3)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:0/20:3(8Z,11Z,14Z))
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Clobetasol
|
16beta-Methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.
|
|
PE(20:2(11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(22:4(10Z,13Z,16Z,19Z)/16:0)
|
|
|
PIP2(16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/16:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(22:0/24:1(15Z)/18:1(9Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/15:0)
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
Quinupristin
|
|
|
TG(24:1(15Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:1(11Z)/20:0)
|
|
|
TG(16:1(9Z)/14:1(9Z)/20:2n6)
|
|
|
12(R)-HPETE
|
A HPETE that is (5Z,8Z,10E,12R,14Z)-icosa-5,8,10,14-tetraenoic acid with the hydroperoxy group located at position 12 (the R-enantiomer).
|
|
Sphingosine
|
A sphing-4-enine in which the double bond is trans.
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/18:1(9Z))
|
|
|
TG(20:3n6/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
PA(20:4(5Z,8Z,11Z,14Z)e/2:0)
|
|
|
TG(16:0/20:1(11Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:1(11Z)/24:1(15Z))
|
|
|
4-Fumarylacetoacetic acid
|
A beta-diketone that has formula C8H8O6.
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/20:3n6)
|
|
|
MG(P-18:0e/0:0/0:0)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(22:1(13Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/15:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:2(11Z,14Z)/16:1(9Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(24:0/18:3(6Z,9Z,12Z))
|
|
|
3-Oxodecanoic acid
|
An oxo fatty acid that is the 3-oxo derivative of decanoic acid.
|
|
7a,12a-Dihydroxy-3-oxo-4-cholenoic acid
|
|
|
PC(18:0/22:1(13Z))
|
|
|
4-Hydroxyestrone-2-S-glutathione
|
|
|
Mephentermine
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
4a-Hydroxytetrahydrobiopterin
|
A tetrahydropterin that is 5,6,7,8-tetrahydrobiopterin carrying an additional hydroxy substituent at the 4a-position.
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/20:3n6)
|
|
|
SAICAR
|
A 1-(phosphoribosyl)imidazolecarboxamide resulting from the formal condesation of the darboxy group of 5-amino-1-(5-O-phosphono-beta-D-ribofuranosyl)-1H-imidazole-4-carboxylic acid with the amino group of L-aspartic acid.
|
|
TG(18:1(9Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/16:0/22:1(13Z))
|
|
|
TG(14:1(9Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
Spirapril
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
PS(14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
Posaconazole
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:0/18:1(11Z))
|
|
|
Mepivacaine
|
A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.
|
|
TG(14:0/20:3n6/20:3n6)
|
|
|
TG(14:0/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(22:0/22:1(13Z)/16:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
(N-Acetylglucosaminyl)2-diphosphodolichol
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/18:0/20:3(5Z,8Z,11Z))
|
|
|
CDP-DG(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/18:1(11Z)/22:1(13Z))
|
|
|
Heme A
|
|
|
TG(18:1(9Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
Heme O
|
A heme that has formula C49H58FeN4O5.
|
|
PC(18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:0/18:2(9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
3a,7a-Dihydroxy-5b-cholestane
|
|
|
TG(16:1(9Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Thiomorpholine 3-carboxylate
|
The conjugate base of thiomorpholine-3-carboxylic acid.
|
|
TG(18:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/24:1(15Z)/15:0)
|
|
|
TG(18:1(9Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(15:0/22:0/22:0)
|
|
|
TG(24:1(15Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Lactosyceramide (d18:1/18:1(9Z))
|
|
|
TG(14:1(9Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:0/22:2(13Z,16Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(16:1(9Z)/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
24-Methylenecholesterol
|
A 3beta-sterol having the structure of cholesterol with a methylene group at C-24.
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:1(15Z)/20:2n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Iminoerythrose 4-phosphate
|
An alditol 4-phosphate that has formula C4H10NO6P.
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:0/16:0)
|
|
|
TG(20:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/24:1(15Z)/24:1(15Z))
|
|
|
TG(14:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
Linoleoyl-CoA
|
The S-linoleoyl derivative of coenzyme A.
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/20:2n6/24:0)
|
|
|
PE(16:1(9Z)/18:1(9Z))
|
|
|
TG(20:2n6/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Dimethylaniline-N-oxide
|
|
|
PI(18:1(9Z)/16:0)
|
|
|
TG(24:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ureidoisobutyric acid
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Sterol
|
A 3-hydroxy steroid closely related to cholestan-3-ol.
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ascorbic acid
|
|
|
DG(20:0/22:1(13Z)/0:0)
|
|
|
3-Methoxy-4-hydroxyphenylglycolaldehyde
|
A glycolaldehyde that has formula C9H10O4.
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:1(11Z)/24:0)
|
|
|
cis-3-Chloroallyl aldehyde
|
An organochlorine compound that has formula C3H3ClO.
|
|
PC(14:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:1(13Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(12:0/12:0/12:0)
|
|
|
TG(20:1(11Z)/20:2n6/24:1(15Z))
|
|
|
Hypothiocyanite
|
|
|
PIP2(16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ximelagatran
|
A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted to the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.
|
|
PE(15:0/14:1(9Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:0/24:1(15Z))
|
|
|
Levamisole
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:1(11Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
PIP(20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
DG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:0/20:3n6)
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/18:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(24:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:1(9Z)/20:2(11Z,14Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
DG(14:1(9Z)/20:0/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/22:2(13Z,16Z))
|
|
|
Nitroxoline
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3b,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
PE(24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:1(9Z)/18:1(9Z))
|
|
|
TG(20:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:1(11Z))[iso3]
|
|
|
TG(18:1(9Z)/14:0/o-18:0)
|
|
|
TG(20:3n6/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
20-Hydroxy-leukotriene B4
|
The 20-hydroxy derivative of leukotriene B4.
|
|
TG(20:3n6/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/15:0/18:2(9Z,12Z))
|
|
|
SM(d18:1/16:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/o-18:0/20:2n6)
|
|
|
TG(18:1(9Z)/14:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(20:1(11Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:0/18:1(11Z))
|
|
|
TG(16:0/15:0/24:1(15Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(14:0/18:0/18:0)
|
|
|
TG(20:3n6/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:2n6/14:1(9Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
N-palmitoyl-phosphoethanolamine
|
|
|
TG(15:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GT1c (d18:0/22:0)
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PI(22:3(10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GM2 (d18:0/20:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:0/18:1(11Z))[iso3]
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:0/20:1(11Z))
|
|
|
PC(dm18:0/dm18:1(9Z))
|
|
|
LysoPE(0:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1c (d18:0/20:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
Ganglioside GT2 (d18:1/14:0)
|
|
|
TG(16:0/14:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(18:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/24:0/20:2n6)
|
|
|
TG(14:0/24:1(15Z)/20:1(11Z))
|
|
|
Carteolol
|
A quinolone that has formula C16H24N2O3.
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3-Fumarylpyruvate
|
|
|
Chlorotrianisene
|
|
|
Uridine diphosphate glucuronic acid
|
|
|
N-Formyl-L-glutamic acid
|
A N-formyl amino acid that has formula C6H9NO5.
|
|
DG(20:3n6/0:0/18:3n3)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/16:0/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(14:1(9Z)/18:1(11Z)/0:0)
|
|
|
PE(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
LysoPC(16:1(9Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Sumatriptan
|
A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family).
|
|
TG(16:0/18:1(9Z)/20:0)[iso6]
|
|
|
Doxepin
|
A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
|
|
PS(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid
|
|
|
PE(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
Oxytocin
|
A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.
|
|
TG(18:1(9Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:3n6/20:1(11Z))
|
|
|
TG(20:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/o-18:0/20:0)
|
|
|
PI(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(22:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
N-[(3a,5b,7a)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine
|
|
|
DG(16:0/0:0/24:1n9)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:1(13Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:0/18:1(11Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
Aliskiren
|
|
|
(2R)-Ethylmalonyl-CoA
|
|
|
TG(14:1(9Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
PC(14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ganglioside GD1a (d18:0/20:0)
|
|
|
PC(22:1(13Z)/18:2(9Z,12Z))
|
|
|
PC(P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/14:1(9Z)/14:1(9Z))
|
|
|
TG(16:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(20:0/14:0/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/15:0/o-18:0)
|
|
|
TG(22:1(13Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Cytidine monophosphate
|
|
|
PC(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/24:1(15Z)/20:2n6)
|
|
|
TG(14:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
8-Hydroxycarvedilol
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GD1a (d18:0/22:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:0/20:2n6)
|
|
|
Adenosine 5'-pentaphosphate
|
An organophosphate oxoanion resulting from the removal of all six protons from the phosphate groups of adenosine 5'-pentaphosphate; the major species at pH 7.3.
|
|
PG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:1(9Z)/P-18:1(9Z))
|
|
|
TG(14:1(9Z)/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
Ethchlorvynol
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/18:1(9Z)/20:1(11Z))
|
|
|
Thromboxane B2
|
A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.
|
|
L-Glutamic gamma-semialdehyde
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Iodotyrosine
|
A tyrosine derivative which has at least one iodo-substituent on the benzyl moiety.
|
|
TG(14:0/15:0/22:0)
|
|
|
Pyridoxamine 5'-phosphate
|
A vitamin B6 phosphate that is the phosphoric ester derivative of pyridoxamine.
|
|
TG(14:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:1(11Z)/14:1(9Z))
|
|
|
TG(24:1(15Z)/20:0/o-18:0)
|
|
|
TG(16:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/14:0/0:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Bortezomib
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/14:0/14:1(9Z))
|
|
|
PIP2(18:1(11Z)/20:1(11Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Deoxyadenosine triphosphate
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
Acetaminophen glucuronide
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
Hydroxypyruvic acid
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z))
|
|
|
PG(16:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Beta-Sitosterol
|
|
|
TG(18:0/14:0/20:0)
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
PC(20:2(11Z,14Z)/14:0)
|
|
|
3-Hydroxy-L-proline
|
The L-stereoisomer of 3-hydroxyproline.
|
|
DG(16:0/24:1(15Z)/0:0)
|
|
|
Bromobenzene-2,3-dihydrodiol
|
An organic hydroxy compound that has formula C6H7BrO2.
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Iloprost
|
|
|
TG(16:1(9Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(24:0/P-18:1(11Z))
|
|
|
TG(20:2n6/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Camelliasaponin A2
|
|
|
Camelliasaponin A1
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
Cromoglicic acid
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
PE(22:0/14:1(9Z))
|
|
|
Sitaxentan
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Lactosylceramide (d18:1/24:1(15Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:1(9Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
D-Lactaldehyde
|
|
|
TG(20:1(11Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
(R)-Mevalonic acid-5-pyrophosphate
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(18:0/14:0/22:0)
|
|
|
TG(22:1(13Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2(9Z,12Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(18:1(9Z)/24:0/18:2(9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cer(d18:0/18:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM2 (d18:0/26:1(17Z))
|
|
|
Leukotriene C4
|
A leukotriene that contains cysteine in their structure.
|
|
PIP(20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(20:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
Chondroitin 4-sulfate
|
A chondroitin sulfate in which the site of sulfation is carbon 4 of the N-acetylgalactosamine (GalNAc) sugar.
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
PE(22:0/14:0)
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
LysoPC(18:3(9Z,12Z,15Z))
|
|
|
Hydralazine
|
The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
|
|
DG(18:1n7/0:0/20:1n9)
|
|
|
TG(16:0/18:1(11Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(14:1(9Z)/20:2n6/20:2n6)
|
|
|
Lidocaine
|
The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
|
|
Ursodeoxycholic acid
|
A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(18:1(9Z)/14:1(9Z)/24:1(15Z))
|
|
|
Moexipril
|
|
|
TG(15:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/0:0)
|
|
|
PE(22:0/16:0)
|
|
|
TG(14:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:0)
|
|
|
4-Hydroxybenzoic acid
|
A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.
|
|
TG(18:0/14:1(9Z)/22:0)
|
|
|
TG(20:1(11Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(15:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/18:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/22:1(13Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(P-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(16:0/0:0/18:3n6)
|
|
|
Methdilazine
|
|
|
TG(18:1(11Z)/20:1(11Z)/18:1(9Z))
|
|
|
2-(3-Carboxy-3-(methylammonio)propyl)-L-histidine
|
An ammonium ion that is a derivative of L-histidine having a 3-carboxy-3-(methylammonio)propyl group at the 2-position on the imidazole ring.
|
|
PC(20:3(8Z,11Z,14Z)/P-18:1(9Z))
|
|
|
TG(18:1(9Z)/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/0:0)
|
|
|
Diadenosine triphosphate
|
|
|
TG(20:0/20:0/14:1(9Z))
|
|
|
TG(24:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GT2 (d18:0/26:1(17Z))
|
|
|
Chenodeoxyglycocholoyl-CoA
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
DG(24:1n9/0:0/20:2n6)
|
|
|
Sedoheptulose
|
A ketoheptose that has formula C7H14O7.
|
|
Diphthamide
|
A quaternary ammonium ion that is the derivative of L-histidine having a 4-amino-4-oxo-3-(trimethylammonio)butyl group at the 2-position of the imidazole ring.
|
|
TG(22:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
Reduced Vitamin K (phylloquinone)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/15:0/16:0)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Dyclonine
|
N-Ethylpiperidine in which one of the hydrogens attached to the methyl group is substituted by a 4-butoxybenzoyl group.
|
|
TG(18:3(9Z,12Z,15Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:1(13Z)/o-18:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Buclizine
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
Glucosamine 6-phosphate
|
|
|
TG(18:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:0/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/24:1(15Z))
|
|
|
TG(14:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
Clodronate
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/15:0/0:0)
|
|
|
3a,21-Dihydroxy-5b-pregnane-11,20-dione
|
|
|
TG(14:0/15:0/15:0)
|
|
|
TG(22:1(13Z)/18:1(9Z)/20:2n6)
|
|
|
PIP(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
7a,12a-Dihydroxy-cholestene-3-one
|
|
|
TG(15:0/15:0/24:0)
|
|
|
Loxapine
|
A dibenzoxazepine that has formula C18H18ClN3O.
|
|
TG(20:2n6/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:2n6/15:0)
|
|
|
TG(18:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
N-Acetylleucine
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
DG(18:3n3/0:0/18:3n3)
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(16:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(o-22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/16:1(9Z)/0:0)
|
|
|
TG(24:0/20:1(11Z)/18:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:0/o-18:0)
|
|
|
Carbidopa
|
The hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.
|
|
TG(18:3(6Z,9Z,12Z)/18:0/20:3n6)
|
|
|
TG(24:0/22:1(13Z)/20:2n6)
|
|
|
PC(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/24:1(15Z)/16:0)
|
|
|
TG(18:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
Phensuximide
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/0:0/20:5n3)
|
|
|
1-Pentanol
|
|
|
PE(18:1(9Z)/22:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(11Z)/20:1(11Z))
|
|
|
LysoPE(0:0/16:1(9Z))
|
|
|
Flutamide
|
A (trifluoromethyl)benzene that has formula C11H11F3N2O3.
|
|
Isopropyl alcohol
|
|
|
5'-Methylthioadenosine
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Tetrahexosylceramide (d18:1/20:0)
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Ganglioside GT3 (d18:1/16:0)
|
|
|
DG(15:0/0:0/22:6n3)
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(14:1(9Z)/o-18:0/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
PI(20:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
Ganglioside GT3 (d18:1/18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
S-(2-Methylbutanoyl)-dihydrolipoamide
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:0/18:2(9Z,12Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/15:0/20:1(11Z))
|
|
|
PC(14:0/18:3(9Z,12Z,15Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
Cevimeline
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
Pirbuterol
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Tranylcypromine
|
An alkylamine that has formula C9H11N.
|
|
PG(18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:4n3/0:0/20:5n3)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:0)
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/o-18:0/16:1(9Z))
|
|
|
DG(15:0/20:1(11Z)/0:0)
|
|
|
PC(15:0/P-18:0)
|
|
|
TG(15:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
Chlordiazepoxide
|
A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP2(18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Agmatine
|
A primary amino compound that has formula C5H14N4.
|
|
Gentian Violet
|
|
|
Temozolomide
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
D-4'-Phosphopantothenate
|
|
|
TG(20:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/o-18:0)
|
|
|
DG(18:2(9Z,12Z)/24:0/0:0)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(24:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
MG(0:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
Ganglioside GT2 (d18:0/23:0)
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
Halofantrine
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
PC(22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(24:0/18:3(9Z,12Z,15Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2(9Z,12Z)/18:0/0:0)
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/20:0)
|
|
|
TG(14:0/20:1(11Z)/20:3n6)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ubiquinone-1
|
A compound composed of the standard 2,3-dimethoxy-5-methylbenzoquinone nucleus common to ubiquinones; and a side chain of a single isoprenoid unit.
|
|
Ubiquinone-2
|
A compound composed of the 2,3-dimethoxy-5-methylbenzoquinone nucleus common to ubiquinones; and a side chain of two isoprenoid units.
|
|
TG(22:0/24:1(15Z)/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Octanoylglucuronide
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Trimethylselenonium
|
An organic cation consisting of three methyl groups covalently bound to a central selenium atom.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/24:1(15Z)/0:0)
|
|
|
TG(24:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
21-Hydroxy-5b-pregnane-3,11,20-trione
|
|
|
TG(20:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
Haloperidol
|
A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
Sulfite
|
Sulfite is an inorganic anion, which is the conjugate base of hydrogen sulfite.
|
|
TG(15:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(dm18:0/18:1(11Z))
|
|
|
PE(18:1(11Z)/18:1(11Z))
|
|
|
2-Phosphoglyceric acid
|
A monophosphoglyceric acid having the phospho group at the 2-position.
|
|
PS(18:2(9Z,12Z)/18:0)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Cer(d18:1/24:1(15Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
PE(18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
Gluconic acid
|
|
|
PC(18:1(9Z)/P-18:1(11Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/24:0/o-18:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
Obtusifoliol
|
A 3beta-sterol that has formula C30H50O.
|
|
TG(22:0/24:1(15Z)/24:0)
|
|
|
6-Phosphogluconic acid
|
|
|
TG(24:1(15Z)/24:1(15Z)/20:3n6)
|
|
|
Quazepam
|
|
|
PC(18:0/20:3(5Z,8Z,11Z))
|
|
|
Inosine 2',3'-cyclic phosphate
|
|
|
Alpha-L-fucose
|
A L-fucopyranose having alpha-configuration at the anomeric centre.
|
|
PS(14:0/16:0)
|
|
|
DG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:0)
|
|
|
Fesoterodine
|
|
|
TG(18:0/24:0/16:1(9Z))
|
|
|
DG(20:2n6/0:0/20:2n6)
|
|
|
4a-Carboxy-4b-methyl-5a-cholesta-8,24-dien-3b-ol
|
|
|
TG(16:0/15:0/20:0)
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:0/20:1(11Z)/20:3n6)
|
|
|
TG(14:1(9Z)/16:0/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
DG(22:0/0:0/18:2n6)
|
|
|
DG(24:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
PE(20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Novobiocin
|
|
|
PC(P-18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
Mecamylamine
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:0/0:0/22:2n6)
|
|
|
TG(14:1(9Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
trans-2-Hexenoyl-CoA
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/20:0/20:3n6)
|
|
|
PC(18:0/P-18:1(11Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/20:2n6)
|
|
|
CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/18:1(9Z))
|
|
|
Clopidogrel
|
A thienopyridine that has formula C16H16ClNO2S.
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
Coenzyme Q9
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Ganglioside GD3 (d18:0/20:0)
|
|
|
Eicosanoyl-CoA
|
|
|
TG(20:0/18:1(11Z)/20:3n6)
|
|
|
11H-14,15-EETA
|
A hydroxy fatty acid that has formula C20H32O4.
|
|
PC(15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
PC(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:1(13Z)/20:1(11Z))
|
|
|
Famciclovir
|
2-Amino-9H-purine in which the hydrogen at position 9 is substituted by a 4-acetoxy-3-(acetoxymethyl)but-1-yl group. A prodrug of the antiviral penciclovir, it is used for the treatment of acute herpes zoster (shingles), for the treatment or suppression of recurrent genital herpes in immunocompetent patients and for the treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(14:1(9Z)/22:0/14:1(9Z))
|
|
|
PS(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
5alpha-Pregnan-20alpha-ol-3-one
|
A corticosteroid hormone that has formula C21H34O2.
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/o-18:0/20:3n6)
|
|
|
TG(14:0/o-18:0/22:1(13Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
14,15-DiHETrE
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/o-18:0)
|
|
|
TG(16:0/22:1(13Z)/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/18:0)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(14:1(9Z)/18:0)
|
|
|
TG(22:2(13Z,16Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:2n6/22:2(13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD1b (d18:0/26:0)
|
|
|
TG(16:0/24:1(15Z)/14:1(9Z))
|
|
|
Ketoprofen
|
An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.
|
|
TG(18:1(11Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/14:0/22:1(13Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
PC(14:0/22:1(13Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
PI(20:3(8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(20:3n6/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Adenosine 2'-phosphate
|
A purine ribonucleoside 2'-monophosphate that has formula C10H14N5O7P.
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(22:2(13Z,16Z)/15:0)
|
|
|
TG(18:1(11Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:2n6/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
3-Hydroxykynurenamine
|
A hydroxykynurenamine that has formula C9H12N2O2.
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
3-O-Sulfogalactosylceramide (d18:1/24:1(15Z))
|
|
|
DG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
PIP2(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
trans-5,6-Dihydro-5,6-dihydroxy-7,12-dimethylbenz[a]anthracene
|
A phenanthrene that has formula C20H18O2.
|
|
TG(18:1(11Z)/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/18:1(9Z)/16:1(9Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3n6/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Disialosyl galactosyl globoside
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(20:2n6/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/14:0/22:2(13Z,16Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/24:0/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Dihydrotachysterol
|
|
|
TG(16:1(9Z)/15:0/24:1(15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(24:1(15Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Trihexosylceramide (d18:1/16:0)
|
|
|
Ethanol
|
A primary alcohol that is ethane in which one of the hydrogens is substituted by a hydroxy group.
|
|
PC(16:0/18:3(6Z,9Z,12Z))
|
|
|
Butabarbital
|
A barbiturate that has formula C10H16N2O3.
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PIP2(18:0/20:3(8Z,11Z,14Z))
|
|
|
Suprofen
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:2n6/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/24:1(15Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
Benzoic acid
|
A compound comprising a benzene ring core carrying a carboxylic acid substituent.
|
|
TG(18:1(11Z)/20:0/22:1(13Z))
|
|
|
DG(20:3n9/0:0/20:3n6)
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/o-18:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(16:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Cyproterone
|
|
|
TG(18:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Naphthalene-1,2-diol
|
A naphthalenediol that has formula C10H8O2.
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/15:0/20:1(11Z))
|
|
|
TG(18:1(9Z)/18:0/o-18:0)
|
|
|
TG(14:0/16:1(9Z)/20:3n6)
|
|
|
TG(18:1(11Z)/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:1n5/0:0/14:1n5)
|
|
|
TG(22:0/20:2n6/18:2(9Z,12Z))
|
|
|
PI(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/24:0/20:2n6)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
beta-nicotinamide D-ribonucleotide
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/o-18:0/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/16:0/20:0)
|
|
|
TG(22:0/15:0/18:1(11Z))
|
|
|
TG(24:0/14:1(9Z)/18:1(9Z))
|
|
|
TG(14:0/16:0/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/o-18:0)
|
|
|
TG(20:3n6/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:1(9Z)/16:1(9Z))
|
|
|
Aldosterone
|
A pregnane-based steroidal hormone produced by the outer-section (zona glomerulosa) of the adrenal cortex in the adrenal gland, and acts on the distal tubules and collecting ducts of the kidney to cause the conservation of sodium, secretion of potassium, increased water retention, and increased blood pressure. The overall effect of aldosterone is to increase reabsorption of ions and water in the kidney.
|
|
PI(18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cortisol
|
A C21-steroid that is pregn-4-ene substituted by oxo groups at positions 3 and 20 and hydroxy groups at positions 11, 17 and 21. Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the stress hormone as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
N2-Galacturonyl-L-lysine
|
|
|
Mifepristone
|
|
|
TG(22:1(13Z)/20:1(11Z)/o-18:0)
|
|
|
TG(22:1(13Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(18:0/18:1(9Z)/20:0)[iso6]
|
|
|
TG(22:1(13Z)/16:1(9Z)/24:1(15Z))
|
|
|
TG(22:0/18:0/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:1(11Z)/24:0)
|
|
|
TG(15:0/18:1(9Z)/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PC(o-16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3n6/14:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
Lacto-N-triaose
|
|
|
TG(22:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:1(11Z)/16:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:0/o-18:0)
|
|
|
TG(18:1(9Z)/24:1(15Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:0/18:1(9Z))[iso6]
|
|
|
TG(14:1(9Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Lactaldehyde
|
A propanal that has formula C3H6O2.
|
|
PIP(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/22:2(13Z,16Z))
|
|
|
PI(16:0/20:0)
|
|
|
Ridogrel
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
PIP2(20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:1(11Z))
|
|
|
PC(15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
2,3-Epoxymenaquinone
|
|
|
Nitroprusside
|
An iron coordination entity that has formula C5FeN6O.
|
|
TG(14:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/0:0/20:4n6)
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/16:1(9Z)/20:2n6)
|
|
|
PC(18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
LPA(18:0e/0:0)
|
|
|
Phentermine
|
A primary amine that has formula C10H15N.
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
11-cis-Retinol
|
A retinol that has formula C20H30O.
|
|
TG(18:3(9Z,12Z,15Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:0/18:1(11Z)/18:1(11Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:1(9Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Beclometasone dipropionate
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GM3 (d18:1/18:0)
|
|
|
NPC
|
A pyranoindolizinoquinoline that has formula C28H30N4O6.
|
|
5,6-Dihydroxyindole
|
A dihydroxyindole that has formula C8H7NO2.
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Acoric acid
|
|
|
TG(24:1(15Z)/14:1(9Z)/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/16:1(9Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/o-18:0)
|
|
|
TG(24:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
CDP
|
A pyrimidine ribonucleoside 5'-diphosphate having cytosine as the nucleobase.
|
|
PC(20:3(8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:1(11Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
DG(24:0/22:1(13Z)/0:0)
|
|
|
PE(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3-Oxohexadecanoic acid
|
An oxo-fatty acid comprising palmitic acid having an oxo group at the 3-position; an intermediate in fatty acid biosynthesis.
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(22:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/14:0)
|
|
|
TG(24:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:1(11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM2 (d18:1/16:0)
|
|
|
Inositol cyclic phosphate
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM3 (d18:1/12:0)
|
|
|
TG(22:1(13Z)/16:0/24:1(15Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/15:0/18:1(9Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PI(20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Labetalol
|
A secondary amino compound formally derived from ammonia by replacing two of the hydrogens by 2-(3-carbamoyl-4-hydroxyphenyl)-2-hydroxyethyl and 4-phenylbutan-2-yl groups. It is an adrenergic antagonist used to treat high blood pressure.
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/16:0)
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
PE(18:0/20:3(8Z,11Z,14Z))
|
|
|
Aldosterone 18-glucuronide
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(18:2(9Z,12Z)/20:2(11Z,14Z))
|
|
|
PI(18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/24:0/20:3n6)
|
|
|
PC(dm18:1(11Z)/dm16:0)
|
|
|
TG(16:1(9Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/20:2n6)
|
|
|
TG(18:1(9Z)/16:0/18:2(9Z,12Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/14:0)
|
|
|
TG(16:1(9Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
PS(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PIP2(20:1(11Z)/16:0)
|
|
|
TG(15:0/16:0/22:2(13Z,16Z))
|
|
|
TG(20:0/14:0/22:1(13Z))
|
|
|
Meloxicam
|
|
|
TG(18:1(11Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/20:0/o-18:0)
|
|
|
DG(20:4n6/0:0/20:4n3)
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/o-18:0/22:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/14:1(9Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(18:1(11Z)/20:1(11Z)/22:1(13Z))
|
|
|
TG(24:0/14:1(9Z)/24:0)
|
|
|
Dihydroxyaluminium
|
|
|
TG(18:1(11Z)/18:1(11Z)/18:1(9Z))
|
|
|
PI(18:1(11Z)/18:1(9Z))
|
|
|
TG(20:2n6/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP2(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
PC(dm18:1(11Z)/dm18:0)
|
|
|
TG(15:0/o-18:0/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:2n6/20:1(11Z))
|
|
|
Hyaluronan
|
|
|
TG(18:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Guanfacine
|
|
|
TG(20:3n6/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(18:0/18:1(9Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
PC(18:1(9Z)/14:1(9Z))
|
|
|
Gentamicin
|
|
|
TG(24:0/14:0/24:1(15Z))
|
|
|
PC(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/18:1(9Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/o-18:0)
|
|
|
PC(14:1(9Z)/18:1(11Z))
|
|
|
Levonordefrin
|
|
|
5beta-Cholestanone
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/16:0/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
PG(18:0/18:0)
|
|
|
TG(15:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PG(16:0/16:1(9Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
Se-Methylselenocysteine
|
An alpha-amino acid compound having methylselanylmethyl as the side-chain.
|
|
DG(14:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
Ganglioside GT1c (d18:0/18:1(11Z))
|
|
|
TG(22:1(13Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PG(18:0/16:0)
|
|
|
Loracarbef
|
|
|
TG(14:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
(6Z,9Z,12Z,15Z,18Z,21Z)-3-Hydroxytetracosahexa-6,9,12,15,18,21-enoyl-CoA
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
3-Hydroxyisovaleryl-CoA
|
A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxyisovaleric acid.
|
|
DG(24:1n9/0:0/18:3n3)
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(20:2n6/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/20:2n6/15:0)
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
PI(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(20:3n6/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(15:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Prostaglandin I2
|
A prostaglandins I that has formula C20H32O5.
|
|
TG(14:1(9Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Dantrolene
|
The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin.
|
|
TG(18:1(9Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
DG(14:1n5/0:0/20:4n6)
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:1(11Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/14:0/16:1(9Z))[iso3]
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(16:0/20:0/22:1(13Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
SM(d18:0/16:0)
|
|
|
Telaprevir
|
|
|
TG(14:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/24:1(15Z)/20:3n6)
|
|
|
PE(18:2(9Z,12Z)/20:1(11Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(15:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Hexachlorophene
|
|
|
TG(18:1(9Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:0/0:0)
|
|
|
TG(14:0/22:0/16:1(9Z))
|
|
|
TG(16:0/18:1(9Z)/24:0)
|
|
|
TG(20:3n6/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
All-trans-retinoic acid
|
A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.
|
|
N-Methyltryptamine
|
A tryptamine alkaloid that has formula C11H14N2.
|
|
TG(16:1(9Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
SM(d18:1/22:1(13Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
DG(14:0/0:0/20:4n6)
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:3n6)
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/16:1(9Z)/20:3n6)
|
|
|
TG(16:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(14:1(9Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
1-(sn-Glycero-3-phospho)-1D-myo-inositol
|
A myo-inositol monophosphate derivative that is 1D-myo-inositol substituted at position 1 by an sn-glycero-3-phospho group.
|
|
TG(16:0/18:1(9Z)/22:0)
|
|
|
TG(14:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:0/24:1(15Z))
|
|
|
TG(14:0/15:0/16:1(9Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Pentobarbital
|
A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.
|
|
Glycyrrhetinic acid
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
PC(20:0/20:0)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(22:1(13Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
Phytanoyl-CoA
|
The S-phytanoyl derivative of coenzyme A.
|
|
19-Oxotestosterone
|
An androstanoid that is testosterone with an oxo group at position 19.
|
|
PE(18:0/24:0)
|
|
|
TG(24:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
Heptanoyl-CoA
|
A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of heptanoic acid.
|
|
(3a,5b,7a,12a)-24-[(carboxymethyl)amino]-1,12-dihydroxy-24-oxocholan-3-yl-b-D-Glucopyranosiduronic acid
|
|
|
TG(22:1(13Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(20:0/22:1(13Z)/20:2n6)
|
|
|
TG(16:0/18:2(9Z,12Z)/18:2(9Z,12Z))[iso3]
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
PC(15:0/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Chenodeoxycholic acid sulfate
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
Cobalamin
|
A cobalt-corrinoid hexaamide that is cobalamin with the oxidation state of the central cobalt atom unspecified.
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Ganglioside GM2 (d18:0/23:0)
|
|
|
TG(18:2(9Z,12Z)/20:0/20:2n6)
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:0/o-18:0)
|
|
|
PC(18:1(11Z)/24:1(15Z))
|
|
|
PE(14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:3n6/18:0)
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/22:0/0:0)
|
|
|
TG(20:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
PE(22:2(13Z,16Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
Ganglioside GM3 (d18:1/26:1(17Z)))
|
|
|
Papaverine
|
A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
OPC8-CoA
|
An organic molecule that has formula C39H64N7O18P3S.
|
|
TG(24:1(15Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
LysoPC(14:1(9Z))
|
|
|
Ganglioside GT1b (d18:0/24:1(15Z))
|
|
|
TG(15:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/15:0/18:2(9Z,12Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/P-18:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Trihexosylceramide (d18:1/25:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0/o-18:0)
|
|
|
TG(18:1(11Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Glimepiride
|
A N-acylurea that has formula C24H34N4O5S.
|
|
TG(20:1(11Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:1(9Z)/20:2n6)
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PS(14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/o-18:0/14:1(9Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(14:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(20:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/20:2n6)
|
|
|
TG(20:3n6/24:0/o-18:0)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
7-Methyladenine
|
Adenine substituted with a methyl group at position N-7.
|
|
DG(24:1n9/0:0/24:1n9)
|
|
|
PC(16:0/15:0)
|
|
|
TG(18:2(9Z,12Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
MG(0:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(18:1(9Z)/16:1(9Z)/24:1(15Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/20:0)[iso6]
|
|
|
PC(dm16:0/dm18:1(11Z))
|
|
|
TG(15:0/18:0/18:1(11Z))
|
|
|
PC(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:2(9Z,12Z)/P-18:1(11Z))
|
|
|
DG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
DG(24:1(15Z)/16:0/0:0)
|
|
|
CL(18:1(11Z)/18:1(11Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/20:0/20:2n6)
|
|
|
TG(16:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/o-18:0/20:1(11Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(20:0/14:0/22:0)
|
|
|
D-Gal alpha 1->6D-Gal alpha 1->6D-Glucose
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(9Z)/20:3n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/15:0/18:1(11Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Alizapride
|
|
|
TG(14:0/18:2(9Z,12Z)/15:0)
|
|
|
Imipramine
|
A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Glucosylsphingosine
|
|
|
TG(24:0/20:3n6/18:1(11Z))
|
|
|
TG(22:0/14:0/22:1(13Z))
|
|
|
Pentosan Polysulfate
|
|
|
Guanidoacetic acid
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/24:1(15Z)/22:1(13Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(18:0/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Hexadecenal
|
|
|
TG(20:1(11Z)/18:0/20:3n6)
|
|
|
TG(24:1(15Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(18:1(9Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3n6/o-18:0)
|
|
|
PE(14:0/18:1(11Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/16:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/24:0/20:3n6)
|
|
|
PI(18:0/18:2(9Z,12Z))
|
|
|
Minaprine
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
I(-)
|
A canonical ribonucleotide residue derived from IMP.
|
|
Pregnenolone
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(P-18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:0)
|
|
|
2-Methylhexanoyl-CoA
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:2(11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT1c (d18:0/16:0)
|
|
|
TG(18:1(11Z)/18:0/22:1(13Z))
|
|
|
TG(24:0/22:1(13Z)/24:0)
|
|
|
TG(14:1(9Z)/16:0/14:1(9Z))
|
|
|
TG(24:0/16:0/18:1(9Z))
|
|
|
Cer(d18:1/26:0)
|
|
|
Olmesartan
|
A biphenylyltetrazole that has formula C24H26N6O3.
|
|
TG(22:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(16:0/22:0/24:1(15Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/14:0/24:1(15Z))
|
|
|
TG(20:3n6/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:3n6/22:2(13Z,16Z))
|
|
|
DG(20:3n6/0:0/22:2n6)
|
|
|
Dienestrol
|
|
|
PE(18:1(11Z)/P-16:0)
|
|
|
Ferrocytochrome
|
Any cytochrome containing a ferroheme.
|
|
TG(20:3(5Z,8Z,11Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:2n6/18:1(11Z))
|
|
|
PE(24:0/P-18:1(9Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:0)
|
|
|
PC(24:0/P-18:1(11Z))
|
|
|
TG(15:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(o-20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Alpha-Muricholic acid
|
A bile acid that has formula C24H40O5.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/o-18:0)
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Adenosyl cobinamide
|
A cobalt-corrinoid hexaamide comprising cobinamide having an adenosyl group attached to cobalt.
|
|
D-Erythrose 4-phosphate
|
An erythrose phosphate that is D-erythrose carrying a phosphate group at position 4. It is an intermediate in the pentose phosphate pathway and Calvin cycle.
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(24:1(15Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/15:0/20:1(11Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/16:1(9Z))
|
|
|
TG(14:1(9Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
PC(20:2(11Z,14Z)/18:1(9Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
2-(a-Hydroxyethyl)thiamine diphosphate
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/14:1(9Z))
|
|
|
Medroxyprogesterone
|
A 3-oxo Delta(4)-steroid that is pregn-4-ene-3,20-dione substituted by an alpha-hydroxy group at position 17 and a methyl group at position 6.
|
|
TG(14:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
PS(18:0/20:3(8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:3n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(15:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
TG(16:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
PC(P-18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/14:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Uridine diphosphate glucose
|
|
|
TG(14:0/20:2n6/24:0)
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/14:0)
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(15:0/20:0/14:1(9Z))[iso6]
|
|
|
TG(22:2(13Z,16Z)/15:0/22:2(13Z,16Z))
|
|
|
TG(24:0/14:1(9Z)/14:1(9Z))
|
|
|
TG(22:1(13Z)/14:0/18:2(9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:1n9/0:0/20:3n6)
|
|
|
TG(24:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/15:0/18:2(9Z,12Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
Lamotrigine
|
A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6.
|
|
TG(18:2(9Z,12Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GM1 (d18:0/16:0)
|
|
|
TG(22:2(13Z,16Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
PC(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Glucosylceramide (d18:1/24:1(15Z))
|
|
|
TG(16:0/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cefazolin
|
A cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.
|
|
(+)-7-Isojasmonic acid CoA
|
An organic molecule that has formula C33H52N7O18P3S.
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(20:3n6/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
PC(16:0/22:1(13Z))
|
|
|
TG(14:0/18:1(9Z)/14:1(9Z))
|
|
|
TG(20:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/14:1(9Z)/0:0)
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:2(9Z,12Z))[iso3]
|
|
|
DG(22:0/18:1(9Z)/0:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:0/0:0/22:6n3)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:0/15:0/o-18:0)
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/0:0)
|
|
|
TG(16:0/22:1(13Z)/20:2n6)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Chlorine
|
A monoatomic chlorine that has formula Cl.
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PIP2(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso3]
|
|
|
TG(18:1(9Z)/24:1(15Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/16:0/20:3n6)
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Metipranolol
|
3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.
|
|
Cytidine 2'-phosphate
|
A cytidine phosphate compound having the phosphate group at the 2'-position.
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP(20:3(8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(20:2n6/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(18:1(9Z)/16:1(9Z))
|
|
|
TG(24:0/20:1(11Z)/20:3n6)
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
dIMP
|
|
|
Fludrocortisone
|
A mineralocorticoid that has formula C21H29FO5.
|
|
TG(22:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Adenine
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(16:1(9Z)/18:0/20:2n6)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
Streptozocin
|
|
|
PE(20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/24:1(15Z)/18:0)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
nicotinate beta-D-ribonucleotide
|
|
|
TG(18:1(9Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:2n6/24:1(15Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/18:1(11Z)/20:2n6)
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
4-alpha-Methyl-5-alpha-cholest-7-en-3-one
|
A cholestanoid that is lathosterone bearing an alpha-methyl substituent at position 4.
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/18:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/P-16:0)
|
|
|
TG(24:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:0/P-18:1(11Z))
|
|
|
PE(15:0/22:1(13Z))
|
|
|
TG(18:0/20:1(11Z)/20:2n6)
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/16:0)
|
|
|
3-Sulfinoalanine
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/24:0/15:0)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
Etiocholanolone
|
|
|
TG(15:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/16:1(9Z)/0:0)
|
|
|
Trimethoprim
|
An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
|
|
TG(20:3n6/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
Galactosylceramide (d18:1/12:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:0/0:0/24:1n9)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(22:0/24:0/20:1(11Z))
|
|
|
TG(20:1(11Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:0/22:0)
|
|
|
PC(24:0/P-18:1(9Z))
|
|
|
Albendazole
|
|
|
Ergoloid mesylate
|
A mixture of hydrogenated ergot alkaloids consisting of the methanesulfonic acid salts of dihydroergocornine (R = CHMe2), dihydroergocristine (R = CH2Ph), and alpha- and beta-dihydroergocryptine (R = CH2CHMe2 and CH(Me)Et, respectively). It is used for the symptomatic treatment of mild to moderate dementia in the elderly, although its value is not established.
|
|
TG(14:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Meclizine
|
|
|
TG(22:0/20:1(11Z)/20:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:2(11Z,14Z)/16:0)
|
|
|
TG(20:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:0/18:2(9Z,12Z))
|
|
|
PS(16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
Ganglioside GT1c (d18:1/12:0)
|
|
|
TG(20:0/18:1(11Z)/20:2n6)
|
|
|
PIP(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
CE(22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/24:0/22:1(13Z))
|
|
|
TG(18:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:1(13Z)/P-18:0)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
Protriptyline
|
An organic tricyclic compound that has formula C19H21N.
|
|
TG(14:0/18:0/24:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/20:3n6)
|
|
|
TG(15:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Molindone
|
|
|
TG(15:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GA1 (d18:1/18:0)
|
|
|
TG(16:1(9Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
4-Hydroxy-3-polyprenylbenzoate
|
A member of the class of benzoates obtained by deprotonation of the carboxy group of any 4-hydroxy-3-polyprenylbenzoic acid; major species at pH 7.3.
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
PC(16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
PIP2(22:4(10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Salbutamol
|
|
|
TG(18:1(9Z)/16:0/o-18:0)
|
|
|
PE(20:2(11Z,14Z)/14:0)
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
Cer(d18:0/16:0)
|
|
|
PE(18:2(9Z,12Z)/14:1(9Z))
|
|
|
TG(18:0/18:1(9Z)/18:2(9Z,12Z))[iso6]
|
|
|
PG(18:1(11Z)/18:1(11Z))
|
|
|
TG(18:0/24:0/14:1(9Z))
|
|
|
DG(22:2n6/0:0/18:3n3)
|
|
|
Heptadecanoyl CoA
|
A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of heptadecanoic acid,
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:2n6/18:2(9Z,12Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(15:0/22:1(13Z)/22:1(13Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/24:0/18:2(9Z,12Z))
|
|
|
4,6-Dideoxy-4-oxo-dTDP-D-glucose
|
|
|
Acetylhydrazine
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:3n6/16:1(9Z))
|
|
|
PE(18:1(11Z)/20:2(11Z,14Z))
|
|
|
PC(20:2(11Z,14Z)/P-18:0)
|
|
|
Ganglioside GT3 (d18:0/26:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/o-18:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/dm18:0)
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:3n6/22:0)
|
|
|
TG(22:1(13Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Malonic semialdehyde
|
|
|
TG(20:0/20:1(11Z)/22:1(13Z))
|
|
|
TG(20:0/20:3n6/16:1(9Z))
|
|
|
Dehydroepiandrosterone sulfate
|
A steroid sulfate that is the 3-sulfate of dehydroepiandrosterone.
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:3n6/20:0)
|
|
|
TG(22:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:1(9Z)/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
2-Methylacetoacetyl-CoA
|
A 3-oxoacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-methylacetoacetic acid.
|
|
Ganglioside GM3 (d18:1/22:1(13Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/0:0)
|
|
|
DG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(20:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
N-Acetyl-D-mannosamine 6-phosphate
|
An N-acyl-D-mannosamine 6-phosphate having the N-acyl specified as acetyl.
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/24:1(15Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/16:0)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(11Z)/14:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GT2 (d18:1/18:1(11Z))
|
|
|
DG(16:1n7/0:0/20:3n9)
|
|
|
DG(22:1n9/0:0/18:3n6)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
Androstenol
|
|
|
TG(15:0/14:0/24:0)
|
|
|
TG(24:0/16:1(9Z)/14:1(9Z))
|
|
|
TG(20:0/16:0/20:3n6)
|
|
|
DG(20:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(16:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
Beta-D-Glucose 6-phosphate
|
A D-glucopyranose 6-phosphate in which the anomeric centre has beta-configuration.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(14:0/22:0)
|
|
|
N1,N12-Diacetylspermine
|
An acetylspermine that has formula C14H30N4O2.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(24:1(15Z)/18:1(9Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
5-Phosphoribosylamine
|
|
|
PE(18:3(9Z,12Z,15Z)/P-16:0)
|
|
|
TG(16:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/22:1(13Z)/20:0)
|
|
|
Pimozide
|
|
|
TG(16:1(9Z)/24:0/18:2(9Z,12Z))
|
|
|
TG(22:0/14:0/16:1(9Z))
|
|
|
PC(dm18:1(9Z)/dm18:1(11Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Amphetamine
|
An amphetamine, the parent of the class of amphetamines, having the structure 1-phenylpropan-2-amine. It exists as a racemate.
|
|
TG(24:1(15Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:4n3/0:0/22:5n3)
|
|
|
PE(22:0/P-16:0)
|
|
|
TG(18:2(9Z,12Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Lablaboside E
|
|
|
Lablaboside D
|
|
|
Nortriptyline
|
An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
|
|
Lablaboside F
|
|
|
Flucloxacillin
|
A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.
|
|
PE(20:0/24:1(15Z))
|
|
|
Hydrogen
|
A monoatomic hydrogen that has formula H.
|
|
PE(20:4(8Z,11Z,14Z,17Z)/14:0)
|
|
|
TG(18:1(11Z)/20:0/18:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
4a-Carbinolamine tetrahydrobiopterin
|
|
|
TG(24:0/24:0/20:3n6)
|
|
|
PE(20:2(11Z,14Z)/22:1(13Z))
|
|
|
PE(22:0/20:0)
|
|
|
DG(20:3(8Z,11Z,14Z)/18:1(9Z)/0:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/20:2(11Z,14Z))
|
|
|
N-Acetylasparagine
|
|
|
(S)-lipoic acid
|
The (S)-enantiomer of lipoic acid. Not found in nature, it may exert detrimental effects on biosystems.
|
|
TG(22:0/16:1(9Z)/14:1(9Z))
|
|
|
TG(20:0/20:3n6/14:1(9Z))
|
|
|
25-Hydroxyvitamin D2 25-(beta-glucuronide)
|
|
|
DG(18:1n7/0:0/20:4n3)
|
|
|
PI(18:0/20:2(11Z,14Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/P-18:1(9Z))
|
|
|
Ecgonine methyl ester
|
The O-debenzoyl analogue of cocaine.
|
|
Tuberoside B (Ullucus tuberosus)
|
|
|
TG(20:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
trans-1,2-Dihydrobenzene-1,2-diol
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
Frovatriptan
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Degarelix
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(15:0/0:0/22:5n3)
|
|
|
TG(18:2(9Z,12Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Estrone
|
A 17-oxo steroid that is estra-1,3,5(10)-triene substituted by an hydroxy group at position 3 and an oxo group at position 17.
|
|
PC(P-18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
LysoPE(0:0/20:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/15:0/0:0)
|
|
|
DG(20:3(5Z,8Z,11Z)/20:1(11Z)/0:0)
|
|
|
Allocystathionine
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/18:1(9Z)/16:1(9Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:2n6/24:1(15Z))
|
|
|
2-Hydroxyestrone
|
A 2-hydroxy steroid that is estrone substituted by a hydroxy group at position 2.
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
Nepafenac
|
|
|
PA(18:0/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/14:0/18:1(11Z))
|
|
|
4-Aminobutyraldehyde
|
|
|
TG(16:1(9Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sulfinpyrazone
|
A pyrazolidine that has formula C23H20N2O3S.
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
PC(15:0/20:2(11Z,14Z))
|
|
|
8Z,11Z,14Z-eicosatrienoyl-CoA
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Entacapone
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(16:0/20:0/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/20:3n6)
|
|
|
CL(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z)/16:0)
|
|
|
TG(15:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(24:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:3n6/15:0/22:2(13Z,16Z))
|
|
|
Sedoheptulose 1,7-bisphosphate
|
A sedoheptulose derivative that has formula C7H16O13P2.
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/18:1(9Z))
|
|
|
17a,20a-Dihydroxycholesterol
|
|
|
Androstanedione
|
|
|
TG(20:0/20:3n6/18:2(9Z,12Z))
|
|
|
Digitoxin
|
|
|
TG(15:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
PC(22:1(13Z)/22:1(13Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(14:0/14:0/24:0)
|
|
|
TG(20:2n6/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
CDP-DG(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:0/0:0/18:3n3)
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Pentamidine
|
A diether compound consisting of pentane-1,5-diol with both hydroxyls bearing 4-amidinophenyl groups.
|
|
TG(20:3n6/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(14:1(9Z)/20:0)
|
|
|
TG(20:0/o-18:0/16:1(9Z))
|
|
|
5-Hydroxykynurenamine
|
A hydroxykynurenamine where the hydroxy group is located at the 5-position.
|
|
TG(14:1(9Z)/18:0/20:3n6)
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Glutethimide
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GQ1c (d18:1/25:0)
|
|
|
TG(15:0/18:1(11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/o-18:0)
|
|
|
DG(18:3(6Z,9Z,12Z)/14:0/0:0)
|
|
|
TG(18:1(9Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/16:0/o-18:0)
|
|
|
PC(20:0/22:1(13Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/15:0/o-18:0)
|
|
|
PE(22:0/20:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Voacamine
|
A citraconoyl group that has formula C43H52N4O5.
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:3n9/0:0/22:2n6)
|
|
|
13-HETE
|
|
|
2-Ethoxyethanol
|
|
|
TG(14:1(9Z)/20:1(11Z)/20:1(11Z))
|
|
|
UDP-L-iduronate
|
A nucleotide-sugar oxoanion arising from deprotonation of the diphosphate and carboxy groups of UDP-L-iduronic acid; major species at pH 7.3.
|
|
TG(20:2n6/18:1(9Z)/o-18:0)
|
|
|
TG(18:1(11Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
(2-Naphthyl)methanol
|
A naphthylmethanol that is methanol in which one of the methyl hydrogens has been replaced by a (2-naphthyl) group.
|
|
Voriconazole
|
A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:3n6/22:2(13Z,16Z))
|
|
|
Cisatracurium Besylate
|
The (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. Cisatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
5-Methoxyindoleacetate
|
An indole-3-acetic acid that has formula C11H11NO3.
|
|
PE(18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
Coprocholic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/16:1(9Z)/16:0)
|
|
|
TG(20:2n6/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:2(13Z,16Z)/24:0/0:0)
|
|
|
TG(18:1(9Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3a,7a-Dihydroxycoprostanic acid
|
|
|
TG(16:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(20:0/24:1(15Z)/22:0)
|
|
|
TG(14:0/16:1(9Z)/14:0)
|
|
|
PC(20:3(8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Chloral hydrate
|
An organochlorine compound that is the hydrate of trichloroacetaldehyde.
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/20:2n6)
|
|
|
DG(18:0/0:0/20:2n6)
|
|
|
TG(18:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PPPi
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:3n6/16:1(9Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(20:3n6/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1n7/0:0/22:5n3)
|
|
|
Ganglioside GD2 (d18:0/18:1(11Z))
|
|
|
PC(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:0/0:0/20:5n3)
|
|
|
PC(14:0/P-18:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(24:1(15Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/15:0/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/o-18:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:3n6)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
p-Synephrine
|
|
|
TG(18:1(9Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/20:3n6)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/20:3n6/20:2n6)
|
|
|
Raltitrexed
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GD1b (d18:1/25:0)
|
|
|
TG(15:0/20:0/18:1(11Z))
|
|
|
PE(24:1(15Z)/14:1(9Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:1(11Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
3-Oxocholic acid
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GD3 (d18:1/16:0)
|
|
|
DG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
3',4'-Dihydrodiol
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(16:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:0/18:2(9Z,12Z))
|
|
|
TG(20:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
Selenite
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PE(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP3(18:1(9Z)/18:1(9Z))
|
|
|
Almitrine
|
|
|
Tolazoline
|
|
|
TG(22:2(13Z,16Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/20:2n6)
|
|
|
Acetamidopropanal
|
|
|
PC(22:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/22:1(13Z))
|
|
|
TG(14:0/18:1(11Z)/20:3n6)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/22:0/22:2(13Z,16Z))
|
|
|
TG(15:0/16:0/20:2(11Z,14Z))[iso6]
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:1(11Z)/14:1(9Z)/20:2n6)
|
|
|
TG(24:0/20:3n6/16:1(9Z))
|
|
|
TG(20:1(11Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:1(11Z)/20:0)
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
PI(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GD3 (d18:1/18:0)
|
|
|
DG(14:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
Norfloxacin
|
A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
|
|
Icatibant
|
|
|
PC(18:1(11Z)/22:0)
|
|
|
PE(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Cytosine
|
An aminopyrimidine that is pyrimidin-2-one having the amino group located at position 4.
|
|
DG(20:0/14:1(9Z)/0:0)
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
7-Hydroxy-3-oxocholanoic acid
|
|
|
TG(24:1(15Z)/14:0/o-18:0)
|
|
|
TG(20:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/o-18:0)
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
Tetracosahexaenoyl CoA
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
Cinitapride
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/24:0/18:1(9Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(14:0/22:0/24:1(15Z))
|
|
|
CDP-Ethanolamine
|
A phosphoethanolamine consisting of ethanolamine having a cytidine 5'-diphosphate moiety attached to the oxygen.
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:0/20:2(11Z,14Z)/0:0)
|
|
|
DG(24:0/0:0/18:4n3)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Metharbital
|
|
|
TG(18:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
11-Dehydrocorticosterone
|
An 11-oxo steroid that is corticosterone in which the hydroxy substituent at the 11beta position has been oxidised to give the corresponding ketone.
|
|
PE(22:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:0/24:1(15Z)/o-18:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Telmisartan
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(16:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/14:0)
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/18:1(9Z)/18:1(9Z))[iso3]
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:1(11Z)/14:1(9Z))
|
|
|
DG(24:0/22:0/0:0)
|
|
|
PC(o-20:0/18:3(6Z,9Z,12Z))
|
|
|
Clindamycin
|
A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.
|
|
PI(18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PS(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(15:0/16:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/24:1(15Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:2n6/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/16:0/20:2n6)
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(P-16:0/18:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
DG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/15:0/20:1(11Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(14:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:2(9Z,12Z)/16:0/0:0)
|
|
|
TG(16:0/20:3n6/22:2(13Z,16Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/P-18:0)
|
|
|
Hydroxyphenylacetylglycine
|
|
|
PE(15:0/14:0)
|
|
|
Etiocholanedione
|
|
|
24,25-Dihydrolanosterol
|
A 3beta-sterol formed from lanosterol by reduction across the C-24-C-25 double bond.
|
|
TG(15:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/15:0/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/o-18:0/20:3n6)
|
|
|
L(-)-Nicotine pestanal
|
|
|
TG(16:1(9Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(15:0/22:0/20:3n6)
|
|
|
DG(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:2n6/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
SM(d18:0/24:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Zanamivir
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Adinazolam
|
A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(14:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
Kudzusaponin SA4
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/o-18:0/20:3n6)
|
|
|
TG(24:0/o-18:0/14:1(9Z))
|
|
|
Azathioprine
|
A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
|
|
Protoporphyrin IX
|
|
|
TG(16:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z))
|
|
|
PC(15:0/18:1(11Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
TG(14:0/20:2n6/14:0)
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:0/16:0)
|
|
|
TG(22:2(13Z,16Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6/o-18:0)
|
|
|
Vincristine
|
A vinca alkaloid that has formula C46H56N4O10.
|
|
15H-11,12-EETA
|
A carbonyl compound that has formula C20H32O4.
|
|
TG(24:1(15Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
PC(22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cefmetazole
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
12-Hydroxynevirapine
|
|
|
Adrenosterone
|
A 3-hydroxy steroid that has formula C19H24O3.
|
|
7a,12a-Dihydroxy-5a-cholestan-3-one
|
|
|
TG(22:1(13Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/18:0)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(20:1(11Z)/24:0/24:1(15Z))
|
|
|
TG(16:0/18:1(9Z)/20:2n6)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
PE(18:0/18:0)
|
|
|
Eucalyptol
|
|
|
Lovastatin
|
A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as a antilipemic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(24:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Mequitazine
|
|
|
TG(16:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/15:0/18:1(9Z))
|
|
|
PG(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
PI(16:1(9Z)/16:0)
|
|
|
Dehydrodolichol diphosphate
|
|
|
PE(22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3-Aminoisobutanoic acid
|
|
|
PC(dm18:1(9Z)/dm18:0)
|
|
|
TG(16:1(9Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
Promazine 5-sulfoxide
|
|
|
TG(15:0/20:0/22:0)
|
|
|
5-Aminolevulinic acid
|
The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group.
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/o-18:0/22:1(13Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(16:0/18:0)
|
|
|
DG(24:1(15Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(15:0/16:1(9Z)/15:0)
|
|
|
TG(18:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GD1b (d18:0/22:1(13Z))
|
|
|
TG(22:0/22:1(13Z)/24:1(15Z))
|
|
|
TG(14:0/16:1(9Z)/24:0)
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
PC(24:1(15Z)/14:0)
|
|
|
DG(18:3(6Z,9Z,12Z)/20:1(11Z)/0:0)
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:0/20:0)
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:3n6)
|
|
|
TG(14:1(9Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Hexanal
|
|
|
TG(16:1(9Z)/20:3n6/18:1(11Z))
|
|
|
TG(14:0/22:0/22:1(13Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:0/20:2n6)
|
|
|
TG(15:0/20:0/20:0)
|
|
|
DG(18:2(9Z,12Z)/24:1(15Z)/0:0)
|
|
|
L-Lactic acid
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:0/0:0/18:3n3)
|
|
|
DG(24:0/0:0/18:2n6)
|
|
|
TG(16:0/18:0/18:1(11Z))
|
|
|
DG(18:3n6/0:0/20:2n6)
|
|
|
TG(16:1(9Z)/16:0/20:2n6)
|
|
|
PE(20:1(11Z)/P-18:1(9Z))
|
|
|
2-Hydroxybutyric acid
|
A hydroxybutyric acid having a single hydroxyl group located at position 2; urinary secretion of 2-hydroxybutyric acid is increased with alcohol ingestion or vigorous physical exercise and is associated with lactic acidosis and ketoacidosis in humans and diabetes in animals.
|
|
1-(alpha-Methyl-4-(2-methylpropyl)benzeneacetate)-beta-D-Glucopyranuronic acid
|
|
|
20a,22b-Dihydroxycholesterol
|
|
|
TG(14:1(9Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Etidronic acid
|
A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
|
|
TG(18:1(9Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(18:1(11Z)/18:0)
|
|
|
TG(14:0/24:1(15Z)/20:0)
|
|
|
PC(20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
epsilon-Caprolactone
|
|
|
PC(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/20:2n6)
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:2n6)
|
|
|
2-Hydroxyestrone-1-S-glutathione
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0/0:0)
|
|
|
Naproxen
|
A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.
|
|
Homocysteine
|
A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Taurolithocholic acid 3-sulfate
|
|
|
1-Hydroxymethylnaphthalene
|
|
|
PE(24:0/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Telithromycin
|
|
|
TG(20:3n6/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/20:2n6)
|
|
|
DG(15:0/18:0/0:0)
|
|
|
MG(24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0/0:0)
|
|
|
TG(14:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Okadaic acid
|
A polycyclic ether that has formula C44H68O13.
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
DG(16:0/16:0/0:0)
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:0/14:0/15:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/20:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
DG(14:1n5/0:0/20:5n3)
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/15:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(18:1(11Z)/16:0/22:2(13Z,16Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PIP(16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Hydroxypropionic acid
|
|
|
3-Methyl-2-oxovaleric acid
|
A 2-oxo monocarboxylic acid that is valeric acid carrying oxo- and methyl substituents at C-2 and C-3, respectively. An alpha-keto acid analogue and metabolite of isoleucine in man, animals and bacteria. Used as a clinical marker for maple syrup urine disease (MSUD).
|
|
TG(20:3(5Z,8Z,11Z)/14:0/20:2n6)
|
|
|
TG(14:0/18:1(9Z)/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1b (d18:0/23:0)
|
|
|
PE(24:0/P-18:0)
|
|
|
TG(18:2(9Z,12Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Aprobarbital
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(18:0/0:0/0:0)
|
A 1-acyl-sn-glycerol that has octadecanoyl (stearoyl) as the 1-acyl group.
|
|
Ibudilast
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:0/24:0)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/P-18:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/16:0)
|
|
|
Ribothymidine
|
A methyluridine having a single methyl substituent at the 5-position on the uracil ring.
|
|
TG(24:0/20:2n6/o-18:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/15:0)
|
|
|
TG(18:1(11Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(24:1(15Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Lipoyl-AMP
|
A purine ribonucleoside 5'-monophosphate having adenine as the nucleobase and a lipoyl group attached to one of the phosphate OH groups.
|
|
Isobutyryl-CoA
|
A short-chain, methyl-branched fatty acyl-CoA that is the S-isobutyryl derivative of coenzyme A.
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
Ketoconazole
|
A N-carbonylpiperazine that has formula C26H28Cl2N4O4.
|
|
PS(18:0/20:0)
|
|
|
Ganglioside GD1b (d18:1/22:1(13Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GQ1c (d18:1/22:1(13Z))
|
|
|
PE(22:1(13Z)/24:0)
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:2n6)
|
|
|
TG(15:0/18:0/20:3n6)
|
|
|
TG(20:0/14:0/18:1(11Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ganglioside GD2 (d18:0/26:0)
|
|
|
TG(20:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
1,7-Dimethyluric acid
|
An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trione substituted by methyl groups at N-1 and N-7. It is a metabolite of caffeine and is often found in human urine samples.
|
|
Sulfide
|
Any sulfur molecular entity that involves either covalently bonded or anionic sulfur.
|
|
PE(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Isosorbide Mononitrate
|
A glucitol derivative that has formula C6H9NO6.
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/0:0)
|
|
|
PC(24:0/18:2(9Z,12Z))
|
|
|
TG(20:0/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
3-hydroxyoctadecanoyl-CoA
|
A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxyoctadecanoic acid.
|
|
Ganglioside GD2 (d18:0/24:0)
|
|
|
Methsuximide
|
|
|
6-Methylthioguanosine monophosphate
|
An organic molecule that has formula C11H16N5O7PS.
|
|
DG(22:1(13Z)/15:0/0:0)
|
|
|
TG(20:2n6/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PIP(18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/24:1(15Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
PE(22:1(13Z)/22:0)
|
|
|
TG(18:1(9Z)/22:0/24:1(15Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:0/20:2n6)
|
|
|
PIP(20:0/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/o-18:0/24:1(15Z))
|
|
|
Galactosylceramide (d18:1/18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:3n6)
|
|
|
TG(15:0/22:1(13Z)/24:0)
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(20:3(5Z,8Z,11Z)/18:1(9Z)/0:0)
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(18:2(9Z,12Z)/18:0)
|
|
|
2-Maleylacetate
|
|
|
TG(22:0/20:0/14:1(9Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(16:0/20:1(11Z)/20:3n6)
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(18:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(18:1(11Z)/14:0/o-18:0)
|
|
|
TG(18:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:0/18:1(11Z))
|
|
|
DG(20:5n3/0:0/20:5n3)
|
|
|
Fludiazepam
|
A 1,4-benzodiazepinone that has formula C16H12ClFN2O.
|
|
TG(20:1(11Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(18:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Carphenazine
|
A propanone that has formula C24H31N3O2S.
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0/0:0)
|
|
|
Drostanolone
|
|
|
Ketotifen
|
|
|
(+)-trans-Carveol
|
|
|
PE(14:0/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/24:1(15Z)/16:0)
|
|
|
TG(18:1(9Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
Alvimopan
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Bretylium
|
|
|
PE(18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
11-cis-Retinyl palmitate
|
The 11-cis-isomer of retinyl palmitate.
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-16:0/15:0)
|
|
|
Copper
|
|
|
PE(15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/24:0/16:1(9Z))
|
|
|
Ubiquinone 6
|
A ubiquinone compound having a (2E,6E,10E,14E,18E)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl substituent at position 2.
|
|
alpha-Fluoro-beta-alanine
|
An organonitrogen compound that has formula C3H6FNO2.
|
|
DG(18:1(9Z)/18:0/0:0)
|
|
|
TG(24:0/20:1(11Z)/o-18:0)
|
|
|
3a,7a-Dihydroxy-5b-cholest-24-enoyl-CoA
|
|
|
DG(14:1(9Z)/18:0/0:0)
|
|
|
TG(16:1(9Z)/18:0/o-18:0)
|
|
|
Ambenonium
|
|
|
TG(24:0/20:0/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/22:1(13Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PI(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(24:0/16:1(9Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
Androstan-3alpha,17beta-diol
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
PC(P-18:0/18:0)
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:0/0:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
PC(22:2(13Z,16Z)/20:1(11Z))
|
|
|
Diphenhydramine
|
An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:1(13Z)/16:1(9Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(18:1(11Z)/14:0/24:1(15Z))
|
|
|
TG(14:1(9Z)/18:0/22:1(13Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(24:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3-Dechloroethylifosfamide
|
A phosphorodiamide that has formula C5H12ClN2O2P.
|
|
2-Propyn-1-al
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/20:3n6)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GD1a (d18:1/20:0)
|
|
|
TG(18:1(9Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Rifampin
|
|
|
TG(18:1(11Z)/20:1(11Z)/20:2n6)
|
|
|
TG(14:1(9Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
PC(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(20:2(11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
Carprofen
|
Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.
|
|
dUMP
|
A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having uracil as the nucleobase.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/18:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
CL(20:1(11Z)/18:2(9Z,12Z)/18:1(9Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/o-18:0)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
PE(P-18:1(9Z)/16:1(9Z))
|
|
|
DG(18:0/0:0/18:0)
|
|
|
Lactosylcermide (d18:1/20:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/14:0/20:1(11Z))
|
|
|
TG(24:0/20:1(11Z)/22:1(13Z))
|
|
|
Alpha-Tocopherol
|
|
|
Uridine diphosphate-N-acetylglucosamine
|
|
|
SM(d17:1/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
L-Glutamic acid 5-phosphate
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
3-Oxotetradecanoyl-CoA
|
A 3-oxo-fatty acyl-CoA that has formula C35H60N7O18P3S.
|
|
Darunavir
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(18:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:2(9Z,12Z)/P-16:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/24:0/18:1(9Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z)/16:0)
|
|
|
PE(14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
5-alpha-Dihydrotestosterone glucuronide
|
|
|
Oxytetracycline
|
A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:0)
|
|
|
Hydrocortamate
|
A glycinyl ester that has formula C27H41NO6.
|
|
PIP(18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/20:0/20:3(5Z,8Z,11Z))
|
|
|
Methyclothiazide
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Oleoyl-CoA
|
An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of oleic acid.
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/14:1(9Z)/20:1(11Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
Galactosylceramide (d18:1/16:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/24:0)
|
|
|
DG(16:0/0:0/20:4n6)
|
|
|
TG(14:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
N6-Methyladenosine
|
A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.
|
|
Doxazosin
|
A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
|
|
TG(18:2(9Z,12Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Guanabenz
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/18:1(9Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(24:1(15Z)/16:1(9Z)/0:0)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:0/22:1(13Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:2n6/24:1(15Z))
|
|
|
MG(18:3(9Z,12Z,15Z)/0:0/0:0)
|
|
|
PE(14:0/22:2(13Z,16Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(24:0/18:1(11Z)/20:1(11Z))
|
|
|
Modafinil
|
|
|
LysoPC(18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(14:0/14:0/o-18:0)
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Thiamylal
|
A member of the class of barbiturates that is 2-thioxodihydropyrimidine-4,6(1H,5H)-dione substituted by a pentan-2-yl and prop-2-en-1-yl group at position 5.
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/20:2n6)
|
|
|
TG(24:1(15Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
Cis-stilbene oxide
|
A stilbene oxide that has formula C14H12O.
|
|
Malonyl-CoA
|
The S-malonyl derivative of coenzyme A.
|
|
TG(18:1(11Z)/16:1(9Z)/20:1(11Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(P-18:1(11Z)/20:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PG(18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:3n6/22:1(13Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
PI(18:1(11Z)/18:1(11Z))
|
|
|
TG(24:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:2(11Z,14Z)/P-16:0)
|
|
|
TG(24:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/16:0/24:1(15Z))
|
|
|
N-Oleoylethanolamine
|
|
|
DG(24:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:1(13Z)/14:0/20:3n6)
|
|
|
PC(20:1(11Z)/14:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
16(R)-HETE
|
An optically active form of 16-HETE having (16R)-configuration.
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
Ganglioside GA1 (d18:1/20:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:0/18:1(11Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Ubiquinol 8
|
A ubiquinol in which the polyprenyl substituent is octaprenyl.
|
|
TG(22:1(13Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/o-18:0)
|
|
|
TG(20:2n6/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(20:1(11Z)/20:2(11Z,14Z))
|
|
|
5-beta-Cholestan-3-one
|
A 3-oxo steroid that is 5beta-cholestane substituted by an oxo group at position 3.
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(22:1(13Z)/20:3n6/o-18:0)
|
|
|
Arsenite
|
An arsenite ion resulting from the removal of all three protons from the hydroxy groups of arsenous acid.
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
Fluoxymesterone
|
An anabolic androgenic steroid that has formula C20H29FO3.
|
|
TG(16:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:0/0:0/18:1n7)
|
|
|
PIP(16:0/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:1(11Z)/16:0)
|
|
|
Pentadecanoic acid
|
A straight-chain, fifteen-carbon carboxylic acid with no heteroatoms; a long-chain of mainly ruminant origin.
|
|
TG(20:0/20:3n6/20:0)
|
|
|
TG(14:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:0/18:2(9Z,12Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/16:1(9Z))[iso]
|
|
|
DG(20:4n6/0:0/22:2n6)
|
|
|
TG(22:0/16:1(9Z)/24:0)
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(18:0/o-18:0/20:2n6)
|
|
|
CDP-DG(18:0/18:0)
|
|
|
Sialyl-Lewis X
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Acrylyl-CoA
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
DG(16:0/0:0/20:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
Budesonide
|
A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.
|
|
Hydrogen carbonate
|
The carbon oxoanion resulting from the removal of a proton from carbonic acid.
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(16:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:0/20:2n6)
|
|
|
TG(20:1(11Z)/20:1(11Z)/o-18:0)
|
|
|
TG(16:0/16:0/18:1(11Z))[iso3]
|
|
|
TG(22:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(14:0/18:1(9Z)/20:1(11Z))
|
|
|
Triprolidine
|
|
|
TG(15:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0/0:0)
|
|
|
TG(20:1(11Z)/22:0/24:1(15Z))
|
|
|
TG(16:1(9Z)/16:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(20:3n6/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
17a,21-Dihydroxy-5b-pregnane-3,11,20-trione
|
|
|
TG(14:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:3n6/22:1(13Z))
|
|
|
PIP(18:1(11Z)/16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GT3 (d18:0/25:0)
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Fosaprepitant
|
A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.
|
|
PC(24:0/22:0)
|
|
|
DG(22:0/14:1(9Z)/0:0)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/0:0)
|
|
|
Repaglinide
|
|
|
PE(24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
Cinolazepam
|
A 1,4-benzodiazepinone compound having a 2-cyanoethyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-fluorophenyl group at the 5-position and a chloro substituent at the 7-position, it has general properties similar to those of diazepam and has been used for the short-term management of sleep disorders.
|
|
TG(24:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(15:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:0)
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/18:2(9Z,12Z))
|
|
|
PE(22:0/P-18:0)
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
Cer(d18:1/26:1(17Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(20:3n6/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
Queuine
|
A pyrrolopyrimidine that has formula C12H15N5O3.
|
|
PE(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GA2 (d18:1/24:1(15Z))
|
|
|
PIP[3'](16:0/18:1(9Z))
|
|
|
PC(24:0/24:0)
|
|
|
TG(16:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:1(13Z)/18:1(11Z))
|
|
|
TG(20:0/15:0/22:0)
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
Fe3+
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/22:1(13Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:0/15:0)
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(20:0/15:0/20:0)
|
|
|
TG(16:0/16:1(9Z)/16:1(9Z))[iso3]
|
|
|
1,4-Dithiothreitol
|
The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:0/20:1(11Z))
|
|
|
D-Ribulose 5-phosphate
|
The D-enantiomer of ribulose 5-phosphate that is one of the end-products of the pentose phosphate pathway.
|
|
Beta-D-Fructose 2-phosphate
|
|
|
TG(22:0/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(20:0/20:0/22:2(13Z,16Z))
|
|
|
Ganglioside GT3 (d18:1/25:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z)/0:0)
|
|
|
TG(15:0/16:1(9Z)/18:0)
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Forasartan
|
|
|
TG(14:0/20:3n6/18:2(9Z,12Z))
|
|
|
Bismuth
|
|
|
TG(22:0/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(22:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(20:1(11Z)/18:2(9Z,12Z)/18:1(9Z)/18:1(9Z))
|
|
|
TG(15:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
15(S)-HPETE
|
The (S)-enantiomer of 15-HPETE.
|
|
TG(14:0/14:0/18:0)
|
|
|
TG(18:1(11Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
QH(2)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PC(16:0/18:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(22:0/16:0/22:1(13Z))
|
|
|
TG(15:0/24:1(15Z)/18:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/15:0/0:0)
|
|
|
12,13-EpOME
|
|
|
TG(20:3n6/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:1(13Z)/15:0)
|
|
|
TG(18:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/14:0)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:1(11Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/o-18:0/20:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(14:0/14:0/18:2(9Z,12Z))
|
|
|
7-Methylxanthine
|
An oxopurine that is xanthine in which the hydrogen attached to the nitrogen at position 7 is replaced by a methyl group. It is an intermediate metabolite in the synthesis of caffeine.
|
|
PE(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:1(9Z)/18:1(9Z))
|
|
|
TG(14:0/24:0/22:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:2(11Z,14Z))[iso6]
|
|
|
D-Glucaric acid
|
The D-enantiomer of glucaric acid.
|
|
Ganglioside GD3 (d18:0/12:0)
|
|
|
Galactosylceramide (d18:1/24:1(15Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
Clofazimine
|
|
|
TG(22:1(13Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:0/22:0)
|
|
|
TG(18:0/22:2(13Z,16Z)/20:2n6)
|
|
|
PE(18:3(9Z,12Z,15Z)/24:0)
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(18:0/22:0/24:0)
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
Adrenochrome
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/P-18:0)
|
|
|
DG(22:1(13Z)/14:0/0:0)
|
|
|
Nonanoyl-CoA
|
A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of nonanoic acid.
|
|
TG(20:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/15:0/16:0)
|
|
|
Prenyl benzoate
|
|
|
Rocuronium
|
A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.
|
|
TG(14:0/20:2n6/20:2n6)
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
PI(16:0/18:1(11Z))
|
|
|
PIP3(18:1(11Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Galactosylceramide (d18:1/14:0)
|
|
|
TG(14:0/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD2 (d18:1/22:0)
|
|
|
DG(15:0/0:0/22:4n6)
|
|
|
Orlistat
|
|
|
DG(18:2n6/0:0/20:2n6)
|
|
|
Gamma-Linolenic acid
|
A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.
|
|
TG(20:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
Tiglylglycine
|
An N-acylglycine that is glycine with an amine hydrogen substituted by a 2-methylbut-2-enoyl (tiglyl) group.
|
|
TG(24:1(15Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
Thromboxane A2
|
A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.
|
|
TG(18:0/20:2n6/14:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:0)[iso3]
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/P-16:0)
|
|
|
TG(20:3n6/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
PC(o-20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Tiotropium
|
|
|
TG(18:0/18:1(11Z)/20:0)
|
|
|
Acarbose
|
A tetrasaccharide derivative consisting of a dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl C7 cyclitol moiety [called valienol (or valienamine)] linked via nitrogen to isomaltotriose.
|
|
DG(22:2n6/0:0/20:5n3)
|
|
|
PC(o-16:0/16:1(9Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Sulfanilamide
|
A sulfonamide in which the sulfamoyl functional group is attached to aniline at the 4-position.
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPC(20:0)
|
A lysophosphatidylcholine in which the remaining acyl group contains 20 carbons and 0 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))
|
|
|
Ursodeoxycholic acid 3-sulfate
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1b (d18:0/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/o-18:0/20:2n6)
|
|
|
TG(14:1(9Z)/14:0/20:1(11Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
LysoPE(0:0/24:1(15Z))
|
|
|
TG(18:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/o-18:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
Taurocholic acid
|
A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.
|
|
TG(18:1(9Z)/22:0/18:2(9Z,12Z))
|
|
|
Bromobenzene-2,3-oxide
|
An epoxide that has formula C6H5BrO.
|
|
TG(22:0/14:1(9Z)/22:0)
|
|
|
PC(18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/20:2n6/18:2(9Z,12Z))
|
|
|
PI(20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
Vitamin D2 3-glucuronide
|
|
|
Cisapride
|
The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
L-Leucine
|
The L-enantiomer of leucine.
|
|
Drospirenone
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(14:0/22:1(13Z)/15:0)
|
|
|
TG(20:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Leukotriene F4
|
A leukotriene composed of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid having (5S)-hydroxy and (6R)-(L-gamma-glutamyl-L-cystein-S-yl) substituents.
|
|
MG(0:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(22:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:0/15:0)
|
|
|
Pyridoxine
|
A hydroxymethylpyridine with hydroxymethyl groups at positions 4 and 5, a hydroxy group at position 3 and a methyl group at position 2.
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Dolichyl phosphate D-mannose
|
|
|
TG(14:1(9Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(24:0/24:1(15Z)/20:2n6)
|
|
|
TG(18:1(11Z)/20:0/20:3(5Z,8Z,11Z))
|
|
|
Docosahexaenoic acid
|
Any C22 polyunsaturated fatty acid containing six double bonds.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/20:0/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(18:1(9Z)/20:0/24:1(15Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
22b-Hydroxycholesterol
|
|
|
Ganglioside GM2 (d18:1/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PIP2(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
DG(22:1(13Z)/16:1(9Z)/0:0)
|
|
|
PC(22:0/20:1(11Z))
|
|
|
2-Amino-3-carboxymuconic acid semialdehyde
|
|
|
PE(P-16:0/22:0)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
PIP(18:0/16:2(9Z,12Z))
|
|
|
Bromocriptine
|
An indole alkaloid that has formula C32H40BrN5O5.
|
|
TG(20:1(11Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
4-Hydroxy-L-proline
|
The L-stereoisomer of 4-hydroxyproline.
|
|
PE(18:4(6Z,9Z,12Z,15Z)/P-18:1(11Z))
|
|
|
TG(15:0/o-18:0/18:1(9Z))
|
|
|
N6-Galacturonyl-L-lysine
|
|
|
TG(16:1(9Z)/20:0/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z)/16:1(9Z))
|
|
|
DG(16:0/0:0/18:3n3)
|
|
|
TG(24:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
PE(P-18:1(9Z)/22:1(13Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
CDP-DG(18:1(11Z)/16:0)
|
|
|
TG(16:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
DG(16:0/0:0/18:1n7)
|
|
|
Dacarbazine
|
A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma.
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/14:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(24:0/20:2n6/18:2(9Z,12Z))
|
|
|
SM(d18:0/16:1(9Z)(OH))
|
|
|
TG(20:3n6/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/o-18:0/18:1(11Z))
|
|
|
PG(16:0/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
4-Acetamido-2-amino-6-nitrotoluene
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0/o-18:0)
|
|
|
Phosphoserine
|
|
|
PE(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Melphalan
|
A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
DG(20:1(11Z)/22:0/0:0)
|
|
|
TG(20:3n6/16:0/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/16:0/0:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
2b,3a,7a,12a-Tetrahydroxy-5b-cholanoic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Thioridazine
|
A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
Lotaustralin
|
A cyanogenic glycoside that has formula C11H19NO6.
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/24:1(15Z))
|
|
|
TG(20:3n6/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(15:0/14:1(9Z)/20:0)
|
|
|
TG(14:1(9Z)/20:2n6/18:1(9Z))
|
|
|
Bromfenac
|
Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.
|
|
TG(18:2(9Z,12Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/20:1(11Z)/20:2n6)
|
|
|
Flurbiprofen
|
A fluorobiphenyl that has formula C15H13FO2.
|
|
TG(18:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
DG(14:1n5/0:0/24:1n9)
|
|
|
5-phosphonooxy-L-lysine
|
|
|
TG(20:2n6/20:2n6/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:0/18:1(9Z))
|
|
|
PC(20:0/P-18:0)
|
|
|
Oxirane
|
A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom.
|
|
TG(14:0/24:0/15:0)
|
|
|
6-Thiourate
|
An oxopurine that has formula C5H4N4O2S.
|
|
Oleic acid
|
An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/14:1(9Z)/22:0)
|
|
|
TG(15:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(24:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(16:1n7/0:0/18:1n9)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
Rosiglitazone
|
|
|
Rifabutin
|
|
|
Adipate semialdehyde
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Gemfibrozil
|
An aromatic ether that has formula C15H22O3.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3a,7a,12a,19-Tetrahydroxy-5b-cholanoic acid
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/o-18:0)
|
|
|
PC(14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Fructosamine
|
|
|
TG(16:1(9Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/24:1(15Z))
|
|
|
Taurochenodesoxycholic acid
|
|
|
Nitrofurantoin
|
An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a (5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.
|
|
QH2
|
|
|
PI(20:0/16:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/24:0/20:2n6)
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/16:1(9Z)/16:0)
|
|
|
DG(22:5n6/0:0/18:4n3)
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/o-18:0)
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
LysoPE(0:0/18:1(9Z))
|
|
|
TG(22:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
Tetrahexosylceramide (d18:1/12:0)
|
|
|
TG(20:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/20:1(11Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/16:0/15:0)
|
|
|
TG(18:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
Chlormerodrin
|
Urea in which one of the hydrogens is substituted by a 3-chloromercury-2-methoxyprop-1-yl group. It was formerly used as a diuretic, but more potent and less toxic drugs are now available. Its radiolabelled ((197)Hg, (203)Hg) forms were used in diagnostic aids in renal imaging and brain scans.
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
Trimethaphan
|
|
|
TG(20:2n6/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:0/22:2(13Z,16Z))
|
|
|
PE(20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3b,7a,12a-Trihydroxy-5a-Cholanoic acid
|
|
|
TG(14:1(9Z)/24:1(15Z)/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
Ganglioside GT2 (d18:0/26:0)
|
|
|
TG(14:1(9Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
DG(15:0/18:1(9Z)/0:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(18:0/16:0/24:1(15Z))
|
|
|
TG(14:1(9Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
PE(P-16:0/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:1(13Z)/16:1(9Z))
|
|
|
Ganglioside GT2 (d18:0/24:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/22:2(13Z,16Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
PC(P-16:0/14:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ciclesonide
|
|
|
TG(16:0/20:2n6/24:1(15Z))
|
|
|
2-Keto-glutaramic acid
|
|
|
DG(16:1(9Z)/24:0/0:0)
|
|
|
TG(15:0/18:1(11Z)/20:0)
|
|
|
TG(14:1(9Z)/20:2n6/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/o-18:0)
|
|
|
Dutasteride
|
Finasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(22:1(13Z)/P-16:0)
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(24:0/20:0/0:0)
|
|
|
Myristic acid
|
A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
PI(20:2(11Z,14Z)/18:0)
|
|
|
TG(20:2n6/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:2n6/22:2(13Z,16Z))
|
|
|
DG(18:0/0:0/22:5n6)
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
1-Salicylate glucuronide
|
A beta-D-glucosiduronic acid that is the glucuronide conjugate of salicyclic acid.
|
|
TG(14:0/18:2(9Z,12Z)/22:0)
|
|
|
PE(18:2(9Z,12Z)/20:0)
|
|
|
TG(14:1(9Z)/24:0/18:1(9Z))
|
|
|
TG(18:0/16:1(9Z)/20:2n6)
|
|
|
DG(18:2(9Z,12Z)/20:0/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
L-Alpha-aminobutyric acid
|
An optically active form of alpha-aminobutyric acid having L-configuration.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/o-18:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/24:0)
|
|
|
TG(15:0/18:0/18:0)
|
|
|
L-Lysine
|
An L-alpha-amino acid; the L-isomer of lysine.
|
|
Chloroacetaldehyde
|
Acetaldehyde substituted at C-2 by chlorine.
|
|
PIP(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
PIP(20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(20:3n6/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
PC(P-16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
LysoPE(20:0/0:0)
|
|
|
DG(20:0/16:0/0:0)
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
3-Oxoadipyl-CoA
|
The S-(3-oxoadipyl) derivative of coenzyme A.
|
|
TG(18:3(6Z,9Z,12Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(20:0/15:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
beta-L-fucose
|
A L-fucopyranose with a beta-configuration at the anomeric position.
|
|
Ceftazidime
|
A cephalosporin bearing pyridinium-1-ylmethyl and {[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.
|
|
TG(15:0/18:2(9Z,12Z)/18:2(9Z,12Z))[iso3]
|
|
|
Luteolin 7-O-[beta-D-glucuronosyl-(1->2)-beta-D-glucuronide]
|
|
|
TG(14:0/20:3n6/20:1(11Z))
|
|
|
TG(14:0/16:1(9Z)/14:1(9Z))
|
|
|
PE(15:0/24:0)
|
|
|
7a-Hydroxy-5b-cholestan-3-one
|
|
|
TG(18:1(11Z)/14:0/18:1(9Z))[iso6]
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(15:0/22:0)
|
|
|
TG(24:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/16:0/o-18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:1(11Z)/20:2n6/22:1(13Z))
|
|
|
PG(16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:1(9Z)/22:2(13Z,16Z)/0:0)
|
|
|
DG(20:2n6/0:0/22:5n3)
|
|
|
Ganglioside GT1c (d18:0/23:0)
|
|
|
Betaxolol
|
A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure.
|
|
TG(15:0/18:3(6Z,9Z,12Z)/15:0)
|
|
|
TG(16:0/14:1(9Z)/20:1(11Z))
|
|
|
TG(14:0/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/o-18:0/20:1(11Z))
|
|
|
TG(15:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/14:1(9Z))
|
|
|
Phosphatidylethanolamine
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Tasosartan
|
|
|
TG(22:1(13Z)/20:1(11Z)/20:2n6)
|
|
|
TG(18:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
Dehydroascorbic acid
|
A tetrahydrofuranone that has formula C6H6O6.
|
|
PIP2(18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
2,4-Diamino-6-nitrotoluene
|
|
|
DG(14:1(9Z)/15:0/0:0)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/22:1n9)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/16:0/18:2(9Z,12Z))
|
|
|
Water
|
An inorganic hydroxy compound that has formula H2O.
|
|
Spermidine
|
A triamine that is the 1,5,10-triaza derivative of decane.
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
PI(16:0/20:2(11Z,14Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GT1c (d18:0/25:0)
|
|
|
S-(2-Methylpropionyl)-dihydrolipoamide-E
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
DG(24:0/0:0/18:3n3)
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:2n6/0:0/20:4n6)
|
|
|
5-Diphosphoinositol pentakisphosphate
|
|
|
N-Acetyl-L-alanine
|
An N-acetyl-L-amino acid that is L-alanine in which one of the nitrogens attached to the nitrogen is replaced by an acetyl group.
|
|
TG(14:1(9Z)/18:0/20:1(11Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(16:0/22:2(13Z,16Z)/20:0)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/20:2n6)
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/14:1(9Z)/20:3n6)
|
|
|
Dimethylallylpyrophosphate
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
DG(22:4n6/0:0/18:3n3)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
DG(15:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Calcipotriol
|
A seco-cholestane that has formula C27H40O3.
|
|
TG(18:0/24:1(15Z)/22:1(13Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/16:0/16:1(9Z))[iso3]
|
|
|
TG(20:2n6/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Achyranthoside D
|
|
|
Achyranthoside C
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
LPA(0:0/18:1(9Z))
|
|
|
TG(14:1(9Z)/20:3n6/14:1(9Z))
|
|
|
LysoPE(0:0/15:0)
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PS(14:0/16:1(9Z))
|
|
|
2-Aminomuconic acid semialdehyde
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/22:2(13Z,16Z))
|
|
|
DG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/o-18:0/20:3n6)
|
|
|
TG(16:1(9Z)/18:0/18:0)[iso3]
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/o-18:0/20:2n6)
|
|
|
Chondroitin
|
A mucopolysaccharide composed of repeating beta-D-glucopyranuronosyl-(1->3)-beta-D-N-acetylgalactosaminyl units.
|
|
TG(18:2(9Z,12Z)/18:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(15:0/15:0/18:0)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/15:0)
|
|
|
PIP2(18:0/16:1(9Z))
|
|
|
4-Fluoromuconolactone
|
A butenolide that has formula C6H5FO4.
|
|
TG(24:1(15Z)/20:2n6/18:2(9Z,12Z))
|
|
|
TG(22:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/18:2(9Z,12Z))
|
|
|
Brimonidine
|
A quinoxaline derivative that has formula C11H10BrN5.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
L-2-Amino-3-oxobutanoic acid
|
A 2-amino-3-oxobutanoic acid that has formula C4H7NO3.
|
|
UDP-N-acetyl-alpha-D-galactosamine
|
A UDP-N-acetyl-D-galactosamine in which the anomeric centre of the galactosamine moiety has alpha-configuration.
|
|
TG(15:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
Geranylgeranyl-PP
|
|
|
TG(14:1(9Z)/20:0/18:1(9Z))
|
|
|
TG(18:1(11Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(P-16:0/18:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
Niacinamide
|
|
|
DG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
Phosphoribosyl pyrophosphate
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
PC(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:1(11Z))
|
|
|
Ganglioside GM1 (18:1/16:0)
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(20:0/15:0/22:1(13Z))
|
|
|
PE(22:2(13Z,16Z)/18:0)
|
|
|
DG(16:0/14:0/0:0)
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
Trihexosylceramide (d18:1/18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(22:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(24:1(15Z)/18:1(9Z))
|
|
|
TG(20:0/14:1(9Z)/22:1(13Z))
|
|
|
TG(22:0/18:0/24:1(15Z))
|
|
|
TG(20:3n6/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/16:1(9Z)/24:1(15Z))
|
|
|
Metolazone
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/24:1(15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
PI(16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:1(11Z)/24:1(15Z))
|
|
|
CL(18:1(11Z)/18:1(11Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
(24S)-7alpha,24-Dihydroxycholesterol
|
A 7alpha,24-dihydroxycholesterol that has formula C27H46O3.
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
PC(P-18:1(9Z)/15:0)
|
|
|
1-Nitronaphthalene-7,8-oxide
|
A nitronaphthalene that has formula C10H7NO3.
|
|
Ganglioside GT2 (d18:0/14:0)
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
LysoPC(17:0)
|
An lysophosphatidylcholine in which the acyl group contains seventeen carbons and no double bonds. If R1 is an acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphoethanolaminecholine. If R1 is a hydrogen and R2 is an acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:0/22:0)
|
|
|
DG(15:0/14:0/0:0)
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(14:0/24:1(15Z)/15:0)
|
|
|
TG(18:1(9Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:2(11Z,14Z)/15:0)
|
|
|
Glutaryl-CoA
|
An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of glutaric acid.
|
|
TG(14:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Arformoterol
|
|
|
TG(18:1(9Z)/16:1(9Z)/18:1(9Z))
|
|
|
TG(20:2n6/18:1(9Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GD1b (d18:0/16:0)
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Secobarbital
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(22:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(16:1n7/0:0/18:2n6)
|
|
|
Ganglioside GD1b (d18:0/14:0)
|
|
|
Ethylmorphine
|
|
|
TG(20:0/20:0/o-18:0)
|
|
|
Trans-2-all-cis-6,9,12,15,18,21-tetracosaheptaenoyl-CoA
|
|
|
TG(20:3n6/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
Cer(d18:0/22:0)
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/o-18:0/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
Rutin
|
A rutinoside that is quercetin with the hydroxy group at position C-3 substituted with glucose and rhamnose sugar groups.
|
|
TG(20:2n6/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:0/15:0)
|
|
|
PS(18:0/16:0)
|
|
|
TG(16:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3n6/24:0/20:3n6)
|
|
|
TG(20:1(11Z)/20:3n6/24:1(15Z))
|
|
|
TG(14:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:2(13Z,16Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
MG(0:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
DG(16:0/22:2(13Z,16Z)/0:0)
|
|
|
PIP(16:1(9Z)/16:1(9Z))
|
|
|
TG(16:0/20:2n6/22:1(13Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
N-Acetylhistamine
|
A member of the class of acetamides that is acetamide comprising histamine having an acetyl group attached to the side-chain amino function.
|
|
TG(24:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Nadolol
|
Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.
|
|
TG(24:1(15Z)/18:0/o-18:0)
|
|
|
TG(18:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronide
|
A glucosiduronic acid that has formula C16H23N3O8.
|
|
TG(24:0/15:0/o-18:0)
|
|
|
DG(15:0/0:0/20:4n3)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:1(9Z)/20:2n6)
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(16:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/14:1(9Z)/20:1(11Z))
|
|
|
Ganglioside GD3 (d18:1/24:1(15Z))
|
|
|
TG(16:1(9Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(24:0/18:1(9Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Scopolamine
|
A tropane alkaloid that is the (S)-tropic acid ester of 6beta,7beta-epoxy-1alphaH,5alphaH-tropan-3alpha-ol.
|
|
PE(P-16:0/15:0)
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Dinoprost Tromethamine
|
An organic molecular entity that has formula C20H34O5.C4H11NO3.
|
|
TG(15:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ivacaftor
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(15:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
MG(16:0/0:0/0:0)
|
|
|
Ganglioside GM2 (d18:0/18:1(11Z))
|
|
|
1-Methylxanthine
|
A monomethylxanthine having the methyl group located at the 1-position. It is a metabolite of caffeine in humans.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/16:0/20:3n6)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
PE(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/20:2n6)
|
|
|
Busulfan
|
|
|
Colchicine
|
An alkaloid that is a carbotricyclic compound comprising 5,6,7,9-tetrahydrobenzo[a]heptalene having four methoxy substituents at the 1-, 2-, 3- and 10-positions as well as an oxo group at the 9-position and an acetamido group at the 7-position. It has been isolated from the plants belonging to genus Colchicum.
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Isometheptene
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(14:0/18:0)
|
|
|
TG(18:0/24:0/22:2(13Z,16Z))
|
|
|
DG(18:1(9Z)/14:1(9Z)/0:0)
|
|
|
DG(20:1n9/0:0/22:4n6)
|
|
|
CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
LysoPE(0:0/22:1(13Z))
|
|
|
PS(16:1(9Z)/18:1(9Z))
|
|
|
Ganglioside GD1a (d18:1/22:1(13Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/15:0/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:0/18:1(9Z))
|
|
|
Dimenhydrinate
|
The diphenhydramine salt of 8-chlorotheophylline. Its effects are similar to those of diphenhydramine, but it is less potent. It was thought that by combining the antiemetic effects of diphenhydramine with the mild stimulant effects of 8-chlorotheophyline, the extreme drowsiness induced by the former would be mitigated. However, the sedation caused by diphenhydramine is considerably stronger than the stimulation caused by 8-chlorotheophylline. Dimenhydrinate is used mainly as an antiemetic in the prevention and treatment of motion sickness.
|
|
Decitabine
|
|
|
PG(18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(16:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Cisplatin
|
A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary.
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/20:3n6)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(9Z)/20:2(11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:4n6/0:0/20:4n6)
|
|
|
PC(P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/P-16:0)
|
|
|
TG(24:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(15:0/16:1(9Z)/22:1(13Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
PC(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Desipramine
|
A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
|
|
TG(14:1(9Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/16:1(9Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
PE(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
Dimethindene
|
|
|
Chitin
|
An aminoglycan consisting of beta-(1->4)-linked N-acetyl-D-glucosamine residues.
|
|
TG(16:1(9Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
TG(18:1(11Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
PG(18:1(9Z)/18:1(9Z))
|
A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which both acyl groups are specified as oleoyl.
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/o-18:0)
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
4-beta-Hydroxymethyl-4-alpha-methyl-5-alpha-cholest-7-en-3-beta-ol
|
A 3beta-hydroxy steroid that has formula C29H50O2.
|
|
TG(22:0/15:0/16:1(9Z))
|
|
|
TG(18:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
CDP-DG(18:0/16:0)
|
|
|
Gefitinib
|
|
|
N-acetyl-O-acetylneuraminate
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
Tetradecanol
|
|
|
TG(16:0/20:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/24:1(15Z)/24:1(15Z))
|
|
|
TG(20:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(P-18:0/18:1(9Z))
|
|
|
TG(15:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
Solanesyl-PP
|
|
|
2-Hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol
|
|
|
DG(16:0/0:0/20:5n3)
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/P-16:0)
|
|
|
TG(20:1(11Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Thyroxine
|
An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
|
|
TG(15:0/22:1(13Z)/o-18:0)
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(22:4(10Z,13Z,16Z,19Z)/18:0)
|
|
|
Vitamin D3
|
|
|
TG(18:1(9Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
6-Thioguanosine monophosphate
|
An organic molecule that has formula C10H14N5O7PS.
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(24:1n9/0:0/18:3n6)
|
|
|
Arsenic
|
A pnictogen that has formula As.
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
Norgestimate
|
|
|
TG(15:0/15:0/14:1(9Z))
|
|
|
PE(P-18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
Clonazepam
|
1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
|
|
TG(22:0/22:0/22:1(13Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PS(18:0/18:3(9Z,12Z,15Z))
|
|
|
Melanin
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Galabiosylceramide (d18:1/20:0)
|
|
|
Dexmedetomidine
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(18:0/18:1(11Z)/o-18:0)
|
|
|
1a,11b-Dihydro-4,9-dimethylbenz[a]anthra[3,4-b]oxirene
|
A phenanthrene that has formula C20H16O.
|
|
Pentacarboxylporphyrin I
|
|
|
TG(22:0/15:0/24:0)
|
|
|
TG(18:2(9Z,12Z)/20:0/20:3n6)
|
|
|
Malathion
|
A diester that is butanedioate substituted by a (dimethoxyphosphorothioyl)sulfanediyl group at position 2.
|
|
TG(14:1(9Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ecgonine
|
A tropane alkaloid that consists of tropane bearing carboxy and hydroxy substituents at positions 2 and 3 respectively and having (1R,2R,3S,5S)-configuration. It is both a metabolite of and a precursor to cocaine.
|
|
L-Fucose
|
Any form of fucose having L configuration.
|
|
DG(18:0/16:1(9Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:3n6/0:0/22:5n3)
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/16:0/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(9Z)/24:0)
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(16:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Maraviroc
|
|
|
Ganglioside GT2 (d18:1/22:0)
|
|
|
Galactan
|
Polysaccharides composed of galactose residues.
|
|
PG(16:0/18:1(9Z))
|
A phosphatidylglycerol(1-) that is the conjugate base of 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-rac-glycerol) obtained by deprotonation of the phosphate hydroxy group; major species at pH 7.3.
|
|
TG(22:1(13Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:2n6/22:1(13Z))
|
|
|
Phosphoribosylformylglycineamidine
|
|
|
MG(16:1(9Z)/0:0/0:0)
|
|
|
TG(20:2n6/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(14:0/0:0/20:4n3)
|
|
|
PE(20:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:1(11Z)/18:0)
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:1(11Z))
|
|
|
PC(16:1(9Z)/24:1(15Z))
|
|
|
TG(18:0/o-18:0/18:1(11Z))
|
|
|
3-Oxohexanoyl-CoA
|
An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of 3-oxohexanoic acid.
|
|
TG(14:1(9Z)/14:0/20:3(5Z,8Z,11Z))
|
|
|
DG(22:5n3/0:0/22:5n3)
|
|
|
TG(18:1(11Z)/24:0/20:3n6)
|
|
|
Ethylene oxide/propylene oxide copolymer (avg m w 9,760 - 13,200)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(dm18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/18:0/20:0)
|
|
|
TG(22:1(13Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(18:0/22:1(13Z)/20:0)
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(15:0/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PI(16:0/22:2(13Z,16Z))
|
|
|
DG(20:1(11Z)/20:0/0:0)
|
|
|
TG(16:1(9Z)/24:0/18:1(9Z))
|
|
|
5-Acetylamino-6-formylamino-3-methyluracil
|
|
|
TG(18:1(9Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
Pyridine
|
An azaarene comprising a benzene core in which one -CH group is replaced by a nitrogen atom. It is the parent compound of the class pyridines.
|
|
Ganglioside GA2 (d18:1/26:0)
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PS(16:1(9Z)/18:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/24:0/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:0/24:0)
|
|
|
TG(18:1(11Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(P-16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/20:0/20:3n6)
|
|
|
DG(18:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:3n6)
|
|
|
DG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/o-18:0)
|
|
|
PC(o-16:1(9Z)/22:0)
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(15:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Galactosylceramide (d18:1/22:0)
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
MG(0:0/20:2(11Z,14Z)/0:0)
|
|
|
TG(24:0/20:1(11Z)/24:0)
|
|
|
PE(22:2(13Z,16Z)/P-18:1(11Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:1(11Z)/18:1(9Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(15:0/20:3n6/16:0)
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:0/18:1(9Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Hyocholic acid
|
A bile acid that has formula C24H40O5.
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/18:1(11Z)/18:0)
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ketoprofen glucuronide
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/0:0)
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Inositol phosphate
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
(2R,3R)-2,3-Butanediol
|
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Nandrolone phenpropionate
|
A 3-phenylpropionate ester that has formula C27H34O3.
|
|
TG(24:0/16:1(9Z)/20:2n6)
|
|
|
PIP(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Sulfathiazole
|
A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.
|
|
trans-3-Decenoyl-CoA
|
|
|
TG(24:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
cis-beta-D-Glucosyl-2-hydroxycinnamate
|
|
|
TG(16:0/20:0/14:1(9Z))
|
|
|
Ganglioside GD1b (d18:1/12:0)
|
|
|
TG(18:1(11Z)/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/14:0/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:0/14:1(9Z)/20:0)
|
|
|
CE(24:1(15Z))
|
|
|
N-Stearoylsphingosine
|
|
|
TG(18:1(9Z)/18:1(9Z)/18:3(6Z,9Z,12Z))[iso6]
|
|
|
Ganglioside GD1b (d18:1/14:0)
|
|
|
TG(16:0/20:1(11Z)/18:0)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
DG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(16:1(9Z)/16:0/16:1(9Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
TG(20:0/14:0/20:2n6)
|
|
|
L-erythro-tetrahydrobiopterin
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(20:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:0/20:1(11Z))[iso6]
|
|
|
TG(18:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
N6,N6,N6-Trimethyl-L-lysine
|
An alpha-amino-acid cation that is the N(6)-trimethyl derivative of L-lysine.
|
|
TG(15:0/18:1(11Z)/14:1(9Z))
|
|
|
TG(20:2n6/18:1(11Z)/o-18:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/24:0)
|
|
|
TG(22:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(16:0/20:0/18:1(9Z))
|
|
|
TG(20:3n6/18:1(9Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
PG(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
D-Tagatose 6-phosphate
|
|
|
PE(18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(9Z)/14:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/18:0)
|
|
|
TG(14:1(9Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0/o-18:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/15:0/16:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Anisindione
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:1(11Z)/20:3n6)
|
|
|
TG(18:0/20:3n6/18:1(9Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/22:0)
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Quinestrol
|
|
|
PC(24:0/22:2(13Z,16Z))
|
|
|
Nutriacholic acid
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
Finasteride e
|
|
|
TG(16:1(9Z)/20:1(11Z)/20:3n6)
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
L-Serine
|
The L-enantiomer of serine.
|
|
Hydroxychloroquine
|
|
|
TG(14:0/18:1(9Z)/16:0)
|
|
|
TG(14:0/20:0/20:1(11Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/15:0/24:1(15Z))
|
|
|
TG(16:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/24:1(15Z)/18:0)
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
15-Hydroxynorandrostene-3,17-dione glucuronide
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Isovaleryl-CoA
|
A short-chain, methyl-branched fatty acyl-CoA that is the S-isovaleryl derivative of coenzyme A.
|
|
7a-Hydroxy-5b-cholanic acid
|
|
|
PI(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
cis,trans-5'-Hydroxythalidomide
|
|
|
TG(20:0/20:3n6/20:1(11Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/o-18:0/24:1(15Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(24:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/o-18:0/20:0)
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Primidone
|
A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.
|
|
TG(15:0/16:0/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GM3 (d18:1/25:0)
|
|
|
1-Piperidinecarboxaldehyde
|
|
|
Ganglioside GT1c (d18:0/12:0)
|
|
|
PE(22:2(13Z,16Z)/18:1(9Z))
|
|
|
TG(20:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/24:0/20:3n6)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
PC(dm16:0/dm18:1(9Z))
|
|
|
TG(24:0/18:0/24:0)
|
|
|
TG(20:0/14:1(9Z)/22:0)
|
|
|
TG(20:2n6/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
7,8-Dihydro-7-hydroxy-8-S-glutathionyl-benzo[a]pyrene
|
A glutathione derivative in which the hydrogen of the side-chain thiol function of glutathione is substituted by a 7-hydroxy-7,8-dihydrobenzo[pqr]tetraphen-8-yl group.
|
|
Cefotiam
|
|
|
PC(20:0/22:2(13Z,16Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:1(13Z)/24:0)
|
|
|
TG(15:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/18:1(9Z))[iso3]
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
DG(16:1n7/0:0/22:2n6)
|
|
|
PC(o-20:0/20:0)
|
|
|
TG(14:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Chlorprothixene
|
|
|
TG(18:2(9Z,12Z)/16:0/20:2(11Z,14Z))[iso6]
|
|
|
TG(14:1(9Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(18:0/24:1(15Z)/16:1(9Z))
|
|
|
Miglustat
|
|
|
TG(22:2(13Z,16Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:0/0:0/16:1n7)
|
|
|
TG(18:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/18:1(9Z)/20:3n6)
|
|
|
PC(16:0/P-18:1(9Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/14:0)
|
|
|
Cefuroxime
|
A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
|
|
TG(18:2(9Z,12Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Travoprost
|
|
|
Hydroxyurea
|
A member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease.
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(18:0/14:1(9Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(9Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
PE(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Gamma-Aminobutyric acid
|
A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
|
|
Hexane
|
An unbranched alkane containing six carbon atoms.
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(P-18:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
PC(24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(22:2(13Z,16Z)/24:0)
|
|
|
DG(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Dihydroxyacetone phosphate
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:2(13Z,16Z)/22:0)
|
|
|
PIP(16:1(9Z)/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Anastrozole
|
A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position.
|
|
Fenoterol
|
|
|
TG(14:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Rasagiline
|
|
|
LysoPE(0:0/20:3(11Z,14Z,17Z))
|
|
|
PI(18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(14:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/20:3n6)
|
|
|
L-Cystathionine
|
A modified amino acid generated by enzymic means from L-homocysteine and L-serine.
|
|
PS(18:3(9Z,12Z,15Z)/16:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cilastatin
|
|
|
PG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
Triazolam
|
A triazolobenzodiazepine that has formula C17H12Cl2N4.
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:1(15Z)/22:1(13Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Androsterone
|
An androstanoid that is 5alpha-androstane having a hydroxy substituent at the 3alpha-position and an oxo group at the 17-position. It is a metabolite of dehydroepiandrosterone .
|
|
TG(16:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/o-18:0)
|
|
|
Dihydrofolic acid
|
A folic acid derivative acted upon by dihydrofolate reductase to produce tetrahydrofolic acid. It interacts with bacteria during cell division and is targeted by various drugs to prevent nucleic acid synthesis.
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
gamma-Glutamyl-beta-cyanoalanine
|
A dipeptide composed of 3-cyano-L-alanine and L-glutamine joined by a peptide linkage formed from the side-chain of glutamine.
|
|
TG(16:1(9Z)/16:0/22:2(13Z,16Z))
|
|
|
1-Methylhistidine
|
A histidine derivative in which the methyl group is located at N-1.
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/16:0/20:3n6)
|
|
|
TG(22:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
dGDP
|
A purine 2'-deoxyribonucleoside 5'-diphosphate having guanine as the nucleobase.
|
|
PE(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
Neostigmine
|
A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
|
|
TG(24:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
DG(20:3n6/0:0/22:4n6)
|
|
|
TG(15:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GM2 (d18:1/18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
3-Phosphoglyceric acid
|
A monophosphoglyceric acid having the phospho group at the 3-position. It is an intermediate in metabolic pathways like glycolysis and calvin cycle.
|
|
Isoetharine
|
|
|
PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:2n6/18:1(11Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
Orciprenaline
|
A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.
|
|
Pseudouridine
|
A C-glycosyl pyrimidine that consists of uracil having a beta-D-ribofuranosyl residue attached at position 5. The C-glycosyl isomer of the nucleoside uridine.
|
|
PE(24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
18-Hydroxycorticosterone
|
A 18-hydroxy steroid that is corticosterone substituted by a hydroxy group at position 18.
|
|
Dihydrothymine
|
|
|
TG(14:1(9Z)/18:1(11Z)/14:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:1(11Z)/20:3n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/16:0/24:0)
|
|
|
3-beta-Hydroxy-4-beta-methyl-5-alpha-cholest-7-ene-4-alpha-carboxylate
|
A steroid acid anion that is the conjugate base of 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylic acid, obtained via deprotonation of the carboxy group; major species at pH 7.3.
|
|
TG(14:0/22:0/20:3n6)
|
|
|
PE(18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
Indan-1-ol
|
An alcohol that has formula C9H10O.
|
|
PIP2(18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/14:1(9Z)/22:1(13Z))
|
|
|
Ganglioside GD3 (d18:1/25:0)
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(16:0/o-18:0/20:2n6)
|
|
|
Hydroquinone
|
A benzenediol comprising benzene core carrying two hydroxy substituents para to each other.
|
|
TG(16:1(9Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(18:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/18:1(11Z))
|
|
|
2-(3,4-Dihydroxybenzoyloxy)-4,6-dihydroxybenzoate
|
A hydroxy monocarboxylic acid anion that is the conjugate base of 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid.
|
|
TG(20:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Dimethylamine
|
A secondary aliphatic amine where both N-substituents are methyl.
|
|
PE(18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/22:1(13Z)/18:1(9Z))
|
|
|
2-(S-Glutathionyl)acetyl chloride
|
A peptide that has formula C12H18ClN3O7S.
|
|
Molybdopterin
|
A molybdopterin that is the O-phospho derivative of [(5aR,8R,9aR)-2-amino-4-oxo-6,7-disulfanyl-3,5,5a,8,9a,10-hexahydro-4H-pyrano[3,2-g]pteridin-8-yl]methanol.
|
|
TG(20:3n6/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(18:1(11Z)/20:2n6/22:2(13Z,16Z))
|
|
|
6-Lactoyltetrahydropterin
|
|
|
DG(16:0/18:1(9Z)/0:0)
|
|
|
Flunisolide
|
A cyclic ketal that has formula C24H31FO6.
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:3n6/18:1(11Z))
|
|
|
DG(18:1(11Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(22:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
Trilostane
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z)/o-18:0)
|
|
|
TG(20:1(11Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
N1-Acetylspermine
|
An acetylspermine carrying an acetyl group at position N(1).
|
|
PIP(20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Oleamide
|
A fatty amide derived from oleic acid.
|
|
4,8 Dimethylnonanoyl carnitine
|
|
|
DG(20:3(5Z,8Z,11Z)/14:0/0:0)
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ganglioside GM1 (d18:1/24:1(15Z))
|
|
|
Ritonavir
|
A L-valine derivative in which the alpha-nitrogen of L-valinamide is substituted with a methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl group and the amide nitrogen by a (2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. An antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir.
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
17a-Hydroxypregnenolone
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
Ganglioside GM1 (d18:0/22:1(13Z))
|
|
|
TG(15:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Octanoyl-CoA
|
A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of octanoic acid.
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:3n6/22:1(13Z))
|
|
|
Lomefloxacin
|
|
|
Udenafil
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
L-Dopachrome
|
The L-enantiomer of dopachrome.
|
|
Phosphoribosyl formamidocarboxamide
|
|
|
PE(18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/15:0)
|
|
|
PC(24:1(15Z)/P-18:1(9Z))
|
|
|
DG(22:4n6/0:0/22:5n6)
|
|
|
N6-Acetyl-L-lysine
|
An N(6)-acyl-L-lysine where the N(6)-acyl group is acetyl.
|
|
Ganglioside GA1 (d18:1/16:0)
|
|
|
TG(22:0/20:3n6/16:1(9Z))
|
|
|
TG(20:1(11Z)/20:0/22:2(13Z,16Z))
|
|
|
Diphenidol
|
|
|
TG(18:0/24:1(15Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Deoxyadenosine
|
|
|
Lucanthone
|
A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone.
|
|
Serotonin
|
A primary amino compound that is the 5-hydroxy derivative of tryptamine.
|
|
PE(15:0/18:3(9Z,12Z,15Z))
|
|
|
DG(24:1(15Z)/18:1(11Z)/0:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Trichloroacetic acid
|
A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/24:0/20:2n6)
|
|
|
Flupenthixol
|
|
|
TG(24:0/15:0/18:1(9Z))
|
|
|
DG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
Doxycycline
|
Tetracycline in which the 5beta-hydrogen is replaced by a hydroxy group, while the 6alpha-hydroxy group is replaced by hydrogen. A semi-synthetic tetracycline antibiotic, it is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with chronic obstructive pulmonary disease (COPD), and adult periodontitis.
|
|
TG(14:1(9Z)/24:1(15Z)/18:1(11Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(16:0/22:1(13Z)/22:1(13Z))
|
|
|
Nicotinic acid adenine dinucleotide
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
TG(18:1(9Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ganglioside GM3 (d18:0/18:1(9Z))
|
|
|
Galabiosylceramide (d18:1/18:0)
|
|
|
PG(18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/14:0/20:1(11Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Tripelennamine
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
PC(P-16:0/22:0)
|
|
|
TG(22:1(13Z)/22:1(13Z)/20:2n6)
|
|
|
TG(22:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:1(11Z)/22:0)
|
|
|
TG(16:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:1(9Z)/22:1(13Z))
|
|
|
Pristanal
|
A 2-methyl-branched fatty aldehyde that has formula C19H38O.
|
|
TG(18:3(9Z,12Z,15Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Taurohyocholate
|
Conjugate base of taurohyocholic acid.
|
|
Sufentanil
|
An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.
|
|
PE(P-16:0e/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:0/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
2,5-Dichloro-4-oxohex-2-enedioate
|
An oxo dicarboxylate obtained by deprotonation of both carboxy groups of 2,5-dichloro-4-oxohex-2-enedioic acid.
|
|
D-Ornithine
|
The D-enantiomer of ornithine. It is an intermediate metabolite produced in the urea cycle.
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
3-trans,5-cis-Octadienoyl-CoA
|
|
|
PC(P-18:1(11Z)/22:2(13Z,16Z))
|
|
|
Adapalene
|
An adamantane that has formula C28H28O3.
|
|
TG(24:0/18:1(11Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Arbutamine
|
|
|
TG(15:0/16:1(9Z)/22:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:1n9/0:0/20:2n6)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/o-18:0/14:1(9Z))
|
|
|
PE(18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
Hyodeoxycholic acid
|
A member of the class of 5beta-cholanic acids that is (5beta)-cholan-24-oic acid substituted by alpha-hydroxy groups at positions 3 and 6.
|
|
PE(14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/20:1(11Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:0/o-18:0)
|
|
|
D-Alanine
|
The D-enantiomer of alanine.
|
|
TG(15:0/15:0/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Glyoxylic acid
|
A 2-oxo monocarboxylic acid that is acetic acid bearing an oxo group at the alpha carbon atom.
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
Hydrochlorothiazide
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(15:0/0:0/24:1n9)
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
DG(22:1n9/0:0/18:2n6)
|
|
|
TG(16:1(9Z)/24:1(15Z)/18:1(11Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Sulfamoxole
|
|
|
Cefixime
|
|
|
TG(16:1(9Z)/24:0/22:1(13Z))
|
|
|
Amyl Nitrite
|
A nitrite ester having n-pentyl as the alkyl group.
|
|
DG(20:2(11Z,14Z)/18:2(9Z,12Z)/0:0)
|
|
|
DG(20:0/0:0/18:1n7)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
DG(20:2(11Z,14Z)/22:1(13Z)/0:0)
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:0/16:1(9Z))
|
|
|
7-a,25-Dihydroxycholesterol
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
1-Methyluric acid
|
An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trione substituted by a methyl group at N-1. It is one of the metabolites of caffeine found in human urine.
|
|
DG(20:0/22:2(13Z,16Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Substance P
|
|
|
Propionic acid
|
|
|
PE(16:1(9Z)/P-16:0)
|
|
|
Ganglioside GT2 (d18:1/16:0)
|
|
|
TG(16:1(9Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(18:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/14:1(9Z)/o-18:0)
|
|
|
PC(14:1(9Z)/20:0)
|
|
|
PS(14:1(9Z)/18:1(9Z))
|
|
|
Ganglioside GD2 (d18:1/22:1(13Z))
|
|
|
TG(14:0/16:1(9Z)/20:1(11Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:1(9Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:1(11Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:2n6/24:1(15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/P-18:0)
|
|
|
Flecainide
|
|
|
TG(24:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Azacitidine
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
PC(P-18:0/20:1(11Z))
|
|
|
Ganglioside GM2 (d18:0/26:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(11Z))
|
|
|
PC(16:0/14:0)
|
|
|
PE(22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(20:0/14:1(9Z)/20:1(11Z))
|
|
|
TG(15:0/20:2n6/18:1(11Z))
|
|
|
TG(22:0/22:0/18:2(9Z,12Z))
|
|
|
DG(20:2n6/0:0/22:4n6)
|
|
|
PE(24:0/20:3(5Z,8Z,11Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
PC(16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/24:0/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/16:0/20:2n6)
|
|
|
TG(14:0/o-18:0/22:0)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(24:0/22:0/24:0)
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/24:0/22:2(13Z,16Z))
|
|
|
Glucosamine
|
|
|
TG(20:3n6/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
1-Phenylethylamine
|
A phenylethylamine that is ethylamine substituted by a phenyl group at position 1.
|
|
TG(24:1(15Z)/14:0/18:2(9Z,12Z))
|
|
|
TG(24:0/16:0/20:2n6)
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:1n9/0:0/22:5n6)
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:0/20:1(11Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(20:1(11Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:1(13Z)/20:1(11Z))
|
|
|
DG(18:1n9/0:0/20:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Codeine
|
A morphinane alkaloid found in the opium poppy, Papaver somniferum var. album; has analgesic, anti-tussive and anti-diarrhoeal properties.
|
|
N-Acetyl-L-tyrosine
|
The N-acetyl derivative of L-tyrosine.
|
|
Quinidine
|
A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.
|
|
TG(20:1(11Z)/14:1(9Z)/20:1(11Z))
|
|
|
Ganglioside GM2 (d18:1/25:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
Tetrahexosylceramide (d18:1/24:0)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/15:0/20:1(11Z))
|
|
|
Glutaconyl-CoA
|
|
|
TG(22:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(20:0/16:1(9Z))
|
|
|
PE(24:1(15Z)/18:0)
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:1(13Z)/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
(S)-2-Methylbutanoyl-CoA
|
An organic molecule that has formula C26H44N7O17P3S.
|
|
Ganglioside GQ1c (d18:0/23:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:2(11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:1(9Z)e/2:0)
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
Ganglioside GD1b (d18:1/26:1(17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(20:3n6/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Apomorphine
|
|
|
TG(14:1(9Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/20:1(11Z)/22:2(13Z,16Z))
|
|
|
DL-Dopa
|
|
|
Balsalazide
|
A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(16:0/24:1(15Z))
|
|
|
CMP-N-glycoloylneuraminate
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:0/18:1(11Z)/20:0)
|
|
|
PS(16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:3n6/24:1(15Z))
|
|
|
Hydroxycobalamin
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(14:1n5/0:0/20:4n3)
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
cis-Aconitic acid
|
The cis-isomer of aconitic acid.
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Aminopropylcadaverine
|
A polyazaalkane that is the 1,4,11-triaza derivative of undecane.
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP(16:2(9Z,12Z)/18:0)
|
|
|
p-Hydroxyphenylacetic acid
|
|
|
TG(18:0/20:0/20:1(11Z))[iso6]
|
|
|
DG(22:5n6/0:0/20:5n3)
|
|
|
PC(20:2(11Z,14Z)/16:0)
|
|
|
Ganglioside GD1b (d18:1/22:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(22:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/15:0/20:3n6)
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
3a,6b,7a,12a-Tetrahydroxy-5b-cholanoic acid
|
|
|
PC(20:1(11Z)/16:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:0/18:1(11Z)/22:0)
|
|
|
TG(24:0/18:1(11Z)/20:3n6)
|
|
|
PC(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Micafungin
|
|
|
TG(14:0/14:0/16:1(9Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
PC(22:0/P-18:1(9Z))
|
|
|
TG(18:0/20:0/o-18:0)
|
|
|
TG(18:0/15:0/20:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0)
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/24:1(15Z))
|
|
|
PE(20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/o-18:0)
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
Sulindac
|
A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.
|
|
TG(24:0/14:0/18:1(11Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
PC(16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
5-Methylthioribose 1-phosphate
|
|
|
TG(16:1(9Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/o-18:0)
|
|
|
Mimosine
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/16:0/20:1(11Z))
|
|
|
PE(22:0/22:1(13Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3a,7a-Dihydroxy-5b-cholestanate
|
|
|
L-2-Aminoadipate adenylate
|
A dicarboxylic acid that has formula C16H23N6O10P.
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/14:0/18:1(9Z))[iso6]
|
|
|
TG(20:0/16:0/22:0)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Mestranol
|
|
|
PC(24:1(15Z)/18:1(9Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/15:0/0:0)
|
|
|
S-Formylglutathione
|
A S-acylglutathione in which the acyl group specified is formyl.
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(18:1(11Z)/14:0)
|
|
|
PC(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
5-Androstenediol
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Carbamoyl phosphate
|
An acyl monophosphate that has formula CH4NO5P.
|
|
TG(22:1(13Z)/16:1(9Z)/20:3n6)
|
|
|
TG(22:0/15:0/24:1(15Z))
|
|
|
TG(20:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
PE(24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
Methoxamine
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/24:1(15Z))
|
|
|
Tridecanoic acid
|
A C13 straight-chain saturated fatty acid.
|
|
TG(20:0/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:1(11Z))[iso3]
|
|
|
TG(16:1(9Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/P-18:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))
|
|
|
TG(20:3n6/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:2n6/o-18:0)
|
|
|
PE(22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GD1b (d18:0/24:0)
|
|
|
N,N'-Diacetylchitobiosyldiphosphodolichol
|
|
|
DG(24:1(15Z)/20:1(11Z)/0:0)
|
|
|
Voglibose
|
|
|
PC(20:3(8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(22:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/0:0)
|
|
|
PC(22:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:2n6)
|
|
|
DG(18:2(9Z,12Z)/22:1(13Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:0/o-18:0)
|
|
|
TG(16:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
Glucosylceramide (d18:1/26:0)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Zalcitabine
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
DG(18:3n6/0:0/20:3n6)
|
|
|
TG(20:3n6/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Glucosylceramide (d18:1/24:0)
|
|
|
Eicosapentaenoic acid
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
Ganglioside GD1b (d18:0/22:0)
|
|
|
TG(18:2(9Z,12Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/14:0)
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/16:0/0:0)
|
|
|
TG(14:1(9Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Alpha-D-Glucose 1,6-bisphosphate
|
A D-glucose 1,6-bisphosphate in which both phosphate groups are monophosphates.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT1b (d18:0/18:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(14:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Fluorescein
|
|
|
TG(22:1(13Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/o-18:0)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
3a,7b,12b-Trihydroxy-5b-cholanoic acid
|
|
|
DG(20:1(11Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(15:0/16:1(9Z)/18:1(11Z))
|
|
|
Pantothenic acid
|
A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.
|
|
TG(24:1(15Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/o-18:0)
|
|
|
TG(18:1(11Z)/o-18:0/18:1(9Z))
|
|
|
PE(20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:0/18:0)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
2,3,5-Trichloromaleylacetate
|
|
|
TG(24:1(15Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
PC(18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
2-Hydroxy-3-(4-hydroxyphenyl)propenoic acid
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
3-Butyn-1-al
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6/o-18:0)
|
|
|
TG(16:0/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Silenoside A
|
|
|
Silenoside C
|
|
|
Silenoside B
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
TG(20:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
Azithromycin
|
A macrolide antibiotic useful for the treatment of bacterial infections.
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
PIP(18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Cer(d18:0/18:0)
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
PI(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
Bicalutamide
|
A sulfone that is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.
|
|
TG(15:0/20:2n6/16:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Vilazodone
|
|
|
PE(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
PC(20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(22:0/24:1(15Z)/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Propionylglycine
|
|
|
TG(20:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:1(11Z)/24:0/0:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GQ1c (d18:0/18:0)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/o-18:0/24:1(15Z))
|
|
|
2-Polyprenyl-6-methoxyphenol
|
|
|
Flumazenil
|
A 1,4-benzodiazepine that has formula C15H14FN3O3.
|
|
TG(15:0/20:3n6/24:0)
|
|
|
3-Hydroxybutyric acid
|
A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
|
|
LPA(0:0/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/20:2n6)
|
|
|
DG(20:0/0:0/18:3n6)
|
|
|
TG(20:2n6/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(24:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:0)
|
|
|
PE(20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/18:1(11Z)/o-18:0)
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(18:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/o-18:0/22:2(13Z,16Z))
|
|
|
PC(14:1(9Z)/P-18:0)
|
|
|
PE(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/20:3n6/20:1(11Z))
|
|
|
PC(14:1(9Z)/P-16:0)
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Jaceidin 4'-glucuronide
|
|
|
PC(18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ibandronate
|
|
|
TG(20:1(11Z)/16:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
LysoPE(0:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/24:0/20:3n6)
|
|
|
TG(20:3n6/20:0/18:3(9Z,12Z,15Z))
|
|
|
Pyridoxamine
|
A monohydroxypyridine that is pyridine substituted by a hydroxy group at position 3, an aminomethyl group at position 4, a hydroxymethyl group at position 5 and a methyl group at position 2.
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(20:1(11Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:0/0:0)
|
|
|
Ganglioside GD3 (d18:0/18:1(11Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Pristanic acid
|
A branched, long-chain saturated fatty acid composed of pentadecanoic acid having methyl substituents at the 2-, 6-, 10- and 14-positions.
|
|
PE(P-18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(20:3(5Z,8Z,11Z)/18:0)
|
|
|
Inosine 2'-phosphate
|
|
|
TG(24:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
PIP3(18:0/18:1(9Z))
|
|
|
Dolichyl b-D-glucosyl phosphate
|
|
|
TG(22:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
SM(d18:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/18:1(11Z))
|
|
|
PC(22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(16:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Hyoscyamine
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/20:2n6)
|
|
|
TG(16:1(9Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
Inositol 1,3,4,5-tetraphosphate
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:2n6/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:1(9Z)/22:1(13Z))
|
|
|
PC(20:1(11Z)/P-18:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/0:0)
|
|
|
TG(15:0/24:0/22:1(13Z))
|
|
|
Propiomazine
|
|
|
PIP2(20:3(8Z,11Z,14Z)/16:0)
|
|
|
O-Desmethylnaproxen
|
|
|
TG(14:0/18:1(9Z)/24:0)
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:3n6/o-18:0)
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PI(18:3(6Z,9Z,12Z)/18:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
PC(P-18:0/24:0)
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
Everolimus
|
|
|
PI(18:1(9Z)/18:1(9Z))
|
|
|
TG(18:1(11Z)/14:0/18:2(9Z,12Z))[iso3]
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(16:0/14:0/22:1(13Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(24:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(22:0/15:0/22:2(13Z,16Z))
|
|
|
TG(14:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
PC(24:1(15Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Bisoprolol
|
A secondary amine that has formula C18H31NO4.
|
|
Ganglioside GT3 (d18:1/26:1(17Z))
|
|
|
Estriol-16-Glucuronide
|
|
|
PIP2(20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(20:2n6/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/20:2n6)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/22:2(13Z,16Z))
|
|
|
DG(24:0/0:0/24:0)
|
|
|
Ganglioside GM2 (d18:0/18:0)
|
|
|
TG(18:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:0/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:0/o-18:0)
|
|
|
PC(o-22:0/18:3(9Z,12Z,15Z))
|
|
|
Paramethadione
|
|
|
TG(24:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:2n6/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Doxacurium chloride
|
The dichloride salt of doxacurium. It is a mixture of the (1R,2S,1'S,2'R), (1R,2S,1'R,2'S) and (1S,2R,1'S,2'R) stereoisomers (a meso isomer and two enantiomers, respectively) of 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxypropane-3,1-diyl)]bis[6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium] dichloride, all of which are in a trans configuration at the 1 and 2 positions of the tetrahydroisoquinolinium rings. A competitive neuromuscular blocker, it is used to provide muscle relaxation in general anaesthesia and to facilitate mechanical ventilation in patients in intensive care.
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/o-18:0/18:1(11Z))
|
|
|
4a-Methyl-5a-cholesta-8,24-dien-3-one
|
|
|
PC(22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:0/15:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2n6/0:0/18:2n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/20:3n6)
|
|
|
TG(22:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(20:2n6/18:0/20:3n6)
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Delphinidin 3-rhamnoside 5-glucoside
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Cyclic GMP
|
|
|
TG(20:0/18:2(9Z,12Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
Capecitabine
|
|
|
TG(15:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:0/0:0/22:0)
|
|
|
TG(18:2(9Z,12Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:2(9Z,12Z)/24:1(15Z))
|
|
|
DG(14:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
MG(0:0/24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0)
|
|
|
TG(14:1(9Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:3n6/20:2n6)
|
|
|
Paraxanthine
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/16:0/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(18:1(11Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(11Z)/20:2(11Z,14Z)/0:0)
|
|
|
S-(3-Methylbutanoyl)-dihydrolipoamide-E
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:1(11Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
L-3-Cyanoalanine
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/24:0/20:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
2-Acetolactate
|
|
|
TG(14:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPE(20:3(5Z,8Z,11Z)/0:0)
|
|
|
L-Cystine
|
The L-enantiomer of the sulfur-containing amino acid cystine.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/16:1(9Z)/18:1(9Z))
|
|
|
PE(14:0/16:1(9Z))
|
|
|
TG(18:1(9Z)/15:0/24:1(15Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/24:0/o-18:0)
|
|
|
PG(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(15:0/16:0/24:0)
|
|
|
TG(15:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Melibiitol
|
An alditol that has formula C12H24O11.
|
|
TG(14:0/20:1(11Z)/20:0)
|
|
|
8,9-DiHETrE
|
|
|
PC(o-18:2(9Z,12Z)/24:0)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
(7R)-7-(5-Carboxy-5-oxopentanoyl)aminocephalosporinate
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
Ovalicin
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/20:2n6)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Imidazoleacetic acid
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GD3 (d18:1/22:1(13Z))
|
|
|
TG(18:1(9Z)/14:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:1(11Z)/16:1(9Z)/24:1(15Z))
|
|
|
PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Fulvestrant
|
|
|
Isoniazid
|
|
|
DG(18:0/0:0/18:2n6)
|
|
|
PE(P-16:0/16:1(9Z))
|
|
|
Oxalosuccinic acid
|
A tricarboxylic acid consisting of 2-oxoglutaric acid having a further carboxy group at the 3-position. It is a substrate of the citric acid cycle.
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
PC(18:2(9Z,12Z)/16:0)
|
|
|
TG(16:1(9Z)/24:1(15Z)/16:1(9Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(16:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/24:1(15Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
6-Carboxy-5,6,7,8-tetrahydropterin
|
|
|
Pantetheine
|
An amide obtained by formal condensation of the carboxy group of pantothenic acid and the maino group of cysteamine.
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(14:1(9Z)/22:0/20:3n6)
|
|
|
PIP(18:1(9Z)/16:1(9Z))
|
|
|
TG(14:0/20:0/20:0)
|
|
|
TG(18:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/20:0/22:1(13Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
PE(20:3(8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Pargyline
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Coproporphyrinogen III
|
A coproporphyrinogen that has formula C36H44N4O8.
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PE(20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(24:0/18:0/18:1(11Z))
|
|
|
TG(22:0/15:0/20:2n6)
|
|
|
TG(24:1(15Z)/16:1(9Z)/24:1(15Z))
|
|
|
PG(18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(24:1(15Z)/15:0)
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/0:0)
|
|
|
1D-Myo-inositol 1,3,4,6-tetrakisphosphate
|
|
|
TG(18:1(11Z)/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
(2E)-Octenoyl-CoA
|
A trans-2,3-didehydroacyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate OH groups of trans-oct-2-enoyl-CoA; major species at pH 7.3.
|
|
TG(16:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Phosphoadenosine phosphosulfate
|
|
|
Ureidosuccinic acid
|
|
|
TG(18:0/22:0/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:2n6)
|
|
|
TG(22:1(13Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
beta-Ionone
|
An ionone that is but-3-en-2-one substituted by a 2,6,6-trimethylcyclohex-1-en-1-yl group at position 4.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(20:3n6/18:0/22:2(13Z,16Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(24:0/24:0/20:1(11Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
3-Hydroxy-3-(4-methylpent-3-en-1-yl)glutaryl-CoA
|
The S-3-hydroxy-3-(4-methylpent-3-en-1-yl)glutaryl derivative of CoA.
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
(R)-3-Hydroxy-Octadecanoic acid
|
|
|
PC(20:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:3n6/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(20:2n6/16:0/20:2n6)
|
|
|
E-3179
|
|
|
TG(20:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/o-18:0)
|
|
|
CL(18:2(9Z,12Z)/18:1(9Z)/18:1(11Z)/16:0)
|
|
|
PE(14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/15:0)
|
|
|
MG(0:0/22:0/0:0)
|
|
|
PE(P-18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(14:1n5/0:0/22:4n6)
|
|
|
PE(18:1(11Z)/18:0)
|
|
|
TG(24:0/14:1(9Z)/18:1(11Z))
|
|
|
TG(15:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(14:0/22:1(13Z)/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
LPA(0:0/18:0)
|
|
|
Isohomovanillic acid
|
A monocarboxylic acid that is the 4-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/24:1(15Z)/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/14:1(9Z)/22:1(13Z))
|
|
|
TG(15:0/20:0/15:0)
|
|
|
TG(20:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(16:0/16:0/22:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:2(9Z,12Z)/22:0/0:0)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Retinal
|
An enal that consists of 3,7-dimethyl-9-nona-2,4,6,8-tetraenal (double bond geometry unspecified) carrying a 2,6,6-trimethylcyclohex-1-en-1-yl group at the 9-position.
|
|
TG(24:1(15Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/14:0/20:1(11Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
3b,7a-Dihydroxy-5b-cholanoic acid
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/16:0)
|
|
|
TG(18:2(9Z,12Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Trihexosylceramide (d18:1/26:1(17Z))
|
|
|
Ganglioside GT1c (d18:0/18:1(9Z))
|
|
|
Sertraline
|
A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(15:0/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM1 (d18:0/18:0)
|
|
|
PIP(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/14:0/22:1(13Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
Propylene glycol
|
|
|
TG(16:1(9Z)/15:0/20:3n6)
|
|
|
TG(16:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
CDP-DG(18:1(11Z)/18:1(9Z))
|
|
|
2-hydroxy-dATP
|
A purine 2'-deoxyribonucleoside 5'-triphosphate in which the 2'-deoxyribonucleoside moiety is 2'-deoxy-2-hydroxyadenosine.
|
|
DG(15:0/0:0/14:1n5)
|
|
|
DG(22:2(13Z,16Z)/15:0/0:0)
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
4-alpha-Methyl-5-alpha-cholest-7-en-3-beta-ol
|
A 3beta-hydroxy steroid that has formula C28H48O.
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
hexadecanoyl-CoA
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(14:1(9Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/18:0/24:1(15Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(24:0/15:0/20:1(11Z))
|
|
|
Ceramide (d18:1/18:0)
|
|
|
TG(16:0/24:1(15Z)/24:1(15Z))
|
|
|
PE(18:1(9Z)/P-16:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/18:0/18:1(11Z))
|
|
|
DG(20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
Dihydroxyacetone
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/24:0)
|
|
|
TG(20:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
4-Methylumbelliferone
|
A hydroxycoumarin that is umbelliferone substituted by a methyl group at position 4.
|
|
TG(20:1(11Z)/18:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Pefloxacin
|
|
|
TG(22:1(13Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Roxithromycin
|
|
|
TG(14:1(9Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:0)
|
|
|
PC(18:0/16:1(9Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:1(9Z)/18:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
DG(20:1n9/0:0/20:2n6)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
PIP2(16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/20:0/20:1(11Z))
|
|
|
Gamma-Glutamylcysteine
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
DG(22:0/0:0/18:3n6)
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:0)[iso6]
|
|
|
Itaconic acid
|
A dicarboxylic acid that is methacrylic acid in which one of the methyl hydrogens is substituted by a carboxylic acid group.
|
|
DG(20:3n6/0:0/20:4n6)
|
|
|
Warfarin
|
A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.
|
|
Guanine
|
A 2-aminopurine carrying a 6-oxo substituent.
|
|
Finasteride
|
An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
5-Phenyl-1,3-oxazinane-2,4-dione
|
A benzene that has formula C10H9NO3.
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PIP(20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/20:0/20:2n6)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
Ganglioside GM3 (d18:0/16:0)
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(24:1(15Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/20:2n6)
|
|
|
TG(18:0/20:2n6/24:1(15Z))
|
|
|
DG(20:3n6/0:0/22:5n3)
|
|
|
2-Methyl-3-hydroxybutyryl-CoA
|
|
|
TG(14:0/22:0/24:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(24:1(15Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/24:1(15Z)/0:0)
|
|
|
Simvastatin
|
A fatty acid ester comprising a dihydroxyheptanoic acid unit condensed into a lactone; a partially reduced naphthalene structure; and a 2,2-dimethylbutyric acyl substituent at C17. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.
|
|
1-Pyrroline-5-carboxylic acid
|
A 1-pyrrolinecarboxylic acid that is 1-pyrroline in which one of the hydrogens at position 5 is replaced by a carboxy group.
|
|
Darifenacin
|
|
|
TG(16:0/14:0/o-18:0)
|
|
|
TG(18:0/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
PE(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
1D-myo-Inositol 3-phosphate
|
A myo-inositol monophosphate that has formula C6H13O9P.
|
|
TG(15:0/18:1(11Z)/15:0)
|
|
|
TG(16:1(9Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
PG(18:1(9Z)/18:1(11Z))
|
|
|
TG(14:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(18:1(11Z)/18:1(11Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
Phylloquinol
|
|
|
PI(16:1(9Z)/18:0)
|
|
|
TG(24:1(15Z)/22:0/20:3n6)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(dm18:1(9Z)/dm16:0)
|
|
|
PG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:2(9Z,12Z)/15:0)
|
|
|
DG(18:0/0:0/20:3n9)
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:0/20:1(11Z))
|
|
|
PC(18:2(9Z,12Z)/P-16:0)
|
|
|
TG(22:2(13Z,16Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:3(8Z,11Z,14Z))[iso6]
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
PC(P-18:0/24:1(15Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
Fenoldopam
|
A benzazepine that has formula C16H16ClNO3.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT3 (d18:1/20:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:1(13Z)/16:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT3 (d18:1/22:0)
|
|
|
PE(22:1(13Z)/14:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:3n3/0:0/20:5n3)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
DG(16:1n7/0:0/22:5n6)
|
|
|
Ganglioside GA2 (d18:1/9Z-18:1)
|
|
|
TG(14:1(9Z)/14:0/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(20:1(11Z)/22:1(13Z)/0:0)
|
|
|
Metocurine
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
Atropine
|
A racemate composed of equimolar concentrations of (S)- and (R)-atropine . It is obtained from deadly nightshade (Atropa belladonna) and other plants of the family Solanaceae.
|
|
PE(P-18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:1(13Z)/20:3n6)
|
|
|
PC(22:0/18:1(9Z))
|
|
|
Cephalexin
|
A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.
|
|
TG(16:1(9Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:0/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:0)[iso3]
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Zidovudine
|
A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.
|
|
TG(16:0/22:1(13Z)/o-18:0)
|
|
|
PC(24:0/20:0)
|
|
|
DG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
Dimethylglycine
|
|
|
TG(22:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(20:1(11Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/o-18:0)
|
|
|
DG(16:0/18:2(9Z,12Z)/0:0)
|
|
|
PIP2(18:2(9Z,12Z)/20:0)
|
|
|
Urea
|
A carbonyl group with two C-bound amine groups.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Heme
|
A heme is any tetrapyrrolic chelate of iron.
|
|
TG(18:1(11Z)/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP2(16:0/16:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/24:0/20:1(11Z))
|
|
|
TG(15:0/24:1(15Z)/20:0)
|
|
|
SR 49498
|
|
|
TG(24:1(15Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/P-18:1(9Z))
|
|
|
Ganglioside GA1 (d18:1/25:0)
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:2n6)
|
|
|
Mivacurium
|
|
|
TG(18:2(9Z,12Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
xi-Norepinephrine
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/14:0/22:2(13Z,16Z))
|
|
|
MG(22:5(4Z,7Z,10Z,13Z,16Z)/0:0/0:0)
|
|
|
TG(18:1(9Z)/16:0/20:1(11Z))
|
|
|
TG(20:1(11Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:3n6/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(24:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/16:1(9Z))
|
|
|
TG(20:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Lubiprostone
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/14:0/16:1(9Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(22:1(13Z)/20:0/20:3n6)
|
|
|
TG(18:1(11Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
(+)-(1R,2R)-1,2-Diphenylethane-1,2-diol
|
A hydrobenzoin that has formula C14H14O2.
|
|
TG(14:0/o-18:0/20:3n6)
|
|
|
Cer(d18:0/23:0)
|
|
|
3-Sulfinylpyruvic acid
|
A pyruvic acid compound having a 3-sulfinyl substituent.
|
|
TG(20:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Teniposide
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/o-18:0)
|
|
|
DG(20:3(8Z,11Z,14Z)/14:0/0:0)
|
|
|
TG(24:1(15Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:4n6/0:0/20:5n3)
|
|
|
TG(22:1(13Z)/16:1(9Z)/20:2n6)
|
|
|
PI(18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/o-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(24:1(15Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/o-18:0)
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(20:0/14:0/20:0)
|
|
|
TG(18:1(11Z)/24:1(15Z)/18:1(9Z))
|
|
|
PI(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
PE(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
1-Nitro-5-glutathionyl-6-hydroxy-5,6-dihydronaphthalene
|
A peptide that has formula C20H24N4O9S.
|
|
DG(20:1(11Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(16:0/20:2n6/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:3n6/o-18:0)
|
|
|
PIP2(22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
trans-Dec-2-enoic acid
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
PC(16:1(9Z)/18:2(9Z,12Z))
|
|
|
trans,cis-Lauro-2,6-dienoyl-CoA
|
|
|
TG(16:1(9Z)/24:0/18:1(11Z))
|
|
|
TG(20:3n6/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/P-18:1(11Z))
|
|
|
TG(22:1(13Z)/16:0/20:2n6)
|
|
|
DG(18:0/0:0/22:0)
|
|
|
PI(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/22:0/18:2(9Z,12Z))
|
|
|
TG(16:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
2,2,2-Trichloroethanol
|
A chloroethanol that has formula C2H3Cl3O.
|
|
TG(22:0/14:0/20:2n6)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
Cinalukast
|
2,2-Diethylsuccinanilic acid substituted at a meta- position by an (E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl group. It selectively antagonizes leukotriene D4 at the cysteinyl leukotriene receptor, in the human airway, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. It is used in the treatment of asthma.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))[iso6]
|
|
|
TG(18:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
Ganglioside GD1a (d18:0/16:0)
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/24:0/20:0)
|
|
|
TG(20:0/22:0/20:0)
|
|
|
Cladribine
|
2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia.
|
|
TG(20:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(24:1(15Z)/18:1(11Z))
|
|
|
TG(18:1(9Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
PC(18:2(9Z,12Z)/P-18:0)
|
|
|
TG(18:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
DG(24:0/20:1(11Z)/0:0)
|
|
|
PE(22:1(13Z)/20:2(11Z,14Z))
|
|
|
2-Methyl-3-oxopropanoic acid
|
The 2-methyl-3-oxo derivative of propanoic acid.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Oxcarbazepine
|
A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.
|
|
PC(22:0/18:1(11Z))
|
|
|
TG(18:1(11Z)/15:0/22:1(13Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/20:3n6)
|
|
|
TG(22:0/o-18:0/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
(3S)-2,3-epoxy-2,3-dihydrosqualene
|
|
|
Cefoperazone
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
Emtricitabine
|
|
|
DG(18:0/0:0/24:0)
|
|
|
TG(18:1(9Z)/20:3n6/24:1(15Z))
|
|
|
MG(0:0/22:1(13Z)/0:0)
|
|
|
PE(20:0/15:0)
|
|
|
TG(15:0/14:0/16:1(9Z))
|
|
|
Ganglioside GD1b (d18:1/18:0)
|
|
|
Inositol 1,3,4,5,6-pentakisphosphate
|
|
|
3-Oxo-OPC8-CoA
|
An organic molecule that has formula C39H62N7O19P3S.
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/o-18:0/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
N4-Acetylaminobutanal
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/o-18:0)
|
|
|
Antrafenine
|
|
|
Midazolam
|
|
|
TG(20:0/22:0/18:2(9Z,12Z))
|
|
|
Myo-inositol hexakisphosphate
|
A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.
|
|
Fructose 1,6-bisphosphate
|
|
|
Pramipexole
|
A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:1(9Z)/20:2n6)
|
|
|
PE(14:1(9Z)/24:1(15Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Geranyl-PP
|
|
|
TG(18:3(9Z,12Z,15Z)/18:0/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(20:0/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(P-18:1(9Z)/20:2(11Z,14Z))
|
|
|
TG(20:3n6/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:1(9Z)/20:1(11Z)/0:0)
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
Trifluoperazine
|
A member of the class of phenothiazines that is phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.
|
|
Pyrocatechol
|
|
|
TG(22:0/14:0/18:2(9Z,12Z))
|
|
|
TG(20:0/20:1(11Z)/24:0)
|
|
|
PC(18:2(9Z,12Z)/15:0)
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
DG(20:2n6/0:0/22:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(16:0/18:1(11Z))
|
|
|
11-beta-Hydroxyandrosterone-3-glucuronide
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Nicotinamide riboside
|
|
|
TG(15:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(11Z))
|
|
|
DG(22:1(13Z)/18:0/0:0)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/0:0)
|
|
|
3-Hexaprenyl-4,5-Dihydroxybenzoic acid
|
A dihydroxybenzoic acid where the hydroxy groups are at the 4- and 5-positions together with a hexaprenyl group at the 3-position.
|
|
TG(16:1(9Z)/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(22:2(13Z,16Z)/P-18:0)
|
|
|
TG(18:1(11Z)/16:1(9Z)/20:3n6)
|
|
|
PE(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Levetiracetam
|
|
|
PC(20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
PE(24:0/24:0)
|
|
|
TG(22:0/20:2n6/20:1(11Z))
|
|
|
DG(14:0/24:0/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
PE(24:0/22:0)
|
|
|
TG(20:2n6/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(24:0/14:1(9Z)/16:1(9Z))
|
|
|
TG(24:0/o-18:0/20:3n6)
|
|
|
TG(20:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(24:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
3-Hydroxyquinine
|
A cinchona alkaloid that has formula C20H24N2O3.
|
|
TG(18:0/24:0/20:0)
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
PC(18:1(9Z)/18:1(11Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(14:0/14:0/22:2(13Z,16Z))
|
|
|
PIP2(16:0/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(20:3n6/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Methantheline
|
|
|
Progabide
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/20:1(11Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/16:1(9Z)/o-18:0)
|
|
|
TG(15:0/14:0/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1b (d18:1/16:0)
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/20:2n6)
|
|
|
TG(14:1(9Z)/16:0/o-18:0)
|
|
|
PIP3(18:1(11Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Methylglutaconyl-CoA
|
|
|
TG(20:1(11Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(24:0/16:0/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/o-18:0)
|
|
|
Allopregnanolone
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Formiminoglutamic acid
|
|
|
SM(d18:1/24:1(15Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/18:1(9Z)/20:2n6)
|
|
|
TG(16:1(9Z)/20:3n6/20:2n6)
|
|
|
Betavulgaroside IV
|
|
|
Heptacarboxylporphyrin I
|
|
|
TG(20:3n6/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(22:0/24:0)
|
|
|
DG(18:2(9Z,12Z)/14:1(9Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
Rotigotine
|
|
|
TG(24:1(15Z)/16:1(9Z)/20:2n6)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/0:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Selenocysteine
|
An alpha-amino acid that consists of alanine where one of the methyl hydrogens is substituted with a seleno group.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/20:3n6/18:2(9Z,12Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
DG(22:1(13Z)/22:0/0:0)
|
|
|
TG(14:1(9Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/18:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
CE(22:1(13Z))
|
|
|
TG(20:1(11Z)/16:0/20:2n6)
|
|
|
2-Hexaprenyl-6-methoxyphenol
|
A monomethoxybenzene that is 6-methoxyphenol substituted by a (all-trans)-hexaprenyl group at position 2.
|
|
(9S,10S)-10-hydroxy-9-(phosphonooxy)octadecanoate
|
Trianion of (9S,10S)-10-hydroxy-9-(phosphonooxy)octadecanoic acid arising from deprotonation of carboxylic acid and phosphate functions.
|
|
TG(16:1(9Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/24:1(15Z)/20:2n6)
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(22:0/20:0/24:0)
|
|
|
PIP2(18:1(9Z)/18:1(11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
LysoPE(15:0/0:0)
|
|
|
DG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
Hexanoyl-CoA
|
A medium-chain fatty acyl-CoA having hexanoyl as the S-acyl group.
|
|
PI(18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:0/20:0/0:0)
|
|
|
TG(20:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:3n6/22:1(13Z))
|
|
|
Cadaverine
|
An alkane-alpha,omega-diamine comprising a straight-chain pentane core with amino substitutents at positions 1 and 5. A colourless syrupy liquid diamine with a distinctive unpleasant odour, it is a homologue of putresceine and is formed by the bacterial decarboxylation of lysine that occurs during protein hydrolysis during putrefaction of animal tissue. It is also found in plants such as soyabean.
|
|
TG(16:1(9Z)/22:1(13Z)/22:1(13Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
PC(20:3(5Z,8Z,11Z)/22:0)
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:2n6/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/14:0/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:2n6)
|
|
|
Nizatidine
|
|
|
PIP2(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
4a-Methylzymosterol
|
|
|
Deoxycorticosterone
|
|
|
TG(14:0/22:1(13Z)/20:2n6)
|
|
|
Nefazodone
|
A triazole that has formula C25H32ClN5O2.
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:1(13Z)/24:1(15Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
(1S,2R)-Naphthalene 1,2-oxide
|
A naphthalene that has formula C10H8O.
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
LysoSM(d18:0)
|
|
|
PC(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:0/0:0/20:3n9)
|
|
|
4-Trimethylammoniobutanal
|
A butanal that has formula C7H16NO.
|
|
PC(20:3(5Z,8Z,11Z)/20:0)
|
|
|
PC(24:1(15Z)/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:0/0:0/20:1n9)
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
(N-acetylneuraminosyl(a2-6)lactosamine)
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/15:0/18:3(9Z,12Z,15Z))
|
|
|
CL(18:2(9Z,12Z)/18:1(11Z)/18:1(11Z)/16:1(9Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GM2 (d18:1/9Z-18:1)
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(20:3n6/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PI(18:2(9Z,12Z)/22:3(10Z,13Z,16Z))
|
|
|
Sinapyl alcohol
|
A primary alcohol, being cinnamyl alcohol hydroxylated at C-4 and methoxylated at C-3 and -5.
|
|
TG(16:1(9Z)/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:3n6/20:3n6)
|
|
|
TG(22:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Mesoxalic acid
|
|
|
7a-Hydroxydehydroepiandrosterone
|
|
|
DG(18:1(11Z)/22:0/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/o-18:0)
|
|
|
TG(20:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/20:2n6/18:2(9Z,12Z))
|
|
|
TG(20:0/14:1(9Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:1(11Z)/15:0)
|
|
|
TG(15:0/18:1(11Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:0/P-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/20:3(5Z,8Z,11Z))
|
|
|
DG(18:2n6/0:0/20:3n6)
|
|
|
TG(16:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/15:0/20:3n6)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
Pantetheine 4'-phosphate
|
A phosphopantetheine that has formula C11H23N2O7PS.
|
|
DG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(14:1(9Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(16:0/16:0)
|
|
|
TG(24:1(15Z)/14:1(9Z)/20:2n6)
|
|
|
TG(22:1(13Z)/20:1(11Z)/20:3n6)
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/18:0/20:3n6)
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GD2 (d18:0/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
PE(14:0/P-18:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Nebivolol
|
|
|
PS(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(15:0/18:0/24:0)
|
|
|
DG(16:0/0:0/22:5n3)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PG(16:0/18:0)
|
|
|
PE(18:1(9Z)/20:2(11Z,14Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/18:0/20:2n6)
|
|
|
TG(20:0/24:0/16:1(9Z))
|
|
|
TG(15:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Succinic acid
|
|
|
TG(24:0/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PIP3(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Butyric acid
|
A four-carbon straight-chain saturated fatty acid.
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(15:0/14:1(9Z))
|
|
|
TG(14:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:1(11Z)/14:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/20:5n3)
|
|
|
TG(24:0/15:0/22:1(13Z))
|
|
|
Cob(I)alamin
|
A cobalamin in which the central cobalt atom has an oxidation state of +1.
|
|
TG(16:1(9Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/20:3n6/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/14:1(9Z)/22:1(13Z))
|
|
|
PE(16:1(9Z)/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
Letrozole
|
A triazole that has formula C17H11N5.
|
|
TG(22:1(13Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(11Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP2(18:0/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/20:2n6)
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Azatadine
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
MG(24:0/0:0/0:0)
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/24:0/0:0)
|
|
|
PC(O-16:0/18:2(9Z,12Z))
|
|
|
CL(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/o-18:0/20:0)
|
|
|
DG(14:1(9Z)/14:0/0:0)
|
|
|
TG(20:1(11Z)/22:0/20:3n6)
|
|
|
PE(18:2(9Z,12Z)/24:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/20:3n6)
|
|
|
PC(18:1(9Z)/P-18:1(9Z))
|
|
|
Fosinopril
|
A phosphinate ester-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. It is used for the treatment of hypertension and heart failure. A pro-drug, it is hydrolysed in vivo to the corresponding phosphininc acid, fosinoprilat, which is the active metabolite.
|
|
TG(22:1(13Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:1(11Z))[iso3]
|
|
|
TG(20:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:0/14:0)
|
|
|
TG(18:0/18:2(9Z,12Z)/18:0)
|
|
|
PE(22:1(13Z)/P-18:1(11Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Proparacaine
|
|
|
5'-Deoxy-5-fluorouridine
|
A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/20:3n6)
|
|
|
Perindopril
|
An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline
|
|
PC(18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
CE(18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/20:0/20:2n6)
|
|
|
Aminoglutethimide
|
|
|
TG(18:1(9Z)/20:2n6/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
Trihexosylceramide (d18:1/24:0)
|
|
|
PC(16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(24:0/22:2(13Z,16Z))
|
|
|
TG(14:0/20:3n6/24:1(15Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:0/0:0/18:3n6)
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3n6/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GM3 (d18:0/24:1(15Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:1(13Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:1(9Z)/18:1(9Z))
|
|
|
TG(18:1(9Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/18:2(9Z,12Z))
|
|
|
3-(3,5-Diiodo-4-hydroxyphenyl)pyruvate
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Diethylstilbestrol
|
|
|
TG(20:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Varanic acid
|
|
|
TG(18:2(9Z,12Z)/24:0/18:2(9Z,12Z))
|
|
|
CL(20:2(11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:1(11Z)/14:1(9Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
4,4-Dimethyl-5a-cholesta-8-en-3b-ol
|
|
|
Cycloserine
|
|
|
PG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
PC(o-18:0/22:0)
|
|
|
TG(14:0/22:0/14:0)
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
PC(o-18:0/20:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Squalene
|
|
|
TG(22:1(13Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:0)
|
|
|
DG(16:0/0:0/20:4n3)
|
|
|
TG(20:0/14:1(9Z)/o-18:0)
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:0/18:0)
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
Methadyl Acetate
|
|
|
TG(24:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/16:1(9Z)/18:1(11Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
Diguanosine tetraphosphate
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(14:0/24:1(15Z))
|
|
|
Hypotaurine
|
An aminosulfinic acid comprising ethylamine having the sulfo group at the 2-position.
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/14:1(9Z))
|
|
|
PE(18:2(9Z,12Z)/P-18:1(11Z))
|
|
|
Deoxyadenosine monophosphate
|
|
|
TG(22:0/18:1(11Z)/o-18:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(16:0/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/24:1(15Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GD1a (d18:1/26:1(17Z))
|
|
|
Cervonyl coenzyme A
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:0/0:0/18:1n9)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/24:0/18:1(9Z))
|
|
|
N-Butyrylglycine
|
|
|
TG(14:1(9Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/16:1(9Z)/22:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0/o-18:0)
|
|
|
TG(15:0/24:0/24:0)
|
|
|
Oxybuprocaine
|
A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester caine) used especially in ophthalmology and otolaryngology.
|
|
Trimipramine
|
A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
3-Chloro-2-methyldienelactone
|
A halo fatty acid that has formula C7H5ClO4.
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(14:0/14:1(9Z))
|
|
|
PC(15:0/20:0)
|
|
|
TG(16:0/22:2(13Z,16Z)/22:0)
|
|
|
PIP2(16:0/20:1(11Z))
|
|
|
Bepridil
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
Histamine
|
A 1H-imidazol-4-yl group substituted at position C-4 by a 2-aminoethyl group.
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:1(13Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:0/18:1(11Z)/16:1(9Z))
|
|
|
PE(20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/24:1(15Z))
|
|
|
PC(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(P-16:0/20:2(11Z,14Z))
|
|
|
TG(14:1(9Z)/20:0/16:1(9Z))
|
|
|
Oxymorphone
|
|
|
DG(20:1n9/0:0/18:3n3)
|
|
|
Oxidized dithiothreitol
|
|
|
TG(22:1(13Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:3n6/14:0)
|
|
|
3-Hydroxy-3-methylglutaryl-CoA
|
An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of 3-hydroxy-3-methylglutaric acid.
|
|
TG(20:0/22:2(13Z,16Z)/22:0)
|
|
|
Sulfolithocholylglycine
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(15:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/16:0/20:2n6)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3a,7a,12a,24-Tetrahydroxy-5b-cholestanoyl-CoA
|
|
|
TG(20:0/22:2(13Z,16Z)/20:0)
|
|
|
TG(20:3n6/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/20:3n6)
|
|
|
TG(14:0/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(20:1(11Z)/20:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/16:0)
|
|
|
Monobenzone
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Methylprednisolone
|
|
|
17-Hydroxyandrostane-3-glucuronide
|
|
|
D-fructose 1-phosphate
|
The D-enantiomer of fructose 1-phosphate.
|
|
TG(18:3(9Z,12Z,15Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:1(11Z)/20:1(11Z))
|
|
|
Sulfapyridine
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:2n6)
|
|
|
Delta 8,14 -Sterol
|
|
|
3-Dehydrosphinganine
|
A 2-amino-1-hydroxyoctadecan-3-one that has S-configuration.
|
|
TG(18:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
PG(18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Bupranolol
|
|
|
Paroxetine
|
A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.
|
|
PE(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:1(9Z)/22:1(13Z)/0:0)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
PE(P-18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
MG(20:0/0:0/0:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
CDP-DG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP3(16:0/18:1(11Z))
|
|
|
CDP-DG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPE(22:2(13Z,16Z)/0:0)
|
|
|
Morphine-3-glucuronide
|
A morphinane alkaloid that has formula C23H27NO9.
|
|
PE(18:0/14:1(9Z))
|
|
|
7a-Hydroxytestosterone
|
|
|
Ganglioside GT1b (d18:0/26:1(17Z))
|
|
|
TG(24:1(15Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:1(9Z)/20:1(11Z))
|
|
|
TG(16:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
PI(20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(20:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/16:0/14:1(9Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GQ1c (d18:1/23:0)
|
|
|
TG(16:1(9Z)/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
Nabumetone
|
|
|
Coenzyme A
|
A thiol comprising a panthothenate unit in phosphoric anhydride linkage with a 3',5'-adenosine diphosphate unit; and an aminoethanethiol unit.
|
|
11,12-DiHETrE
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/20:2n6)
|
|
|
DG(16:0e/18:0/0:0)
|
|
|
TG(16:1(9Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/18:2(9Z,12Z))[iso6]
|
|
|
PI(18:0/20:4(5Z,8Z,11Z,14Z))
|
is_a CHEBI:65055, is_a CHEBI:74240
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(P-18:0/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GD1b (d18:0/18:0)
|
|
|
PS(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
Tetrahydrodeoxycorticosterone
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
Amlexanox
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Chlordecone alcohol
|
An organochlorine compound that has formula C10H2Cl10O.
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(20:2n6/14:1(9Z)/22:2(13Z,16Z))
|
|
|
DG(24:0/0:0/20:3n9)
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(16:0/16:2(9Z,12Z))
|
|
|
Aflatoxin B1
|
An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.
|
|
DG(24:0/0:0/20:1n9)
|
|
|
Fructose 6-phosphate
|
|
|
PC(14:0/18:2(9Z,12Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
2-Aminoacrylic acid
|
A dehydroamino acid that is the 2,3-didehydro derivative of alanine.
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Felbamate
|
|
|
TG(18:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:2n6/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPE(0:0/20:1(11Z))
|
|
|
TG(24:1(15Z)/24:0/20:2n6)
|
|
|
PE(P-16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Acetyl adenylate
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
N-Sulfo-D-glucosamine
|
The N-sulfoglucosamine formed by sulfating the amino group of D-glucosamine.
|
|
TG(24:0/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(14:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(18:2(9Z,12Z)/18:1(9Z))
|
|
|
DG(20:2(11Z,14Z)/14:1(9Z)/0:0)
|
|
|
DG(24:1n9/0:0/18:2n6)
|
|
|
(S)-2-Aceto-2-hydroxybutanoic acid
|
|
|
PE(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:0/20:1(11Z))
|
|
|
TG(16:0/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(11Z)/18:1(11Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(22:0/20:2n6/22:1(13Z))
|
|
|
TG(20:1(11Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
DG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
DG(16:1n7/0:0/22:4n6)
|
|
|
TG(22:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
1-Nitro-7-glutathionyl-8-hydroxy-7,8-dihydronaphthalene
|
A peptide that has formula C20H24N4O9S.
|
|
TG(18:1(9Z)/15:0/o-18:0)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
DG(18:0/0:0/20:4n6)
|
|
|
TG(15:0/22:0/20:1(11Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:2(13Z,16Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:1(9Z)/16:0/0:0)
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(24:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:3n6/22:1(13Z))
|
|
|
Lactosylceramide (d18:1/16:0)
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/24:0)
|
|
|
TG(22:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Rifaximin
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(20:1(11Z)/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
Ergonovine
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(15:0/24:0/18:0)
|
|
|
N-Acetylserine
|
|
|
TG(16:0/o-18:0/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
N-Acetyldapsone
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/16:1(9Z)/16:1(9Z))
|
|
|
TG(16:0/22:0/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(18:4n3/0:0/20:5n3)
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
L-Dopa
|
An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease
|
|
TG(18:1(9Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
3-Hydroxymethylglutaric acid
|
|
|
PIP3(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:2n6/18:1(9Z))
|
|
|
PC(14:0/15:0)
|
|
|
Ganglioside GM1 (d18:1/23:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/24:0/0:0)
|
|
|
PG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/0:0)
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cilostazol
|
A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substiuted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group.
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(16:1(9Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:1(11Z)/14:1(9Z))
|
|
|
Uridine 2',3'-cyclic phosphate
|
|
|
Perillyl aldehyde
|
An aldehyde that has formula C10H14O.
|
|
TG(18:1(11Z)/22:1(13Z)/22:1(13Z))
|
|
|
Acetaldehyde
|
The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.
|
|
PE(22:1(13Z)/16:1(9Z))
|
|
|
Ivermectin
|
A mixture consisting of >= 90% 22,23-dihydroavermectin B1a (R = Me) and <= 10% 22,23-dihydroavermectin B1b (R = H). A semi-synthetic derivative of abamectin, it is used as a broad-spectrum antiparasite medication, particularly against worms (except tapeworms), although it is also effective against most mites and some lice.
|
|
PIP(20:2(11Z,14Z)/18:0)
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
LysoPE(0:0/20:3(8Z,11Z,14Z))
|
|
|
Cyclopentolate
|
A carboxylic ester resulting from the formal condensation of (1-hydroxycyclopentyl)(phenyl)acetic acid with N,N-dimethylethanolamine. A tertiary amine antimuscarinic with actions similar to atropine, it is used as its hydrochloride salt to produce mydriasis (excessive dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) for opthalmic diagnostic procedures. It acts more quickly than atropine and has a shorter duration of action.
|
|
TG(15:0/16:0/20:3n6)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT1c (d18:0/24:0)
|
|
|
N-Acetyl-D-glucosaminyldiphosphodolichol
|
|
|
PE(15:0/P-18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/22:1(13Z)/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:1(9Z)/18:2(9Z,12Z))[iso6]
|
|
|
16a-Hydroxyandrost-4-ene-3,17-dione
|
|
|
TG(18:1(11Z)/24:1(15Z)/o-18:0)
|
|
|
TG(14:1(9Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:2n6)
|
|
|
DG(20:3n9/0:0/22:4n6)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
PI(20:3(5Z,8Z,11Z)/18:0)
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
17-alpha-Estradiol-3-glucuronide
|
|
|
PC(22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
PI(22:3(10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/14:0/o-18:0)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
D-Glutamine
|
The D-enantiomer of glutamine.
|
|
TG(18:0/20:2n6/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/18:0/22:2(13Z,16Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/0:0)
|
|
|
Isopentenyl pyrophosphate
|
|
|
TG(18:1(9Z)/20:0/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sertindole
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/16:0)
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
Latanoprost
|
A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/16:1(9Z)/0:0)
|
|
|
TG(18:0/16:0/14:1(9Z))
|
|
|
TG(20:0/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:2n6/o-18:0)
|
|
|
TG(24:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Hippuric acid
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:2n6/16:0)
|
|
|
TG(18:2(9Z,12Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
1-Methoxyphenanthrene
|
A phenanthrene that has formula C15H12O.
|
|
TG(15:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
ADP
|
A purine ribonucleoside 5'-diphosphate having adenine as the nucleobase.
|
|
TG(20:2n6/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Glycocholic acid
|
A bile acid glycine conjugate having cholic acid as the bile acid component.
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:3n6)
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
SM(d18:0/22:0)
|
|
|
TG(24:1(15Z)/22:0/24:1(15Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/22:0)
|
|
|
TG(16:1(9Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Leukotriene A4
|
A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid.
|
|
TG(20:0/16:1(9Z)/20:3n6)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/24:0/16:1(9Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:5n3/0:0/22:6n3)
|
|
|
Paclitaxel
|
A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark.
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/14:1(9Z)/24:1(15Z))
|
|
|
TG(24:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Chitobiose
|
|
|
TG(15:0/18:0/16:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/18:1(9Z))
|
|
|
DG(20:3n6/0:0/20:5n3)
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
5-HPETE
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Valdecoxib
|
|
|
DG(20:4n3/0:0/20:4n3)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
LysoPE(22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/o-18:0)
|
|
|
TG(20:1(11Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/20:0)
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(15:0/16:0/14:1(9Z))
|
|
|
TG(18:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
3-Oxo-4,6-choladienoic acid
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GQ1c (d18:0/18:1(9Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/24:1(15Z))
|
|
|
PE(14:0/14:0)
|
|
|
Benzonatate
|
The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.
|
|
TG(20:0/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
Carbonic acid
|
A chalcocarbonic acid that has formula CH2O3.
|
|
TG(14:0/18:0/18:2(9Z,12Z))
|
|
|
PC(24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Hydroflumethiazide
|
|
|
N1-(alpha-D-ribosyl)-5,6-dimethyl-benzimidazole
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PIP2(18:3(6Z,9Z,12Z)/18:0)
|
|
|
PC(24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(14:1(9Z)/20:1(11Z)/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/16:0/18:1(11Z))
|
|
|
TG(16:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:2n6/16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(16:1(9Z)/14:0)
|
|
|
Glycerylphosphorylethanolamine
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(16:0/o-18:0/24:1(15Z))
|
|
|
PS(18:2(9Z,12Z)/16:0)
|
|
|
TG(20:1(11Z)/14:0/22:2(13Z,16Z))
|
|
|
TG(20:2n6/20:2n6/o-18:0)
|
|
|
PS(16:1(9Z)/14:1(9Z))
|
|
|
TG(18:0/20:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:0/18:1(9Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/24:0)
|
|
|
TG(20:1(11Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
(E)-but-2-enoyl-CoA
|
|
|
PS(18:2(9Z,12Z)/14:0)
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(24:0/o-18:0/20:2n6)
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
PE(18:1(9Z)/20:0)
|
|
|
TG(16:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Dihydrocortisol
|
|
|
PS(16:1(9Z)/16:0)
|
|
|
5,6-Dihydroxyindole-2-carboxylic acid
|
A dihydroxyindole that is indole-2-carboxylic acid substituted by hydroxy groups at positions 5 and 6.
|
|
PI(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(22:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
PI(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/18:0/20:2n6)
|
|
|
Vecuronium
|
A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.
|
|
Amlodipine
|
A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
|
|
TG(16:0/16:0/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(22:0/20:2n6/18:1(9Z))
|
|
|
TG(20:3n6/18:0/18:3(9Z,12Z,15Z))
|
|
|
PI(20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(16:1(9Z)/22:1(13Z)/0:0)
|
|
|
TG(18:0/22:1(13Z)/16:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/o-18:0/18:1(9Z))
|
|
|
Iodine
|
A monoatomic iodine that has formula I.
|
|
DG(18:3(9Z,12Z,15Z)/18:1(9Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/20:3n6)
|
|
|
Terazosin
|
A piperazine that has formula C19H25N5O4.
|
|
TG(20:1(11Z)/16:0/20:3n6)
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:3n6)
|
|
|
PIP2(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/15:0/20:2n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Acepromazine
|
A member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl group at position 10.
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/14:0)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(18:1(9Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Anisotropine Methylbromide
|
A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.
|
|
PE(20:3(8Z,11Z,14Z)/24:0)
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(18:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
Amsacrine
|
|
|
PE(18:1(9Z)/24:0)
|
|
|
TG(8:0/8:0/8:0)
|
|
|
TG(24:1(15Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:2n6/14:1(9Z))
|
|
|
PC(15:0/22:1(13Z))
|
|
|
TG(20:3n6/20:2n6/20:3n6)
|
|
|
TG(18:1(9Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Demecarium
|
|
|
Tenofovir
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Mycophenolic acid
|
|
|
DG(18:1(9Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
Noradrenochrome
|
|
|
TG(20:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(24:0/18:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/16:0/24:1(15Z))
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
Xanthine
|
A purine nucleobase found in humans and other organisms.
|
|
Linoleic acid
|
An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) steeochemistry.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Cinacalcet
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:0/16:1(9Z))
|
|
|
SM(d18:1/18:1(9Z))
|
A sphingomyelin d18:1 in which the acyl group specified is 9Z-octadecenoyl.
|
|
Atracurium
|
A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.
|
|
TG(18:2(9Z,12Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(11Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
(24R)-Cholest-5-ene-3-beta,24-diol
|
A 24-hydroxycholesterol that has formula C27H46O2.
|
|
Iminoaspartic acid
|
A succinic acid derivative having an imino group at the 2-position.
|
|
DG(18:1n9/0:0/18:2n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:0/20:0/16:0)
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
PG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PI(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(14:0/18:0/24:1(15Z))
|
|
|
DG(16:1n7/0:0/20:2n6)
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/22:0)
|
|
|
TG(18:1(9Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Zopiclone
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/20:0)
|
|
|
TG(16:0/22:1(13Z)/16:0)
|
|
|
Putrescine
|
A four-carbon alkane-alpha,omega-diamine. It is obtained by the breakdown of amino acids and is responsible for the foul odour of putrefying flesh.
|
|
TG(18:1(9Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(24:0/16:0/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/18:0)
|
|
|
Physostigmine
|
An indole alkaloid that has formula C15H21N3O2.
|
|
PA(16:0/18:1(9Z))
|
|
|
PC(P-18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/20:1(11Z))[iso3]
|
|
|
TG(18:0/20:0/24:1(15Z))
|
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(20:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/20:3n6)
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/0:0)
|
|
|
TG(20:0/18:1(11Z)/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
HClO
|
|
|
TG(18:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/24:1(15Z))
|
|
|
TG(16:0/18:1(11Z)/18:1(9Z))
|
|
|
D-Glucuronic acid
|
The D-enantiomer of glucuronic acid.
|
|
TG(24:1(15Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Cyclohexane
|
An alicyclic hydrocarbon comprising a ring of six carbon atoms; the cyclic form of hexane, used as a raw material in the manufacture of nylon.
|
|
Tetrahexosylceramide (d18:1/22:0)
|
|
|
TG(24:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:0/P-16:0)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:1(9Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT3 (d18:0/26:1(17Z))
|
|
|
TG(15:0/24:1(15Z)/20:1(11Z))
|
|
|
Gabapentin
|
|
|
Ganglioside GD2 (d18:0/26:1(17Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/18:1(9Z)/20:1(11Z))
|
|
|
Phenylephrine
|
A member of the class of the class of phenylethanolamines that is 2-(methylamino)ethanol substituted by a 3-hydroxyphenyl group at position 1.
|
|
Tetracosanoic acid
|
A C24 straight-chain saturated fatty acid.
|
|
TG(18:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
PE(14:1(9Z)/18:0)
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:1(9Z)/14:0)
|
|
|
Tamsulosin
|
A sulfonamide that has formula C20H28N2O5S.
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
DG(22:1(13Z)/14:1(9Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
PI(18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/o-18:0)
|
|
|
TG(14:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/16:0/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/15:0/24:1(15Z))
|
|
|
TG(22:2(13Z,16Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(15:0/22:0/20:2n6)
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(14:1(9Z)/20:0/20:1(11Z))
|
|
|
5-Hydroxypyrazinamide
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
N-Acetyl-b-D-galactosamine
|
|
|
Tolbutamide
|
An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.
|
|
TG(24:1(15Z)/18:0/20:2n6)
|
|
|
PE(P-16:0e/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
DG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
PE(14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:0/o-18:0)
|
|
|
TG(14:1(9Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:1(11Z)/20:3n6)
|
|
|
TG(20:0/18:1(9Z)/20:2n6)
|
|
|
TG(20:2n6/15:0/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/15:0/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
7-Dehydrodesmosterol
|
A 3beta-sterol having the structure of desmosterol with an extra double bond at C-7--C-8.
|
|
TG(24:1(15Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Sertaconazole
|
|
|
TG(16:0/14:0/20:3n6)
|
|
|
TG(15:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:1n5/0:0/22:6n3)
|
|
|
trans-3-Hydroxycotinine glucuronide
|
|
|
DG(18:0/0:0/22:1n9)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:1(9Z)/15:0/0:0)
|
|
|
PE(P-18:1(9Z)/14:0)
|
|
|
PC(20:1(11Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/14:0/20:3(5Z,8Z,11Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:2(11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
Thiocysteine
|
|
|
N-Acetyl-glucosamine 1-phosphate
|
|
|
DG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/15:0/18:2(9Z,12Z))
|
|
|
Oxazepam
|
A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
DG(20:2(11Z,14Z)/22:0/0:0)
|
|
|
(R)-3-Hydroxybutyric acid
|
The R-enantiomer of 3-hydroxybutyric acid. Involved in the synthesis and degradation of ketone bodies, it can be used as an energy source by the brain during hypoglycaemia, and for the synthesis of biodegradable plastics.
|
|
DG(16:1(9Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(18:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/22:1(13Z))
|
|
|
Ganglioside GT1b (d18:0/12:0)
|
|
|
Guaiacol
|
|
|
TG(22:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/P-18:1(11Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:1(13Z)/14:1(9Z))
|
|
|
DG(20:2(11Z,14Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(24:0/18:0/o-18:0)
|
|
|
TG(18:1(11Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ethyl carbamate
|
A carbamate ester obtained by the formal condensation of ethanol with carbamic acid. It has been found in alcoholic beverages.
|
|
TG(22:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/15:0/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/20:2n6)
|
|
|
DG(24:0/18:1(11Z)/0:0)
|
|
|
DG(20:4n6/0:0/18:4n3)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
PG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3n9/0:0/22:1n9)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(14:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
(2E)-Dodecenoyl-CoA
|
|
|
PE(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Dorzolamide
|
5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
SM(d18:0/26:1(17Z))
|
|
|
Picrotoxin
|
|
|
N-Lignoceroylsphingosine
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
3'-Ketolactose
|
A keto-disaccharide that is beta-D-galactosyl-(1->4)-beta-D-glucose in which the hydroxy group at position 3 of the galactosyl moiety has been oxidised to the corresponding ketone.
|
|
TG(14:0/24:1(15Z)/16:1(9Z))
|
|
|
DG(24:0/0:0/18:3n6)
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Triamterene
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/16:1(9Z))
|
|
|
TG(16:1(9Z)/16:0/20:3n6)
|
|
|
Miconazole
|
A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.
|
|
TG(16:1(9Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Isolithocholic acid
|
A bile acid that has formula C24H40O3.
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Amisulpride
|
|
|
DG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
Ganglioside GD3 (d18:1/20:0)
|
|
|
Ergocalciferol
|
|
|
PC(22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ramelteon
|
|
|
DG(20:0/22:0/0:0)
|
|
|
TG(20:0/20:0/24:1(15Z))
|
|
|
Ganglioside GD3 (d18:1/22:0)
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/22:0)
|
|
|
TG(22:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:0/20:1(11Z)/24:1(15Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(16:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/16:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/20:3n6)
|
|
|
Atorvastatin
|
A dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cer(t18:0/16:0)
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/14:1(9Z)/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/20:3n6)
|
|
|
TG(24:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/14:0/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
(S)-Ureidoglycolic acid
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(16:0/0:0/18:4n3)
|
|
|
TG(22:1(13Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Clofibrate
|
A carboxylic ester that is the ethyl ester of clofibric acid.
|
|
Inosinic acid
|
|
|
TG(24:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cer(d18:0/26:1(17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1c (d18:1/26:0)
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/22:1(13Z)/20:3n6)
|
|
|
TG(20:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:0/22:1(13Z))
|
|
|
Ganglioside GT1c (d18:1/20:0)
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD3 (d18:0/23:0)
|
|
|
Bromodiphenhydramine
|
|
|
PI(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
PE(20:2(11Z,14Z)/20:2(11Z,14Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/24:1(15Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Acetone cyanohydrin
|
|
|
DG(20:0/0:0/20:4n3)
|
|
|
PC(18:0/18:2(9Z,12Z))
|
|
|
PE(20:2(11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
Tafluprost free acid
|
|
|
MG(18:2(9Z,12Z)/0:0/0:0)
|
|
|
TG(18:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:1(11Z)/24:1(15Z))
|
|
|
Azelaic acid
|
An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups.
|
|
TG(16:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:2n6/16:1(9Z))
|
|
|
PC(22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
5-alpha-Cholesta-7,24-dien-3-beta-ol
|
A 3beta-sterol that has formula C27H44O.
|
|
TG(22:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/o-18:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(20:0/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Levobupivacaine
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(24:0/22:0/16:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:3n6/o-18:0)
|
|
|
DG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
Deserpidine
|
|
|
DG(20:3(5Z,8Z,11Z)/20:2(11Z,14Z)/0:0)
|
|
|
DG(20:3(8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:1(11Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:2n6/20:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Carbon monoxide
|
A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
|
|
TG(20:0/20:2n6/22:0)
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Idarubicin
|
An anthracycline antibiotic that has formula C26H27NO9.
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/o-18:0/24:1(15Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
Prazosin
|
A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/16:0/22:2(13Z,16Z))
|
|
|
Tetrahydropteridine
|
|
|
TG(20:2n6/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/16:0)
|
|
|
TG(18:1(9Z)/15:0/18:1(9Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
DG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
Enoxaparin
|
|
|
TG(20:2n6/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/15:0)
|
|
|
PC(P-18:0/18:1(9Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:0/20:0)
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(14:1(9Z)/20:2n6/22:1(13Z))
|
|
|
PE(18:0/22:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/16:0/0:0)
|
|
|
PC(18:1(9Z)/20:0)
|
|
|
TG(16:0/20:1(11Z)/14:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
PE(22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:0/18:1(11Z)/0:0)
|
|
|
Cinnarizine
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:0)
|
|
|
TG(16:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
N-Glycolylneuraminic acid
|
|
|
PG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(15:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/18:0/18:1(9Z))
|
|
|
LysoPE(0:0/24:6(6Z,9Z,12Z,15Z,18Z,21Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Dipyridamole
|
A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
|
|
TG(22:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
Stearic acid
|
A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.
|
|
S-Adenosylmethioninamine
|
The S-adenosyl derivative of methioninamine.
|
|
Lamivudine
|
|
|
TG(24:1(15Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/20:4n6)
|
|
|
DG(20:3n9/0:0/20:4n3)
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
DG(18:1n7/0:0/22:1n9)
|
|
|
PC(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/24:0)
|
|
|
Fencamfamine
|
|
|
TG(24:0/20:0/20:2n6)
|
|
|
PC(P-18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Polythiazide
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Myo-inositol 1-phosphate
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
Bumetanide
|
A member of the class of benzoic acids that is 4-phenoxybenzoic acid in which the hydrogens ortho to the phenoxy group are substituted by butylamino and sulfamoyl groups. Bumetanide is a diuretic, and is used for treatment of oedema associated with congestive heart failure, hepatic and renal disease.
|
|
Cefaclor
|
A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2(11Z,14Z)/0:0)
|
|
|
DG(20:0/0:0/18:2n6)
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
TG(18:1(9Z)/20:0/22:2(13Z,16Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(11Z)/15:0)
|
|
|
TG(20:2n6/18:1(11Z)/20:2n6)
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(24:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/18:0/24:1(15Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Dihydroneopterin phosphate
|
|
|
PS(18:1(9Z)/18:1(9Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Ganglioside GD2 (d18:1/26:0)
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:1n9/0:0/22:6n3)
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/16:0/18:3(9Z,12Z,15Z))
|
|
|
(R)-3-Hydroxydecanoic acid
|
|
|
TG(20:0/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/24:0/18:1(11Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/16:0/18:1(9Z))
|
|
|
Heptacarboxylporphyrin III
|
|
|
Ganglioside GD2 (d18:1/20:0)
|
|
|
DG(18:1(11Z)/20:1(11Z)/0:0)
|
|
|
PIP2(20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:1(9Z)/18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/16:0/20:2n6)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(18:1(11Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/22:0/24:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/20:0/20:3n6)
|
|
|
TG(16:1(9Z)/20:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
PI(22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/14:1(9Z)/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Chlorpheniramine
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/o-18:0/14:0)
|
|
|
PA(18:1(9Z)/18:1(9Z))
|
|
|
TG(18:0/16:0/20:0)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
CDP-DG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(20:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:1(9Z)/20:3n6/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/o-18:0)
|
|
|
TG(20:0/o-18:0/20:1(11Z))
|
|
|
TG(22:0/20:3n6/18:2(9Z,12Z))
|
|
|
TG(20:0/18:1(11Z)/24:0)
|
|
|
Methylamine
|
The simplest of the methylamines, consisting of ammonia bearing a single methyl substituent.
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:0/P-16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(18:1(11Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
CE(18:2(9Z,12Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/20:1(11Z)/18:1(11Z))
|
|
|
PI(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
L-Histidine
|
The L-enantiomer of the amino acid histidine.
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/16:0/18:0)
|
|
|
TG(14:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Indanone
|
An ortho-fused bicyclic compound consisting of a benzene ring fused to a cyclopentanone.
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:0)[iso6]
|
|
|
Morphine
|
A morphinane alkaloid that is a highly potent opiate analgesic psychoactive drug. Morphine acts directly on the central nervous system (CNS) to relieve pain but has a high potential for addiction, with tolerance and both physical and psychological dependence developing rapidly. Morphine is the most abundant opiate found in Papaver somniferum (the opium poppy).
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/o-18:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:0/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(20:2n6/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/18:1(9Z))
|
|
|
DG(22:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(14:0/24:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))[iso3]
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/16:1(9Z)/20:0)
|
|
|
TG(15:0/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:0)[iso6]
|
|
|
Glucosylceramide (d18:1/26:1(17Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:2(11Z,14Z)/24:1(15Z)/0:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
PE(22:2(13Z,16Z)/P-18:0)
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(15:0/16:0/20:2n6)
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/15:0/18:1(9Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(18:2(9Z,12Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM3 (d18:1/26:0)
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:2n6)
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
Ganglioside GT1c (d18:0/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso3]
|
|
|
Xanthurenic acid
|
A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by hydroxy groups at C-4 and C-8.
|
|
TG(16:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
DG(20:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(24:1(15Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:4n6/0:0/22:4n6)
|
|
|
TG(22:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:3n6/24:1(15Z))
|
|
|
DG(20:3n9/0:0/22:5n6)
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(18:1n7/0:0/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:0/o-18:0)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/16:1(9Z))
|
|
|
Mepenzolate
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/20:3n6)
|
|
|
TG(24:0/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Glycineamideribotide
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/20:3n6)
|
|
|
Ganglioside GM3 (d18:1/20:0)
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/18:1(9Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(15:0/20:1(11Z)/20:1(11Z))
|
|
|
Folic acid
|
An N-acyl-amino acid that is a form of the water-soluble vitamin B9. Its biologically active forms (tetrahydrofolate and others) are essential for nucleotide biosynthesis and homocysteine remethylation.
|
|
MG(0:0/24:0/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(o-22:0/22:3(10Z,13Z,16Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Pilocarpine
|
|
|
3-Oxo-OPC6-CoA
|
An organic molecule that has formula C37H58N7O19P3S.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(P-18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3a,7a,12a-Trihydroxy-5b-cholestanoyl-CoA
|
|
|
PE(20:3(8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ondansetron
|
|
|
TG(16:0/18:0/24:1(15Z))
|
|
|
PC(P-16:0/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/24:0/18:1(11Z))
|
|
|
TG(22:1(13Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
Biliverdin
|
A linear tetrapyrrole produced in the reticuloendothelial system by the first step of heme degradation, catalysed by heme oxygenase.
|
|
TG(24:0/15:0/18:1(11Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/22:1(13Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP(16:0/22:4(10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/15:0/18:1(9Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/20:3n6)
|
|
|
TG(14:1(9Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Methocarbamol
|
|
|
TG(15:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:3n6/20:1(11Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(15:0/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/24:1(15Z)/22:1(13Z))
|
|
|
PE(20:2(11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
All-trans-hexaprenyl diphosphate
|
A hexaprenyl diphosphate that has formula C30H52O7P2.
|
|
TG(16:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
13-L-Hydroperoxylinoleic acid
|
|
|
CL(18:2(9Z,12Z)/18:1(9Z)/18:1(11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Dextrorphan O-glucuronide
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/22:1(13Z))
|
|
|
PC(24:1(15Z)/22:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:3n6/18:1(9Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/o-18:0)
|
|
|
TG(18:1(11Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Phenol
|
An organic hydroxy compound that consists of benzene bearing a single hydroxy substituent. The parent of the class of phenols.
|
|
PC(24:1(15Z)/24:0)
|
|
|
Amodiaquine
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/0:0)
|
|
|
DG(15:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(16:0/15:0/14:1(9Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:2(11Z,14Z)/P-18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
Mitotane
|
|
|
TG(16:0/22:0/o-18:0)
|
|
|
PC(14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/22:1(13Z)/20:1(11Z))
|
|
|
TG(20:0/22:1(13Z)/14:1(9Z))
|
|
|
TG(15:0/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/o-18:0)
|
|
|
TG(18:0/o-18:0/22:2(13Z,16Z))
|
|
|
TG(15:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GD2 (d18:0/24:1(15Z))
|
|
|
TG(16:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
Chlophedianol
|
|
|
N-Acetylornithine
|
|
|
TG(18:0/18:1(9Z)/o-18:0)
|
|
|
PI(22:2(13Z,16Z)/16:0)
|
|
|
Adenosine phosphosulfate
|
|
|
TG(14:1(9Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Acebutolol
|
An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(24:1(15Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PG(18:1(9Z)/16:0)
|
|
|
PE(15:0/18:2(9Z,12Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/o-18:0)
|
|
|
N-Acryloylglycine
|
|
|
PC(14:1(9Z)/16:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PC(P-18:1(9Z)/24:0)
|
|
|
PE(20:1(11Z)/16:0)
|
|
|
TG(15:0/15:0/20:1(11Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
Cortisone acetate
|
A corticosteroid hormone that has formula C23H30O6.
|
|
TG(15:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
D-Fructose 2,6-bisphosphate
|
|
|
PC(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
4-(2-Aminophenyl)-2,4-dioxobutanoic acid
|
A 4-oxo monocarboxylic acid that has formula C10H9NO4.
|
|
DG(20:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
Proguanil
|
|
|
TG(20:3n6/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/22:0/24:1(15Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Docosa-4,7,10,13,16-pentaenoyl CoA
|
|
|
MG(15:0/0:0/0:0)
|
|
|
TG(15:0/18:1(11Z)/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:0/22:2(13Z,16Z))
|
|
|
3-Oxododecanoic acid
|
A 3-oxo monocarboxylic acid that has formula C12H22O3.
|
|
Pamidronate
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
Undecaprenyl diphosphate
|
A polyprenol diphosphate compound having eleven prenyl units with undefined stereochemistry about the double bonds.
|
|
TG(22:1(13Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/24:1(15Z)/14:1(9Z))
|
|
|
TG(20:3n6/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(20:1(11Z)/14:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
Ciliatine
|
|
|
Atazanavir
|
|
|
Ganglioside GD2 (d18:0/18:0)
|
|
|
TG(18:1(9Z)/14:0/20:2n6)
|
|
|
L-Phenylalanine
|
The L-enantiomer of phenylalanine.
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
DG(18:3(9Z,12Z,15Z)/22:0/0:0)
|
|
|
Ganglioside GT2 (d18:0/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
PE(P-18:1(11Z)/18:0)
|
|
|
SM(d18:0/22:3(10Z,13Z,16Z))
|
|
|
DG(18:1(11Z)/15:0/0:0)
|
|
|
TG(15:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:0)
|
|
|
PC(16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/18:2(9Z,12Z))
|
|
|
Lactose 6-phosphate
|
A lactose phosphate in which a single monophosphate substituent is placed at position 6 on the galactose ring of lactose.
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/24:0/0:0)
|
|
|
PIP(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:1n9/0:0/20:3n6)
|
|
|
TG(20:2n6/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(18:1(11Z)/14:1(9Z))
|
|
|
TG(24:1(15Z)/20:3n6/o-18:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0)
|
|
|
TG(20:0/18:2(9Z,12Z)/18:1(11Z))
|
|
|
LysoPE(0:0/22:2(13Z,16Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:3n6/18:1(11Z))
|
|
|
TG(20:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
Amobarbital
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/24:0/20:3n6)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/14:0/0:0)
|
|
|
TG(16:0/20:0/22:2(13Z,16Z))
|
|
|
TG(16:0/18:0/14:1(9Z))
|
|
|
TG(24:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:1(11Z)/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Muricholic acid
|
|
|
PE(20:2(11Z,14Z)/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
3-Dehydroquinate
|
A hydroxy monocarboxylic acid anion that is obtained by removal of a proton from the carboxylic acid group of 3-dehydroquinic acid.
|
|
TG(22:1(13Z)/24:1(15Z)/20:3n6)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
PIP2(18:3(9Z,12Z,15Z)/18:0)
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(24:0/24:1(15Z)/14:1(9Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/18:0/22:1(13Z))
|
|
|
PC(14:1(9Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/o-18:0/20:1(11Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(14:1(9Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:2n6/20:3n6)
|
|
|
Pregabalin
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/18:2(9Z,12Z))
|
|
|
Carbinoxamine
|
An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/o-18:0)
|
|
|
TG(20:2n6/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/14:0)
|
|
|
Arachidyl alcohol
|
|
|
TG(15:0/20:2n6/18:1(9Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(16:0/14:1(9Z)/20:0)
|
|
|
TG(15:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/20:3n6)
|
|
|
TG(15:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
Gadopentetate dimeglumine
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Lactosylceramide (d18:1/24:0)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Lactosylceramide (d18:1/22:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
Duloxetine
|
|
|
PC(18:1(11Z)/20:1(11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
N-[(3a,5b,7a,12a)-3,12-dihydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-Glycine
|
|
|
TG(22:0/22:0/18:1(9Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/24:0/0:0)
|
|
|
Cabergoline
|
An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.
|
|
7alpha-Hydroxypregnenolone
|
A corticosteroid hormone that has formula C21H32O3.
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(18:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(20:1(11Z)/22:0/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/16:0/22:1(13Z))
|
|
|
TG(24:1(15Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(14:1n5/0:0/20:3n9)
|
|
|
TG(18:2(9Z,12Z)/20:2n6/20:3n6)
|
|
|
PC(22:1(13Z)/20:3(8Z,11Z,14Z))
|
|
|
PC(dm18:0/dm18:1(11Z))
|
|
|
Chenodeoxyglycocholic acid
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
Etomidate
|
The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.
|
|
TG(24:1(15Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/15:0/20:2n6)
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
ADP-ribose 2'-phosphate
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:0)
|
|
|
DG(20:0/0:0/20:2n6)
|
|
|
DG(14:1n5/0:0/18:1n9)
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
DG(22:0/0:0/22:1n9)
|
|
|
PC(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
PE(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/18:1(9Z)/20:3n6)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:1(11Z))
|
|
|
TG(20:3n6/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:2n6/22:2(13Z,16Z))
|
|
|
CL(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
5,6-Dihydro-5-fluorouracil
|
A 9,11,15-octadecatrienoic acid that has formula C4H5FN2O2.
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(14:0/20:0)
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GA1 (d18:1/26:1(17Z))
|
|
|
TG(24:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(24:0/14:0)
|
|
|
TG(16:0/22:0/22:2(13Z,16Z))
|
|
|
TG(24:0/o-18:0/16:1(9Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))
|
|
|
PC(24:0/16:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/20:3n6)
|
|
|
PS(14:0/14:1(9Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
PC(o-18:1(9Z)/22:0)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:0)
|
|
|
TG(14:1(9Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:0/24:1(15Z))
|
|
|
MG(18:1(11Z)/0:0/0:0)
|
|
|
DG(15:0/16:0/0:0)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:1(9Z)/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/20:3n6)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(P-16:0/18:2(9Z,12Z))
|
|
|
(S)-5-Diphosphomevalonic acid
|
|
|
Erlotinib
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(22:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/14:0/0:0)
|
|
|
TG(18:0/16:1(9Z)/20:0)
|
|
|
TG(18:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:2(11Z,14Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(14:1(9Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD1a (d18:0/23:0)
|
|
|
TG(20:0/14:1(9Z)/24:1(15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
13-OxoODE
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/18:1(9Z)/18:1(11Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
1-Methylnicotinamide
|
A pyridinium ion comprising nicotinamide having a methyl group at the 1-position.
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PS(14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:2n6/18:1(11Z))
|
|
|
7-Aminomethyl-7-carbaguanine
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
2-Methyl-1-hydroxypropyl-ThPP
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Alpha-hydroxyalprazolam
|
|
|
Remifentanil
|
A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.
|
|
2-Furoylglycine
|
|
|
1-Nitro-5-hydroxy-6-glutathionyl-5,6-dihydronaphthalene
|
A peptide that has formula C20H24N4O9S.
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
CE(16:1(9Z))
|
|
|
TG(22:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/16:1(9Z))
|
|
|
DG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(15:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/16:0/22:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
Morphine-6-glucuronide
|
A morphinane alkaloid that has formula C23H27NO9.
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
Ganglioside GT2 (d18:1/12:0)
|
|
|
TG(24:1(15Z)/24:1(15Z)/o-18:0)
|
|
|
TG(14:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/24:1(15Z)/24:0)
|
|
|
Calenduloside H
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GD1a (d18:0/25:0)
|
|
|
Ampicillin
|
A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Dibucaine
|
|
|
Ganglioside GQ1c (d18:1/24:1(15Z))
|
|
|
TG(18:1(11Z)/14:0/22:1(13Z))
|
|
|
Pindolol
|
A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
|
|
Fluconazole
|
A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It has been shown to exhibit antifungal activity.
|
|
3'-Hydroxyhexobarbital
|
A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a cyclohex-1-en-1-yl group at position 5, a hydroxy group at position 1 and methyl groups at positions 3 and 5.
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
PIP(18:0/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganciclovir
|
An oxopurine that is guanine substituted by a [(1,3-dihydroxypropan-2-yl)oxy]methyl group at position 9. Ganciclovir is an antiviral drug used to treat or prevent AIDS-related cytomegalovirus infections.
|
|
PE(16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
3-Carbamoyl-2-phenylpropionic acid
|
A monocarboxylic acid that has formula C10H11NO4.
|
|
TG(24:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(14:0/o-18:0/24:0)
|
|
|
TG(18:1(11Z)/o-18:0/18:2(9Z,12Z))
|
|
|
PIP(18:1(9Z)/18:0)
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
TG(16:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/18:0/18:3(9Z,12Z,15Z))
|
|
|
Estrone sulfate
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(15:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:2(13Z,16Z)/16:1(9Z)/0:0)
|
|
|
DG(20:2n6/0:0/20:5n3)
|
|
|
DG(14:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/16:0/24:0)
|
|
|
Ganglioside GT2 (d18:0/16:0)
|
|
|
TG(14:0/16:0/24:0)
|
|
|
Linamarin
|
A beta-D-glucoside that has formula C10H17NO6.
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
D-Glucosaminide
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
PE(20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
4-Nitrocatechol
|
A member of the class of catechols that is benzene-1,2-diol substituted by a nitro group at position 4.It is the by-product of the hydroxylation of p-nitrophenol.
|
|
Epinephrine glucuronide
|
|
|
Ephedrine
|
A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.
|
|
TG(24:1(15Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/o-18:0/22:2(13Z,16Z))
|
|
|
Ganglioside GD3 (d18:1/18:1(11Z))
|
|
|
TG(16:0/24:1(15Z)/22:0)
|
|
|
PE(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
4-Pyridoxic acid
|
A methylpyridine that is 2-methylpyridine substituted by a hydroxy group at C-3, a carboxy group at C-4, and a hydroxymethyl group at C-5.
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/14:0/20:2n6)
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:0)
|
|
|
PE(24:0/14:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/o-18:0)
|
|
|
PE(20:0/18:2(9Z,12Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/24:0/24:1(15Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(22:0/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(14:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/24:0/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(18:1(9Z)/18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/20:0/0:0)
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GM3 (d18:1/18:1(11Z))
|
|
|
DG(20:1(11Z)/22:2(13Z,16Z)/0:0)
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(18:1(11Z)/15:0/22:2(13Z,16Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)
|
|
|
Guanethidine
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
2-Methyl-1-hydroxybutyl-ThPP
|
A thiamine phosphate that has formula C17H29N4O8P2S.
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP(18:1(11Z)/18:0)
|
|
|
TG(10:0/10:0/10:0)[iso]
|
|
|
DG(20:1(11Z)/18:1(9Z)/0:0)
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/22:2(13Z,16Z))
|
|
|
PE(16:1(9Z)/14:1(9Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/14:0/14:1(9Z))
|
|
|
TG(18:1(11Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
DG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Dasatinib
|
|
|
PC(14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(P-16:0/24:1(15Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
LysoPC(18:0)
|
A lysophosphatidylcholine in which the acyl group has a fully saturated C18 chain and is attached to the glycero moiety at either position 1 or 2.
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:2n6/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
7-Methyluric acid
|
An oxopurine that has formula C6H6N4O3.
|
|
Levonorgestrel
|
A 17beta-hydroxy steroid that has formula C21H28O2.
|
|
TG(16:1(9Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:2n6/20:2n6)
|
|
|
TG(24:1(15Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/16:0/18:2(9Z,12Z))
|
|
|
Nilotinib
|
|
|
TG(16:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:0/18:1(9Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:0/24:0/20:2n6)
|
|
|
TG(18:0/20:0/24:0)
|
|
|
DG(18:3n6/0:0/18:4n3)
|
|
|
TG(24:1(15Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Propantheline
|
|
|
PE(20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:2n6/o-18:0)
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/0:0)
|
|
|
LPA(0:0/16:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Campest-4-en-3-one
|
A 3-oxo steroid that has formula C28H46O.
|
|
Dhurrin
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:1(11Z)/18:1(11Z))
|
|
|
TG(20:2n6/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/14:0/18:0)[iso3]
|
|
|
Ganglioside GT3 (d18:0/18:1(11Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
PIP(20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
MG(0:0/24:1(15Z)/0:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
Mitomycin
|
|
|
Dexmethylphenidate
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/0:0)
|
|
|
TG(24:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Cer(d18:0/24:0)
|
|
|
Mandelonitrile
|
A cyanohydrin that has formula C8H7NO.
|
|
DG(20:1(11Z)/14:1(9Z)/0:0)
|
|
|
TG(20:3n6/o-18:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(24:0/15:0/14:1(9Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:3n9/0:0/24:1n9)
|
|
|
TG(22:0/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:0/18:3(9Z,12Z,15Z))
|
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl substituents at positions 1 and 2 are specified as stearoyl and alpha-linolenoyl respectively.
|
|
DG(22:0/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(16:1(9Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/18:1(11Z)/20:3n6)
|
|
|
DG(24:0/14:0/0:0)
|
|
|
TG(18:0/16:1(9Z)/20:3n6)
|
|
|
TG(16:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
9,10-Epoxyoctadecenoic acid
|
|
|
TG(16:0/18:0/22:2(13Z,16Z))
|
|
|
TG(16:0/24:1(15Z)/16:1(9Z))
|
|
|
TG(16:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:1(11Z)/15:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/22:0/22:2(13Z,16Z))
|
|
|
PC(14:1(9Z)/15:0)
|
|
|
PG(18:1(11Z)/18:1(9Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPE(0:0/18:3(6Z,9Z,12Z))
|
|
|
PIP2(18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Daunorubicin
|
A natural product found in Actinomadura roseola.
|
|
Ibutilide
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GT1b (d18:1/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPE(0:0/24:0)
|
|
|
(S)-2,3,4,5-tetrahydropyridine-2-carboxylate
|
|
|
Ouabain
|
|
|
PE(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/20:2n6)
|
|
|
TG(20:0/24:0/18:1(9Z))
|
|
|
4-Trimethylammoniobutanoic acid
|
A quaternary ammonium ion that is the conjugate acid of 4-(trimethylammonio)butanoate.
|
|
PIP2(16:0/18:0)
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
PG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(14:0/16:0/18:0)
|
|
|
TG(24:1(15Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Prostaglandin D2
|
A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).
|
|
TG(14:0/15:0/20:2n6)
|
|
|
Ganglioside GD2 (d18:1/18:1(11Z))
|
|
|
TG(16:0/15:0/20:2n6)
|
|
|
N-Palmitoylsphingosine
|
|
|
TG(18:1(11Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Sulfate
|
A sulfur oxoanion obtained by deprotonation of both OH groups of sulfuric acid.
|
|
DG(20:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))
|
|
|
Ganglioside GD1b (d18:0/24:1(15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/14:0/18:1(11Z))[iso3]
|
|
|
TG(18:1(9Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(15:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/20:2n6)
|
|
|
TG(22:1(13Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/16:1(9Z)/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/o-18:0/20:3n6)
|
|
|
PS(14:0/18:2(9Z,12Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
PC(20:1(11Z)/14:1(9Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
Ganglioside GT2 (d18:1/26:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:1(11Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
Acetoacetyl-CoA
|
A 3-oxoacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of acetoacetic acid.
|
|
PE(22:2(13Z,16Z)/20:1(11Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
TG(24:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:1n9/0:0/22:5n3)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(16:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GT2 (d18:1/20:0)
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3-alpha-hydroxy-5-alpha-androstane-17-one 3-D-glucuronide
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
(1R)-Hydroxy-(2R)-glutathionyl-1,2-dihydronaphthalene
|
A peptide that has formula C20H25N3O7S.
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
N-Acetylneuraminate 9-phosphate
|
|
|
TG(18:0/20:3n6/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Lapatinib
|
|
|
TG(14:0/24:1(15Z)/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Trimethylamine
|
A tertiary amine that is ammonia in which each hydrogen atom is substituted by an methyl group.
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Trypanothione
|
A glutathione derivative that has formula C27H49N9O10S2.
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PE(16:1(9Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Melatonin
|
A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen atom is replaced by a 2-(5-methoxy-1H-indol-3-yl)ethyl group. It is a hormone secreted by the pineal gland in humans.
|
|
DG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
PE(22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:1(13Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/0:0/24:1n9)
|
|
|
TG(24:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/22:1(13Z)/24:0)
|
|
|
Tetrahydrobiopterin
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
7-Ketodeoxycholic acid
|
|
|
3-Methylcrotonyl-CoA
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:1(13Z)/22:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1n7/0:0/18:4n3)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(15:0/o-18:0/14:1(9Z))
|
|
|
TG(18:1(11Z)/24:0/18:1(11Z))
|
|
|
Ganglioside GT3 (d18:1/12:0)
|
|
|
TG(20:1(11Z)/15:0/22:2(13Z,16Z))
|
|
|
Clomipramine
|
A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.
|
|
1-Phosphatidyl-D-myo-inositol
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/o-18:0/20:3n6)
|
|
|
PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:1(11Z)/15:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
Guanosine 2',3'-cyclic phosphate
|
|
|
DG(20:3(8Z,11Z,14Z)/18:0/0:0)
|
|
|
TG(18:1(9Z)/18:0/20:2n6)
|
|
|
TG(20:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Androstanediol
|
|
|
PC(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:1n7/0:0/20:3n6)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
PC(14:0/24:1(15Z))
|
|
|
PE(24:0/20:1(11Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/16:0)
|
|
|
Caspofungin
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
5-Methyltetrahydropteroyltri-L-glutamate
|
A peptide anion arising from deprotonation of all four carboxy groups of 5-methyltetrahydropteroyltri-L-glutamic acid; major species at pH 7.3.
|
|
Ganglioside GT3 (d18:1/14:0)
|
|
|
Clofarabine
|
|
|
PC(24:1(15Z)/20:2(11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/24:1(15Z)/18:1(9Z))
|
|
|
Tetrahexosylceramide (d18:1/26:0)
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/14:0/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Oxooctanoyl-CoA
|
An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of 3-oxooctanoic acid.
|
|
Ganglioside GD3 (d18:0/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/24:1(15Z))
|
|
|
Adenylsuccinic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Yohimbine
|
An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.
|
|
TG(14:1(9Z)/22:0/20:2n6)
|
|
|
7a-Hydroxycholesterol
|
|
|
PE(P-16:0/18:1(9Z))
|
|
|
PC(P-18:1(11Z)/20:1(11Z))
|
|
|
TG(18:1(11Z)/18:0/20:1(11Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
Gallium nitrate
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(16:0/P-18:0)
|
|
|
TG(20:0/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
PE(O-18:1(1Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:1(11Z)/22:1(13Z))
|
|
|
PIP2(16:0/16:0)
|
|
|
TG(22:0/o-18:0/22:0)
|
|
|
Acetyl-CoA
|
An acyl-CoA having acetyl as its S-acetyl component.
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPC(18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/24:1(15Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
MG(0:0/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PE(18:2(9Z,12Z)/18:0)
|
|
|
TG(24:1(15Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/24:0/o-18:0)
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/20:1(11Z))
|
|
|
PE(20:2(11Z,14Z)/20:1(11Z))
|
|
|
Piperazine
|
An azacycloalkane that consists of a six-membered ring containing two nitrogen atoms at opposite positions.
|
|
5-Hydroxyomeprazole
|
A sulfoxide that is omeprazole in which one of the methyl hydrogens at position 5 on the pyridine ring is substituted by a hydroxy group.
|
|
TG(18:1(11Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/16:0/16:0)
|
|
|
Carbimazole
|
|
|
DG(22:5n6/0:0/22:6n3)
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:2(13Z,16Z)/16:1(9Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/20:2n6)
|
|
|
TG(20:3n6/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:3n6)
|
|
|
TG(16:1(9Z)/20:2n6/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
12(S)-Leukotriene B4
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/o-18:0)
|
|
|
TG(22:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
Tetracosanoyl-CoA
|
A very long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of tetracosanoic (lignoceric) acid. It is an intermediate in the biosynthesis of unsaturated fatty acids.
|
|
TG(22:1(13Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Phosphoric acid
|
A phosphorus oxoacid that consits of one oxo and three hydroxy groups joined covalently to a central phosphorus atom.
|
|
Ganglioside GA2 (d18:1/24:0)
|
|
|
TG(14:1(9Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:0/15:0)
|
|
|
1,2-Di-(9Z,12Z,15Z-octadecatrienoyl)-3-(Galactosyl-alpha-1-6-Galactosyl-beta-1)-glycerol
|
|
|
TG(15:0/20:1(11Z)/24:1(15Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
PE(24:0/P-16:0)
|
|
|
TG(22:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(P-18:1(9Z)/24:1(15Z))
|
|
|
TG(14:0/o-18:0/15:0)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Cetirizine
|
A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(20:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/14:1(9Z)/o-18:0)
|
|
|
DG(20:4n6/0:0/18:3n3)
|
|
|
TG(15:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
Lithocholic acid glycine conjugate
|
|
|
TG(18:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(16:0/16:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:2n6/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
1,3-Diaminopropane
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/24:1(15Z))
|
|
|
Paraoxon
|
An aryl dialkyl phosphate where both the alkyl groups are ethyl and the aryl group is 4-nitrophenyl.
|
|
PE(20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(15:0/15:0)
|
|
|
TG(18:0/22:2(13Z,16Z)/22:0)
|
|
|
TG(18:2(9Z,12Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(24:0/18:1(11Z)/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Iduronic acid
|
A member of the class of iduronic acids that is the major uronic acid component of the dermatan sulfate and heparin.
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
DG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
TG(14:0/16:0/18:2(9Z,12Z))
|
|
|
PE(24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Naphthalene epoxide
|
|
|
TG(18:1(11Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
Thyroxine sulfate
|
An iodothyronine having iodo substituents in the 3-, 3'-, 5- and 5'-positions and a sulfate group attached to the phenol function.
|
|
TG(22:0/16:0/o-18:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:0)
|
|
|
PIP(16:0/18:1(11Z))
|
|
|
PC(18:1(11Z)/22:1(13Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Pyridostigmine
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Aprepitant
|
|
|
PE(P-18:0/22:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Trifluridine
|
|
|
TG(22:0/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GD1a (d18:0/14:0)
|
|
|
PC(P-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
4-Nitrophenol
|
A mononitrophenol having the nitro group placed at the 4-position.
|
|
LysoPC(18:1(9Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/18:1(11Z)/22:0)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
Phosphoglycolic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Deferasirox
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
11-Epi-PGF2a
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/16:0/18:1(11Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
Omeprazole
|
A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/18:1(11Z)/0:0)
|
|
|
TG(18:1(9Z)/16:1(9Z)/22:1(13Z))
|
|
|
TG(18:0/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:0/0:0/20:3n6)
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(16:1(9Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:0/22:2(13Z,16Z))
|
|
|
PIP2(20:3(5Z,8Z,11Z)/18:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:2(11Z,14Z)/16:1(9Z)/0:0)
|
|
|
TG(16:0/22:1(13Z)/18:1(9Z))
|
|
|
TG(22:0/24:1(15Z)/o-18:0)
|
|
|
TG(22:0/22:0/o-18:0)
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
Bromobenzene-3,4-dihydrodiol
|
An organic hydroxy compound that has formula C6H7BrO2.
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(14:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/16:0/o-18:0)
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(18:2(9Z,12Z)/18:0)
|
|
|
PC(18:1(9Z)/15:0)
|
|
|
4-Imidazolone-5-propionic acid
|
|
|
TG(14:1(9Z)/22:1(13Z)/24:1(15Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/0:0)
|
|
|
TG(14:0/15:0/14:1(9Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:1(9Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/16:1(9Z)/24:0)
|
|
|
Valerylglycine
|
|
|
(2E)-Decenoyl-CoA
|
An acyl-CoA oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of trans-dec-2-enoyl-CoA; major species at pH 7.3.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
PE(14:1(9Z)/P-16:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:2(11Z,14Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/14:0/18:3(9Z,12Z,15Z))
|
|
|
3,4-Dihydro-3-hydroxy-4-S-glutathionyl bromobenzene
|
A peptide that has formula C16H22BrN3O7S.
|
|
TG(14:1(9Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(14:1(9Z)/P-18:0)
|
|
|
DG(18:1(9Z)/24:0/0:0)
|
|
|
TG(16:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(20:2(11Z,14Z)/20:0/0:0)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(24:0/20:3(8Z,11Z,14Z))
|
|
|
PC(24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Se-Adenosylselenohomocysteine
|
|
|
TG(20:3n6/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
4-Hydroxybutyric acid
|
A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Isovalerylsarcosine
|
|
|
TG(14:1(9Z)/24:0/20:3(5Z,8Z,11Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/15:0/0:0)
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(24:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(14:1(9Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
OPC6-CoA
|
An organic molecule that has formula C37H60N7O18P3S.
|
|
TG(15:0/20:3n6/20:0)
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:0/0:0/22:6n3)
|
|
|
TG(24:0/20:0/18:2(9Z,12Z))
|
|
|
Magnesium salicylate
|
|
|
PE(P-18:1(9Z)/20:2(11Z,14Z))
|
|
|
TG(14:1(9Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
PC(18:0/16:0)
|
|
|
TG(20:2n6/22:1(13Z)/20:2n6)
|
|
|
TG(16:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Hydroxy-2,6-dimethyl-5-methylene-heptanoyl-CoA
|
A polyol that has formula C31H52N7O18P3S.
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
DG(16:1n7/0:0/22:1n9)
|
|
|
TG(16:1(9Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(14:0/20:2n6/18:1(11Z))
|
|
|
beta-Carotene-15,15'-epoxide
|
An epoxycarotenoid obtained by epoxidation across the 15,15'-double bond of beta-carotene.
|
|
DG(18:1(11Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(16:1(9Z)/14:0/20:1(11Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/16:0)
|
|
|
PG(18:1(9Z)/16:1(9Z))
|
|
|
TG(18:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
Pranlukast
|
|
|
TG(18:2(9Z,12Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
N-Glycoloylganglioside GM2
|
|
|
N-Glycoloylganglioside GM1
|
|
|
PC(20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:3n6/22:2(13Z,16Z))
|
|
|
DG(18:0/24:1(15Z)/0:0)
|
|
|
TG(14:0/20:1(11Z)/20:2n6)
|
|
|
DG(16:0/0:0/16:1n7)
|
|
|
TG(22:0/24:0/14:1(9Z))
|
|
|
CDP-DG(16:0/18:1(11Z))
|
|
|
TG(16:1(9Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(15:0/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/o-18:0)
|
|
|
3a,7b,12a-Trihydroxy-5a-Cholanoic acid
|
|
|
TG(20:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:1(9Z)/P-16:0)
|
|
|
TG(18:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(14:0/22:0/20:1(11Z))
|
|
|
Vinorelbine
|
A vinca alkaloid with a norvinblastine skeleton.
|
|
Deoxycholic acid
|
A dihydroxy-5beta-cholanic acid that has formula C24H40O4.
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(18:0/24:1(15Z)/22:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/20:3n6)
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Temsirolimus
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(22:2(13Z,16Z)/0:0/0:0)
|
|
|
TG(18:0/24:1(15Z)/20:2n6)
|
|
|
TG(14:0/14:0/24:1(15Z))
|
|
|
Pyridoxal
|
|
|
TG(20:2n6/18:2(9Z,12Z)/20:2n6)
|
|
|
DG(16:1n7/0:0/18:1n7)
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
11,12,15-THETA
|
A hydroxy fatty acid that has formula C20H34O5.
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:1(13Z)/20:1(11Z)/0:0)
|
|
|
PC(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GM3 (d18:0/22:1(13Z))
|
|
|
TG(20:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/24:0/22:1(13Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Saccharopine
|
|
|
PE(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(14:0/0:0/20:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/P-18:1(11Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Sulfodeoxycholic acid
|
|
|
TG(22:0/22:0/14:1(9Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/o-18:0/20:2n6)
|
|
|
Isoflurophate
|
|
|
DG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:0/18:1(11Z))
|
|
|
TG(18:0/14:0/14:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Lorazepam
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
SM(d18:0/14:1(9Z)(OH))
|
|
|
TG(18:1(9Z)/o-18:0/20:3n6)
|
|
|
PE(24:0/24:1(15Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
DG(20:1(11Z)/14:0/0:0)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:3n6)
|
|
|
TG(16:0/24:0/18:1(11Z))
|
|
|
TG(20:2n6/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/16:0/20:3n6)
|
|
|
TG(14:1(9Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:1(13Z)/18:1(9Z))
|
|
|
TG(18:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM3 (d18:0/26:1(17Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Trimethylammonioacetate
|
The amino acid betaine derived from glycine.
|
|
TG(16:0/20:2n6/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:1n7/0:0/18:1n7)
|
|
|
TG(20:1(11Z)/14:0/18:2(9Z,12Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(22:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(16:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
trans-Tetra-dec-2-enoic acid
|
|
|
Thymidine 5'-triphosphate
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(22:0/14:0/20:3n6)
|
|
|
TG(22:0/20:0/20:2n6)
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(24:0/22:1(13Z)/18:1(9Z))
|
|
|
TG(18:1(9Z)/20:0/20:3n6)
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
LysoPE(0:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Nitrendipine
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:1(11Z)/24:0)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/14:0/20:2n6)
|
|
|
PE(P-18:0/15:0)
|
|
|
TG(20:3n6/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:2n6/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
trans-2-Enoyl-OPC6-CoA
|
An organic molecule that has formula C37H58N7O18P3S.
|
|
TG(24:1(15Z)/20:3n6/20:3n6)
|
|
|
11b-Hydroxyprogesterone
|
|
|
Levobunolol
|
A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma.
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM3 (d18:1/16:0)
|
|
|
Se-Adenosylselenomethionine
|
|
|
PC(18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
PC(18:0/18:0)
|
|
|
PC(20:1(11Z)/18:0)
|
|
|
TG(14:1(9Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
2,2-Dichloroacetaldehyde
|
An organochlorine compound that has formula C2H2Cl2O.
|
|
TG(15:0/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(24:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Vitamin A
|
A group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.
|
|
PE(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM3 (d18:1/14:0)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:1(9Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
gamma-Glutamyl-beta-aminopropiononitrile
|
A nitrile that is L-glutamine in which one of the hydrogens attached to the amide nitrogen is replaced by a 2-cyanoethyl group.
|
|
TG(24:0/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/16:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/14:0/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/14:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(18:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
5'-Deoxyadenosine
|
A 5'-deoxyribonucleoside compound having adenosine as the nucleobase.
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
PG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/20:1(11Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GQ1c (d18:1/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Estrone-3,4-quinone
|
|
|
TG(24:0/18:1(11Z)/24:1(15Z))
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
Sphinganine 1-phosphate
|
A sphingoid 1-phosphate that is the monophosphorylated derivative of sphinganine.
|
|
TG(18:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(16:1(9Z)/20:2(11Z,14Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
Methylselenopyruvate
|
An oxo carboxylic acid that has formula C4H6O3Se.
|
|
Allysine
|
An alpha-amino acid consisting of lysine having an oxo group in place of the side-chain amino group.
|
|
TG(18:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/o-18:0/20:1(11Z))
|
|
|
DG(20:1n9/0:0/20:1n9)
|
|
|
PE(20:0/20:0)
|
|
|
TG(22:0/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Cobinamide
|
A cobalt-corrinoid hexaamide that has formula C48H72CoN11O8.
|
|
Alfuzosin
|
A tetrahydrofuranol that has formula C19H27N5O4.
|
|
PC(18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:1(11Z)/16:1(9Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/15:0/24:1(15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/24:0/18:2(9Z,12Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Azidocillin
|
|
|
TG(18:1(11Z)/14:0/20:3n6)
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:3n6/22:1(13Z))
|
|
|
L-Dihydroorotic acid
|
|
|
DHAP(18:0e)
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CE(5:0)
|
|
|
Clarithromycin
|
The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.
|
|
DG(22:2(13Z,16Z)/14:0/0:0)
|
|
|
LysoPE(0:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/18:1(9Z)/16:1(9Z))
|
|
|
TG(22:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
CMP-N-trimethyl-2-aminoethylphosphonate
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(18:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:1n9/0:0/20:3n9)
|
|
|
17-beta-Estradiol-3-glucuronide
|
|
|
TG(24:1(15Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/o-18:0)
|
|
|
DG(16:1(9Z)/20:1(11Z)/0:0)
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(P-18:1(9Z)/24:0)
|
|
|
TG(20:1(11Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:0/20:3(5Z,8Z,11Z))
|
|
|
D-Glucose
|
A glucose with D-configuration.
|
|
TG(22:1(13Z)/20:3n6/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
2,5-Diamino-6-(5'-triphosphoryl-3',4'-trihydroxy-2'-oxopentyl)-amino-4-oxopyrimidine
|
|
|
PC(14:1(9Z)/24:0)
|
|
|
TG(18:2(9Z,12Z)/14:0/22:2(13Z,16Z))
|
|
|
DG(14:0/14:1(9Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
D-4-Hydroxy-2-oxoglutarate
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(14:1(9Z)/22:0)
|
|
|
TG(14:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/16:0/22:1(13Z))
|
|
|
TG(20:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:1(9Z)/20:1(11Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
Ganglioside GA1 (d18:1/24:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
DG(18:1(11Z)/18:1(11Z)/0:0)
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
all-trans-18-Hydroxyretinoic acid
|
A retinoid that has formula C20H28O3.
|
|
PE(18:1(11Z)/18:1(9Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(15:0/20:3n6/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GM2 (d18:0/22:0)
|
|
|
5a-Cholesta-7,24-dien-3b-ol
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
6-Hydroxyhexanoic acid
|
An omega-hydroxy fatty acid comprising hexanoic acid having a hydroxy group at the 6-position.
|
|
TG(18:0/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/14:0)
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
Ganglioside GM2 (d18:0/24:0)
|
|
|
PIP(16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(18:0/22:1(13Z)/14:1(9Z))
|
|
|
TG(15:0/14:0/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(15:0/16:1(9Z))
|
|
|
PC(o-16:0/22:0)
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Galabiosylceramide (d18:1/9Z-18:1)
|
|
|
TG(16:1(9Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/18:2(9Z,12Z))
|
|
|
TG(22:0/o-18:0/20:1(11Z))
|
|
|
Acenocoumarol
|
|
|
TG(18:1(11Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:1(11Z)/18:0/o-18:0)
|
|
|
TG(15:0/18:2(9Z,12Z)/16:0)[iso6]
|
|
|
Ganglioside GA1 (d18:1/22:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/20:2n6)
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/20:2n6/20:3n6)
|
|
|
TG(18:1(11Z)/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
Flunitrazepam
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/18:1(9Z)/20:2n6)
|
|
|
DG(22:2(13Z,16Z)/18:1(9Z)/0:0)
|
|
|
PE(20:1(11Z)/18:1(11Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3n6/22:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/o-18:0/16:1(9Z))
|
|
|
Tadalafil
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/18:1(9Z)/18:0)
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
Alprenolol
|
|
|
TG(15:0/24:0/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))
|
|
|
TG(24:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:2n6/22:2(13Z,16Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
MG(0:0/22:2(13Z,16Z)/0:0)
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(22:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
6-Hydroxymethyletoricoxib
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/22:2(13Z,16Z))
|
|
|
PC(22:1(13Z)/P-18:1(11Z))
|
|
|
Glyceric acid
|
A trionic acid that consists of propionic acid substituted at positions 2 and 3 by hydroxy groups.
|
|
TG(20:3n6/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Gluconolactone
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
PC(14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:0)
|
|
|
4-Hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one
|
A benzene that has formula C10H11NO3.
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/15:0/20:3n6)
|
|
|
TG(14:0/14:1(9Z)/15:0)
|
|
|
PE(P-18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Magnesium Sulfate
|
A magnesium salt having sulfate as the counterion.
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
PE(16:0/15:0)
|
|
|
TG(16:0/18:0/o-18:0)
|
|
|
Bexarotene
|
|
|
TG(16:1(9Z)/20:3n6/24:1(15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Tetradecanoyl-CoA
|
|
|
LysoPE(0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z)/0:0)
|
|
|
TG(16:0/24:0/20:2n6)
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:0/0:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:0/20:3(5Z,8Z,11Z))
|
|
|
Oxitriptan
|
|
|
PE(22:2(13Z,16Z)/20:0)
|
|
|
Norethindrone
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/20:0)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
PC(15:0/24:0)
|
|
|
TG(14:0/20:0/22:1(13Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Nitisinone
|
|
|
DG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(20:3n6/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/14:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
3-O-Sulfogalactosylceramide (d18:1/22:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/o-18:0)
|
|
|
DG(18:0/14:0/0:0)
|
|
|
dCDP
|
A 2'-deoxycytidine phosphate that is the 2'- deoxy derivative of cytidine 5'-diphosphate (CDP).
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/22:1(13Z)/20:1(11Z))
|
|
|
3-O-Sulfogalactosylceramide (d18:1/20:0)
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
TG(14:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
LysoPE(18:1(9Z)/0:0)
|
|
|
PIP(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(16:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
N-Acetylputrescine
|
An N-monoacetylalkane-alpha,omega-diamine that is the N-monoacetyl derivative of putrescine.
|
|
1-Undecanol
|
|
|
Artemether
|
|
|
DG(20:3n6/0:0/22:5n6)
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(20:1(11Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
DG(22:2(13Z,16Z)/20:2(11Z,14Z)/0:0)
|
|
|
PE(18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3n6/0:0/20:4n3)
|
|
|
MG(20:2(11Z,14Z)/0:0/0:0)
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
L-Threo-2-pentulose
|
|
|
8(S)-HPETE
|
A HPETE in which the hydroperoxy group is located at position 8S and the four double bonds at position 5, 9, 11 and 14 (the 5Z,9E,11Z,14Z-geoisomer).
|
|
DG(24:1(15Z)/20:2(11Z,14Z)/0:0)
|
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
TG(20:0/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
DG(20:3(8Z,11Z,14Z)/15:0/0:0)
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/14:0/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/20:3n6)
|
|
|
PG(16:1(9Z)/16:0)
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:1(11Z)/o-18:0/20:2n6)
|
|
|
LysoPC(P-18:1(9Z))
|
|
|
TG(18:0/15:0/24:0)
|
|
|
DG(24:0/0:0/20:2n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:0/o-18:0)
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
3-Methylindole
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
DG(14:0/20:1(11Z)/0:0)
|
|
|
TG(16:1(9Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(14:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Naloxone
|
A morphinane alkaloid that has formula C19H21NO4.
|
|
PG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
(S)-2-Acetolactate
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z)/o-18:0)
|
|
|
L-Formylkynurenine
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(16:1(9Z)/18:1(11Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PI(20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(20:1(11Z)/22:0/20:2n6)
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(14:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Beta-D-Fructose 6-phosphate
|
|
|
Thiotepa
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
3-Phenylpropionylglycine
|
|
|
N-Acetyl-9-O-acetylneuraminic acid
|
A N-acetyl-O-acetylneuraminic acid that has formula C13H21NO10.
|
|
TG(22:0/24:1(15Z)/20:1(11Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(20:2(11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(24:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/o-18:0/20:2n6)
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
Procyclidine
|
|
|
SM(d18:0/20:2(11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
Delavirdine
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:3n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:1(9Z)/18:1(11Z))
|
|
|
PE(P-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP(22:3(10Z,13Z,16Z)/16:2(9Z,12Z))
|
|
|
PC(20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/15:0)
|
|
|
Ganglioside GT3 (d18:0/16:0)
|
|
|
TG(18:1(9Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Uracil
|
|
|
TG(14:1(9Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:2n6/20:0)
|
|
|
PC(14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(14:1(9Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
Cytidine 2',3'-cyclic phosphate
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Coumaric acid
|
|
|
TG(18:1(11Z)/16:1(9Z)/18:2(9Z,12Z))[iso6]
|
|
|
Carboprost Tromethamine
|
The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.
|
|
TG(14:0/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:1(11Z)/18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT2 (d18:0/18:1(9Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(15:0/22:2(13Z,16Z)/0:0)
|
|
|
PE(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
Cer(d18:0/12:0)
|
|
|
Alginic acid
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:1(13Z)/18:1(11Z)/0:0)
|
|
|
Metanephrine
|
|
|
TG(18:3(9Z,12Z,15Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/20:1(11Z))
|
|
|
PIP(18:1(11Z)/18:1(9Z))
|
|
|
DG(22:0/22:0/0:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:2n6)
|
|
|
Metyrosine
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(16:1(9Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
PC(22:1(13Z)/20:2(11Z,14Z))
|
|
|
Methotrimeprazine
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))[iso6]
|
|
|
TG(18:0/16:1(9Z)/22:1(13Z))
|
|
|
DG(22:1(13Z)/22:1(13Z)/0:0)
|
|
|
Esomeprazole
|
A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.
|
|
Alpha-D-Glucose
|
D-Glucopyranose having alpha-configuration at the anomeric centre.
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/20:3n6)
|
|
|
PC(16:1(9Z)/P-16:0)
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/24:0/20:3n6)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
PC(o-18:1(9Z)/18:0)
|
|
|
S-6-Hydroxywarfarin
|
|
|
Normetanephrine
|
|
|
17-alpha,20-alpha-Dihydroxypregn-4-en-3-one
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Quinidine barbiturate
|
|
|
TG(14:1(9Z)/o-18:0/18:2(9Z,12Z))
|
|
|
DG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/18:2(9Z,12Z))[iso3]
|
|
|
PC(24:0/20:2(11Z,14Z))
|
|
|
Ezetimibe
|
A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).
|
|
PIP2(18:1(11Z)/16:0)
|
|
|
TG(14:0/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/o-18:0/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
11b-Hydroxyandrost-4-ene-3,17-dione
|
|
|
TG(22:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
PA(16:0e/18:0)
|
|
|
TG(20:0/14:1(9Z)/14:1(9Z))
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Estramustine
|
|
|
Allantoin
|
An imidazolidine-2,4-dione that is 5-aminohydantoin in which a carbamoyl group is attached to the exocyclic nitrogen.
|
|
PIP3(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
Lansoprazole
|
A sulfoxide that has formula C16H14F3N3O2S.
|
|
DG(22:1n9/0:0/18:4n3)
|
|
|
PE(16:1(9Z)/20:1(11Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Maleylacetoacetic acid
|
|
|
3-Chloro-2-methylmaleylacetate
|
A halo fatty acid that has formula C7H7ClO5.
|
|
TG(18:0/18:2(9Z,12Z)/20:0)[iso6]
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Progesterone
|
A C21-steroid hormone in which a pregnane skeleton carries oxo substituents at positions 3 and 20 and is unsaturated at C(4)-C(5). As a hormone, it is involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species.
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PI(20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/22:1(13Z))
|
|
|
TG(16:0/16:0/20:0)[iso3]
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/15:0/20:2n6)
|
|
|
DG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
LysoPC(20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/o-18:0/20:2n6)
|
|
|
TG(20:0/16:0/o-18:0)
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
Floxuridine
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
PIP2(18:1(11Z)/18:0)
|
|
|
TG(15:0/18:1(9Z)/24:0)
|
|
|
TG(20:3n6/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Hexacosanoic acid
|
A 26-carbon, straight-chain, saturated fatty acid.
|
|
TG(22:2(13Z,16Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
cis-3-Chloroacrylic acid
|
A 3-chloroacrylic acid that has formula C3H3ClO2.
|
|
Trisalicylate-choline
|
|
|
TG(14:0/18:1(11Z)/18:0)
|
|
|
Gentisic acid
|
|
|
TG(20:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Sulfisoxazole
|
A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.
|
|
PC(o-22:1(13Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(18:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3a,7b,12a-Trihydroxyoxocholanyl-Glycine
|
|
|
TG(14:1(9Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/o-18:0)
|
|
|
PI(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
Enoxacin
|
|
|
Leukotriene D4
|
A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/18:1(9Z))
|
|
|
TG(14:1(9Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT2 (d18:1/24:1(15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Durupcoside A
|
|
|
Durupcoside B
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/o-18:0/20:1(11Z))
|
|
|
Cholesterol glucuronide
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
Pseudoephedrine
|
A secondary amine that has formula C10H15NO.
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Maltotriose
|
A maltotriose trisaccharide in which the glucose residue at the reducing end is in the aldehydo open-chain form.
|
|
TG(14:1(9Z)/24:0/14:1(9Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Tetrahydrocortisone
|
|
|
PE(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Itaconyl-CoA
|
The S-itaconyl derivative of coenzyme A.
|
|
Fludarabine
|
|
|
Formoterol
|
|
|
TG(20:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(22:0/18:3(6Z,9Z,12Z))
|
|
|
3-Aminopropionaldehyde
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
PIP2(18:0/20:2(11Z,14Z))
|
|
|
TG(20:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(P-18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(16:1(9Z)/24:1(15Z)/24:1(15Z))
|
|
|
TG(24:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:0/22:0)
|
|
|
PE(P-16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/18:1(11Z)/0:0)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(11Z)/22:0)
|
|
|
TG(20:1(11Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoyl-CoA
|
An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (5Z,8Z,11Z,14Z,17Z)-icosapentaenoic acid. It is a member of n-3 PUFA and by-product of alpha-linolenic acid metabolism.
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:2(11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
Beta-Alanine
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP(16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/24:0/20:2n6)
|
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
PC(P-18:0/16:1(9Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
DG(24:1n9/0:0/20:4n3)
|
|
|
TG(14:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(11Z)/20:0)
|
|
|
TG(16:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)/0:0)
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/16:0)
|
|
|
TG(14:0/20:3n6/24:0)
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(o-18:1(9Z)/20:1(11Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/15:0/0:0)
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/20:0/20:3n6)
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:1n7/0:0/22:4n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:0/18:1(11Z))
|
|
|
DG(15:0/0:0/18:1n9)
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/15:0/18:1(11Z))
|
|
|
Ganglioside GM1 (d18:0/22:0)
|
|
|
PC(o-16:0/14:1(9Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:2(13Z,16Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Hydrogen phosphate
|
A phosphate ion that is the conjugate base of dihydrogenphosphate.
|
|
PC(P-18:1(9Z)/16:1(9Z))
|
|
|
PI(16:0/22:3(10Z,13Z,16Z))
|
|
|
TG(14:0/18:1(11Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:0/20:0)[iso3]
|
|
|
TG(22:0/16:1(9Z)/o-18:0)
|
|
|
TG(20:0/22:2(13Z,16Z)/20:3n6)
|
|
|
DG(20:3n6/0:0/18:4n3)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z)/0:0)
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:0/16:1(9Z))
|
|
|
Milnacipran
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(24:0/24:0/24:1(15Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/18:0)
|
|
|
TG(22:0/15:0/22:1(13Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
4-Hydroxycinnamic acid
|
|
|
PE(24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
DG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Phenylacetylglycine
|
A N-acylglycine that is glycine substituted on nitrogen with a phenylacetyl group.
|
|
18-Hydroxyarachidonic acid
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:1(11Z)/20:1(11Z))
|
|
|
D-Limonene
|
|
|
TG(18:0/18:1(11Z)/18:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
GDP-L-fucose
|
A GDP-fucose in which the fucosyl residue has L-configuration.
|
|
Guanidine
|
An aminocarboxamidine, the parent compound of the guanidines.
|
|
TG(18:0/18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
TG(20:0/24:0/14:1(9Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(14:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(22:0/20:3n6/14:1(9Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/16:0)
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(14:0/P-18:0)
|
|
|
TG(18:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GQ1c (d18:0/22:0)
|
|
|
2,3,5-Trichlorodienelactone
|
|
|
Rifapentine
|
|
|
N-(o)-Hydroxyarginine
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(o-18:2(9Z,12Z)/20:0)
|
|
|
PIP(18:3(9Z,12Z,15Z)/18:0)
|
|
|
27-Deoxy-5b-cyprinol
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/dm18:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(16:0/20:0/18:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Miglitol
|
|
|
TG(18:2(9Z,12Z)/o-18:0/18:2(9Z,12Z))
|
|
|
DG(24:1(15Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(20:1(11Z)/20:2n6/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
Furosemide
|
A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
|
|
DG(24:1(15Z)/15:0/0:0)
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:0/20:0/0:0)
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(18:1(11Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GT2 (d18:1/22:1(13Z))
|
|
|
PE(14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/24:0/22:0)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
Exemestane
|
A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer.
|
|
Gemcitabine
|
A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.
|
|
TG(20:0/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(18:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
Hordenine
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
SM(d17:1/24:0)
|
|
|
2,3-Epoxyaflatoxin B1
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:0/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(14:0/22:1(13Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Saxagliptin
|
|
|
DG(24:0/0:0/22:4n6)
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:3n6/22:1(13Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GM1 (d18:0/18:1(9Z))
|
|
|
TG(22:0/18:0/14:1(9Z))
|
|
|
TG(14:0/20:0/24:0)
|
|
|
Deoxycholic acid glycine conjugate
|
|
|
DG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(18:1(11Z)/20:0/22:2(13Z,16Z))
|
|
|
PE(P-16:0/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/16:0/18:1(11Z))[iso6]
|
|
|
TG(20:3n6/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
CDP-DG(16:0/16:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/24:0/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/o-18:0)
|
|
|
PIP2(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/20:1(11Z))
|
|
|
TG(15:0/20:1(11Z)/18:0)
|
|
|
TG(14:0/20:0/22:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/14:0/18:1(9Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/P-18:1(9Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Deslanoside
|
|
|
DG(16:0/0:0/22:5n6)
|
|
|
Ganglioside GM1 (d18:0/26:0)
|
|
|
2-(3-Carboxy-3-aminopropyl)-L-histidine
|
A 2-(3-amino-3-carboxypropyl)-L-histidine zwitterion obtained by transfer of a proton from the amino to the carboxy group of 2-[(3S)-3-amino-3-carboxypropyl]-L-histidine residue.
|
|
adenosylcob(III)yrinic acid a,c-diamide
|
A cobalt corrinoid that is cob(III)yrinic acid a,c-diamide having a 5'-adenosyl group attached to the central cobalt atom.
|
|
PE(24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Butethal
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
PC(24:1(15Z)/P-18:1(11Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:1(11Z)/20:1(11Z))
|
|
|
PIP2(20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
TG(15:0/24:0/14:1(9Z))
|
|
|
TG(20:3n6/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/20:3n6)
|
|
|
TG(24:0/18:1(9Z)/20:3n6)
|
|
|
TG(20:1(11Z)/16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
Josamycin
|
|
|
Ganglioside GM2 (d18:0/12:0)
|
|
|
Dextromethorphan
|
An organic heterotetracyclic compound that is morphinan substituted by a methoxy group at position 3 and a methyl group at position 7. It is used as an antitussive drug for suppressing cough.
|
|
TG(20:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(11Z)/24:0)
|
|
|
TG(24:1(15Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(22:0/o-18:0/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Glycolic acid
|
A 2-hydroxy monocarboxylic acid that is acetic acid where the methyl group has been hydroxylated.
|
|
TG(14:1(9Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Cabazitaxel
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/22:1(13Z))
|
|
|
Palmitoleic acid
|
A hexadecenoic acid with a cis-double bond at position C-9.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Adenosine monophosphate
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))[iso3]
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/24:1(15Z))
|
|
|
TG(24:1(15Z)/20:3n6/20:2n6)
|
|
|
7-Dehydrocholesterol
|
|
|
TG(14:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(16:0/P-16:0)
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/16:0)
|
|
|
PIP3(18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(24:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:1(11Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/20:3n6)
|
|
|
PC(24:0/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(22:0/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/14:1(9Z)/20:3n6)
|
|
|
TG(22:1(13Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Hydrochloric acid
|
|
|
TG(16:0/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(20:0/16:0/18:1(9Z))
|
|
|
Homatropine Methylbromide
|
An organic bromide salt that has formula C17H24NO3.Br.
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
GDP-4-Dehydro-6-deoxy-D-mannose
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:1(11Z))
|
|
|
TG(15:0/o-18:0/16:1(9Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
Pyroglutamic acid
|
|
|
TG(14:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/24:0/18:3(9Z,12Z,15Z))
|
|
|
Droxidopa
|
A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension
|
|
CL(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
PG(16:0/20:3(8Z,11Z,14Z))
|
|
|
DG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(16:1(9Z)/20:0)
|
|
|
PC(24:1(15Z)/P-18:0)
|
|
|
PC(20:3(8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
Butyryl-CoA
|
A short-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of butyric acid.
|
|
PE(P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Phytosphingosine-1-P
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Ziprasidone
|
A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.
|
|
Isosorbide Dinitrate
|
A glucitol derivative that has formula C6H8N2O8.
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
PE(22:0/P-18:1(11Z))
|
|
|
TG(14:1(9Z)/15:0/18:1(11Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/20:3n6)
|
|
|
DG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
Tetracosapentaenoyl coenzyme A, n-6
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Adenosine diphosphate ribose
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/24:0/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
Methysergide
|
|
|
PIP2(20:3(8Z,11Z,14Z)/18:0)
|
|
|
TG(24:0/15:0/22:2(13Z,16Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/o-18:0)
|
|
|
N,N'-Diacetylhydrazine
|
A carbohydrazide that has formula C4H8N2O2.
|
|
TG(20:2n6/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:1(9Z)/14:0/0:0)
|
|
|
DG(24:0/14:1(9Z)/0:0)
|
|
|
TG(24:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
DG(22:0/20:0/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(18:3n3/0:0/22:5n3)
|
|
|
Ganglioside GM2 (d18:0/18:1(9Z))
|
|
|
Dihomo-gamma-linolenyl coenzyme A
|
|
|
TG(22:2(13Z,16Z)/20:3n6/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:1(9Z)/20:3n6)
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3n9/0:0/22:6n3)
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
PI(22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(18:1(11Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
PC(14:0/16:0)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GD3 (d18:1/12:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM3 (d18:0/14:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(22:1(13Z)/P-18:1(9Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/24:0)
|
|
|
PE(P-18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GD3 (d18:1/14:0)
|
|
|
TG(20:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Uridine 2'-phosphate
|
A pyrimidine ribonucleoside 2'-monophosphate having uracil as the nucleobase
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/14:0)
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/18:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Adenylyl-molybdopterin
|
|
|
PIP(20:2(11Z,14Z)/16:0)
|
|
|
TG(22:2(13Z,16Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Ganglioside GD3 (d18:0/22:1(13Z))
|
|
|
TG(20:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(P-18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
DG(20:4n6/0:0/22:6n3)
|
|
|
TG(20:1(11Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ropinirole
|
An indolone that has formula C16H24N2O.
|
|
Dichlorphenamide
|
|
|
Remikiren
|
A N-acyl-amino acid that has formula C33H50N4O6S.
|
|
Bosentan
|
|
|
TG(15:0/18:1(9Z)/22:1(13Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM1 (d18:1/26:0)
|
|
|
TG(24:0/16:0/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
4-Hydroxyphenylacetyl-CoA
|
A phenylacetyl-CoA that has formula C29H42N7O18P3S.
|
|
Adenylylselenate
|
The 5'-selenonooxyphosphate ester of adenosine.
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
LysoPE(22:0/0:0)
|
|
|
TG(22:0/14:0/14:1(9Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/20:2n6)
|
|
|
TG(18:1(9Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Mirtazapine
|
A tetracyclic antidepressant that has formula C17H19N3.
|
|
TG(22:0/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
Ornithine
|
An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.
|
|
TG(24:1(15Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
Vanillylmandelic acid
|
An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/24:0/18:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
cis-2-Chloro-4-carboxymethylenebut-2-en-1,4-olide
|
The 2-chloro derivative of cis-4-carboxymethylenebut-2-en-1,4-olide.
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/15:0/22:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z)/o-18:0)
|
|
|
PS(20:3(8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PG(18:3(6Z,9Z,12Z)/16:0)
|
|
|
PE(15:0/P-18:1(9Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
DG(16:1n7/0:0/20:3n6)
|
|
|
TG(24:0/16:0/18:1(11Z))
|
|
|
TG(15:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
CDP-DG(16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
PE(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(22:1(13Z)/15:0)
|
|
|
DG(14:0/0:0/22:2n6)
|
|
|
TG(24:1(15Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/20:1(11Z))[iso3]
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
Ethynodiol Diacetate
|
A terminal acetylenic compound that has formula C24H32O4.
|
|
TG(20:3n6/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(20:3n6/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
DG(16:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
D-Sedoheptulose 7-phosphate
|
|
|
PC(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
PE(22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/14:0/20:1(11Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(16:1(9Z)/20:0/0:0)
|
|
|
DG(20:3(8Z,11Z,14Z)/20:0/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:2n6/o-18:0)
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/14:1(9Z)/o-18:0)
|
|
|
TG(15:0/18:0/15:0)
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
Dihydrouracil
|
|
|
TG(22:0/18:1(9Z)/14:1(9Z))
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:0/0:0)
|
|
|
TG(22:0/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/20:3n6/o-18:0)
|
|
|
TG(24:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Dipivefrin
|
The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(22:2(13Z,16Z)/P-18:1(9Z))
|
|
|
Nateglinide
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/20:1(11Z))
|
|
|
Ganglioside GD3 (d18:1/24:0)
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/22:0/22:0)
|
|
|
O-Desmethylverapamil (D-702)
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
TG(18:2(9Z,12Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/24:0/0:0)
|
|
|
TG(18:1(11Z)/18:1(9Z)/20:3n6)
|
|
|
L-4-Hydroxyglutamate semialdehyde
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(14:0/20:1(11Z)/16:0)
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
LysoPE(18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(14:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(20:2n6/20:0/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/24:1(15Z))
|
|
|
TG(14:0/20:1(11Z)/14:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
Amygdalin
|
A gentiobioside that has formula C20H27NO11.
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(18:0/14:0)
|
|
|
17-beta-Estradiol glucuronide
|
|
|
Zafirlukast
|
A carbamate ester that has formula C31H33N3O6S.
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
5,6,7,8-Tetrahydromethanopterin
|
A tetrahydromethanopterin that has formula C30H45N6O16P.
|
|
Cholic acid
|
A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.
|
|
PG(18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:0/0:0/20:3n6)
|
|
|
TG(20:2n6/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
L-Acetylcarnitine
|
|
|
TG(16:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Zinc (II) ion
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/22:2(13Z,16Z))
|
|
|
PE(14:0/14:1(9Z))
|
|
|
DG(16:1(9Z)/22:2(13Z,16Z)/0:0)
|
|
|
TG(20:0/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/o-18:0/24:1(15Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
DG(14:0/0:0/14:0)
|
|
|
TG(22:0/14:1(9Z)/18:1(9Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
CL(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(20:2n6/16:1(9Z)/22:2(13Z,16Z))
|
|
|
DG(24:1n9/0:0/22:6n3)
|
|
|
TG(18:1(11Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:3n6/14:1(9Z))
|
|
|
3 alpha,7 alpha,26-Trihydroxy-5beta-cholestane
|
|
|
Bradykinin
|
A linear nonapeptide messenger belonging to the kinin group of proteins, with amino acid sequence RPPGFSPFR. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation.
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PIP2(18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
PC(P-18:0/22:2(13Z,16Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/22:1(13Z)/20:3n6)
|
|
|
Permethrin
|
A cyclopropanecarboxylate ester in which the esterifying alcohol is 3-phenoxybenzyl alcohol and the cyclopropane ring is substituted with a 2,2-dichlorovinyl group and with gem-dimethyl groups.
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(15:0/20:0/24:0)
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(22:0/20:3n6/22:0)
|
|
|
TG(14:1(9Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/14:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Deferoxamine
|
|
|
TG(24:1(15Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:1n9/0:0/22:2n6)
|
|
|
TG(20:2n6/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
D-Glutamic acid
|
An optically active form of glutamic acid having D-configuration.
|
|
PC(20:4(5Z,8Z,11Z,14Z)/24:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(16:1(9Z)/15:0/o-18:0)
|
|
|
TG(20:1(11Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:0/24:0)
|
|
|
TG(24:1(15Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
Chlorambucil
|
|
|
PE(14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
Isopropamide
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(22:0/20:3n6/24:0)
|
|
|
5-Methyl-3-oxo-4-hexenoyl-CoA
|
An organic molecule that has formula C28H44N7O18P3S.
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(14:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso3]
|
|
|
Ureidopropionic acid
|
|
|
PG(18:3(6Z,9Z,12Z)/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Pirenzepine
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
7 alpha-Hydroxy-3-oxo-4-cholestenoate
|
A bile acid that has formula C27H42O4.
|
|
TG(15:0/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
2-O-(4-O-Methyl-a-D-glucopyranuronosyl)-D-xylose
|
|
|
TG(20:1(11Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(15:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
PC(20:2(11Z,14Z)/20:2(11Z,14Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
N1-Methyl-2-pyridone-5-carboxamide
|
|
|
TG(14:1(9Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/24:0)
|
|
|
TG(15:0/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
4-Hydroxyvalsartan
|
|
|
DG(24:1(15Z)/14:0/0:0)
|
|
|
TG(18:1(11Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(14:1n5/0:0/22:5n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
Dolichyl diphosphate
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PS(18:0/18:2(9Z,12Z))
|
|
|
3-Hexaprenyl-4-hydroxybenzoic acid
|
A monohydroxybenzoic acid that has formula C37H54O3.
|
|
DG(14:0/0:0/22:6n3)
|
|
|
TG(22:2(13Z,16Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(20:4(8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(20:2n6/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
Triflupromazine
|
|
|
TG(18:0/20:1(11Z)/18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
Plerixafor
|
|
|
TG(22:1(13Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(14:0/P-18:0)
|
|
|
TG(20:0/22:0/22:0)
|
|
|
TG(18:1(11Z)/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
CE(18:0)
|
|
|
TG(22:1(13Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
3-Carboxy-1-hydroxypropylthiamine diphosphate
|
A 1,3-thiazolium cation that is 1,3-thiazol-3-ium substituted by a methyl group at position 4, a (4-amino-2-methylpyrimidin-5-yl)methyl group at position 3, a 3-carboxy-1-hydroxypropyl at position 2 and a 2-{[hydroxy(phosphonooxy)phosphoryl]oxy}ethyl group at position 5.
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(24:0/20:2n6/24:0)
|
|
|
TG(14:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/18:0)
|
|
|
TG(20:2n6/14:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
Glucosylceramide
|
Any of the cerebrosides in which the monosaccharide head group is glucose.
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(22:0/14:1(9Z)/18:1(11Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Decanal
|
A fatty aldehyde formally arising from reduction of the carboxy group of capric acid (decanoic acid).
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
3-Oxooctadecanoyl-CoA
|
A 3-oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxooctadecanoic acid.
|
|
TG(16:0/18:0/22:0)
|
|
|
L-Glutamine
|
An optically active form of glutamine having L-configuration.
|
|
TG(24:0/20:3n6/22:1(13Z))
|
|
|
Ganglioside GD2 (d18:0/20:0)
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
DG(18:1(11Z)/18:1(9Z)/0:0)
|
|
|
TG(22:2(13Z,16Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/18:2(9Z,12Z))[iso3]
|
|
|
DG(22:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
PC(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(P-18:0/20:2(11Z,14Z))
|
|
|
TG(20:2n6/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:0)[iso3]
|
|
|
PE(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
alpha-Fluoro-beta-ureidopropionic acid
|
An organohalogen compound that has formula C4H7FN2O3.
|
|
TG(15:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GT1b (d18:1/12:0)
|
|
|
TG(14:0/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
3-(3,5-Diiodo-4-hydroxyphenyl)lactate
|
|
|
TG(20:1(11Z)/15:0/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Undecanoyl-CoA
|
A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of undecanoic acid.
|
|
TG(22:0/18:0/18:3(9Z,12Z,15Z))
|
|
|
PE(18:1(11Z)/22:1(13Z))
|
|
|
Cortexolone
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
DG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/18:1(11Z))
|
|
|
Quinapril
|
An isoquinoline that has formula C25H30N2O5.
|
|
TG(22:0/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
Phosphatidylinositol-3,4,5-trisphosphate
|
|
|
TG(20:0/15:0/16:1(9Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/20:2n6)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:3n6/o-18:0)
|
|
|
TG(22:0/20:3n6/o-18:0)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(20:3n6/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Formylanthranilic acid
|
|
|
TG(18:1(11Z)/o-18:0/20:3n6)
|
|
|
TG(20:3n6/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
Ganglioside GD2 (d18:1/25:0)
|
|
|
TG(24:0/18:1(9Z)/24:1(15Z))
|
|
|
Acetylphosphate
|
An acyl monophosphate(2-) that has formula C2H3O5P.
|
|
TG(24:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(22:0/16:0/20:2n6)
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
Econazole
|
A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.
|
|
TG(20:3n6/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
Trovafloxacin
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PIP2(20:3(8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(20:0/o-18:0/22:1(13Z))
|
|
|
Prazepam
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
CL(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/20:0/22:1(13Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/14:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:0)
|
|
|
TG(14:1(9Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
SM(d18:1/26:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Sirolimus
|
|
|
PC(20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/20:2n6/20:0)
|
|
|
Cer(d18:0/22:1(13Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
(R)-lipoic acid
|
The (R)-enantiomer of lipoic acid. A vitamin-like, C8 thia fatty acid with anti-oxidant properties.
|
|
TG(20:3n6/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/16:0/18:1(9Z))
|
|
|
1,4'-Bipiperidine-1'-carboxylic acid
|
A carboxylic acid that has formula C11H20N2O2.
|
|
PC(18:1(11Z)/15:0)
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Sorbitol-6-phosphate
|
|
|
MG(20:3(8Z,11Z,14Z)/0:0/0:0)
|
|
|
7b,12a-Dihydroxycholanoic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Cyclacillin
|
|
|
TG(20:3n6/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
5,6-DHET
|
A DHET obtained by formal dihydroxylation across the 5,6-double bond of arachidonic acid.
|
|
1,3,7,12-Tetrahydroxycholan-24-oic acid
|
|
|
TG(18:1(11Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso3]
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))
|
|
|
TG(16:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(15:0/20:1(11Z)/24:0)
|
|
|
TG(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(14:1(9Z)/22:0/20:1(11Z))
|
|
|
TG(14:1(9Z)/18:1(11Z)/18:1(11Z))
|
|
|
PI(16:1(9Z)/16:1(9Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:0/18:1(11Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/20:0/20:2n6)
|
|
|
TG(18:1(9Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/24:0/22:1(13Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/16:0/24:1(15Z))
|
|
|
DG(20:0/24:1(15Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/o-18:0)
|
|
|
TG(22:1(13Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Thymidine
|
A pyrimidine 2'-deoxyribonucleoside having thymine as the nucleobase.
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Campesterol
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(15:0/20:0/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/15:0/16:1(9Z))
|
|
|
beta-Lactose
|
The beta-anomer of lactose.
|
|
TG(15:0/20:3(5Z,8Z,11Z)/16:0)
|
|
|
TG(24:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/24:0/20:3n6)
|
|
|
PI(18:2(9Z,12Z)/18:1(11Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:0)
|
|
|
TG(18:0/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
Ganglioside GD1b (d18:0/23:0)
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/14:0/20:2n6)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(20:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(14:1(9Z)/P-18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/24:1(15Z)/22:2(13Z,16Z))
|
|
|
FAD
|
A flavin adenine dinucleotide that has formula C27H33N9O15P2.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/18:0)
|
|
|
TG(20:0/16:1(9Z)/20:2n6)
|
|
|
TG(16:0/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Kynurenic acid
|
A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
|
|
TG(15:0/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Trazodone
|
An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
|
|
PE(18:3(9Z,12Z,15Z)/20:2(11Z,14Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(14:1(9Z)/20:2(11Z,14Z))
|
|
|
Benazepril
|
A benzazepine that has formula C24H28N2O5.
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6/o-18:0)
|
|
|
LysoPE(14:1(9Z)/0:0)
|
|
|
PE(22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
TG(15:0/15:0/24:1(15Z))
|
|
|
TG(15:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
2-Hydroxyestradiol
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
MG(22:5(7Z,10Z,13Z,16Z,19Z)/0:0/0:0)
|
|
|
TG(20:0/24:1(15Z)/18:1(9Z))
|
|
|
TG(18:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(18:0/20:0/20:0)[iso3]
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
D-Xylose
|
Any xylose with D-configuration.
|
|
TG(24:1(15Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
PE(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(22:1(13Z)/20:1(11Z))
|
|
|
PE(20:1(11Z)/18:0)
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
3,4-Dihydroxyphenylglycol
|
|
|
CDP-DG(16:0/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(15:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
24-Hydroxycalcitriol
|
|
|
TG(22:1(13Z)/20:2n6/o-18:0)
|
|
|
TG(22:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:0/20:2n6)
|
|
|
TG(18:1(11Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Deoxyguanosine
|
|
|
TG(20:3n6/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:0/16:0)
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:0/0:0)
|
|
|
CDP-DG(18:0/18:1(9Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/20:0/0:0)
|
|
|
DG(15:0/20:0/0:0)
|
|
|
Ganglioside GD1a (d18:1/18:1(11Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(20:0/0:0/20:3n6)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:2n6/16:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/o-18:0)
|
|
|
TG(20:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/22:2(13Z,16Z))
|
|
|
PC(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Phenylacetaldehyde
|
An aldehyde that consists of acetaldehyde bearing a methyl substituent; the parent member of the phenylacetaldehyde class of compounds.
|
|
TG(16:1(9Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PG(18:2(9Z,12Z)/16:0)
|
|
|
TG(16:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PS(16:0/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GT3 (d18:0/24:0)
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Timolol
|
1,2,5-Thiadiazole substituted at the 3 position by a 3-(tert-butylamino)-2-hydroxypropoxy group and at the 4 position by a morpholin-4-yl group. The (S)-(-) enantiomer, also known as timolol, is a beta-adrenergic antagonist and is used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.
|
|
TG(14:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Adenosine 2',3'-cyclic phosphate
|
|
|
TG(24:0/16:1(9Z)/18:1(9Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/20:3n6)
|
|
|
(S)-3-Hydroxyisobutyryl-CoA
|
A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (S)-3-hydroxyisobutyric acid.
|
|
Carisoprodol
|
A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.
|
|
Ganglioside GT3 (d18:0/22:0)
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/14:0/18:1(9Z))
|
|
|
TG(22:1(13Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Aciclovir
|
|
|
TG(14:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP2(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PI(18:1(11Z)/18:2(9Z,12Z))
|
|
|
PE(24:1(15Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
(13E)-11a-Hydroxy-9,15-dioxoprost-13-enoic acid
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Phenylacetyl-CoA
|
An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of phenylacetic acid.
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(16:1(9Z)/o-18:0/20:1(11Z))
|
|
|
D-Aspartic acid
|
The D-enantiomer of aspartic acid.
|
|
TG(16:1(9Z)/14:0/18:1(9Z))[iso6]
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
TG(18:1(9Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/o-18:0)
|
|
|
Ganglioside GM3 (d18:0/20:0)
|
|
|
TG(15:0/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/18:0/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
CL(18:2(9Z,12Z)/18:1(11Z)/18:1(11Z)/16:0)
|
|
|
TG(18:0/o-18:0/22:1(13Z))
|
|
|
PC(o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPE(20:1(11Z)/0:0)
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(18:2(9Z,12Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
SM(d18:1/18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(14:0/18:0/16:0)
|
|
|
DG(18:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
N-Formyl-L-aspartate
|
A doubly-charged N-acyl-L-alpha-amino acid anion resulting from deprotonation of both carboxy groups of N-formyl-L-aspartic acid.
|
|
TG(14:1(9Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(16:1(9Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
Ganglioside GM3 (d18:0/22:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:0/20:3(5Z,8Z,11Z))
|
|
|
Cholest-5-ene-3-beta,7-alpha-diol
|
The 7alpha-hydroxy derivative of cholesterol.
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
PG(16:0/18:1(11Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(14:1n5/0:0/18:4n3)
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/o-18:0/20:2n6)
|
|
|
DG(18:2(9Z,12Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(24:0/20:2n6/22:1(13Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(18:0/14:1(9Z)/18:1(11Z))
|
|
|
TG(22:0/16:1(9Z)/22:0)
|
|
|
TG(24:1(15Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
Spermine
|
A polyazaalkane that is tetradecane in which the carbons at positions 1, 5, 10 and 14 are replaced by nitrogens. Spermine has broad actions on cellular metabolism.
|
|
DG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(24:0/24:0/o-18:0)
|
|
|
Drotaverine
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(15:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:2n6/0:0/18:4n3)
|
|
|
DG(20:3(8Z,11Z,14Z)/18:1(11Z)/0:0)
|
|
|
Uridine diphosphate-N-acetylgalactosamine
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/P-18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Lopinavir
|
|
|
TG(18:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/16:0/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
2-Methoxyestrone
|
A 17-oxo steroid that is estrone in which the hydrogen at position 2 is substituted by a methoxy group.
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:0/20:1(11Z))[iso3]
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(24:0/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:0/18:1(9Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(16:0/0:0/22:0)
|
|
|
TG(16:0/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
PE(P-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
15-Keto-prostaglandin F2a
|
|
|
TG(24:0/14:0/20:2n6)
|
|
|
PE(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/16:0/o-18:0)
|
|
|
Mannitol
|
A hexitol produced by a variety of organisms including bacteria, fungi, lichens and plants.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Vasopressin
|
A family of cyclic nonapeptide hormones found in most mammals. Synthesised in the hypothalamus and stored in the post-pituitary, vasopressins play a key role in homeostasis, particularly in regulating the body's water content. Together with the similar neuropeptide oxytocin, they are believed to influence social cognition and behaviour.
|
|
TG(18:3(6Z,9Z,12Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/22:0/o-18:0)
|
|
|
TG(20:3n6/14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
PI(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z)/0:0)
|
|
|
TG(18:1(11Z)/16:0/20:3(5Z,8Z,11Z))
|
|
|
Galacturonic acid
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Galactose 1-phosphate
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
PI(22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/o-18:0)
|
|
|
TG(14:0/22:0/16:0)
|
|
|
TG(22:1(13Z)/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
Goserelin
|
|
|
Dehydroepiandrosterone 3-glucuronide
|
|
|
TG(14:1(9Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:0/22:1(13Z)/20:3n6)
|
|
|
TG(16:0/o-18:0/18:0)
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/0:0)
|
|
|
Nifedipine
|
A dihydropyridine that has formula C17H18N2O6.
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
(2E)-Hexadecenoyl-CoA
|
An acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (E)-hexadec-2-enoyl-CoA; major species at pH 7.3.
|
|
PG(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:1n7/0:0/22:5n3)
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/15:0)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:1(9Z)/16:1(9Z))
|
|
|
4,6-Dihydroxyquinoline
|
|
|
L-Pipecolic acid
|
The L-enantiomer of pipecolic acid. It is a metabolite of lysine.
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:0/18:2(9Z,12Z))[iso6]
|
|
|
TG(20:2n6/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
Phenylpropionylglycine
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:0/0:0/24:1n9)
|
|
|
TG(24:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
Deoxyinosine
|
|
|
TG(24:1(15Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD3 (d18:0/16:0)
|
|
|
Lactosylceramide (d18:1/25:0)
|
|
|
TG(16:1(9Z)/22:0/18:1(9Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Manganese
|
A manganese group element atom that has formula Mn.
|
|
PE(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Dofetilide
|
|
|
Fucose 1-phosphate
|
|
|
(E)-2-Methylglutaconic acid
|
|
|
TG(16:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT2 (d18:1/26:1(17Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
SM(d18:0/16:1(9Z))
|
|
|
Ganglioside GD3 (d18:0/14:0)
|
|
|
2-Hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone
|
|
|
DG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(15:0/16:1(9Z)/20:1(11Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:1(11Z)/18:1(9Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(18:0/14:0/16:1(9Z))[iso6]
|
|
|
GDP-glucose
|
A GDP-hexose that has formula C16H25N5O16P2.
|
|
PE(P-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/22:0/0:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/o-18:0/22:0)
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
PE(18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(14:1(9Z)/16:1(9Z)/18:1(9Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/24:0/22:2(13Z,16Z))
|
|
|
Dodecanol
|
|
|
TG(18:2(9Z,12Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(16:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/18:2(9Z,12Z))
|
|
|
S-(PGJ2)-glutathione
|
|
|
TG(15:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
1-Nitronaphthalene-5,6-oxide
|
A nitronaphthalene that has formula C10H7NO3.
|
|
TG(15:0/22:1(13Z)/18:0)
|
|
|
PE(20:0/P-16:0)
|
|
|
D-Myo-inositol 4-phosphate
|
|
|
DG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
Retapamulin
|
|
|
TG(20:0/20:2n6/14:1(9Z))
|
|
|
TG(20:3n6/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:0/15:0)
|
|
|
Ganglioside GD1a (d18:0/18:1(11Z))
|
|
|
TG(20:0/14:1(9Z)/20:3n6)
|
|
|
dCTP
|
A 2'-deoxycytidine phosphate having cytosine as the nucleobase.
|
|
Chlorothiazide
|
4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.
|
|
TG(20:0/o-18:0/14:1(9Z))
|
|
|
TG(18:1(9Z)/18:1(9Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Glutathione episulfonium ion
|
A peptide that has formula C12H20N3O6S.
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ganglioside GT2 (d18:1/18:1(9Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(15:0/18:1(11Z)/20:3n6)
|
|
|
TG(16:0/24:0/22:1(13Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
19(S)-HETE
|
A HETE having a (19S)-hydroxy group and all-cis double bonds at positions 5, 8, 11 and 14.
|
|
TG(18:0/15:0/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
7-Sulfocholic acid
|
|
|
TG(24:1(15Z)/15:0/20:2n6)
|
|
|
TG(16:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:1n9/0:0/22:4n6)
|
|
|
TG(20:2n6/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/o-18:0)
|
|
|
IDP
|
A purine ribonucleoside 5'-diphosphate having inosine as the nucleobase.
|
|
TG(18:1(9Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Cob(I)yrinate a,c diamide
|
A cobyrinic acid a,c diamide that has formula C45H61CoN6O12.
|
|
PIP(18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Butorphanol
|
Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:1(11Z)/20:2(11Z,14Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(22:0/20:0/18:3(6Z,9Z,12Z))
|
|
|
DG(14:1n5/0:0/22:5n3)
|
|
|
TG(16:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
Butalbital
|
A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.
|
|
TG(18:0/o-18:0/18:0)
|
|
|
Boron
|
|
|
TG(16:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Gamma-Glutamyl-Se-methylselenocysteine
|
A glutamyl-L-amino acid that has formula C9H16N2O5Se.
|
|
DG(20:3n9/0:0/20:4n6)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
(E)-3-(2,3-Dihydroxyphenyl)-2-propenoic acid
|
|
|
DG(20:2(11Z,14Z)/18:0/0:0)
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(22:0/24:1(15Z)/18:1(11Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Caffeine
|
A trimethylxanthine in which the three methyl groups are located at positions 1, 3, and 7. A purine alkaloid that occurs naturally in tea and coffee.
|
|
PE(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Desmosterol
|
A cholestanoid that is cholesta-5,24-diene substituted by a beta-hydroxy group at position 3. It is an intermediate metabolite obtained during the synthesis of cholesterol.
|
|
Deoxycytidine
|
|
|
TG(18:2(9Z,12Z)/22:0/20:2n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/14:1(9Z)/24:0)
|
|
|
TG(18:2(9Z,12Z)/20:2n6/20:2n6)
|
|
|
Glycodiazine
|
|
|
TG(22:0/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/24:1(15Z)/o-18:0)
|
|
|
DG(18:1(9Z)/14:0/0:0)
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(18:0/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
CE(18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:0/18:2(9Z,12Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
Salsalate
|
|
|
Echothiophate
|
|
|
DG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/18:1(9Z))
|
|
|
DG(22:2n6/0:0/22:2n6)
|
|
|
PE(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(24:1(15Z)/16:1(9Z))
|
|
|
TG(18:0/20:0/20:2n6)
|
|
|
PIP3(18:1(9Z)/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/18:2(9Z,12Z))
|
|
|
1,4-beta-D-Glucan
|
A beta-D-glucan in which the glucose units are connected by (1->4) linkages.
|
|
PE(P-16:0/20:0)
|
|
|
TG(18:1(9Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:2n6/18:1(9Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT1b (d18:1/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Propynoic acid
|
A terminal acetylenic compound that is a 3-carbon, straight-chain, monounsaturated fatty acid having one acetylenic bond.
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GT1b (d18:1/22:0)
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Mercaptopurine
|
A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6.
|
|
PC(24:1(15Z)/18:1(11Z))
|
|
|
PE(22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(22:0/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Nabilone
|
|
|
TG(20:1(11Z)/20:1(11Z)/22:1(13Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Moclobemide
|
|
|
TG(22:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:0/20:2n6/o-18:0)
|
|
|
Desflurane
|
|
|
TG(20:0/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/14:1(9Z)/24:0)
|
|
|
TG(14:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:1(13Z)/24:1(15Z))
|
|
|
3-Polyprenyl-4,5-dihydroxybenzoate
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-16:0)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
PE(20:1(11Z)/22:1(13Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:2(11Z,14Z)/18:1(9Z)/0:0)
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
PC(20:0/14:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/20:1(11Z))[iso6]
|
|
|
PS(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:3n6/14:1(9Z))
|
|
|
CL(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z)/16:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Naratriptan
|
A heteroarylpiperidine that has formula C17H25N3O2S.
|
|
TG(20:1(11Z)/20:0/18:2(9Z,12Z))
|
|
|
TG(24:0/16:0/22:1(13Z))
|
|
|
Glipizide
|
|
|
TG(16:1(9Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-16:0)
|
|
|
Glycopyrrolate
|
|
|
TG(24:0/16:1(9Z)/24:1(15Z))
|
|
|
DG(24:1(15Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/15:0)
|
|
|
TG(20:0/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Carbamazepine
|
A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
|
|
PE(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/14:1(9Z)/24:0)
|
|
|
Desloratadine
|
Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.
|
|
TG(14:0/20:0/18:2(9Z,12Z))
|
|
|
TG(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(16:0/22:0/18:0)
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/22:1(13Z)/o-18:0)
|
|
|
Retinyl palmitate
|
A palmitate ester of retinol with undefined geometry about the C=C bonds.
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Methyltestosterone
|
A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.
|
|
TG(16:0/14:1(9Z)/18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:0/20:2n6)
|
|
|
TG(20:0/24:1(15Z)/14:1(9Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/0:0)
|
|
|
Quercetin-4'-glucuronide
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP(16:1(9Z)/18:1(9Z))
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
(3a,5b)-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl-b-D-Glucopyranosiduronic acid
|
|
|
TG(22:0/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
PC(16:0/20:1(11Z))
|
|
|
TG(18:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z))
|
|
|
TG(14:0/22:0/o-18:0)
|
|
|
11,14,15-THETA
|
A leukotriene that has formula C20H34O5.
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/o-18:0/16:1(9Z))
|
|
|
PG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/14:1(9Z)/22:0)
|
|
|
TG(16:0/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:0/22:1(13Z))
|
|
|
Lithocholate 3-O-glucuronide
|
|
|
PIP2(18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Sepiapterin
|
A pterin that has formula C9H11N5O3.
|
|
Propionyl-CoA
|
An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of propionic acid.
|
|
PIP(16:1(9Z)/18:0)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/o-18:0)
|
|
|
5-Dehydroepisterol
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(11Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
Methylarsonite
|
An arsenic oxoanion obtained deprotonation of both arsenite OH groups of methylarsonous acid.
|
|
DG(16:0/0:0/20:3n9)
|
|
|
2-Polyprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone
|
|
|
trans-2-Enoyl-OPC4-CoA
|
An organic molecule that has formula C35H54N7O18P3S.
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
CDP-DG(18:1(9Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(20:2n6/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:1n7/0:0/20:3n9)
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/18:2(9Z,12Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(14:0/14:1(9Z)/24:0)
|
|
|
DG(18:1(11Z)/24:1(15Z)/0:0)
|
|
|
5alpha-Dihydrodeoxycorticosterone
|
A 21-hydroxy steroid that has formula C21H32O3.
|
|
PE(16:1(9Z)/16:0)
|
|
|
TG(24:1(15Z)/o-18:0/22:2(13Z,16Z))
|
|
|
DG(20:3n9/0:0/22:5n3)
|
|
|
TG(18:1(9Z)/22:0/o-18:0)
|
|
|
TG(20:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/14:0/18:3(6Z,9Z,12Z))
|
|
|
DG(15:0/0:0/16:0)
|
|
|
TG(16:0/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:0/20:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(15:0/0:0/18:0)
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
Marimastat
|
A tricarboxylic acid triamide that has formula C15H29N3O5.
|
|
TG(16:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
PE(P-18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/o-18:0)
|
|
|
TG(22:1(13Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Chlorhexidine
|
A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.
|
|
TG(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:0/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
2-Hydroxyglutarate
|
|
|
TG(18:0/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
D-Proline
|
The D-enantiomer of proline.
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Estradiol
|
A 3-hydroxy steroid that is estra-1,3,5(10)-triene substituted by hydroxy groups at positions 3 and 17.
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
Ganglioside GT2 (d18:0/22:0)
|
|
|
TG(14:1(9Z)/20:0/14:1(9Z))
|
|
|
TG(15:0/22:1(13Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(18:1(9Z)/P-18:1(9Z))
|
|
|
Ganglioside GT2 (d18:0/20:0)
|
|
|
DG(16:0/16:1(9Z)/0:0)
|
|
|
Rivastigmine
|
|
|
TG(20:3n6/o-18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/15:0/20:3n6)
|
|
|
PC(18:1(9Z)/16:1(9Z))
|
|
|
PE(20:3(5Z,8Z,11Z)/22:1(13Z))
|
|
|
TG(18:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:1(13Z)/18:1(9Z))
|
|
|
TG(22:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(14:1(9Z)/P-18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/20:0/16:1(9Z))
|
|
|
TG(20:2n6/24:1(15Z)/20:3n6)
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/16:1(9Z))
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0)
|
|
|
DG(16:1n7/0:0/24:1n9)
|
|
|
TG(24:1(15Z)/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
DG(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Benzthiazide
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
Sarcosine
|
|
|
PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:3n6/14:1(9Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(20:3n6/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:1(9Z)/18:1(11Z))
|
|
|
6a,12a-Dihydroxylithocholic acid
|
|
|
CL(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/18:0/0:0)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Sapropterin
|
|
|
TG(22:2(13Z,16Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/20:2n6)
|
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:3n6)
|
|
|
TG(18:1(11Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/18:1(11Z))
|
|
|
PE(20:0/16:1(9Z))
|
|
|
TG(20:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(15:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(P-16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/24:0/24:1(15Z))
|
|
|
TG(22:0/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/20:0)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
LysoPC(24:1(15Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
DG(22:1(13Z)/24:0/0:0)
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:1(13Z)/20:3n6)
|
|
|
Trihexosylceramide (d18:1/9Z-18:1)
|
|
|
DG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(14:1(9Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(14:0/0:0/20:3n6)
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
PC(20:0/P-18:1(9Z))
|
|
|
TG(22:1(13Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z)/18:1(11Z))
|
|
|
PC(15:0/P-16:0)
|
|
|
TG(22:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
PIP2(16:0/20:2(11Z,14Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/14:0/20:3n6)
|
|
|
PC(15:0/P-18:1(9Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Coproporphyrin III
|
A coproporphyrin that has formula C36H38N4O8.
|
|
DG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/20:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(15:0/20:3(8Z,11Z,14Z))
|
|
|
2-(Formamido)-N1-(5-phospho-D-ribosyl)acetamidine
|
A ribose monophosphate that has formula C8H16N3O8P.
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:0/18:0/o-18:0)
|
|
|
TG(18:1(9Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(22:0/18:1(11Z)/16:1(9Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))
|
|
|
PI(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(14:0/14:1(9Z)/o-18:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Stigmasterol
|
|
|
Chloramphenicol
|
An organochlorine compound that is dichloro-substituted acetamide containing a nitrobenzene ring, an amide bond and two alcohol functions.
|
|
TG(20:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
Hydrocodone
|
An organic heteropentacyclic compound that has formula C18H21NO3.
|
|
TG(22:0/14:0/18:1(11Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:1(13Z)/22:1(13Z))
|
|
|
Phosphohydroxypyruvic acid
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/16:1(9Z)/20:1(11Z))[iso6]
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:1n9/0:0/24:1n9)
|
|
|
Thiabendazole
|
A member of the class of benzimidazoles carrying a 1,3-thiazol-4-yl substituent at position 2. A mainly post-harvest fungicide used to control a wide range of diseases including Aspergillus, Botrytis, Cladosporium and Fusarium.
|
|
TG(18:1(9Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Dehydroepiandrosterone
|
An androstanoid that is androst-5-ene substituted by an beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/20:3n6)
|
|
|
Adefovir Dipivoxil
|
|
|
CE(20:0)
|
|
|
TG(20:2n6/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/14:1(9Z)/22:2(13Z,16Z))
|
|
|
Heptadecanoic acid
|
A C17 saturated fatty acid and trace component of fats in ruminants.
|
|
TG(20:3n6/14:0/22:2(13Z,16Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/16:1(9Z)/24:0)
|
|
|
TG(14:1(9Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PA(18:1(9Z)/18:1(11Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ceramide (d18:1/24:0)
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(15:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
(S)-3-Hydroxyhexadecanoyl-CoA
|
|
|
Acaciabiuronic acid
|
|
|
TG(14:0/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:0/o-18:0)
|
|
|
TG(15:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Acetylcysteine
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/15:0/16:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/15:0/20:3n6)
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
Hydrogen peroxide
|
An inorganic peroxide that has formula H2O2.
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))
|
|
|
MG(22:0/0:0/0:0)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
Zolpidem
|
An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
|
|
TG(14:0/16:0/22:0)
|
|
|
TG(16:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Capryloylglycine
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(16:1(9Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
Lumefantrine
|
|
|
TG(22:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
D-Dopachrome
|
The D-enantiomer of dopachrome.
|
|
TG(18:1(11Z)/18:1(9Z)/o-18:0)
|
|
|
TG(20:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
PC(15:0/18:0)
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
N'-Formylkynurenine
|
A non-proteinogenic amino acid derivative that has formula C11H12N2O4.
|
|
TG(20:1(11Z)/20:3(5Z,8Z,11Z)/20:3n6)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(24:1(15Z)/24:1(15Z))
|
|
|
Paramethasone
|
|
|
2-Methoxy-estradiol-17b 3-glucuronide
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/o-18:0)
|
|
|
PC(P-18:0/20:0)
|
|
|
Cer(d18:0/18:1(11Z))
|
|
|
TG(14:0/18:1(9Z)/20:3n6)
|
|
|
TG(24:0/22:1(13Z)/22:1(13Z))
|
|
|
PI(16:0/16:1(9Z))
|
|
|
PE(20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
Dopamine 4-sulfate
|
|
|
PE(24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Anileridine
|
|
|
TG(22:1(13Z)/20:3n6/18:3(6Z,9Z,12Z))
|
|
|
5'-phosphoribosyl-a-N-formylglycineamidine
|
|
|
Alverine
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/16:1(9Z)/14:1(9Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)/0:0)
|
|
|
TG(18:1(9Z)/24:0/o-18:0)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso3]
|
|
|
TG(20:3n6/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/15:0/20:3n6)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/18:0/20:0)
|
|
|
PE(P-18:1(11Z)/22:2(13Z,16Z))
|
|
|
PG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))
|
|
|
4-Amino-1-piperidinecarboxylic acid
|
|
|
TG(18:1(9Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/24:1(15Z)/20:3n6)
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Lisdexamfetamine
|
|
|
TG(20:3n6/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
3a,7a,12b-Trihydroxy-5b-cholanoic acid
|
|
|
Atovaquone
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/15:0/18:3(6Z,9Z,12Z))
|
|
|
Dimethyl-L-arginine
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:2n6/20:1(11Z))
|
|
|
Dydrogesterone
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(20:0/20:2(11Z,14Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(20:0/16:0/22:2(13Z,16Z))
|
|
|
TG(20:0/18:0/22:2(13Z,16Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
Tranexamic Acid
|
|
|
PE(18:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PI(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Dicumarol
|
|
|
TG(16:0/24:1(15Z)/o-18:0)
|
|
|
TG(22:0/20:2n6/18:3(6Z,9Z,12Z))
|
|
|
(S)-Methylmalonic acid semialdehyde
|
|
|
Uridine 5'-diphosphate
|
|
|
TG(16:0/18:1(11Z)/20:1(11Z))
|
|
|
TG(22:0/22:0/24:1(15Z))
|
|
|
TG(24:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:5n6/0:0/22:5n3)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:1(11Z)/20:1(11Z))[iso3]
|
|
|
PC(P-18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
p-Cresol glucuronide
|
|
|
DG(22:2(13Z,16Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(14:0/22:2(13Z,16Z)/14:1(9Z))
|
|
|
TG(20:2n6/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(16:0/20:2n6/24:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
PE(18:1(9Z)/20:1(11Z))
|
|
|
TG(20:2n6/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/o-18:0/16:1(9Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/16:0/20:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/14:1(9Z)/15:0)
|
|
|
PE(P-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:2(9Z,12Z)/22:0)
|
|
|
PE(18:1(11Z)/16:0)
|
|
|
TG(15:0/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cefamandole
|
|
|
TG(14:1(9Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:1(11Z))
|
|
|
TG(14:1(9Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(14:0/0:0/18:4n3)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
S-Lactoylglutathione
|
|
|
Methacholine
|
|
|
TG(20:0/18:1(9Z)/o-18:0)
|
|
|
Isobutyrylglycine
|
|
|
3-beta-Hydroxy-4-beta-methyl-5-alpha-cholest-7-ene-4-alpha-carbaldehyde
|
A 3beta-sterol that has formula C29H48O2.
|
|
TG(16:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
21-Hydroxypregnenolone
|
A hydroxypregnenolone that has formula C21H32O3.
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(15:0/20:1(11Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GM3 (d18:0/18:1(11Z))
|
|
|
TG(20:1(11Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Imidazole-4-acetaldehyde
|
An imidazolylacetaldehyde that has formula C5H6N2O.
|
|
DG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:2n6/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Sulfadiazine
|
A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.
|
|
TG(18:0/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
LysoPC(22:1(13Z))
|
|
|
DG(24:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
PC(18:3(9Z,12Z,15Z)/P-18:1(9Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
LysoPE(16:1(9Z)/0:0)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:1(13Z)/20:0/0:0)
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Cer(d18:0/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:0/22:0)
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
PE(24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:3n6/24:1(15Z))
|
|
|
TG(20:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PI(18:2(9Z,12Z)/16:0)
|
|
|
TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD2 (d18:1/18:0)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(18:2(9Z,12Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/24:0/o-18:0)
|
|
|
DG(20:0/0:0/22:2n6)
|
|
|
TG(18:0/16:0/o-18:0)
|
|
|
Methamphetamine
|
A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.
|
|
TG(16:1(9Z)/24:0/20:1(11Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/o-18:0/24:0)
|
|
|
Thiamine triphosphate
|
Trianion of thiamine(1+) diphosphate arising from deprotonation of the four OH groups of the triphosphate.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
MG(20:3(11Z,14Z,17Z)/0:0/0:0)
|
|
|
TG(22:1(13Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
PS(16:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
Ganglioside GM3 (d18:0/18:0)
|
|
|
TG(18:0/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
1-Hydroxy-6-methoxypyrene
|
A pyrene that has formula C17H12O2.
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(15:0/16:1(9Z)/o-18:0)
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
Nicergoline
|
|
|
TG(24:1(15Z)/16:0/18:2(9Z,12Z))
|
|
|
TG(14:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/18:0)
|
|
|
TG(20:2n6/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Moricizine
|
|
|
Benzo[a]pyrene-7,8-oxide
|
A pyrene that has formula C20H12O.
|
|
TG(16:0/18:1(11Z)/22:1(13Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:0/0:0)
|
|
|
DG(24:1n9/0:0/20:5n3)
|
|
|
DG(15:0/0:0/20:3n9)
|
|
|
TG(15:0/14:0/o-18:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
7-Methyl-3-oxo-6-octenoyl-CoA
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Vinylacetylglycine
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:3n6/24:0)
|
|
|
DG(15:0/18:1(11Z)/0:0)
|
|
|
DG(15:0/0:0/20:1n9)
|
|
|
Mazindol
|
|
|
TG(14:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/22:0)
|
|
|
Choline
|
A choline that is the parent compound of the cholines class, consisting of ethanolamine having three methyl substituents attached to the amino function.
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/24:0)
|
|
|
TG(18:0/18:1(9Z)/24:0)
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Succinylcholine
|
A quaternary ammonium ion that is the bis-choline ester of succinic acid.
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
PC(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Galactitol
|
An optically inactive hexitol having meso-configuration.
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(20:3n6/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(18:1(11Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(15:0/22:0/0:0)
|
|
|
TG(22:1(13Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PIP2(20:2(11Z,14Z)/16:0)
|
|
|
DG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
DG(20:0/0:0/20:0)
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/22:2(13Z,16Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(18:1(9Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0/o-18:0)
|
|
|
DG(20:0/0:0/22:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(14:1(9Z)/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Phosphate
|
Salts and esters of phosphoric and oligophosphoric acids and their chalcogen analogues. In inorganic chemistry, the term is also used to describe anionic coordination entities with phosphorus as central atom.
|
|
Tetrabenazine
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
Deoxyribose 5-phosphate
|
|
|
PG(16:1(9Z)/18:1(9Z))
|
|
|
TG(15:0/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:1(11Z)/18:0/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PE(16:0/22:1(13Z))
|
|
|
TG(20:3n6/22:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/24:1(15Z)/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/0:0)
|
|
|
PC(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
(3S)-3-Hydroxyadipyl-CoA
|
A polyol that has formula C27H44N7O20P3S.
|
|
DG(14:0/0:0/20:1n9)
|
|
|
Methaneselenol
|
An organoselenium compound that is a selenium analogue of methanol, comprising a methyl group covalently bound to a selenol group.
|
|
TG(15:0/20:2n6/16:0)
|
|
|
TG(20:1(11Z)/22:0/20:3(5Z,8Z,11Z))
|
|
|
3a,6b,7b,12a-Tetrahydroxy-5b-cholanoic acid
|
|
|
PE(20:0/22:0)
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
3-Mercaptolactate-cysteine disulfide
|
|
|
(S)-Propane-1,2-diol
|
A propane-1,2-diol that has formula C3H8O2.
|
|
Valaciclovir
|
|
|
TG(15:0/20:2n6/18:0)
|
|
|
Dextroamphetamine
|
|
|
CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)/18:1(11Z)/18:1(9Z))
|
|
|
PC(20:2(11Z,14Z)/24:1(15Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
Metaraminol
|
|
|
PC(22:0/16:1(9Z))
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/24:0)
|
|
|
PI(20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:1(9Z))
|
|
|
TG(20:2n6/22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(18:0/0:0/22:6n3)
|
|
|
Octreotide
|
A homodetic cyclic peptide that has formula C49H66N10O10S2.
|
|
TG(22:0/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
SN38 glucuronide
|
A pyranoindolizinoquinoline that has formula C28H28N2O11.
|
|
N-Methyltyramine
|
A tyramine that has formula C9H13NO.
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Desmopressin
|
A synthetic analogue of vasopressin in which 3-mercaptopropionic acid replaces the cysteine residue at position 1 and D-arginine replaces the residue at position 8. An antidiuretic, it increases urine concentration and decreases urine production, and is used (usually as the trihydrate of the acetic acid salt) to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions. It is also used in the diagnosis and treatment of cranial diabetes insipidus and in tests of renal function.
|
|
PE(22:1(13Z)/18:0)
|
|
|
PC(24:1(15Z)/16:1(9Z))
|
|
|
TG(20:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Methadone
|
A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
|
|
TG(18:1(9Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/20:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:2n6/16:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(18:1(9Z)/16:1(9Z)/0:0)
|
|
|
TG(20:3n6/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Chlordecone
|
An organochlorine compound with insecticidal activity.
|
|
TG(20:3n6/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
PC(18:0/18:1(11Z))
|
|
|
TG(14:1(9Z)/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Octanol
|
A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of eight carbon atoms.
|
|
Droperidol
|
An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.
|
|
TG(16:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:0/22:1(13Z))
|
|
|
PS(14:1(9Z)/16:1(9Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(16:1(9Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:2(9Z,12Z)/22:0)
|
|
|
Dihydroergotoxine
|
|
|
TG(20:3n6/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(16:1(9Z)/14:1(9Z)/18:1(11Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/22:0/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PG(16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
PC(14:0/20:1(11Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/16:1(9Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/15:0)
|
|
|
TG(22:0/20:3n6/22:2(13Z,16Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
Chenodeoxycholic acid disulfate
|
|
|
PIP(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/0:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
Naftifine
|
|
|
TG(24:0/18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
CL(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/o-18:0)
|
|
|
Ganglioside GA2 (d18:1/22:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/20:2n6)
|
|
|
DG(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
PE(18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/18:1(11Z)/0:0)
|
|
|
TG(18:0/18:2(9Z,12Z)/20:1(11Z))[iso6]
|
|
|
TG(18:1(9Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Anserine
|
A dipeptide comprising of beta-alanine and 3-methyl-L-histidine units.
|
|
TG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))
|
|
|
MG(0:0/15:0/0:0)
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/P-18:0)
|
|
|
TG(24:1(15Z)/20:3(5Z,8Z,11Z)/20:2n6)
|
|
|
TG(14:1(9Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/14:0/20:2n6)
|
|
|
TG(14:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:2(9Z,12Z)/24:0)
|
|
|
TG(16:0/14:1(9Z)/20:3n6)
|
|
|
TG(18:1(11Z)/22:0/20:1(11Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/22:1(13Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(22:0/18:0/o-18:0)
|
|
|
TG(20:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GA2 (d18:1/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/18:2(9Z,12Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
SM(d18:0/14:0)
|
|
|
TG(22:0/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
3,4-Dihydroxymandelaldehyde
|
An aldehyde consisting of phenylacetaldehyde having three hydroxy substituents located at the alpha-, 3- and 4-positions
|
|
PE(dm18:0/18:0)
|
|
|
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(9Z))
|
|
|
TG(20:1(11Z)/18:0/24:1(15Z))
|
|
|
L-Arabitol
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/20:3n6)
|
|
|
LysoPE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
Ganglioside GT1c (d18:0/18:0)
|
|
|
PIP2(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(o-16:1(9Z)/20:0)
|
|
|
DG(14:1n5/0:0/22:1n9)
|
|
|
Menadione
|
A naphthoquinone having a methyl substituent at the 2-position.
|
|
TG(20:1(11Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(24:0/0:0/18:1n9)
|
|
|
TG(20:0/18:0/22:0)
|
|
|
TG(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(16:1(9Z)/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(P-18:1(9Z)/22:1(13Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/18:0/0:0)
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Enol-phenylpyruvate
|
A hydroxy monocarboxylic acid anion that has formula C9H7O3.
|
|
PC(20:0/18:1(9Z))
|
|
|
TG(20:1(11Z)/16:0/20:1(11Z))
|
|
|
TG(18:0/20:3n6/18:0)
|
|
|
TG(16:0/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/16:0/20:2(11Z,14Z))[iso6]
|
|
|
PC(20:2(11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
DG(24:0/18:1(9Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:1n9/0:0/20:4n3)
|
|
|
TG(20:2n6/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
5-Hydroxy-L-tryptophan
|
The L-enantiomer of 5-hydroxytryptophan.
|
|
TG(15:0/20:2n6/o-18:0)
|
|
|
TG(20:1(11Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
dUDP
|
A pyrimidine 2'-deoxyribonucleoside 5'-diphosphate that has formula C9H14N2O11P2.
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/o-18:0)
|
|
|
N,N-Dimethylaniline
|
A tertiary amine that is aniline in which the amino hydrogens are replaced by two methyl groups.
|
|
TG(18:0/22:2(13Z,16Z)/16:1(9Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(20:1(11Z)/24:0/18:3(6Z,9Z,12Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/20:3(5Z,8Z,11Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:0)
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Pipecuronium
|
|
|
DG(18:1n9/0:0/22:1n9)
|
|
|
TG(22:0/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Isradipine
|
|
|
PC(18:3(9Z,12Z,15Z)/20:2(11Z,14Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(20:3n6/18:2(9Z,12Z)/20:3n6)
|
|
|
TG(20:2n6/20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
LysoPC(22:0)
|
A lysophosphatidylcholine in which the remaining acyl group contains 22 carbons and 0 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
|
|
TG(16:0/24:0/22:0)
|
|
|
PG(16:1(9Z)/18:0)
|
|
|
PE(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Chenodeoxycholic acid 3-sulfate
|
|
|
TG(18:0/20:2n6/20:3n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PG(18:0/18:3(9Z,12Z,15Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
PC(20:2(11Z,14Z)/20:0)
|
|
|
UDP-D-Xylose
|
|
|
PC(22:2(13Z,16Z)/P-16:0)
|
|
|
TG(16:0/18:1(9Z)/16:1(9Z))
|
|
|
TG(20:0/15:0/18:3(6Z,9Z,12Z))
|
|
|
LysoPC(24:0)
|
A lysophosphatidylcholine in which the remaining acyl group (position not specified) contains 24 carbons and 0 double bonds.
|
|
TG(20:0/18:1(11Z)/22:0)
|
|
|
TG(14:1(9Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/18:0/18:2(9Z,12Z))
|
|
|
PI(18:1(11Z)/16:0)
|
|
|
TG(18:1(11Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Testosterone sulfate
|
A steroid sulfate that is testosterone substituted by a sulfoxy group at position 17.
|
|
DG(20:0/24:0/0:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/P-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/14:0/24:0)
|
|
|
TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:1(11Z)/22:2(13Z,16Z))
|
|
|
Cobalt
|
A cobalt group element atom that has formula Co.
|
|
Naphazoline
|
|
|
PE(P-18:0/16:1(9Z))
|
|
|
MG(0:0/20:3(11Z,14Z,17Z)/0:0)
|
|
|
TG(16:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(16:1(9Z)/18:0/0:0)
|
|
|
PIP(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(15:0/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Mebendazole
|
A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
|
|
2-Amino-4-oxo-6-(1',2'-dioxoprolyl)-7,8-dihydroxypteridine
|
|
|
TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/15:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Furazolidone
|
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/15:0/22:1(13Z))
|
|
|
TG(18:1(11Z)/24:0/20:1(11Z))
|
|
|
PI(16:2(9Z,12Z)/16:0)
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:1(13Z)/22:0)
|
|
|
TG(20:0/14:1(9Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(11Z)/o-18:0)
|
|
|
TG(24:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
Methylselenic acid
|
|
|
TG(16:1(9Z)/15:0/20:2n6)
|
|
|
PC(18:0/18:1(9Z))
|
|
|
TG(16:0/24:0/24:0)
|
|
|
Ceruletide
|
A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.
|
|
PC(20:2(11Z,14Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Magnesium
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
DG(18:1n7/0:0/22:6n3)
|
|
|
DG(18:1(9Z)/18:1(11Z)/0:0)
|
|
|
Beta-Alanyl-CoA
|
An acyl-CoA that is the S-(beta-alanyl) derivative of coenzyme A.
|
|
TG(24:1(15Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
Penicillin G
|
|
|
PE(18:1(11Z)/P-18:0)
|
|
|
Sulfadimethoxine
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PIP3(16:0/18:1(9Z))
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:0/14:0/22:2(13Z,16Z))
|
|
|
TG(18:1(9Z)/14:0/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(22:1(13Z)/24:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)
|
|
|
PE(16:1(9Z)/18:1(11Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/16:1(9Z))
|
|
|
TG(14:0/18:1(11Z)/14:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/o-18:0/24:1(15Z))
|
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GA2 (d18:1/26:1(17Z))
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/24:0/24:1(15Z))
|
|
|
TG(18:1(11Z)/20:2n6/o-18:0)
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
5-Formiminotetrahydrofolic acid
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
PE(15:0/24:1(15Z))
|
|
|
TG(20:2n6/20:0/20:2n6)
|
|
|
TG(15:0/14:1(9Z)/18:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
LPA(18:1(9Z)/0:0)
|
|
|
PIP(18:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
Dimethylarsinate
|
The arsenic oxoanion that is the conjugate base of dimethylarsinic acid.
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(24:1n9/0:0/18:4n3)
|
|
|
TG(18:1(11Z)/18:1(9Z)/20:1(11Z))
|
|
|
TG(20:1(11Z)/18:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(18:0/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(20:1(11Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
3-Hydroxymethylantipyrine
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/o-18:0)
|
|
|
Ganglioside GD3 (d18:0/24:0)
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/20:1(11Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Hyaluronic acid
|
A mucopolysaccharide composed of N-acetylglucosamine and glucuronic acid subunits. It is found in the connective tissues of vertebrates.
|
|
TG(24:1(15Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z)/18:1(9Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/15:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
PC(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Glucosylceramide (d18:1/16:0)
|
|
|
PIP2(16:1(9Z)/16:0)
|
|
|
PE(14:1(9Z)/18:1(9Z))
|
|
|
Ganglioside GD3 (d18:0/22:0)
|
|
|
TG(14:1(9Z)/15:0/o-18:0)
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
4-Methylumbelliferyl acetate
|
An acetate ester consiting of umbelliferone carrying a 7-O-acetyl group.
|
|
7,8-Dihydroneopterin
|
A neopterin where positions C-7 and C-8 have been hydrogenated.
|
|
TG(18:2(9Z,12Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/24:1(15Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
Ritodrine
|
|
|
Orphenadrine
|
A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.
|
|
trans-2-Enoyl-OPC8-CoA
|
An organic molecule that has formula C39H62N7O18P3S.
|
|
(S)-ethylmalonyl-CoA
|
|
|
TG(16:0/22:2(13Z,16Z)/18:2(9Z,12Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
4-Oxoretinal
|
|
|
Betaine
|
|
|
TG(15:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/24:1(15Z))
|
|
|
Ganglioside GA1 (d18:1/9Z-18:1)
|
|
|
Tramadol
|
|
|
TG(24:0/18:0/16:1(9Z))
|
|
|
LysoPE(0:0/14:1(9Z))
|
|
|
TG(20:2n6/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:2n6/22:2(13Z,16Z))
|
|
|
PC(16:0/20:2(11Z,14Z))
|
|
|
Nedocromil
|
|
|
TG(22:1(13Z)/14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PS(14:1(9Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(22:1(13Z)/P-16:0)
|
|
|
PC(o-22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/dm18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
Raffinose
|
A trisaccharide composed of alpha-D-galactopyranose, alpha-D-glucopyranose and beta-D-fructofuranose joined in sequence by 1->6 and 1<->2 glycosidic linkages, respectively.
|
|
PE(16:0/22:0)
|
|
|
TG(18:1(9Z)/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/P-16:0)
|
|
|
TG(24:0/20:0/16:1(9Z))
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))
|
|
|
PG(18:1(11Z)/16:1(9Z))
|
|
|
TG(16:0/16:0/16:0)[iso]
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/20:0/o-18:0)
|
|
|
19-Oxoandrost-4-ene-3,17-dione
|
|
|
TG(14:1(9Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(14:0/0:0/24:0)
|
|
|
TG(14:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
PE(14:1(9Z)/14:1(9Z))
|
|
|
Oxymetazoline
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(11Z)/20:2n6)
|
|
|
TG(14:0/24:0/16:0)
|
|
|
TG(24:1(15Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/24:0/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(14:0/0:0/20:2n6)
|
|
|
PE(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP(20:4(8Z,11Z,14Z,17Z)/16:0)
|
|
|
TG(20:0/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Adenosine tetraphosphate
|
|
|
DG(14:0/0:0/22:1n9)
|
|
|
PE(16:0/20:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GM2 (d18:1/20:0)
|
|
|
DG(24:0/16:1(9Z)/0:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:2n6/o-18:0)
|
|
|
PC(14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
DG(18:0/0:0/22:2n6)
|
|
|
TG(20:1(11Z)/24:1(15Z)/24:1(15Z))
|
|
|
Chloroacetyl chloride
|
An acyl halide that has formula C2H2Cl2O.
|
|
9-cis-Retinal
|
A retinal in which the double bond at position 9 has cis configuration, whilst the remaining acyclic double bonds have trans configuration.
|
|
TG(18:0/20:0/14:1(9Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))
|
|
|
DG(18:3n6/0:0/20:4n3)
|
|
|
DG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(16:1(9Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Pioglitazone
|
A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
|
|
Theophylline
|
A dimethylxanthine having the two methyl groups located at positions 1 and 3. It is structurally similar to caffeine and is found in green and black tea.
|
|
TG(16:1(9Z)/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/20:2n6/o-18:0)
|
|
|
TG(14:1(9Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/22:2(13Z,16Z)/20:3n6)
|
|
|
PE(24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/14:0/18:1(9Z))[iso3]
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
PE(15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/14:0)
|
|
|
TG(20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/16:1(9Z)/16:1(9Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
PI(18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/15:0/20:3n6)
|
|
|
trans-Octadec-2-enoyl-CoA
|
|
|
DG(16:0/20:2(11Z,14Z)/0:0)
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
Ganglioside GT3 (d18:1/24:1(15Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
Pergolide
|
A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.
|
|
PI(18:1(9Z)/18:1(11Z))
|
|
|
PE(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
LysoPE(20:2(11Z,14Z)/0:0)
|
|
|
TG(24:0/15:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
CDP-DG(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:2(13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(18:0/o-18:0/16:1(9Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:0)
|
|
|
TG(18:0/14:1(9Z)/20:0)
|
|
|
Methylmalonic acid
|
A dicarboxylic acid that is malonic acid in which one of the methylene hydrogens is substituted by a methyl group.
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
N1-(5-Phospho-a-D-ribosyl)-5,6-dimethylbenzimidazole
|
|
|
Ganglioside GT1c (d18:1/18:0)
|
|
|
TG(16:0/o-18:0/20:1(11Z))
|
|
|
Methylscopolamine
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
DG(16:0/20:4(5Z,8Z,11Z,14Z)/0:0)
|
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
Tinidazole
|
1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.
|
|
TG(18:0/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
6-(N-Acetyl-alpha-D-glucosaminyl)-1-phosphatidyl-1D-myo-inositol
|
The alpha-anomer of 6-(N-acetyl-D-glucosaminyl)-1-phosphatidyl-1D-myo-inositol.
|
|
TG(16:1(9Z)/20:3n6/18:1(9Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/24:1(15Z)/0:0)
|
|
|
TG(18:0/24:1(15Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
3-Indolebutyric acid
|
|
|
PG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Benzquinamide
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/24:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(24:0/18:1(11Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/24:0/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
Iodide
|
A monoatomic iodine that has formula I.
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:1(9Z)/14:1(9Z)/o-18:0)
|
|
|
PC(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
Tamibarotene
|
A tetralin that has formula C22H25NO3.
|
|
DG(20:1n9/0:0/20:4n3)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
PE(16:0/22:2(13Z,16Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:0/o-18:0)
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GA1 (d18:1/12:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:0/22:2(13Z,16Z))
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/22:1(13Z))
|
|
|
PE(18:0/24:1(15Z))
|
|
|
TG(14:1(9Z)/20:0/18:1(11Z))
|
|
|
TG(22:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
PI(20:2(11Z,14Z)/20:2(11Z,14Z))
|
|
|
TG(22:1(13Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Liothyronine
|
|
|
TG(15:0/24:0/18:1(11Z))
|
|
|
PIP2(16:2(9Z,12Z)/18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
Acetophenazine
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(14:0/20:0/0:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/15:0)
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/14:0/16:1(9Z))
|
|
|
DG(20:2(11Z,14Z)/24:0/0:0)
|
|
|
TG(18:1(11Z)/15:0/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3n6/20:3(5Z,8Z,11Z))
|
|
|
TG(20:0/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(20:2(11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(20:3n6/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/14:0/18:1(11Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/20:0)
|
|
|
DG(14:0/0:0/18:2n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(24:0/22:2(13Z,16Z)/0:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
Citicoline
|
|
|
3-Dehydro-L-gulonate
|
The conjugate base of 3-dehydro-L-gulonic acid; major species at pH 7.3.
|
|
PC(o-18:0/24:0)
|
|
|
DG(18:1(11Z)/22:1(13Z)/0:0)
|
|
|
Epinastine
|
A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine.
|
|
TG(14:0/18:1(11Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PIP2(16:0/18:1(9Z))
|
|
|
PE(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
DG(14:1n5/0:0/18:3n6)
|
|
|
TG(16:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(24:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:1(9Z)/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))
|
|
|
PE(P-18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(14:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/22:1(13Z))
|
|
|
TG(16:0/20:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/14:0/o-18:0)
|
|
|
TG(16:0/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
2,3-Dihydro-2-S-glutathionyl-3-hydroxy bromobenzene
|
A peptide that has formula C16H22BrN3O7S.
|
|
TG(18:1(11Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/24:1(15Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(15:0/o-18:0/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/20:2n6)
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
PG(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/20:3n6)
|
|
|
TG(15:0/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
(6Z,9Z,12Z,15Z,18Z)-3-Hydroxytetracosapenta-6,9,12,15,18-enoyl-CoA
|
A polyol that has formula C45H72N7O18P3S.
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(14:1(9Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/15:0/22:2(13Z,16Z))
|
|
|
TG(22:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
PG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
PE(20:2(11Z,14Z)/22:0)
|
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
PC(20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3n6/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(16:0/16:0)
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
4,4-Dimethyl-5a-cholesta-8,24-dien-3-b-ol
|
|
|
PC(20:0/14:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:0)
|
|
|
TG(16:0/22:1(13Z)/24:0)
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/o-18:0/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
L-Glutamic acid
|
An optically active form of glutamic acid having L-configuration.
|
|
TG(14:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))
|
|
|
PG(18:2(9Z,12Z)/18:1(9Z))
|
|
|
TG(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
CE(22:2(13Z,16Z))
|
|
|
Parathion
|
An organothiophosphate insecticide that has formula C10H14NO5PS.
|
|
TG(22:2(13Z,16Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Acetaminophen
|
|
|
TG(22:1(13Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/20:0/0:0)
|
|
|
TG(22:1(13Z)/22:0/o-18:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(20:0/16:0)
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(20:2n6/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CDP-DG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/20:3n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
1-Hydroxypyrene
|
A pyrene that has formula C16H10O.
|
|
PC(18:0/20:3(8Z,11Z,14Z))
|
|
|
PC(o-18:1(9Z)/24:0)
|
|
|
Lercanidipine
|
|
|
TG(18:0/18:0/18:0)
|
|
|
TG(24:0/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
2-Hexaprenyl-3-methyl-6-methoxy-1,4 benzoquinone
|
|
|
DG(16:0/0:0/18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:1(13Z)/22:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/22:0/o-18:0)
|
|
|
PC(18:0/24:1(15Z))
|
|
|
PE(P-18:1(11Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/20:1(11Z)/16:1(9Z))
|
|
|
PC(o-16:1(9Z)/18:0)
|
|
|
TG(14:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/24:1(15Z)/0:0)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Trihexosylceramide (d18:1/20:0)
|
|
|
TG(20:3n6/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
LysoPE(0:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
DG(18:1n7/0:0/22:2n6)
|
|
|
Tetrahydrofolic acid
|
A group of heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid units.
|
|
L-Valine
|
The L-enantiomer of valine.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/24:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
D-Lactic acid
|
|
|
TG(18:1(11Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(11Z)/20:2n6)
|
|
|
TG(20:0/20:2n6/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:0/20:3n6/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/20:2(11Z,14Z)/0:0)
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/15:0)
|
|
|
Atenolol
|
An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
|
|
TG(20:2n6/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PS(18:0/16:1(9Z))
|
|
|
Enflurane
|
An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)
|
|
|
PIP3(18:0/16:1(9Z))
|
|
|
TG(20:0/20:0/22:0)
|
|
|
TG(24:0/20:0/18:1(11Z))
|
|
|
TG(16:1(9Z)/20:3n6/20:3n6)
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(16:1(9Z)/18:2(9Z,12Z))
|
|
|
Ganglioside GT2 (d18:1/18:0)
|
|
|
TG(14:1(9Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
6-Thioinosine-5'-monophosphate
|
|
|
Androsterone glucuronide
|
|
|
TG(15:0/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/20:2n6)
|
|
|
PC(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/24:0/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/14:1(9Z)/24:1(15Z))
|
|
|
TG(16:0/24:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:2n6/20:1(11Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:1(11Z)/20:1(11Z))[iso3]
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PC(16:0/P-18:0)
|
|
|
TG(20:0/20:0/20:0)
|
|
|
Epinephrine
|
|
|
P1,P4-Bis(5'-uridyl) tetraphosphate
|
A pyrimidine ribonucleoside 5'-tetraphosphate compound having 5'-uridinyl residues at the P(1)- and P(4)-positions.
|
|
PE(22:1(13Z)/14:1(9Z))
|
|
|
TG(15:0/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
Taurine
|
An amino sulfonic acid that is the 2-amino derivative of ethanesulfonic acid. It is a naturally occurring amino acid derived from methionine and cysteine metabolism.
|
|
PC(P-18:0/20:3(5Z,8Z,11Z))
|
|
|
MG(20:3(5Z,8Z,11Z)/0:0/0:0)
|
|
|
N-Heptanoylglycine
|
An N-acylglycine with an acyl group that is heptanoyl.
|
|
PE(P-18:1(11Z)/18:1(11Z))
|
|
|
PC(22:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(16:0/16:0)
|
|
|
TG(24:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
DG(14:0/20:2(11Z,14Z)/0:0)
|
|
|
PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/14:0/20:3n6)
|
|
|
Methacrylyl-CoA
|
An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of methacrylic acid.
|
|
TG(24:1(15Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
Homogentisic acid
|
A dihydroxyphenylacetic acid having the two hydroxy substituents at the 2- and 5-positions.
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
4,5-Dihydro-4-hydroxy-5-S-glutathionyl-benzo[a]pyrene
|
A peptide that has formula C30H29N3O7S.
|
|
TG(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(24:1(15Z)/24:1(15Z)/0:0)
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))
|
|
|
Pentagastrin
|
|
|
TG(15:0/20:1(11Z)/15:0)
|
|
|
TG(18:0/24:1(15Z)/18:1(9Z))
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/18:1(9Z))
|
|
|
PIP3(16:0/16:0)
|
|
|
PS(14:0/20:3(8Z,11Z,14Z))
|
|
|
TG(14:0/22:1(13Z)/20:3n6)
|
|
|
PC(P-18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
Ganglioside GQ1c (d18:0/25:0)
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3n6)
|
|
|
TG(18:1(11Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PIP(20:1(11Z)/16:0)
|
|
|
TG(16:1(9Z)/18:0/22:2(13Z,16Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
SM(d18:0/24:1(15Z)(OH))
|
|
|
Clemastine
|
2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.
|
|
TG(20:2n6/16:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GD1a (d18:1/25:0)
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/o-18:0/16:1(9Z))
|
|
|
TG(18:1(11Z)/18:0/20:3n6)
|
|
|
PC(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:2n6/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/18:1(9Z)/24:0)
|
|
|
PC(14:0/16:1(9Z))
|
|
|
Prilocaine
|
An amide-type local anaesthetic in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond.
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))
|
|
|
TG(22:0/20:3n6/22:1(13Z))
|
|
|
TG(16:1(9Z)/16:1(9Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:0/20:0/20:3n6)
|
|
|
PC(16:0/16:1(9Z))
|
|
|
TG(16:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:0/14:1(9Z)/20:3n6)
|
|
|
Lithocholyltaurine
|
|
|
Chloroquine
|
An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
|
|
TG(18:2(9Z,12Z)/20:0/o-18:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
6-Hydroxymelatonin
|
A member of the class of tryptamines that is melatonin with a hydroxy group substituent at position 6.
|
|
TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
3b,12a-Dihydroxy-5b-cholanoic acid
|
|
|
PE(20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
DG(20:3n9/0:0/18:4n3)
|
|
|
TG(18:1(11Z)/24:0/18:1(9Z))
|
|
|
TG(16:0/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/20:3n6/18:0)
|
|
|
TG(14:0/16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ketazolam
|
|
|
PC(24:1(15Z)/15:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/20:3n6/16:0)
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/o-18:0)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
L-2,4-diaminobutyric acid
|
A 2,4-diaminobutyric acid that has S-configuration.
|
|
TG(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:1(13Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(15:0/16:1(9Z)/0:0)
|
|
|
PC(o-20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
LysoPC(10:0)
|
|
|
PC(20:2(11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/16:0/18:3(6Z,9Z,12Z))
|
|
|
Trabectedin
|
A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
|
|
Retinyl beta-glucuronide
|
|
|
Flunarizine
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/16:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:0/22:1(13Z)/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(18:3(9Z,12Z,15Z)/14:1(9Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
Deoxyribose 5-monophosphate
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:1(11Z)/18:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PC(18:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(18:0/15:0/18:1(9Z))
|
|
|
PC(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/20:2n6/18:1(11Z))
|
|
|
TG(18:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/o-18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/o-18:0/24:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/15:0/22:2(13Z,16Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PC(18:1(9Z)/24:1(15Z))
|
|
|
TG(18:0/20:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:1(9Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:1(9Z)/14:0/24:1(15Z))
|
|
|
TG(22:1(13Z)/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Formyl-CoA
|
An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of formic acid.
|
|
Ethyl glucuronide
|
|
|
PIP2(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/15:0/0:0)
|
|
|
TG(22:0/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:4(7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
Glycerol 3-phosphate
|
|
|
TG(18:0/18:1(11Z)/18:1(11Z))
|
|
|
TG(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))
|
|
|
DG(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z)/0:0)
|
|
|
PC(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Tartaric acid
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(20:1(11Z)/18:0/o-18:0)
|
|
|
Ganglioside GT1c (d18:1/23:0)
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(P-16:0/14:0)
|
|
|
Diadenosine tetraphosphate
|
|
|
TG(14:0/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Aminoadipic acid
|
|
|
Pemetrexed
|
|
|
L-Canaline
|
|
|
1b,3a,7a-Trihydroxy-5b-cholanoic acid
|
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(15:0/18:0)
|
|
|
TG(18:1(11Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/24:0/20:1(11Z))
|
|
|
TG(24:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(9Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/o-18:0)
|
|
|
TG(24:0/o-18:0/24:1(15Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
NNAL-N-glucuronide
|
An amino acid that has formula C16H23N3O8.
|
|
TG(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Sulfolithocholic acid
|
|
|
TG(22:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:0/o-18:0)
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/24:0)
|
|
|
Glucosylceramide (d18:1/22:0)
|
|
|
DG(24:0/0:0/22:1n9)
|
|
|
Glucosylceramide (d18:1/20:0)
|
|
|
TG(24:0/20:4(8Z,11Z,14Z,17Z)/16:1(9Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Spironolactone
|
A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(20:0/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/24:0/16:0)
|
|
|
TG(18:0/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
Eugenol
|
|
|
TG(14:0/22:0/22:2(13Z,16Z))
|
|
|
TG(24:0/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
PC(P-16:0/20:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GD2 (d18:0/18:1(9Z))
|
|
|
TG(20:0/20:3n6/22:1(13Z))
|
|
|
TG(22:1(13Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PC(20:3(5Z,8Z,11Z)/P-18:0)
|
|
|
TG(14:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:2(11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(20:1(11Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
Astemizole
|
|
|
PI(18:0/16:1(9Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/22:2(13Z,16Z))
|
|
|
PG(18:1(11Z)/16:0)
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:0)
|
|
|
Tetrahexosylceramide (d18:1/9Z-18:1)
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(15:0/22:1(13Z)/22:2(13Z,16Z))
|
|
|
PS(16:1(9Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/18:3(9Z,12Z,15Z))
|
|
|
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Tipranavir
|
A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.
|
|
TG(15:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/18:0/20:2n6)
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
DG(24:1n9/0:0/22:5n3)
|
|
|
PC(16:0/P-18:1(11Z))
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:0)
|
|
|
TG(24:0/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(16:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:3n6)
|
|
|
TG(20:3(5Z,8Z,11Z)/14:0/24:1(15Z))
|
|
|
TG(22:0/22:0/20:3n6)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(18:0/22:2(13Z,16Z)/20:1(11Z))
|
|
|
PC(20:2(11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:0/18:1(9Z)/20:2n6)
|
|
|
Galactinol
|
|
|
TG(18:1(11Z)/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
4a-Methylfecosterol
|
|
|
2-(S-Glutathionyl)acetyl glutathione
|
A peptide that has formula C22H34N6O13S2.
|
|
TG(14:1(9Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Estriol 3-sulfate 16-glucuronide
|
|
|
Phenylacetic acid
|
A monocarboxylic acid that is benzene substituted with a carboxymethyl functional group.
|
|
TG(20:1(11Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/22:1(13Z)/14:1(9Z))
|
|
|
TG(22:1(13Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:1(15Z)/20:0/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(14:0/0:0/14:1n5)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
TG(18:1(11Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
17a,21-Dihydroxypreg-nenolone
|
|
|
TG(20:1(11Z)/24:1(15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:2n6/20:2n6/18:3(9Z,12Z,15Z))
|
|
|
PC(20:0/18:2(9Z,12Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
PIP2(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/18:1(9Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/24:1(15Z)/18:1(9Z))
|
|
|
TG(24:1(15Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(18:2n6/0:0/22:6n3)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(15:0/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(20:3n6/20:3n6/18:3(9Z,12Z,15Z))
|
|
|
DG(14:1(9Z)/14:1(9Z)/0:0)
|
|
|
DG(20:1n9/0:0/22:6n3)
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/14:0/18:1(11Z))[iso6]
|
|
|
TG(14:1(9Z)/16:0/20:1(11Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:0/16:0)
|
|
|
PE(20:2(11Z,14Z)/15:0)
|
|
|
TG(18:1(9Z)/20:0/o-18:0)
|
|
|
TG(20:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/P-18:0)
|
|
|
TG(22:0/24:0/22:2(13Z,16Z))
|
|
|
TG(14:0/20:0/14:0)
|
|
|
TG(20:3n6/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))
|
|
|
PS(18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
15,15'-Dihydroxy-beta-carotene
|
A carotenol obtained by formal dihydroxylation across the 15,15'-double bond of beta-carotene.
|
|
TG(20:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
N-Acetyl-D-glucosamine
|
The pyranose form of N-acetyl-D-glucosamine.
|
|
PE(P-18:0/22:1(13Z))
|
|
|
DG(14:0/0:0/16:0)
|
|
|
1,2-Dibromoethane
|
A bromoalkane that is ethane carrying bromo substituents at positions 1 and 2. It is produced by marine algae.
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(16:1(9Z)/24:1(15Z)/22:1(13Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:1(11Z)/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:2n6/22:1(13Z))
|
|
|
TG(18:1(11Z)/20:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
Benzatropine
|
Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.
|
|
1-Pyrroline-2-carboxylic acid
|
The product resulting from formal oxidation of DL-proline by loss of hydrogen from the nitrogen and from the carbon alpha to the carboxylic acid, with the formation of a C=N bond.
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/0:0)
|
|
|
3a,7a-Dihydroxy-5b-cholestanoyl-CoA
|
|
|
TG(20:1(11Z)/20:3n6/22:2(13Z,16Z))
|
|
|
Coumarin
|
|
|
TG(16:1(9Z)/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Guanosine triphosphate
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
Nickel
|
Chemical element (nickel group element atom) with atomic number 28.
|
|
Sevoflurane
|
An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.
|
|
TG(16:0/22:2(13Z,16Z)/18:0)
|
|
|
Quinolinic acid
|
A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
|
|
TG(14:1(9Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PE(20:3(8Z,11Z,14Z)/22:0)
|
|
|
Fluphenazine
|
A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position.
|
|
Phenylpyruvic acid
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/o-18:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(P-16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/22:0)
|
|
|
TG(18:0/18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:0)
|
|
|
PE(14:0/20:3(5Z,8Z,11Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
TG(24:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/20:3n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(24:1(15Z)/22:1(13Z))
|
|
|
DG(22:5n6/0:0/20:4n3)
|
|
|
TG(18:1(11Z)/20:1(11Z)/18:2(9Z,12Z))
|
|
|
Aminofructose 6-phosphate
|
A phospho sugar that has formula C6H14NO8P.
|
|
TG(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:0)
|
|
|
TG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
Epimelibiose
|
A glycosylgalactose composed of alpha-D-mannopyranose and alpha-D-galactopyranose units.
|
|
Caffeic acid
|
A hydroxycinnamic acid that is cinnamic acid in which the phenyl ring is substituted by hydroxy groups at positions 3 and 4. It exists in cis and trans forms; the latter is the more common.
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(20:1(11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/18:0/0:0)
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(18:1(11Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:1(11Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/o-18:0/18:1(11Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(16:1(9Z)/24:0/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
TG(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:1n9/0:0/22:4n6)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/24:1(15Z))
|
|
|
TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/20:2n6)
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Desogestrel
|
|
|
TG(18:1(9Z)/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/16:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(15:0/0:0/18:2n6)
|
|
|
TG(20:2n6/20:0/20:3n6)
|
|
|
TG(22:2(13Z,16Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
TG(20:0/o-18:0/18:1(9Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/15:0)
|
|
|
Diphenoxylate
|
A piperidinecarboxylate ester that is the ethyl ester of difenoxin.
|
|
Ethinamate
|
|
|
TG(20:0/14:0/20:1(11Z))
|
|
|
TG(24:1(15Z)/20:3n6/24:1(15Z))
|
|
|
PC(18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3,17-Androstanediol glucuronide
|
|
|
TG(14:0/18:1(11Z)/18:1(9Z))
|
|
|
TG(24:0/24:1(15Z)/20:1(11Z))
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/18:0/0:0)
|
|
|
TG(14:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/20:3n6/22:2(13Z,16Z))
|
|
|
TG(18:0/22:2(13Z,16Z)/24:0)
|
|
|
TG(18:1(9Z)/15:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(20:3n6/20:2n6/22:2(13Z,16Z))
|
|
|
TG(20:3n6/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:1(11Z))
|
|
|
PC(P-18:1(11Z)/18:0)
|
|
|
PC(20:1(11Z)/18:1(9Z))
|
|
|
TG(22:0/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
PG(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Dexfenfluramine
|
|
|
PC(20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
Dexrazoxane
|
A razoxane that has formula C11H16N4O4.
|
|
TG(14:1(9Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Metoprolol
|
A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
|
|
TG(14:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Propanal
|
An aldehyde that consists of ethane bearing a formyl substituent. The parent of the class of propanals.
|
|
PC(18:4(6Z,9Z,12Z,15Z)/P-16:0)
|
|
|
Mitiglinide
|
|
|
TG(22:0/14:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
CE(14:0)
|
|
|
TG(20:1(11Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:1(15Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z)/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/16:0/24:1(15Z))
|
|
|
5,10-Methenyltetrahydrofolic acid
|
|
|
(R)-3-Hydroxy-hexadecanoic acid
|
|
|
Enprofylline
|
Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
|
|
Dicyclomine
|
The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
3-Polyprenyl-4-hydroxy-5-methoxybenzoate
|
|
|
PE(20:0/18:0)
|
|
|
PC(20:1(11Z)/22:2(13Z,16Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
PC(24:0/20:3(5Z,8Z,11Z))
|
|
|
CE(16:0)
|
|
|
TG(18:2(9Z,12Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))[iso3]
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(22:0/0:0/24:0)
|
|
|
TG(20:0/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))
|
|
|
PE(20:4(5Z,8Z,11Z,14Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:2n6)
|
|
|
Glycine
|
The simplest (and the only achiral) proteinogenic amino acid, with a hydrogen atom as its side chain.
|
|
TG(18:1(9Z)/20:2n6/24:1(15Z))
|
|
|
TG(20:0/18:2(9Z,12Z)/20:0)
|
|
|
Diltiazem
|
A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.
|
|
TG(20:1(11Z)/16:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(24:1(15Z)/18:0/0:0)
|
|
|
TG(20:0/18:2(9Z,12Z)/22:0)
|
|
|
TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
CL(18:2(9Z,12Z)/18:1(11Z)/18:1(9Z)/16:0)
|
|
|
Trans-3-hydroxy-L-proline
|
The (3S)-trans-diastereomer of 3-hydroxy-L-proline.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PG(16:0/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/16:1(9Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
3-Hydroxyhippuric acid
|
|
|
TG(20:1(11Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM2 (d18:0/14:0)
|
|
|
TG(14:0/20:1(11Z)/20:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:0/16:1(9Z))
|
|
|
TG(20:3n6/16:1(9Z)/o-18:0)
|
|
|
TG(22:0/o-18:0/18:1(11Z))
|
|
|
PC(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(22:0/24:0/18:3(6Z,9Z,12Z))
|
|
|
PIP(18:0/18:3(6Z,9Z,12Z))
|
|
|
PE(22:1(13Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(20:1(11Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:2n6/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GT2 (d18:0/18:1(11Z))
|
|
|
TG(24:1(15Z)/20:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/o-18:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/18:3(6Z,9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(22:0/18:1(11Z)/24:0)
|
|
|
TG(18:1(11Z)/14:0/20:2n6)
|
|
|
DG(16:1(9Z)/20:3(5Z,8Z,11Z)/0:0)
|
|
|
PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/18:0)
|
|
|
PE(14:1(9Z)/14:0)
|
|
|
TG(14:0/20:0/22:2(13Z,16Z))
|
|
|
TG(18:0/o-18:0/14:1(9Z))
|
|
|
Halofuginone
|
|
|
PE(14:1(9Z)/16:0)
|
|
|
DG(15:0/14:1(9Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(20:2n6/22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/16:0)
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PC(14:1(9Z)/18:1(9Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GA2 (d18:1/16:0)
|
|
|
1,2-Dioctadecanoyl-3-(galactosyl-B-1-6-galactosyl-B-1)-glycerol
|
|
|
TG(22:0/24:1(15Z)/14:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:0/14:1(9Z)/20:1(11Z))
|
|
|
N(6)-(1,2-dicarboxyethyl)AMP
|
The N(6)-(1,2-dicarboxyethyl) derivative of adenosine 5'-monophosphate.
|
|
PIP2(18:0/16:2(9Z,12Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(18:2(9Z,12Z)/P-18:1(9Z))
|
|
|
Isovalerylglucuronide
|
|
|
TG(15:0/20:3n6/18:1(11Z))
|
|
|
TG(22:1(13Z)/20:3n6/18:2(9Z,12Z))
|
|
|
LysoPC(0:0/18:0)
|
|
|
TG(18:1(11Z)/18:4(6Z,9Z,12Z,15Z)/20:2n6)
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:0)
|
|
|
TG(18:2(9Z,12Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
MG(14:0/0:0/0:0)
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(20:3n6/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
5-L-Glutamyl-taurine
|
|
|
TG(18:0/14:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(18:0/20:1(11Z))
|
|
|
TG(20:0/18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:0/20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
DG(18:1(11Z)/16:1(9Z)/0:0)
|
|
|
PE(20:2(11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
PE(22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ceftizoxime
|
|
|
PC(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(15:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:0/18:0/18:1(11Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(24:1(15Z)/24:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
MG(0:0/18:1(9Z)/0:0)
|
|
|
TG(14:1(9Z)/24:0/18:2(9Z,12Z))
|
|
|
DG(14:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/16:1(9Z)/o-18:0)
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:3n6/22:2(13Z,16Z))
|
|
|
TG(16:0/16:1(9Z)/18:0)[iso6]
|
|
|
TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(24:1(15Z)/22:0/0:0)
|
|
|
DG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/0:0)
|
|
|
TG(14:0/18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
dermatan L-iduronate
|
|
|
PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))
|
|
|
TG(18:0/16:0/16:1(9Z))
|
|
|
3a,6b,7b-Trihydroxy-5b-cholanoic acid
|
|
|
TG(20:2n6/18:2(9Z,12Z)/22:2(13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Dexamethasone
|
A fluorinated steroid that is 9-fluoropregna-1,4-diene substituted by hydroxy groups at positions 11, 17 and 21, a methyl group at position 16 and oxo groups at positions 3 and 20. It is a synthetic member of the class of glucocorticoids.
|
|
11b,21-Dihydroxy-3,20-oxo-5b-pregnan-18-al
|
|
|
TG(20:0/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(o-14:0/16:0)
|
|
|
TG(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/o-18:0/22:2(13Z,16Z))
|
|
|
TG(15:0/16:1(9Z)/24:0)
|
|
|
TG(16:1(9Z)/20:2n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(18:3(9Z,12Z,15Z)/18:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(14:0/16:1(9Z)/15:0)
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
|
|
|
Ganglioside GD1a (d18:0/22:1(13Z))
|
|
|
DG(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
DG(24:0/0:0/14:1n5)
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:1(11Z)/22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:3(5Z,8Z,11Z)/18:0)
|
|
|
TG(20:0/16:1(9Z)/o-18:0)
|
|
|
TG(16:0/20:3n6/20:3n6)
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:2(13Z,16Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))
|
|
|
TG(16:1(9Z)/14:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:2n6)
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Levocabastine
|
|
|
TG(14:0/15:0/20:3(5Z,8Z,11Z))
|
|
|
TG(24:1(15Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/P-16:0)
|
|
|
TG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
PC(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
SM(d16:1/24:1(15Z))
|
|
|
TG(14:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:2n6/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/16:1(9Z)/22:1(13Z))
|
|
|
TG(18:1(11Z)/24:0/o-18:0)
|
|
|
Levomethadyl Acetate
|
|
|
Ticagrelor
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:0/18:3(9Z,12Z,15Z))[iso6]
|
|
|
PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:0)
|
|
|
Thymidine 3',5'-cyclic monophosphate
|
|
|
PC(P-18:0/20:2(11Z,14Z))
|
|
|
TG(24:1(15Z)/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PG(18:0/18:1(9Z))
|
|
|
TG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
PS(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GD1b (d18:1/18:1(9Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/22:0/20:2n6)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(18:2(9Z,12Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
TG(16:1(9Z)/18:1(11Z)/18:1(9Z))
|
|
|
TG(14:0/15:0/18:1(9Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Bifonazole
|
|
|
TG(22:0/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
PI(18:3(9Z,12Z,15Z)/22:3(10Z,13Z,16Z))
|
|
|
TG(16:0/16:1(9Z)/18:1(11Z))
|
|
|
TG(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/20:0)
|
|
|
TG(18:1(11Z)/20:2n6/22:1(13Z))
|
|
|
Methohexital
|
A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.
|
|
TG(15:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/o-18:0)
|
|
|
TG(15:0/20:1(11Z)/20:2n6)
|
|
|
TG(22:1(13Z)/22:0/20:3n6)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/24:0)
|
|
|
Hydroxycotinine
|
|
|
PG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(24:0/20:3(8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/14:1(9Z)/18:0)
|
|
|
TG(20:0/18:1(9Z)/16:1(9Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/16:1(9Z))
|
|
|
TG(18:0/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(16:1(9Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/18:1(9Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:2(9Z,12Z)/20:2n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Inosine
|
A purine nucleoside in which hypoxanthine is attached to ribofuranose via a beta-N(9)-glycosidic bond.
|
|
Bethanidine
|
|
|
N1-Acetylspermidine
|
An acetylspermidine having the acetyl group at the N1-position.
|
|
9-cis-Retinoic acid
|
A retinoic acid in which the exocyclic double bonds have 7E,9Z,11E,13E geometry.
|
|
TG(24:0/20:3n6/22:2(13Z,16Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/22:1(13Z))
|
|
|
SM(d18:0/18:1(11Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(18:0/18:0)
|
|
|
PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:0/18:1(11Z)/24:1(15Z))
|
|
|
TG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:0/18:4(6Z,9Z,12Z,15Z)/18:0)
|
|
|
TG(15:0/20:4(8Z,11Z,14Z,17Z)/18:1(9Z))
|
|
|
TG(22:0/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
Homocarnosine
|
A modified histidine derivative with a aminobutanoyl group substituted on the alpha-amino group.
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/16:0/18:0)[iso3]
|
|
|
TG(15:0/20:0/18:0)
|
|
|
3,7-Dimethyluric acid
|
An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trione substituted by methyl groups at N-3 and N-7.
|
|
TG(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(18:1(9Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Citric acid
|
A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
|
|
TG(24:1(15Z)/20:2n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PI(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/20:3n6/20:4(8Z,11Z,14Z,17Z))
|
|
|
Homo-L-arginine
|
|
|
Xylulose 5-phosphate
|
A xylulose phosphate carrying a phospahte group at position 5. It is an intermediate metabolite in the pentose phosphate pathway.
|
|
TG(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
3-Oxododecanoyl-CoA
|
|
|
TG(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))
|
|
|
DG(16:0/22:0/0:0)
|
|
|
Fluvoxamine
|
A 5-methoxyvalerophenone O-(2-aminoethyl)oxime that has formula C15H21F3N2O2.
|
|
TG(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/18:3(9Z,12Z,15Z))
|
|
|
Selenohomocysteine
|
A selenoamino acid that is the selenium analogue of L-homocysteine.
|
|
TG(18:1(11Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:1(13Z)/o-18:0/22:1(13Z))
|
|
|
Gulonic acid
|
A hexonic acid formed by oxidising the aldehyde group of gulose to a carboxylic acid group.
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PE(15:0/15:0)
|
|
|
TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Ganglioside GD2 (d18:0/12:0)
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/18:0/o-18:0)
|
|
|
Estazolam
|
A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.
|
|
TG(24:1(15Z)/20:3n6/18:2(9Z,12Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PS(16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PG(16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(20:3n6/20:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:1(9Z)/18:0/18:1(11Z))[iso6]
|
|
|
Guanosine diphosphate mannose
|
|
|
TG(20:3(5Z,8Z,11Z)/18:1(9Z)/22:1(13Z))
|
|
|
TG(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(14:1(9Z)/24:1(15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(14:1(9Z)/14:1(9Z)/18:1(9Z))
|
|
|
PE(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(18:1(9Z)/15:0/20:3(5Z,8Z,11Z))
|
|
|
DG(22:0/16:0/0:0)
|
|
|
TG(22:2(13Z,16Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
PI(18:0/22:4(10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:0/22:1(13Z))
|
|
|
TG(15:0/22:2(13Z,16Z)/24:1(15Z))
|
|
|
TG(18:0/18:0/24:1(15Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
Trimethylamine N-oxide
|
An N-oxide derived from triethylamine.
|
|
PE(14:1(9Z)/15:0)
|
|
|
TG(22:0/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:2n6/20:3(5Z,8Z,11Z))
|
|
|
TG(24:0/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
Allylestrenol
|
|
|
PI(18:0/16:2(9Z,12Z))
|
|
|
TG(14:0/18:0/20:3(5Z,8Z,11Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
DG(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/0:0)
|
|
|
DG(18:0/0:0/18:3n3)
|
|
|
PE(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:2(13Z,16Z)/18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/20:2n6/18:0)
|
|
|
TG(18:1(9Z)/14:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/24:1(15Z))
|
|
|
Ganglioside GA1 (d18:1/26:0)
|
|
|
DG(20:2n6/0:0/18:4n3)
|
|
|
6-Methylmercaptopurine
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/22:2(13Z,16Z)/22:1(13Z))
|
|
|
TG(16:0/22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PIP2(18:2(9Z,12Z)/20:2(11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:0/o-18:0)
|
|
|
TG(16:1(9Z)/20:1(11Z)/20:3(5Z,8Z,11Z))
|
|
|
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
24-Methylenelophenol
|
|
|
TG(18:1(9Z)/18:1(11Z)/22:1(13Z))
|
|
|
Tizanidine
|
2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
|
|
TG(18:3(9Z,12Z,15Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/22:0/18:2(9Z,12Z))
|
|
|
TG(22:0/18:0/16:1(9Z))
|
|
|
TG(22:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:2(13Z,16Z)/22:1(13Z)/0:0)
|
|
|
TG(18:2(9Z,12Z)/14:0/o-18:0)
|
|
|
DG(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(20:1(11Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
|
|
|
DG(15:0/18:2(9Z,12Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/16:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:0/0:0/22:4n6)
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)
|
|
|
TG(16:0/o-18:0/22:1(13Z))
|
|
|
TG(24:1(15Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
8-Methoxykynurenate
|
|
|
TG(18:0/14:1(9Z)/14:1(9Z))
|
|
|
Uroporphyrinogen III
|
An uroporphyrinogen that has formula C40H44N4O16.
|
|
TG(18:1(11Z)/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
Ganglioside GT3 (d18:1/24:0)
|
|
|
TG(22:1(13Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(20:0/18:3(9Z,12Z,15Z)/18:1(9Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/0:0)
|
|
|
TG(20:2n6/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
N-Acetylneuraminic acid 9-phosphate
|
An amino sugar phosphate that has formula C11H20NO12P.
|
|
Ganglioside GT3 (d18:1/26:0)
|
|
|
TG(16:0/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/18:2(9Z,12Z)/14:1(9Z))
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(24:1(15Z)/18:1(11Z)/20:3n6)
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
PC(18:0/14:1(9Z))
|
|
|
Succinic acid semialdehyde
|
|
|
TG(14:1(9Z)/20:2n6/16:1(9Z))
|
|
|
DG(22:2(13Z,16Z)/18:1(11Z)/0:0)
|
|
|
DG(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
(S)-Hydroxyhexanoyl-CoA
|
|
|
PE(15:0/18:1(9Z))
|
|
|
PI(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PI(18:3(6Z,9Z,12Z)/18:1(9Z))
|
|
|
TG(14:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(14:0/18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PG(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
D-Glucurono-6,3-lactone
|
A glucuronolactone that has formula C6H8O6.
|
|
TG(22:1(13Z)/18:1(9Z)/22:1(13Z))
|
|
|
TG(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:2n6)
|
|
|
TG(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/o-18:0)
|
|
|
2-Oxo-3-hydroxy-4-phosphobutanoic acid
|
|
|
TG(16:1(9Z)/18:3(6Z,9Z,12Z)/22:1(13Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/22:0/o-18:0)
|
|
|
Guanosine diphosphate
|
|
|
TG(20:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(16:0/22:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:2n6/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:1(13Z)/18:1(9Z)/20:3n6)
|
|
|
TG(18:1(11Z)/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
NADH
|
A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/22:0/o-18:0)
|
|
|
NADP
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/16:1(9Z))
|
|
|
Thiocyanate
|
A pseudohalide anion obtained by deprotonation of the thiol group of thiocyanic acid.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/18:0)
|
|
|
TG(16:1(9Z)/15:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/22:1(13Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:1(13Z)/20:2n6/18:2(9Z,12Z))
|
|
|
TG(18:2(9Z,12Z)/16:1(9Z)/18:2(9Z,12Z))
|
|
|
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
TG(22:1(13Z)/20:4(8Z,11Z,14Z,17Z)/20:3n6)
|
|
|
Chlorzoxazone
|
A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.
|
|
TG(24:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
PE(P-18:1(11Z)/14:1(9Z))
|
|
|
cis-4-Hydroxy-D-proline
|
D-proline in which a hydrogen at the 4-position of the pyrrolidine ring is substituted by a hydroxy group (R-configuration).
|
|
PI(18:2(9Z,12Z)/20:2(11Z,14Z))
|
|
|
DG(22:2(13Z,16Z)/24:1(15Z)/0:0)
|
|
|
TG(14:0/20:0/20:2n6)
|
|
|
Lomustine
|
|
|
TG(18:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:0/18:3(6Z,9Z,12Z)/16:1(9Z))
|
|
|
Ipratropium bromide
|
The anhydrous form of the bromide salt of ipratropium. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstructive pulmonary disease and acute asthma.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Torasemide
|
An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea.
|
|
Carboplatin
|
A platinum coordination entity with cis square-planar geometry in which platinum(II) is coordinated to two ammonia ligands and a bidentate cyclobutane-1,1-dicarboxylate ligand.
|
|
TG(22:0/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Ganglioside GD2 (d18:1/26:1(15Z))
|
|
|
TG(16:0/22:0/20:2n6)
|
|
|
PC(16:1(9Z)/18:1(9Z))
|
|
|
TG(20:1(11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
PS(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z))
|
|
|
Docosanoyl-CoA
|
An acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of behenoyl-CoA; major species at pH 7.3.
|
|
TG(22:5(7Z,10Z,13Z,16Z,19Z)/15:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Bacitracin
|
A mixture of at least nine closely related homodetic cyclic peptides produced by Bacillus subtilis and B. licheniformis, which is particularly active against Gram-positive bacteria.
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
Glycochenodeoxycholate-3-sulfate
|
|
|
Benzoyl phosphate
|
An acyl monophosphate that has formula C7H7O5P.
|
|
TG(20:3(5Z,8Z,11Z)/20:2n6/22:2(13Z,16Z))
|
|
|
TG(14:1(9Z)/20:0/o-18:0)
|
|
|
TG(18:0/14:0/18:1(9Z))[iso6]
|
|
|
TG(16:0/24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
Danazol
|
A 17beta-hydroxy steroid that has formula C22H27NO2.
|
|
Mefloquine
|
A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.
|
|
TG(22:0/22:1(13Z)/o-18:0)
|
|
|
TG(20:0/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
DG(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
LysoPE(20:3(11Z,14Z,17Z)/0:0)
|
|
|
PI(18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
Resveratrol
|
|
|
DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)/0:0)
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))
|
|
|
TG(20:1(11Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PE(14:0/P-16:0)
|
|
|
Aldophosphamide
|
A nitrogen mustard that has formula C7H15Cl2N2O3P.
|
|
TG(16:0/22:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/20:3(5Z,8Z,11Z)/20:1(11Z))
|
|
|
5-Deoxyribose-1-phosphate
|
|
|
TG(20:3n6/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/14:1(9Z)/18:2(9Z,12Z))
|
|
|
Protoporphyrinogen IX
|
A porphyrinogen that has formula C34H40N4O4.
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
DG(22:0/22:2(13Z,16Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
PE(P-16:0/22:1(13Z))
|
|
|
TG(22:1(13Z)/24:0/22:2(13Z,16Z))
|
|
|
TG(20:3n6/20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/14:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PS(16:0/14:1(9Z))
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:0/o-18:0)
|
|
|
TG(16:1(9Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Ganglioside GT1b (d18:0/20:0)
|
|
|
DG(20:1(11Z)/16:0/0:0)
|
|
|
PS(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(20:0/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/18:0/24:1(15Z))
|
|
|
Dolasetron
|
|
|
TG(20:1(11Z)/22:1(13Z)/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
TG(16:1(9Z)/22:2(13Z,16Z)/24:1(15Z))
|
|
|
DG(15:0/22:1(13Z)/0:0)
|
|
|
Tetrahydrocorticosterone
|
A 21-hydroxy steroid that has formula C21H34O4.
|
|
Escitalopram
|
|
|
17-HETE
|
A HETE that consists of arachidonic acid bearing an additional hydroxy substituent at position 17.
|
|
TG(24:1(15Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(20:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:2n6)
|
|
|
TG(18:0/16:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP2(18:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
CE(20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
MG(0:0/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/14:0/24:1(15Z))
|
|
|
DG(15:0/0:0/18:3n3)
|
|
|
TG(14:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/18:1(9Z)/20:1(11Z))[iso6]
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/16:0/20:3(5Z,8Z,11Z))
|
|
|
Nicotinate D-ribonucleoside
|
|
|
Ganglioside GD2 (d18:0/25:0)
|
|
|
PC(P-16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
4-Phosphopantothenoylcysteine
|
|
|
trans-3-Hexenoyl-CoA
|
|
|
TG(22:1(13Z)/20:3n6/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(20:0/22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(14:0/16:1(9Z)/16:1(9Z))
|
|
|
DG(18:0/0:0/20:0)
|
|
|
(R)-b-aminoisobutyric acid
|
|
|
DG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/0:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GD2 (d18:1/24:0)
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(24:0/20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:2(9Z,12Z)/22:0/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
3-Methylthiopropionic acid
|
A thia fatty acid acid consisting of propionic acid with a methylthio substituent at the 3-position; an intermediate in mammalian methionine metabolism in vitro. The simplest known phytotoxin, it is a blight-inducing toxin produced by the cassava pathogen Xanthomonas campestris manihotis.
|
|
TG(18:1(11Z)/20:3n6/22:1(13Z))
|
|
|
2-Naphthaldehyde
|
A naphthaldehyde that is naphthalene substituted by a formyl group at position 2.
|
|
TG(15:0/18:1(9Z)/18:2(9Z,12Z))[iso6]
|
|
|
TG(16:0/16:1(9Z)/24:1(15Z))
|
|
|
TG(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Cyproheptadine
|
The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
|
|
TG(15:0/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:0/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Beta-D-Galactose
|
A D-galactopyranose having beta-configuration at the anomeric centre.
|
|
PC(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))
|
|
|
TG(22:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
CL(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)/18:2(9Z,12Z)/16:1(9Z))
|
|
|
TG(16:0/22:1(13Z)/14:1(9Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)
|
|
|
TG(22:0/20:3n6/24:1(15Z))
|
|
|
TG(18:1(9Z)/14:1(9Z)/22:1(13Z))
|
|
|
TG(16:1(9Z)/14:0/20:3n6)
|
|
|
TG(16:0/20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(14:0/14:1(9Z)/24:1(15Z))
|
|
|
Oxaliplatin
|
A platinum coordination entity that has formula C6H14N2.C2O4.Pt.
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:0/15:0/20:1(11Z))
|
|
|
TG(20:2n6/o-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]
|
|
|
TG(20:3(5Z,8Z,11Z)/18:0/18:3(6Z,9Z,12Z))
|
|
|
TG(20:0/20:1(11Z)/20:0)
|
|
|
TG(24:0/o-18:0/20:1(11Z))
|
|
|
Lumiracoxib
|
An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.
|
|
Bleomycin
|
A glycopeptide antibiotic produced by the bacterium Streptomyces verticillus. The term, 'bleomycin' refers to a family of structurally related compounds. When used as an anti-cancer agent, the chemotherapeutical forms are primarily bleomycin A2 and B2.
|
|
TG(18:1(9Z)/16:1(9Z)/o-18:0)
|
|
|
TG(18:1(9Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
O-Phospho-4-hydroxy-L-threonine
|
|
|
TG(20:3(5Z,8Z,11Z)/22:2(13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)
|
|
|
Angiotensin I
|
A peptide that has formula C63H91N17O13.
|
|
TG(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:1(11Z)/20:3n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Etiocholanolone glucuronide
|
|
|
TG(16:0/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(14:0/18:0/20:3n6)
|
|
|
21-Deoxycortisol
|
A deoxycortisol that has formula C21H30O4.
|
|
Phentolamine
|
|
|
TG(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
2-Methylbutyrylglycine
|
|
|
TG(18:3(9Z,12Z,15Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
(E)-2-Butenal
|
|
|
TG(18:1(11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/14:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(20:3n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/24:0/24:0)
|
|
|
PC(22:0/14:1(9Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:0/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)/0:0)
|
|
|
TG(18:1(11Z)/16:0/18:1(9Z))[iso6]
|
|
|
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:1(11Z)/18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))
|
|
|
NTP
|
|
|
TG(18:0/20:3n6/18:1(11Z))
|
|
|
TG(20:3n6/o-18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
DG(24:1n9/0:0/22:2n6)
|
|
|
TG(20:0/20:1(11Z)/22:0)
|
|
|
TG(16:1(9Z)/14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ganglioside GM2 (d18:1/22:0)
|
|
|
TG(16:0/22:2(13Z,16Z)/18:1(11Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3n6/22:0/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/o-18:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Cysteic acid
|
An amino sulfonic acid that is the sulfonic acid analogue of cysteine.
|
|
TG(20:0/22:2(13Z,16Z)/o-18:0)
|
|
|
TG(18:0/18:1(11Z)/22:0)
|
|
|
TG(22:0/24:0/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:2(9Z,12Z)/18:0/20:2n6)
|
|
|
PE(20:3(5Z,8Z,11Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))
|
|
|
Hydrogen sulfide
|
A sulfur hydride consisting of s single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.
|
|
TG(20:0/22:1(13Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/16:0/20:3n6)
|
|
|
TG(18:2(9Z,12Z)/16:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/24:0/22:0)
|
|
|
PG(18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Bambuterol
|
|
|
DG(18:3n3/0:0/20:4n3)
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:0)
|
|
|
PC(18:4(6Z,9Z,12Z,15Z)/P-18:1(9Z))
|
|
|
Dihydrotestosterone
|
|
|
TG(20:1(11Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(P-18:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/20:3n6/14:1(9Z))
|
|
|
TG(15:0/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))
|
|
|
TG(24:1(15Z)/18:1(9Z)/20:3n6)
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/20:2n6/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(24:0/o-18:0/18:3(6Z,9Z,12Z))
|
|
|
Homovanillic acid
|
A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
|
|
TG(20:2n6/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))
|
|
|
Guanosine monophosphate
|
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
PE(P-18:1(9Z)/18:2(9Z,12Z))
|
|
|
PC(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
PC(18:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/14:0/20:3n6)
|
|
|
DG(20:2n6/0:0/22:6n3)
|
|
|
Loperamide
|
A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
|
|
LysoPC(18:3(6Z,9Z,12Z))
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
|
|
|
TG(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))
|
|
|
TG(22:0/18:1(9Z)/22:1(13Z))
|
|
|
PI(18:1(11Z)/20:1(11Z))
|
|
|
PE(P-16:0/24:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/20:3n6)
|
|
|
TG(15:0/22:0/18:3(9Z,12Z,15Z))
|
|
|
Dehydroisoandrosterone 3-glucuronide
|
A steroid glucosiduronic acid having dehydroepiandrosterone as the steroid component.
|
|
TG(14:0/20:3(5Z,8Z,11Z)/14:0)
|
|
|
TG(20:1(11Z)/24:1(15Z)/22:2(13Z,16Z))
|
|
|
TG(20:2n6/18:1(11Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(18:1(9Z)/22:2(13Z,16Z)/20:3(5Z,8Z,11Z))
|
|
|
Isoproterenol
|
|
|
TG(18:0/18:3(6Z,9Z,12Z)/14:1(9Z))
|
|
|
TG(18:1(9Z)/16:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:2n6/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:1(13Z)/15:0/18:2(9Z,12Z))
|
|
|
TG(14:0/22:2(13Z,16Z)/20:3n6)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/22:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:3n6/20:0/o-18:0)
|
|
|
PE(14:0/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Ramipril
|
A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.
|
|
Ganglioside GM3 (d18:0/12:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/16:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/24:0/24:1(15Z))
|
|
|
TG(18:0/20:4(8Z,11Z,14Z,17Z)/14:1(9Z))
|
|
|
TG(20:2n6/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
(S)-3-Hydroxydodecanoyl-CoA
|
|
|
TG(20:2n6/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(20:2n6/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/20:0/18:3(9Z,12Z,15Z))
|
|
|
PC(o-24:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/20:1(11Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))
|
|
|
TG(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3n6)
|
|
|
TG(22:0/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(18:2(9Z,12Z)/22:1(13Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))
|
|
|
DG(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)/0:0)
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/o-18:0/22:2(13Z,16Z))
|
|
|
PI(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))
|
|
|
DG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/0:0)
|
|
|
S-Glutaryldihydrolipoamide
|
|
|
TG(20:2n6/18:0/18:3(9Z,12Z,15Z))
|
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:3(5Z,8Z,11Z))
|
|
|
Saquinavir
|
|
|
TG(14:0/20:1(11Z)/24:1(15Z))
|
|
|
TG(22:1(13Z)/22:1(13Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z)/o-18:0)
|
|
|
TG(24:0/18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:1(11Z)/o-18:0)
|
|
|
TG(18:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/o-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
6-Hydroxy-5-methoxyindole glucuronide
|
|
|
TG(24:0/22:0/22:2(13Z,16Z))
|
|
|
TG(16:0/22:0/16:0)
|
|
|
TG(18:1(9Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
3-Keto-4-methylzymosterol
|
|
|
TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/15:0/16:0)
|
|
|
Clotiazepam
|
|
|
TG(20:0/20:4(8Z,11Z,14Z,17Z)/22:1(13Z))
|
|
|
PIP2(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))
|
|
|
TG(14:1(9Z)/18:2(9Z,12Z)/24:1(15Z))
|
|
|
TG(18:1(11Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:0/o-18:0)
|
|
|
Ethoxzolamide
|
1,3-Benzothiazole substituted a sulfonamide and an ethoxy group at positions 2 and 6, respectively. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.
|
|
Roxatidine acetate
|
|
|
TG(24:0/24:1(15Z)/o-18:0)
|
|
|
PC(18:0/20:2(11Z,14Z))
|
|
|
(-)-trans-Carveol
|
|
|
TG(22:0/20:0/22:0)
|
|
|
5alpha-Pregnane-3alpha,20alpha-diol
|
A corticosteroid hormone that has formula C21H36O2.
|
|
TG(18:1(11Z)/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:2(13Z,16Z)/20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(20:2n6/22:0/18:3(9Z,12Z,15Z))
|
|
|
TG(22:0/22:1(13Z)/20:2n6)
|
|
|
PC(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
CE(22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/14:0/20:3(5Z,8Z,11Z))
|
|
|
DG(24:0/0:0/22:5n6)
|
|
|
TG(22:0/22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))
|
|
|
Bilirubin glucuronide
|
|
|
Cer(d18:0/14:0)
|
|
|
TG(18:1(11Z)/22:0/20:2n6)
|
|
|
TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(14:0/15:0/14:0)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)/22:2(13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/20:0/20:0)[iso3]
|
|
|
TG(22:2(13Z,16Z)/16:1(9Z)/22:2(13Z,16Z))
|
|
|
4-Aminohippuric acid
|
|
|
TG(18:0/20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(24:0/16:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
TG(20:3n6/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PS(14:1(9Z)/16:0)
|
|
|
TG(16:0/20:2n6/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:0/o-18:0/18:3(9Z,12Z,15Z))
|
|
|
Triiodothyronine glucuronide
|
|
|
TG(20:1(11Z)/24:0/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(14:0/18:0/20:1(11Z))
|
|
|
TG(15:0/24:0/20:2n6)
|
|
|
PS(14:1(9Z)/14:0)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/20:3n6/22:2(13Z,16Z))
|
|
|
PE(18:0/22:1(13Z))
|
|
|
TG(16:1(9Z)/18:0/20:4(5Z,8Z,11Z,14Z))[iso6]
|
|
|
TG(18:1(9Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
D-Serine
|
The R-enantiomer of serine.
|
|
Hydroxypropanedioic acid
|
A dicarboxylic acid that is malonic acid substituted by a hydroxy group at position 2.
|
|
Galactaric acid
|
A hexaric acid resulting from formal oxidative ring cleavage of galactose.
|
|
TG(20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/20:2n6/20:4(5Z,8Z,11Z,14Z))
|
|
|
PIP(20:3(5Z,8Z,11Z)/18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
D-Glyceraldehyde 3-phosphate
|
A glyceraldehyde 3-phosphate that has formula C3H7O6P.
|
|
PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
CDP-DG(18:1(9Z)/18:0)
|
|
|
DG(18:3n3/0:0/18:4n3)
|
|
|
Bisnorcholic acid
|
|
|
13-cis-Retinoic acid
|
|
|
PC(24:1(15Z)/20:0)
|
|
|
TG(16:0/22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
Midodrine
|
An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
|
|
PC(16:0/24:1(15Z))
|
|
|
TG(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)/o-18:0)
|
|
|
PC(20:0/20:1(11Z))
|
|
|
L-Methionine
|
The L-enantiomer of methionine.
|
|
TG(20:1(11Z)/24:0/20:3n6)
|
|
|
Bromobenzene-3,4-oxide
|
An epoxide that has formula C6H5BrO.
|
|
PE(P-16:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:2(13Z,16Z)/14:0/o-18:0)
|
|
|
TG(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(16:0/24:0/20:3n6)
|
|
|
TG(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(18:1(11Z)/20:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))
|
|
|
PE(22:4(7Z,10Z,13Z,16Z)/P-18:1(11Z))
|
|
|
TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z))
|
|
|
PC(P-16:0/18:3(6Z,9Z,12Z))
|
|
|
Bilirubin diglucuronide
|
|
|
TG(16:1(9Z)/18:1(11Z)/22:1(13Z))
|
|
|
TG(15:0/24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
PE(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:1(9Z)/14:1(9Z))
|
|
|
TG(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/20:3(5Z,8Z,11Z)/o-18:0)
|
|
|
PE(20:3(5Z,8Z,11Z)/18:1(11Z))
|
|
|
TG(20:2n6/24:0/22:2(13Z,16Z))
|
|
|
TG(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))
|
|
|
TG(18:1(9Z)/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(15:0/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
PC(20:0/P-16:0)
|
|
|
PG(16:1(9Z)/16:1(9Z))
|
|
|
PE(16:1(9Z)/18:0)
|
|
|
TG(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Ganglioside GT1b (d18:0/22:1(13Z))
|
|
|
TG(16:0/22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
TG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0/o-18:0)
|
|
|
TG(18:0/o-18:0/20:1(11Z))
|
|
|
TG(18:1(9Z)/20:1(11Z)/20:1(11Z))[iso3]
|
|
|
DG(22:0/22:1(13Z)/0:0)
|
|
|
TG(15:0/18:1(11Z)/o-18:0)
|
|
|
PE(20:3(8Z,11Z,14Z)/18:0)
|
|
|
Acetylisoniazid
|
|
|
TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))[iso3]
|
|
|
TG(22:0/22:5(4Z,7Z,10Z,13Z,16Z)/o-18:0)
|
|
|
TG(14:1(9Z)/16:1(9Z)/20:2n6)
|
|
|
TG(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:0/18:3(9Z,12Z,15Z)/22:2(13Z,16Z))
|
|
|
TG(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)/o-18:0)
|
|
|
TG(24:1(15Z)/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
All-trans-13,14-dihydroretinol
|
A retinol that has formula C20H32O.
|
|
PC(15:0/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(18:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))
|
|
|
Sucrose
|
Sucrose is a disaccharide formed by glucose and fructose units joined by an acetal oxygen bridge from hemiacetal of glucose to the hemiketal of the fructose.
|
|
TG(20:1(11Z)/18:2(9Z,12Z)/20:3n6)
|
|
|
Vancomycin
|
A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.
|
|
Doxapram
|
A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
|
|
DG(18:3(6Z,9Z,12Z)/18:1(9Z)/0:0)
|
|
|
TG(20:0/14:1(9Z)/20:2n6)
|
|
|
TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Bilirubin
|
A member of the class of biladienes that is a linear tetrapyrrole, product of heme degradation. It is produced in the reticuloendothelial system by the reduction of biliverdin and transported to the liver as a complex with serum albumin.
|
|
Benzphetamine
|
Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.
|
|
TG(22:0/20:3n6/20:2n6)
|
|
|
TG(16:0/18:3(9Z,12Z,15Z)/20:3n6)
|
|
|
TG(24:0/20:0/22:2(13Z,16Z))
|
|
|
Citalopram
|
A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
|
|
TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(16:1(9Z)/24:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
Biotin amide
|
A monocarboxylic acid amide derived from biotin.
|
|
TG(20:2n6/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))
|
|
|
TG(24:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(20:2n6/14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/0:0)
|
|
|
TG(18:1(11Z)/22:0/18:3(6Z,9Z,12Z))
|
|
|
TG(24:0/24:0/22:2(13Z,16Z))
|
|
|
Ganglioside GM3 (d18:0/24:0)
|
|
|
Phosphoenolpyruvic acid
|
A monocarboxylic acid that is acrylic acid substituted by a phosphonooxy group at position 2. It is a metabolic intermediate in pathways like glycolysis and gluconeogenesis.
|
|
TG(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)/22:1(13Z))
|
|
|
TG(14:0/22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:2(13Z,16Z)/14:1(9Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
Tridihexethyl
|
|
|
DG(18:0/20:3(8Z,11Z,14Z)/0:0)
|
|
|
TG(18:1(9Z)/16:0/24:1(15Z))
|
|
|
TG(18:0/22:0/14:1(9Z))
|
|
|
TG(20:3n6/20:3n6/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:0/18:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(15:0/22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
DG(18:2n6/0:0/20:4n6)
|
|
|
PC(18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
|
|
|
TG(14:1(9Z)/22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2n6)
|
|
|
PE(14:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PE(24:0/20:2(11Z,14Z))
|
|
|
PC(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
TG(20:3(5Z,8Z,11Z)/24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
TG(16:1(9Z)/22:0/18:1(11Z))
|
|
|
TG(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))
|
|
|
TG(18:1(11Z)/22:0/24:1(15Z))
|
|
|
TG(18:3(6Z,9Z,12Z)/24:1(15Z)/20:2n6)
|
|
|
DG(20:4(8Z,11Z,14Z,17Z)/22:0/0:0)
|
|
|
Alcophosphamide
|
A nitrogen mustard that has formula C7H17Cl2N2O3P.
|
|
TG(18:4(6Z,9Z,12Z,15Z)/14:0/20:4(8Z,11Z,14Z,17Z))
|
|
|
DG(22:5(7Z,10Z,13Z,16Z,19Z)/16:0/0:0)
|
|
|
TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso6]
|
|
|
TG(18:4(6Z,9Z,12Z,15Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(22:1(13Z)/18:2(9Z,12Z)/20:2n6)
|
|
|
TG(24:1(15Z)/16:1(9Z)/18:3(9Z,12Z,15Z))
|
|
|
D-Pantothenoyl-L-cysteine
|
|
|
TG(18:0/20:3n6/20:3n6)
|
|
|
TG(18:1(9Z)/18:1(11Z)/18:2(9Z,12Z))[iso6]
|
|
|
Lithium
|
An alkali metal atom that has formula Li.
|
|
TG(14:0/22:0/22:4(7Z,10Z,13Z,16Z))
|
|
|
PC(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))
|
|
|
TG(20:1(11Z)/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
Sphinganine
|
A 2-aminooctadecane-1,3-diol having (2S,3R)-configuration.
|
|
8-Oxo-dGMP
|
A purine 2'-deoxyribonucleoside 5'-monophosphate having 8-oxo-7,8-dihydroguanine as the nucleobase.
|
|
Tioconazole
|
|
|
Procarbazine
|
|
|
TG(18:1(9Z)/18:2(9Z,12Z)/20:1(11Z))[iso6]
|
|
|
MG(0:0/18:1(11Z)/0:0)
|
|
|
LysoPE(24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0)
|
|
|
TG(18:0/22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))
|
|
|
Uridine triphosphate
|
|
|
PC(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))
|
|
|
TG(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))
|
|
|
DG(22:0/24:1(15Z)/0:0)
|
|
|
PE(18:0/18:1(9Z))
|
|